| - | An assessment of nucleic acid amplification testing for active mycobacterial infection |
| --- | --- |
| -- |  |
|  | December 2014 |
| - | - |
| - | MSAC application no. 1234  -  Assessment report |

**© Commonwealth of Australia 2014**

This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the *Copyright Act 1968*, all other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to Commonwealth Copyright Administration, [Attorney-General’s Department](http://www.ag.gov.au/), Robert Garran Offices, National Circuit, Barton ACT 2600.

Electronic copies of the report can be obtained from the [Medical Service Advisory Committee’s](http://www.msac.gov.au/) internet site.

Enquiries about the content of the report should be emailed to [hta@health.gov.au](mailto:hta@health.gov.au).

The technical information in this document is used by the Medical Services Advisory Committee (MSAC) to inform its deliberations. MSAC is an independent committee that has been established to provide advice to the Minister for Health on the strength of evidence available on new and existing medical technologies and procedures in terms of their safety, effectiveness and cost-effectiveness. This advice will help to inform government decisions about which medical services should attract funding under Medicare.

**MSAC’s advice does not necessarily reflect the views of all individuals who participated in the MSAC evaluation.**

This report was prepared for by Dr Judy Morona, Ms Arlene Vogan, Ms Sharon Kessels, Dr Debra Gum, Ms Jo Milverton, Ms Jacqueline Parsons, Ms Skye Newton, Ms Camille Schubert and Assoc. Prof. Tracy Merlin from Adelaide Health Technology Assessment (AHTA), University of Adelaide. Clinical advice was provided by Assoc. Prof. Jim Black, a member of the Health Expert Standing Panel. The report was commissioned by the Australian Government Department of Health. It was edited by Jo Mason of MasonEdit, Adelaide.

The suggested citation for this document is:

Morona JK, Vogan A, Kessels S, Gum D, Milverton J, Parsons J, Newton S, Schubert C & Merlin T (2014). *Nucleic acid amplification testing for active mycobacterial infection.* MSAC application no. 1234, Assessment Report. Commonwealth of Australia, Canberra, ACT.



**Contents**

[Executive summary xvii](#_Toc406659731)

[Glossary and abbreviations 31](#_Toc406659747)

[Introduction 33](#_Toc406659748)

[Background 34](#_Toc406659749)

[Approach to assessment 50](#_Toc406659750)

[Objective 50](#_Toc406659751)

[Clinical pathway 50](#_Toc406659752)

[Comparator 55](#_Toc406659753)

[The reference standard 55](#_Toc406659754)

[Research questions 55](#_Toc406659755)

[Diagnostic assessment framework 56](#_Toc406659756)

[Review of literature 57](#_Toc406659757)

[Expert advice: Health Expert Standing Panel (HESP) 70](#_Toc406659758)

[Results of assessment and discussion 71](#_Toc406659759)

[Is it safe? 71](#_Toc406659760)

[Is it effective? 72](#_Toc406659761)

[Direct evidence of the effectiveness of NAAT in the diagnosis of MTB 72](#_Toc406659762)

[Linked evidence of effectiveness of NAAT in the diagnosis of MTB 77](#_Toc406659763)

[Linked evidence of diagnostic effectiveness of NAAT in the diagnosis of NTM 120](#_Toc406659767)

[Other relevant considerations 129](#_Toc406659769)

[TB in the Australian Indigenous population 129](#_Toc406659770)

[What are the economic considerations? 133](#_Toc406659771)

[Economic evaluation 133](#_Toc406659772)

[Financial implications 165](#_Toc406659777)

[Conclusions 173](#_Toc406659781)

[Is NAAT safe? 173](#_Toc406659782)

[Is NAAT effective? 173](#_Toc406659783)

[Is NAAT cost-effective? 181](#_Toc406659784)

[Costing 182](#_Toc406659785)

[Appendix A Health Expert Standing Panel and Assessment Group 184](#_Toc406659786)

[Appendix B Search strategies 185](#_Toc406659787)

[Appendix C Diagnostic accuracy 2x2 data from included studies 188](#_Toc406659788)

[Appendix D Analysis of diagnostic accuracy data 217](#_Toc406659789)

[Appendix E Meta-analysis of studies assessing the diagnostic accuracy of AFB compared with culture 233](#_Toc406659790)

[Appendix F Study profiles of studies included in the assessment 238](#_Toc406659791)

[Appendix G Excluded studies 287](#_Toc406659792)

[Appendix H Economic literature search 307](#_Toc406659793)

[Appendix I Additional information relating to the economic evaluation 308](#_Toc406659794)

[Appendix J Alternative NAAT fees 315](#_Toc406659795)

[References 316](#_Toc406659796)

**Boxes**

[Box 1 PICO criteria for studies assessing the safety of NAAT in patients suspected of TB where AFB microscopy is obtained 71](#_Toc406659912)

[Box 2 PICO criteria for identification of studies relevant to an assessment of effectiveness of NAAT for patients where AFB microscopy is obtained 72](#_Toc406659913)

[Box 3 PICO criteria for identification of studies relevant to an assessment of the accuracy of NAAT 79](#_Toc406659914)

[Box 4 PICO criteria for identification of studies relevant to an assessment of change in management following NAAT in patients able to have an AFB microscopy test 99](#_Toc406659915)

[Box 5 PICO criteria for direct evidence in patients with tissue biopsy consistent with NTM infection 122](#_Toc406659916)

**Tables**

[Table ES 1 Suggested MBS item descriptors xix](#_Toc406660309)

[Table ES 2 Summary of the economic evaluation xxvii](#_Toc406660310)

[Table ES 3 The incremental cost-effectiveness of NAAT xxviii](#_Toc406660311)

[Table ES 4 Financial implications of proposed NAAT listings xxix](#_Toc406660312)

[Table 1 Clinical presentations of TB 34](#_Toc406659797)

[Table 2 Proportion of mycobacterial isolates causing clinically significant and non-significant pulmonary and extrapulmonary disease in Queensland, 2005 37](#_Toc406659798)

[Table 3 Current MBS item descriptors for diagnosing active mycobacterial infections 47](#_Toc406659799)

[Table 4 Suggested MBS item descriptors 48](#_Toc406659800)

[Table 5 Electronic databases searched 58](#_Toc406659801)

[Table 6 Search terms used for NAAT for MTB (direct evidence, accuracy and change in management) 58](#_Toc406659802)

[Table 7 Search terms used for NAAT for NTM (direct evidence, accuracy and change in management) 58](#_Toc406659803)

[Table 8 Search terms used for impact of early identification of drug resistance and alternative treatment 59](#_Toc406659804)

[Table 9 Search terms used for impact of early versus delayed treatment for TB 59](#_Toc406659805)

[Table 10 Search terms used for impact of inappropriate antibiotic use 59](#_Toc406659806)

[Table 11 Diagnostic accuracy data extraction for NAAT 64](#_Toc406659807)

[Table 12 Evidence dimensions 66](#_Toc406659808)

[Table 13 Designations of levels of evidence according to type of research question (including table notes) 66](#_Toc406659809)

[Table 14 Grading system used to rank included studies 68](#_Toc406659810)

[Table 15 Body of evidence matrix 69](#_Toc406659811)

[Table 16 Body of evidence matrix for studies reporting direct evidence on the effectiveness of NAAT in the diagnosis of MTB 73](#_Toc406659812)

[Table 17 TB-related morbidity at recruitment, 2 months and 6 months, according to baseline culture status in patients given anti-TB treatment, per group 74](#_Toc406659813)

[Table 18 Mortality after NAAT versus no NAAT 76](#_Toc406659814)

[Table 19 Body of evidence matrix for studies reporting on the accuracy of AFB and NAAT compared with culture in diagnosing MTB infections 80](#_Toc406659815)

[Table 20 Body of evidence matrix for studies reporting change in management outcomes due to NAAT 99](#_Toc406659816)

[Table 21 Median time to TB diagnosis/detection using NAAT versus comparator 101](#_Toc406659817)

[Table 22 Median time to therapy using GeneXpert versus comparator 101](#_Toc406659818)

[Table 23 Proportion of patients initiating treatment based on AFB microscopy or NAAT results, by day 102](#_Toc406659819)

[Table 24 PICO criteria for identification of studies relevant to an assessment of health outcomes following a change in management 106](#_Toc406659820)

[Table 25 Body of evidence matrix for studies assessing the health impact of early versus delayed treatment of TB 107](#_Toc406659821)

[Table 26 Summary of studies assessing the health impact of early versus delayed treatment of TB on the individual and their contacts 109](#_Toc406659822)

[Table 27 Body of evidence matrix for studies investigating the effect of change in management due to detection of drug resistant MTB 110](#_Toc406659823)

[Table 28 Association between treatment characteristics and health outcomes among rifampicin-resistant TB patients 111](#_Toc406659824)

[Table 29 Association between treatment characteristics and poor treatment outcome among rifampicin-resistant and MDR-TB patients, Thailand 2004–08 111](#_Toc406659825)

[Table 30 Body of evidence matrix for studies assessing the health impact of inappropriate antibiotic treatment 112](#_Toc406659826)

[Table 31 Summary of hepatic AEs to isoniazid from prospective and retrospective studies 114](#_Toc406659827)

[Table 32 Incidence of AEs for drugs and regimens for first-line and prophylactic TB treatment 115](#_Toc406659828)

[Table 33 Incidence of adverse reactions to TB drugs in children 116](#_Toc406659829)

[Table 34 AEs reported in treatment trials for TB in children 117](#_Toc406659830)

[Table 35 AEs reported for treatment regimens for children with severe TB disease or TB meningitis 117](#_Toc406659831)

[Table 36 Appropriate treatment regimens for TB patients with strains that have certain drug-resistance patterns 118](#_Toc406659832)

[Table 37 Definitions of MDR-TB, acquired MDR-TB, recurrence, relapse and reinfection 118](#_Toc406659833)

[Table 38 Patients who acquired MDR-TB following appropriate or inappropriate TB treatment 119](#_Toc406659834)

[Table 39 Meta-analysis of two studies showing the risk ratio of inappropriate treatment and risk of developing multidrug-resistant TB 119](#_Toc406659835)

[Table 40 Body of evidence matrix for studies reporting on the accuracy of NAAT in diagnosing NTM infections 122](#_Toc406659836)

[Table 41 Prevalence of NTM culture-positive specimens in the included studies 124](#_Toc406659837)

[Table 42 Economic evaluations identified that investigate NAAT for active TB in low-prevalence countries 135](#_Toc406659838)

[Table 43 Summary of the economic evaluation 137](#_Toc406659839)

[Table 44 Summary of decision tree outcome states in the economic evaluation 141](#_Toc406659840)

[Table 45 Prevalence estimates used in previously published economic evaluations of NAAT 143](#_Toc406659841)

[Table 46 Test parameters used in the economic evaluation 144](#_Toc406659842)

[Table 47 Resource items associated with treatment of TB used in the economic evaluation 147](#_Toc406659843)

[Table 48 Cost per treatment regimen, per month 148](#_Toc406659844)

[Table 49 Total months in treatment and regimen costs, by outcome state 148](#_Toc406659845)

[Table 50 Cost of treating AEs, by treatment regimen 149](#_Toc406659846)

[Table 51 Resource use associated with the management of TB used in the economic evaluation, by outcome state, discounted (where appropriate) 151](#_Toc406659847)

[Table 52 Total cost of hospital isolation 152](#_Toc406659848)

[Table 53 Total cost of identification and treatment of TB transmissions 154](#_Toc406659849)

[Table 54 Total costs, by outcome state, discounted (where appropriate) 155](#_Toc406659850)

[Table 55 Utility values used in previously published economic evaluations of NAAT 155](#_Toc406659851)

[Table 56 Utility values used in the economic evaluation 156](#_Toc406659852)

[Table 57 Overall utility, by outcome state, discounted (where appropriate) 157](#_Toc406659853)

[Table 58 Outcome state utilities, adjusted for TB transmissions 158](#_Toc406659854)

[Table 59 Outcome state probabilities, TB mixed scenario 159](#_Toc406659855)

[Table 60 Breakdown of incremental costs, TB mixed scenario 160](#_Toc406659856)

[Table 61 Weighted utility by outcome state, TB mixed scenario 160](#_Toc406659857)

[Table 62 Stepped economic evaluation, TB mixed scenario 161](#_Toc406659858)

[Table 63 Incremental cost-effectiveness ratios for additional scenarios 161](#_Toc406659859)

[Table 64 Sensitivity analysis using test accuracy results of AFB, NAAT from all studies identified in the systematic review 166](#_Toc406659860)

[Table 65 Data sources used in the financial analysis 166](#_Toc406659861)

[Table 66 Number of patients who accessed MC&S services, 2009–13 167](#_Toc406659862)

[Table 67 Number of patients eligible and cost of NAAT for TB 169](#_Toc406659863)

[Table 68 Number of patients eligible and cost of NAAT for NTM 169](#_Toc406659864)

[Table 69 Total cost of NAAT for requested listings 170](#_Toc406659865)

[Table 70 Sensitivity analyses 171](#_Toc406659866)

[Table 71 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in mixed specimens 188](#_Toc406659867)

[Table 72 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in mixed specimens 191](#_Toc406659868)

[Table 73 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in sputum 194](#_Toc406659869)

[Table 74 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in sputum 198](#_Toc406659870)

[Table 75 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in bronchoalveolar lavage, bronchial aspirates and washings 200](#_Toc406659871)

[Table 76 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in bronchoalveolar lavage, bronchial aspirates and washings 200](#_Toc406659872)

[Table 77 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in gastric aspirates 201](#_Toc406659873)

[Table 78 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in stools 202](#_Toc406659874)

[Table 79 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in cerebrospinal fluid 202](#_Toc406659875)

[Table 80 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in cerebrospinal fluid 203](#_Toc406659876)

[Table 81 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in body fluids 204](#_Toc406659877)

[Table 82 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in body fluids 205](#_Toc406659878)

[Table 83 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in fine-needle aspirates 206](#_Toc406659879)

[Table 84 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in fine-needle aspirates 206](#_Toc406659880)

[Table 85 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in abscesses/pus 208](#_Toc406659881)

[Table 86 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in abscesses/pus 208](#_Toc406659882)

[Table 87 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in urine 209](#_Toc406659883)

[Table 88 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in tissue biopsies 209](#_Toc406659884)

[Table 89 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in tissue biopsies 211](#_Toc406659885)

[Table 90 Diagnostic accuracy of NAAT compared with drug sensitivity testing for the detection of drug-resistant MTB infections 211](#_Toc406659886)

[Table 91 Diagnostic accuracy of NAAT and AFB microscopy using culture as the reference standard for diagnosis of NTM 213](#_Toc406659887)

[Table 92 Diagnostic accuracy of NAAT, AFB microscopy and culture using a clinical reference standard for diagnosis of NTM 215](#_Toc406659888)

[Table 93 Prevalence of MTB culture-positive patients in included studies 217](#_Toc406659889)

[Table 94 Pooled sensitivity and specificity of AFB and NAAT in non-sputum specimens compared with extrapulmonary specimens 221](#_Toc406659890)

[Table 95 Study profiles of included studies providing direct evidence on the effectiveness of NAAT on patients suspected of having TB 238](#_Toc406659891)

[Table 96 Study profiles of included studies on diagnostic accuracy 239](#_Toc406659892)

[Table 97 Study profiles of included studies providing linked evidence on the change in management following NAAT on patients suspected of having TB 273](#_Toc406659893)

[Table 98 Study profiles of included studies on the effectiveness of change in management due to early treatment of TB in those with low pre-test probability of having active TB 279](#_Toc406659894)

[Table 99 Study profiles of included studies on the effectiveness of change in management due to rifampicin-resistance mutations being identified 280](#_Toc406659895)

[Table 100 Study profiles of SRs assessing the safety and adverse effects of active TB therapies 282](#_Toc406659896)

[Table 101 Study profiles of included studies on the effectiveness of NAAT in diagnosing NTM infections 283](#_Toc406659897)

[Table 102 Amikacin administration costs 308](#_Toc406659898)

[Table 103 Utility values identified in studies that elicit utilities in a TB population 308](#_Toc406659899)

[Table 104 Outcome state probabilities, TB low scenario 311](#_Toc406659900)

[Table 105 Breakdown of incremental costs, TB low scenario 311](#_Toc406659901)

[Table 106 Weighted utility by outcome state, TB low scenario 311](#_Toc406659902)

[Table 107 Outcome state probabilities, perfect clinical judgement scenario 312](#_Toc406659903)

[Table 108 Breakdown of incremental costs, perfect clinical judgement scenario 312](#_Toc406659904)

[Table 109 Weighted utility by outcome state, perfect clinical judgement scenario 312](#_Toc406659905)

[Table 110 Outcome state probabilities, TB high scenario 313](#_Toc406659906)

[Table 111 Breakdown of incremental costs, TB high scenario 313](#_Toc406659907)

[Table 112 Weighted utility by outcome state, TB high scenario 314](#_Toc406659908)

[Table 113 Stepped economic evaluation, TB low and TB high scenarios 314](#_Toc406659909)

[Table 114 The effect on the ICER of alternative NAAT item fees 315](#_Toc406659910)

[Table 115 The effect on the financial implications of alternative NAAT item fees 315](#_Toc406659911)

**Figures**

[Figure 1 Principles of the LAMP method 40](#_Toc406659917)

[Figure 2 The 81-bp MTB-specific rifampicin-resistance determining region of the *rpoB* gene 42](#_Toc406659918)

[Figure 3 Current clinical management of TB and proposed use of NAAT for active TB where AFB is obtained 52](#_Toc406659919)

[Figure 4 Current clinical management and proposed algorithm with use of NAAT for active TB where AFB microscopy is not able to be obtained 53](#_Toc406659920)

[Figure 5 Current clinical management algorithm and proposed algorithm with use of NAAT for patients who are suspected of having an NTM infection 54](#_Toc406659921)

[Figure 6 Summary of the process used to identify and select studies investigating the use of NAAT to diagnose MTB (direct evidence, accuracy and change in management) 61](#_Toc406659922)

[Figure 7 Summary of the process used to identify and select studies investigating the use of NAAT to diagnose NTM (direct evidence, accuracy and change in management) 61](#_Toc406659923)

[Figure 8 Summary of the process used to identify and select studies for the impact of early identification of drug resistance and alternative treatment 62](#_Toc406659924)

[Figure 9 Summary of the process used to identify and select studies for the impact of early versus delayed treatment for TB 62](#_Toc406659925)

[Figure 10 Summary of the process used to identify and select studies for the impact of inappropriate antibiotic use 63](#_Toc406659926)

[Figure 11 Forest plot showing the pooled sensitivity and specificity values for culture compared with NAAT, using a clinical reference standard, and for NAAT compared with culture in the same subset of studies 81](#_Toc406659927)

[Figure 12 Forest plot showing the pooled sensitivity and specificity values for AFB plus NAAT compared with culture for studies grouped according to the NAAT comparator, specimen type and incidence of TB in the country in which the study was conducted 82](#_Toc406659928)

[Figure 13 LR scattergram for diagnosis of MTB infection by AFB plus NAAT compared with culture in studies using either in-house NAAT or commercial Xpert NAAT 83](#_Toc406659929)

[Figure 14 SROC curve for all studies investigating the sensitivity and specificity of AFB plus NAAT versus culture in the diagnosis of TB for all studies based on NAAT methodology (A), and for sputum (B) and non-sputum (C) specimens based on incidence of TB 84](#_Toc406659930)

[Figure 15 Forest plot showing the pooled sensitivity and specificity values for NAAT compared with culture for studies grouped according to the NAAT comparator, specimen type and incidence of TB in the country in which the study was conducted 85](#_Toc406659931)

[Figure 16 Deek’s Funnel plot asymmetry test to assess publication bias for the diagnostic accuracy of NAAT compared with culture 86](#_Toc406659932)

[Figure 17 LR scattergram for diagnosis of MTB infection by NAAT compared with culture in studies using either in-house NAAT or commercial Xpert NAAT 87](#_Toc406659933)

[Figure 18 SROC curve for all studies investigating the sensitivity and specificity of NAAT versus culture in the diagnosis of TB for studies based on NAAT methodology (A), specimen type (B) and incidence of TB (C) 88](#_Toc406659934)

[Figure 19 Forest plot showing the pooled sensitivity and specificity values for NAAT compared with culture for AFB-positive (A) and AFB-negative (B) specimens grouped according to NAAT methodology, specimen type and incidence of TB in the country in which the study was conducted 90](#_Toc406659935)

[Figure 20 LR scattergram for diagnosis of MTB infection by NAAT compared with culture for AFB-positive specimens according to NAAT methodology 91](#_Toc406659936)

[Figure 21 LR scattergram for diagnosis of MTB infection by NAAT compared with culture for AFB-negative specimens according to NAAT methodology 92](#_Toc406659937)

[Figure 22 SROC curve for all studies investigating the sensitivity and specificity of NAAT versus culture in the diagnosis of TB for AFB-positive specimens based on NAAT methodology 92](#_Toc406659938)

[Figure 23 SROC curve for all studies investigating the sensitivity and specificity of NAAT versus culture in the diagnosis of TB for AFB-negative specimens based on NAAT methodology (A) and specimen type (B) 93](#_Toc406659939)

[Figure 24 Forest plot showing the pooled sensitivity and specificity values for AFB, NAAT and AFB plus NAAT compared with culture according to specimen type 93](#_Toc406659940)

[Figure 25 LR scattergram for diagnosis of MTB infection by AFB (A), NAAT (B) and AFB plus NAAT (C) compared with culture in studies using either in-house NAAT or the commercial Xpert NAAT 95](#_Toc406659941)

[Figure 26 Forest plot showing the pooled sensitivity and specificity values for AFB and NAAT compared with culture according to HIV status 96](#_Toc406659942)

[Figure 27 Forest plot comparing the pooled sensitivity and specificity values for NAAT versus culture according to AFB result and specimen type in HIV-positive specimens 97](#_Toc406659943)

[Figure 28 Forest plot of the sensitivity and specificity of NAAT compared with culture-based DST to detect drug-resistant MTB infections 98](#_Toc406659944)

[Figure 29 Percentage of patients initiating treatment based on smear (AFB microscopy) or NAAT results, by day 102](#_Toc406659945)

[Figure 30 Forest plot showing the pooled sensitivity and specificity values for AFB and NAAT compared with culture or a clinical reference standard in diagnosing NTM infections in various types of specimens 125](#_Toc406659946)

[Figure 31 LR scattergram for diagnosis of NTM infection by AFB microscopy (A) and NAAT (B) compared with culture 126](#_Toc406659947)

[Figure 32 SROC curve for all studies investigating the sensitivity and specificity of AFB and NAAT versus culture in the diagnosis of NTM 127](#_Toc406659948)

[Figure 33 Decision analytic structure of the economic evaluation, comparator (AFB) model arm 139](#_Toc406659949)

[Figure 34 Decision analytic structure of the economic evaluation, intervention (AFB plus NAAT) model arm 140](#_Toc406659950)

[Figure 35 Percentage of TB cases that exhibited multidrug resistance in Australia, 1995–2010 144](#_Toc406659951)

[Figure 36 Tornado sensitivity analysis 164](#_Toc406659952)

[Figure 37 Number of patients who accessed MC&S services, observed 2009–13 and projected 2014–19 167](#_Toc406659953)

[Figure 38 Forest plot of the sensitivity and specificity of AFB microscopy compared with culture, grouped according to use of in-house or commercial NAAT, for studies conducted in countries with low and medium incidence of TB 219](#_Toc406659954)

[Figure 39 Forest plot of the sensitivity and specificity of AFB microscopy compared with culture, grouped according to use of in-house or commercial NAAT, for studies conducted in countries with high incidence of TB 220](#_Toc406659955)

[Figure 40 Forest plot showing the pooled sensitivity and specificity values for AFB, NAAT and AFB plus NAAT compared with culture, according to specimen type 222](#_Toc406659956)

[Figure 41 Forest plot of the sensitivity and specificity of NAAT compared with culture, grouped according to use of in-house or commercial NAAT, for studies conducted in countries with low and medium incidence of TB 223](#_Toc406659957)

[Figure 42 Forest plot of the sensitivity and specificity of NAAT compared with culture, grouped according to use of in-house or commercial NAAT, for studies conducted in countries with high incidence of TB 224](#_Toc406659958)

[Figure 43 Forest plot of the sensitivity and specificity of AFB plus NAAT compared with culture, grouped according to use of in-house or commercial NAAT, for studies conducted in countries with low and medium incidence of TB 225](#_Toc406659959)

[Figure 44 Forest plot of the sensitivity and specificity of AFB plus NAAT compared with culture, grouped according to use of in-house or commercial NAAT, for studies conducted in countries with high incidence of TB 226](#_Toc406659960)

[Figure 45 Forest plot of the sensitivity and specificity of NAAT compared with culture in AFB-positive specimens, grouped according to type of NAAT and incidence of TB 227](#_Toc406659961)

[Figure 46 Forest plot of the sensitivity and specificity of NAAT compared with culture in AFB-negative specimens, grouped according to use of in-house or commercial NAAT and incidence of TB 228](#_Toc406659962)

[Figure 47 Forest plot of the sensitivity and specificity of AFB and/or NAAT compared with culture in HIV-positive patients suspected of having TB 229](#_Toc406659963)

[Figure 48 Forest plot of the sensitivity and specificity of AFB and/or NAAT compared with culture in HIV-negative patients suspected of having TB 230](#_Toc406659964)

[Figure 49 Forest plot of the sensitivity and specificity of AFB and NAAT compared with culture or a clinical reference standard in diagnosing NTM infections 231](#_Toc406659965)

[Figure 50 Forest plot of the sensitivity and specificity of culture compared with a clinical reference standard and subgroup analysis of NAAT compared with culture, based on HIV and AFB status 232](#_Toc406659966)

[Figure 51 Forest plot showing the pooled sensitivity and specificity values for AFB microscopy compared with culture for studies grouped according to NAAT comparator, AFB methodology and incidence of TB in the country in which the study was conducted 234](#_Toc406659967)

[Figure 52 Deek’s Funnel plot asymmetry test to assess publication bias for the diagnostic accuracy of AFB microscopy compared with culture 235](#_Toc406659968)

[Figure 53 LR scattergram for diagnosis of MTB infection by AFB microscopy compared with culture in studies using in-house NAAT or the Xpert NAAT 236](#_Toc406659969)

[Figure 54 SROC curve for all studies investigating the sensitivity and specificity of AFB microscopy versus culture in the diagnosis of TB 237](#_Toc406659970)

[Figure 55 Results of the economic evaluation, AFB model arm 309](#_Toc406659971)

[Figure 56 Results of the economic evaluation, AFB plus NAAT model arm 311](#_Toc406659972)

# Executive summary

## An assessment of nucleic acid amplification testing for active mycobacterial infection

### Main issues for MSAC consideration

| **Effectiveness issues**   * The two studies that provided direct evidence are likely not generalisable to the Australian setting and the results are probably confounded; therefore, the results are unreliable. * Culture is an imperfect reference standard; thus, a large proportion of false-positive patients (i.e. NAAT-positive and culture-negative) will likely have clinical disease (see ‘Comparison of NAAT and culture, using clinical diagnosis as a reference standard’).   **Economic issues**   * The cost of NAAT is the main driver of the incremental costs in the economic modelling. Large variations in test cost were observed across Australian pathology providers. * The cost-effectiveness of NAAT is highly sensitive to reductions in the prevalence of TB in the tested population and reductions in the specificity parameters of NAAT.   **Financial issues**   * The population eligible for NAAT may be an overestimate, as the approach used may include patients who are ineligible for NAAT, such as those suspected of Mycobacterium leprae, patients receiving testing across multiple years for the same infection, or patients who do not have clinical signs and symptoms of a mycobacterial infection. * As NAAT is currently being used (the extent of which is uncertain), some shifting of costs from the states to the federal health budget is likely but has not been costed in the financial analyses. |
| --- |

### Rationale for assessment

Douglass Hanly Moir Pathology Pty Ltd has submitted an application to the Department of Health that requests listing on the Medicare Benefits Schedule (MBS) of nucleic acid amplification testing (NAAT) to diagnose (1) *Mycobacterium tuberculosis* (MTB) infections in persons with clinical signs and symptoms of tuberculosis (TB), or (2) non-tuberculous mycobacteria (NTM) infection in patients suspected of having an NTM infection.

The public funding questions addressed in this contracted assessment of NAAT are largely consistent with the approach pre-specified in the protocol that was ratified by the Protocol Advisory Subcommittee (PASC). In the evidence collated for this assessment there were no studies with patients who presented with the clinical signs and symptoms of active TB but for whom it was not possible to obtain a specimen suitable for acid-fast bacilli (AFB) microscopy. Therefore, there were no data available to address the clinical management algorithm proposed in Figure 4 (see ‘Clinical pathway’), and therefore this clinical indication has not been considered further. It should also be noted that the NTM population eligible for NAAT has been expanded from that specified in the protocol, in order to include all patients suspected of having an NTM infection.

### Proposed medical service

NAAT for the detection of active mycobacterial infection is intended to be used in patients suspected of having TB or NTM infections to confirm the presence of the organism and help direct patient management. NAAT to detect MTB will be a separate test from NAAT to detect NTM infections and will require two MBS item numbers.

##### Nucleic acid amplification test (NAAT)

NAAT can be undertaken using either an in-house (diagnostic laboratory-designed) method or a commercial assay. The methods used for in-house NAAT are usually polymerase chain reaction (PCR)-based, where DNA is amplified via a temperature-mediated DNA polymerase using specific primers complementary to the ends of the targeted sequence. The most widely used commercial NAAT for detection of MTB is the GeneXpert MTB/RIF assay (Xpert, Cepheid, Sunnyvale, CA, USA), which is endorsed by the World Health Organization and has been approved by the Therapeutic Goods Administration (TGA) for use on patient material, regardless of the AFB smear microscopy result. There are no commercially available kits for the detection of NTM approved by the TGA in Australia.

The Guidelines for Australian mycobacteriology laboratories ([National Tuberculosis Advisory Committee 2006](#_ENREF_153)) state that ‘All NAAT methods must be properly validated before routine use’. Commercial tests that have been modified (e.g. for a novel use) and in-house methodologies must be validated according to the *NPAAC guidelines for requirements for the development and use of in-house in-vitro diagnostic medical devices* ([National Pathology Accreditation Advisory Council 2014](#_ENREF_152)).

### Current funding arrangements

Treatment for TB is provided free of charge to patients in Australia. The test to confirm active mycobacterial infection is covered by the state and territory health systems if the patient is a public patient in a public hospital, or by the MBS if the test being performed is listed on the MBS. The tests currently listed on the MBS are AFB microscopy and culture of suitable specimens. NAAT is not currently listed on the MBS.

### Proposal for public funding

An MBS item descriptor was not proposed in the PASC-ratified protocol. Suggested MBS item descriptors, as recommended by the relevant policy area in the Department of Health are provided in Table ES 1.

Table ES 1 Suggested MBS item descriptors

| **Category 6 – PATHOLOGY SERVICES** |
| --- |
| MBS item number  Nucleic acid amplification test for the detection of *Mycobacterium tuberculosis* complex in patients with signs and symptoms consistent with active tuberculosis.  **Fee:** To be advised |
| MBS item number  Nucleic acid amplification test for the detection of nontuberculous mycobacteria species in patients with a compatible clinical disease.  Fee: To be advised |

### Comparator details

Patients with the clinical signs and symptoms of active TB will receive NAAT in addition to AFB microscopy. Standard microbial testing in Australia for TB, in people with signs and symptoms of active disease, involves AFB microscopy and culture of suitable specimens. As both the intervention and comparator groups receive AFB testing, the main comparator for NAAT is culture alone.

The patient population suspected of having an NTM infection receive NAAT in addition to culture, and this may replace further testing such as additional biopsies. Therefore, the appropriate comparator in the identified population is current testing without NAAT.

### Clinical use of the intervention

The use of NAAT in the diagnosis and management of active TB infection is proposed to be an additional diagnostic tool and not a substitute for any of the current tests. NAAT is intended for use with specimens from untreated patients (< 3 days of anti-TB drug treatment) for whom there is clinical suspicion of TB. As the number of bacilli reduces rapidly within days to 2 weeks after commencing appropriate TB treatment (providing the MTB is not drug resistant), MTB cannot be reliably detected in treated patients.

In clinical practice, diagnosis of TB and the selection of an appropriate treatment regimen would be determined by the clinician after taking into account the patient’s history and clinical symptoms along with the results of AFB microscopy, NAAT and culture plus drug susceptibility testing (DST). The AFB microscopy and NAAT results would both be available within a day or two, and the interpretation of the AFB and NAAT results would be inter-related. For example, a positive AFB could be the result of an NTM infection rather than MTB, and this would be resolved by the NAAT result.

### Key differences in the delivery of the proposed medical service and the main comparator

Currently, most testing for MTB occurs using the AFB smear microscopy and culture tests. Although they are two separate tests, they are usually performed at the same time using the same specimen. The results for the two tests are delivered at different times; AFB microscopy results are reported within 24–48 hours whereas culture results are reported at 6–8 weeks. NAAT would be performed at the same time as AFB microscopy and culture, with results available in the same timeframe as the AFB results.

### Clinical claim

##### Tuberculosis

The applicant proposed that patient outcomes will differ according to the pre-test probability of a patient having TB. Patients with a high pre-test probability of having TB commence antibiotic treatment immediately (i.e. prior to diagnostic confirmation); therefore, NAAT will have limited impact on patient management. In patients at risk of active TB it is proposed that the use of NAAT is non-inferior to current TB testing. However, if NAAT detects rifampicin resistance, its use may cause the treating health professional to change the anti-tubercular drug regimen. This could have public health benefits by reducing the infectiousness of the patient earlier than the 6–8 weeks required for culture and DST. The use of NAAT in this circumstance is proposed to be superior to current testing approaches.

For patients in whom the pre-test probability of TB is low (i.e. AFB-negative and with indeterminate clinical symptoms), the clinical claim is that NAAT is superior to the current standard testing because a positive NAAT would result in immediate treatment that would not have been indicated based on the low pre-test probability of TB.

##### Non-tuberculous mycobacteria

In patients suspected of having NTM infections, the applicant proposed that NAAT is expected to provide additional diagnostic information to the tests currently performed to diagnose NTM. The use of NAAT in this population is, therefore, proposed to be superior to the situation where NAAT is not available.

### Approach taken to the evidence assessment

A systematic review (SR) of published medical literature was undertaken. Searches to identify relevant studies and reviews for the period between 1990 and June 2014 were conducted for the Cochrane Library, Current Contents, Embase, PubMed, Web of Science, Cinahl, Econlit and Scopus databases, as well as Australian and international health technology assessment (HTA) websites.

For TB infections, studies that investigated the use of NAAT (with or without AFB microscopy) compared with ‘no NAAT’ (AFB microscopy and culture for diagnostic accuracy studies) in patients suspected of having TB and who have had < 3 days of anti-TB treatment and reported appropriate outcomes, as outlined in Box 1 to Box 4 and Table 24, were included for further review.

For NTM infections, studies that investigated the use of NAAT (with or without AFB microscopy) compared with ‘no NAAT’ (AFB microscopy and culture or clinical diagnosis) in patients suspected of having an NTM infection were included (see Box 5).

### Characteristics of the evidence base

Two studies assessed the direct health impact of NAAT compared with no NAAT on patients suspected of having TB. Seventeen studies reported on the impact of NAAT on the clinical management of patients and 9 studies provided data on the impact of these changes in management on the health outcomes of patients.

Due to the large volume of evidence available on the accuracy of NAAT relative to culture, only studies published after 2005, with 2x2 data suitable for meta-analysis, were included in the final analysis. Studies on the only commercial NAAT product (Xpert) available in Australia were published in 2006 onwards. In-house NAAT, on the other hand, was available before 2005. However, as there have been significant changes in laboratory practice over the past 10 years ([Boyle & Pai 2012](#_ENREF_31); [Moore, Guzman & Mikhail 2005](#_ENREF_146); [Nybo 2012](#_ENREF_161); [Public Health and Ambulatory Care 2012](#_ENREF_171)), it seemed reasonable to limit study eligibility to publications in the previous decade. A total of 79 studies provided extractable data and were included.

Twelve studies were identified that reported on the diagnostic accuracy of NAAT for the detection of NTM infections and were included in the review. Literature searches spanned the period 1990–2014.

### Results of assessment

##### Safety

No studies were identified that reported on the safety of NAAT compared with current testing. As NAAT is usually conducted on the same samples used for other testing, and there is no need for resampling, no adverse events (AEs) are expected from the testing procedure.

However, more patients will receive a false-positive NAAT than a false-positive AFB result. Therefore, more patients will receive treatment for a disease they do not have and will possibly have an adverse reaction to the anti-TB drugs until clinical unresponsiveness is noted or culture results become available.

##### Effectiveness of NAAT in the diagnosis of MTB

###### Direct evidence: does NAAT improve health outcomes?

Both studies assessing the direct health impact of NAAT were conducted in a setting with a high TB prevalence; therefore, the applicability to the Australian healthcare system is questionable. A high-quality randomised controlled trial (RCT) reported no difference in morbidity outcomes at 2 and 6 months follow-up when NAAT and AFB microscopy were compared. However, a strong trend indicating fewer deaths in the NAAT group compared with the AFB microscopy group was observed at 2 months, but this trend was no longer apparent at 6 months. A historical control study of medium quality found no difference in the mortality rate at 2 months follow-up when comparing NAAT with no NAAT. However, both studies were confounded by high levels of treatment initiation based on clinical evidence in the comparator groups.

The difference in treatment initiation between groups in the study by Theron et al. ([2014](#_ENREF_200)) is unlikely to be reflected in treatment initiation rates in Australia because NAAT is suggested to be used as an adjunct to AFB testing. The incremental impact of NAAT over current testing practice in Australia, and the impact on patient morbidity and mortality, cannot be estimated from this study.

###### Linked evidence of effectiveness of NAAT in the diagnosis of MTB

###### Is it accurate?

Meta-analysis of studies investigating the diagnostic accuracy of NAAT compared with culture showed that both in-house NAATs and the commercial Xpert NAAT have diagnostic value for confirming or excluding culture-positive disease. Overall, patients with a positive NAAT result are likely to have culture-positive TB, whereas patients with a negative NAAT result are unlikely to be falsely negative.

In the context of interpreting NAAT results in conjunction with AFB findings, when specimens are AFB-positive a negative NAAT result can confidently exclude the likelihood of an MTB infection (as determined by culture), but a positive NAAT result does not eliminate the possibility of being culture-negative. The explanation for this is that culture is an imperfect reference standard. Culture in AFB-positive specimens likely resulted in misclassification of many of the 22% false-positive results recorded for NAAT.

In AFB-negative specimens a positive NAAT result is likely to correctly confirm the presence of MTB. However, interpretation of a negative NAAT result is dependent on the type of specimen tested. In patients with AFB-negative sputum, a negative NAAT result indicates that the patient may not be culture-positive but it cannot be ruled out. In patients with AFB-negative non-sputum specimens, a negative NAAT result provides no additional useful information. This is likely due to the low numbers of bacilli present in AFB-negative specimens. It should be noted that if few bacilli are present in the specimen, the possibility of a false-negative result would increase for all three tests.

When the results of the included studies were meta-analysed (k=11), NAAT was found to be both highly sensitive (93%, 95%CI 85, 97) and highly specific (98%, 95%CI 96, 99), compared with culture-based DST, in identifying rifampicin-resistant MTB.

Further analyses indicated that there was no difference in the diagnostic accuracy of AFB microscopy or NAAT, compared with culture, in HIV-positive and HIV-negative patients (k=7 and k=6 studies, respectively). As HIV-positive patients commonly produce AFB-negative sputum samples, the difficulty associated with diagnosis of TB in HIV-positive patients is related to the reduced sensitivity of NAAT in this specimen type when compared with AFB-positive specimens.

###### Does it change patient management?

Not surprisingly, all studies were in agreement that the use of NAAT resulted in a quicker diagnosis of patients with TB, especially in those who were AFB-negative (k=14). Predictably, this also resulted in earlier treatment in NAAT-positive patients. A historical control study of poor quality and a retrospective cohort study of medium quality reported that the median duration of unnecessary and/or over-treatment of TB was shorter in patients when NAAT was used to guide treatment decisions compared with when NAAT was not available.

There were conflicting data on the likely impact of NAAT in the clinical setting. A retrospective cohort study of poor quality and a high risk of bias, conducted in the UK (medium TB incidence), concluded that clinician decision-making would be affected by NAAT results and that there would be significant clinical benefits from the use of NAAT in low-prevalence settings. Two cohort studies of medium quality, one retrospective and conducted in Saudi Arabia (medium TB incidence) and the other conducted in Canada (low TB incidence), suggest that clinicians would be reluctant to change patient management based on the NAAT result.

###### Does change in management improve patient outcomes?

Two prospective cohort studies of poor quality, conducted in countries with a low incidence of TB, reported that a delay in time to diagnosis was significantly associated with an increased risk of transmission of TB among contacts. A retrospective cohort study of poor quality, conducted in New Zealand, indicated that, for the individual patient, the time between development of symptoms and diagnosis was not significantly associated with achieving a favourable treatment outcome (i.e. cure or treatment completed).

Three cohort studies (two retrospective) of medium quality provided some evidence that patients with rifampicin-resistant TB who received a rifampicin-containing Category II treatment, before receiving the results of DST had slightly poorer health outcomes than those who did not.

All TB patients are at risk of adverse health events (e.g. hepatitis) associated with first-line treatment. Two SRs, one of medium quality and one of poor quality, found that some, but not all, AEs as a consequence of patients with active TB receiving inappropriate antibiotic treatment (due to MTB resistance) may be avoided with appropriate treatment, to which the MTB strain is sensitive. One SR of good quality found that patients have a higher risk of developing multidrug-resistant TB (MDR-TB) if they receive inappropriate drug treatment.

###### Overall conclusion with respect to comparative effectiveness

Comparison of AFB, NAAT, and AFB plus NAAT, using culture as the reference standard, showed that AFB plus NAAT (the testing strategy proposed in the application) had the highest false-positive rate of 12%, with NAAT alone at 6% and AFB alone at 2%. A false-positive result means that a patient will receive treatment for a short time (until clinical unresponsiveness is noted or culture results are available) for a disease they do not have. However, as culture is an imperfect reference standard, a large proportion of these false-positive patients may actually have clinical disease. AFB microscopy alone had the highest false-negative rate at 38%, whereas NAAT alone or AFB plus NAAT were much lower at 11% and 6%, respectively. The consequences of a false-negative result are much more severe, as the patient may remain untreated for a longer time period and could potentially spread the disease to more individuals in the community.

The results of the meta-analyses presented in this report suggest that NAAT would be a useful addition to AFB microscopy and culture in the diagnosis of both pulmonary and extrapulmonary TB. Patients with a positive AFB test or NAAT result are likely to have culture-positive TB, and it becomes almost certain if both tests are positive. No useful information can be obtained directly from a negative AFB result, as these patients may or may not have TB. A negative NAAT result should be interpreted with reference to the AFB result—in a patient who was AFB-positive it almost completely eliminates the likelihood of being MTB culture-positive; conversely, in a patient who was AFB-negative it does not eliminate the possibility of culture-positive disease.

The use of NAAT enables quicker diagnosis and treatment of patients with TB, especially in those who are NAAT-positive and AFB-negative. It also reduces the duration of unnecessary and/or over-treatment for TB, particularly in those patients who are NAAT-negative and AFB-positive.

The accuracy of NAAT compared with culture-based DST indicates that NAAT can accurately identify patients with rifampicin-resistant MTB. Thus, NAAT could be used to inform the type of antibacterial treatment offered to TB patients. This would help avoid side effects such as hepatitis from inappropriate use of rifampicin, and earlier appropriate treatment for rifampicin resistance would also reduce the risk of developing MDR-TB.

##### Linked evidence of diagnostic effectiveness of NAAT in the diagnosis of NTM

NAAT to detect NTM could be separated into three distinct categories: detecting NTMs in general (NTM-NAAT), specifically detecting *M. avian* complex (MAC) strains (MAC-NAAT), and detecting *M. ulcerans* in patients suspected of having Buruli ulcer. The pooled accuracy of MAC-NAAT compared with culture showed that patients with a positive MAC-NAAT result were most likely to be infected with *M. avian*, but it is equivocal whether patients with a negative result have a culture-positive MAC infection (k=5 studies). Patients with a positive NTM-NAAT were more likely to have an infection than not, and patients with a negative result were more likely to be uninfected with NTM than to be infected (k=5 studies). The area under the summary receiver–operator characteristic (SROC) curve indicated that both NTM- and MAC-NAAT performed well in predicting culture positivity. There was insufficient evidence of the accuracy of NAAT in the diagnosis of NTM in AFB-positive or -negative specimens, so no conclusions could be reached about the value of NAAT in conjunction with AFB microscopy in the detection of NTM infections.

It should be noted that culture is an imperfect reference standard. When compared with a clinical reference standard, the median sensitivity for NTM-NAAT (k=2) was higher than for culture or AFB microscopy. NAAT appears to be able to identify a larger proportion of patients with an NTM infection than either AFB microscopy or culture. The results of these meta-analyses should be viewed with caution due to the small number of studies included and the wide 95% confidence intervals (CIs) for many of the analyses.

### Other relevant considerations

##### TB in the Indigenous population

The incidence of TB in the Australian Indigenous population was 11 times higher than in the Australian non-Indigenous population in 2010[[1]](#footnote-1). Higher rates of hospitalisation and mortality from TB also occur in the Indigenous population. The rapid diagnosis and treatment of TB is essential in remote communities in order to quickly contain the spread of infection. This is particularly important for children and infants, given the challenges in accessing adequate health care in these communities. Point-of-care testing with same-day results would likely offer easier access to diagnosis and more rapid treatment initiation in small regional hospitals and clinics in rural areas of Australia, if suitable training of personnel was available.

Xpert is the first fully automated NAAT developed for the point-of-care diagnosis of MTB and rifampicin-resistant MTB, and was endorsed by the World Health Organization (WHO) in December 2010 ([WHO 2014](#_ENREF_223)). Three studies that met the inclusion criteria looked at the use of Xpert in a point-of-care setting. One study reported that nurse-administered Xpert results had substantial agreement with those done by a laboratory technician on paired sputum specimens (κ=0·69, 95%CI 0·64, 0·74), and a similar sensitivity and proportion of unusable results. Two studies reported that most patients who were Xpert-positive were started on anti-TB treatment on the same day as specimen collection, compared with a median delay of 13–14 days for Xpert-negative patients.

In addition, the early knowledge of rifampicin resistance may influence treatment decisions, ensuring that appropriate anti-TB drugs are given immediately, thus reducing the likelihood of developing MDR-TB.

### Economic evaluation

A cost–utility analysis is presented to assess the cost-effectiveness of adding NAAT to AFB smear microscopy, and culture and sensitivity (C&S), testing in a population with clinical signs and symptoms of active TB. A summary of the structure of the mechanics of the economic model is presented in Table ES 2.

Table ES 2 Summary of the economic evaluation

|  |  |
| --- | --- |
| **Time horizon** | 20 months |
| **Outcomes** | Quality-adjusted life-years (QALYs) |
| **Costs** | Australian dollars, 2014 prices |
| **Methods used to generate results** | Decision tree analysis |
| **Discount rate** | 5% costs and outcomes accrued beyond 1 year |
| **Software packages used** | Microsoft Excel |

QALY = quality-adjusted life-year

As clinical management in Australia differs depending on the clinical suspicion (pre-test probability) of TB, the model is separated into patients with:

* a high clinical suspicion of TB, where treatment is initiated based on clinical suspicion, and the benefit of NAAT is to identify resistance mutations and initiate appropriate earlier treatment for MDR; and
* a low clinical suspicion of TB, where treatment decisions are initiated or delayed based on AFB ± NAAT results. In addition to earlier MDR treatment initiation, additional benefits of NAAT include the ability to differentiate between patients with MTB and NTM infections (who would have previously been treated on the basis of the AFB results alone), and to reduce the delay in treatment in those with true TB who returned a negative AFB result (who would not have been treated without the availability of NAAT).

Additional scenarios are presented to examine the extent to which treatment initiation decisions based on clinical suspicion affect the cost-effectiveness of NAAT.

###### Key model assumptions

* When AFB and NAAT are discordant, the treatment decision is based on NAAT (i.e. consistent with PASC protocol).
* C&S testing (the reference standard) is assumed to be 100% sensitive and specific, as all patients have C&S testing and at the end of 2 months all will have a correct diagnosis (i.e. MDR-TB, TB or no TB).
* Once the decision to initiate or delay treatment has been made, the model assumes that there will be no change in treatment until the results of C&S are available. This assumption may favour NAAT, as the earlier initiation of resistant drugs in the comparator arm would reduce the benefit of introducing NAAT.
* Cost and utility penalties associated with the secondary transmission of TB are applied for each index case in the model, but the consequences (i.e. cost or health outcome) of further ongoing transmissions (e.g. tertiary transmissions and beyond) are not included in the base-case.

The incremental cost-effectiveness of NAAT is presented, incorporating costs in a stepped manner. The base-case incremental cost-effectiveness ratio (ICER) for NAAT is $90,728/ QALY. The addition of NAAT leads to more patients initially receiving the correct treatment, due to improved sensitivity in conjunction with AFB and the ability of NAAT to identify MDR-TB. The incremental cost of NAAT is driven predominantly by the cost of testing, offset by reduced TB transmissions and hospitalisation costs. The incremental QALY gain is driven by the shift in patients from being initially untreated TB (or standard treatment in the case of MDR-TB) to receiving correct treatment.

Table ES 3 The incremental cost-effectiveness of NAAT

| Utilities considered | Costs included (NAAT cost applied in AFB + NAAT arm) | ICER |
| --- | --- | --- |
| Index patient utility | Treatment only | $188,307 |
| Index patient utility | Treatment and AEs | $188,238 |
| Index patient utility | Treatment, AEs and management | $185,882 |
| Index patient utility | Treatment, AEs, management and hospitalisation | $145,956 |
| Index patient utility | Treatment, AEs, management, hospitalisation and transmission | $103,978 |
| Index and secondary case utility | Treatment, AEs, management, hospitalisation and transmission | **$90,728** |

AEs = adverse events; ICER = incremental cost-effectiveness ratio

Sensitivity analyses for the base-case (TB mixed) scenario were conducted around a number of parameters included in the economic modelling (using 95%CI or plausible upper and lower limits). The ICER is most sensitive to changes in the prevalence of TB in the tested population (decreasing the prevalence from 22% to 10% in the tested population increases the ICER to $967,000) and the specificity of NAAT (ICERs exceeding $200,000 when the lower limit of NAAT specificity estimates are used).

#### Financial implications

A market-based approach is taken, using MBS data to estimate the number of patients who utilised at least one item of mycobacterial AFB microscopy, culture and sensitivity (MC&S) testing in 2009−13, and to project the expected number of patients who would be eligible for NAAT for TB and NTM (as requested) in 2015−19. One NAAT is assumed per eligible patient. However, as this assumption may underestimate the number of tests when multiple mycobacteria are suspected (i.e. TB may be initially suspected with a pulmonary infection, but if negative then NAAT may be used to test for *M. kansasii* and/or MAC). It is unclear how often this situation would occur—the applicant has estimated this in approximately 30% of patients initially suspected of TB.

As NAAT is not intended to replace current testing, the estimated net financial implication to the MBS is equal to the cost of the requested NAAT listings multiplied by the expected number of services. The financial implications to the MBS resulting from the proposed listings of NAAT are summarised in Table ES 4.

Table ES 4 Financial implications of proposed NAAT listings

| - | 2015 | 2016 | 2017 | 2018 | 2019 |
| --- | --- | --- | --- | --- | --- |
| Projected number of patients eligible for NAAT | 37,575 | 39,299 | 41,022 | 42,745 | 44,468 |
| *Population suspected of TB* | - | - | - | - | - |
| Proportion of patients suspected of TB | 50% | 50% | 50% | 50% | 50% |
| Number of patients suspected of TB | 18,788 | 19,650 | 20,511 | 21,373 | 22,234 |
| Proposed NAAT fee | $130.00 | $130.00 | $130.00 | $130.00 | $130.00 |
| Proportion of patients bulk-billed | 61% | 61% | 61% | 61% | 61% |
| **MBS fees associated with TB listing** | **$2,442,440** | **$2,554,500** | **$2,666,430** | **$2,778,490** | **$2,890,420** |
| MBS benefits payable (85%) | $2,076,074 | $2,171,325 | $2,266,466 | $2,361,717 | $2,456,857 |
| Patient co-payments a | $144,715 | $151,354 | $157,986 | $164,626 | $171,257 |
| *Population suspected of NTM* | - | - | - | - | - |
| Proportion of patients suspected of NTM | 50% | 50% | 50% | 50% | 50% |
| Number of patients suspected of NTM | 18,788 | 19,650 | 20,511 | 21,373 | 22,234 |
| Proportion of initial TB suspects tested | 30% | 30% | 30% | 30% | 30% |
| Number of initial TB suspects tested | 5,636 | 5,895 | 6,153 | 6,412 | 6,670 |
| Total number of patients tested for NTM | 24,424 | 25,545 | 26,664 | 27,785 | 28,904 |
| Proposed NAAT fee | $50.00 | $50.00 | $50.00 | $50.00 | $50.00 |
| Proportion of patients bulk-billed | 61% | 61% | 61% | 61% | 61% |
| **MBS fees associated with NTM listing** | **$1,221,220** | **$1,277,250** | **$1,333,215** | **$1,389,245** | **$1,445,210** |
| MBS benefits payable (85%) | $1,038,037 | $1,085,663 | $1,133,233 | $1,180,858 | $1,228,429 |
| Patient co-payments a | $72,357 | $75,677 | $78,993 | $82,313 | $85,629 |
| **MBS fees associated with NAAT listings** | **$3,663,660** | **$3,831,750** | **$3,999,645** | **$4,167,735** | **$4,335,630** |
| MBS benefits payable (85%) | $3,114,111 | $3,256,988 | $3,399,698 | $3,542,575 | $3,685,286 |
| Patient co-payments a | $217,072 | $227,031 | $236,979 | $246,938 | $256,886 |

a Only payable by patients who are not bulk-billed

NAAT = nucleic acid amplification test; NTM = non-tuberculous mycobacteria; TB = tuberculosis

The approach used may overestimate the population eligible for NAAT, as testing of patients suspected of *M. leprae* may be included (but would not be eligible for NAAT) and, as these tests are used to monitor treatment effectiveness, patients may receive testing across multiple years for the same infection. Furthermore, the current MBS items are not restricted to patients with clinical signs and symptoms of a mycobacterial infection; as testing may be ordered as part of the initial work-up of a chronic obstructive pulmonary disease or some renal diseases, this approach may further overestimate the eligible population.

Given the uncertainties in estimating the eligible population, the financial implications of introducing NAAT are uncertain. However, as NAAT is proposed to be used as an add-on test, net costs to the MBS are implied. Estimates presented in the assessment ($3.7—$4.3 million over the 5-year period) are likely to represent the upper limits of proposed use, as all assumptions regarding the eligible population are likely to be overestimated. The financial implications are most sensitive to changes in the cost per test. While benefits associated with reduced transmissions may be expected, these have not been quantified.

As NAAT is currently being used (the extent of which is uncertain), some shifting of costs from the states to the federal health budget is anticipated, and so the net societal cost of NAAT may be lower than the net costs to the MBS.

# Glossary and abbreviations

| **Abbreviation** | **Definition** |
| --- | --- |
| AE | adverse event |
| AFB | acid-fast bacilli |
| AHTA | Adelaide Health Technology Assessment |
| ARTG | Australian Register of Therapeutic Goods |
| AUC | area under the curve |
| CI | confidence interval |
| CSF | cerebrospinal fluid |
| C&S | culture and sensitivity |
| DST | drug susceptibility testing |
| FNA | fine-needle aspirate |
| HESP | Health Expert Standing Panel |
| HIV | human immunodeficiency virus |
| HTA | health technology assessment |
| ICER | incremental cost-effectiveness ratio |
| IVD | in-vitro diagnostic |
| KPS | Karnofsky performance score |
| LAMP | loop-mediated isothermal amplification |
| LR+ | positive likelihood ratio |
| LR– | negative likelihood ratio |
| MAC | *Mycobacterium avium* complex |
| MBS | Medicare Benefits Schedule |
| MDR | multidrug resistant/resistance |
| MDR-TB | multidrug-resistant tuberculosis |
| MC&S | AFB microscopy, culture and sensitivity |
| MSAC | Medical Services Advisory Committee |
| MTB | *Mycobacterium tuberculosis* |
| NAAT | nucleic acid amplification test(ing) |
| NHMRC | National Health and Medical Research Council |
| NTM | non-tuberculous mycobacteria |
| PASC | Protocol Advisory Subcommittee (of MSAC) |
| PBS | Pharmaceutical Benefits Schedule |
| PCR | polymerase chain reaction |
| QALY | quality-adjusted life-year |
| QoL | quality of life |
| RCT | randomised controlled trial |
| SR | systematic review |
| SROC | summary receiver–operator characteristic |
| TB | tuberculosis |
| TGA | Therapeutic Goods Administration |
| ZN | Ziehl-Neelsen |

# Introduction

This assessment report is intended for the Medical Services Advisory Committee (MSAC). MSAC evaluates new and existing health technologies and procedures for which funding is sought under the Medicare Benefits Schedule (MBS) in terms of their safety, effectiveness and cost-effectiveness, while taking into account other issues such as access and equity. MSAC adopts an evidence-based approach to its assessments based on reviews of the scientific literature and other information sources, including clinical expertise.

Adelaide Health Technology Assessment (AHTA), School of Population Health, University of Adelaide, was commissioned by the Australian Government Department of Health to conduct a systematic literature review and economic evaluation of the nucleic acid amplification test (NAAT) in the diagnosis of active mycobacterial infection. This evaluation has been undertaken in order to inform MSAC’s decision-making regarding public funding of NAAT.

The proposed use of NAAT for active mycobacterial infection in Australian clinical practice was outlined in a protocol that guided the evaluation undertaken by AHTA. The protocol was released for public comment in March 2014. No public consultation responses were received. The protocol was finalised as a result of PASC deliberations at a meeting on 12–13 December 2013.

#### Rationale for assessment

Douglass Hanly Moir Pathology Pty Ltd submitted an application to the Department of Health to create new MBS item(s) for NAAT to diagnose: (1) *Mycobacterium tuberculosis* (MTB) infections in persons with clinical signs and symptoms of tuberculosis (TB) or (2) non-tuberculous mycobacteria (NTM) infection in patients who have tissue biopsies with histopathology consistent with an NTM infection.

It should be noted that the NTM population eligible for NAAT has been expanded from the population specified in the protocol, in order to include all patients suspected of having an NTM infection. The expanded population base was necessary due to the the insufficient evidence-base for NTM infections as a whole. There was also value in including information on patients with specimen types other than tissue biopsies, such as HIV-positive patients presenting with *M. avium* complex (MAC) disease or patients with disseminated bacteraemia.

# Background

#### Tuberculosis

Tuberculosis (TB) is an infectious disease caused by the bacterial genus *Mycobacterium*. The majority of disease is caused by MTB-complex species (including *M. tuberculosis, M. africanum, M. bovis, M. microti, M. canettii, M. caprae, M. pinnipedii* and *M. mungi*). However, disease caused by NTM, such as *M. avium*, *M. kansasii*, *M. xenopi* and *M. malmoense,* also occurs. It is a major global health problem; in 2012 an estimated 8.6 million people developed TB and 1.3 million died from the disease, including 320,000 deaths among human immunodeficiency virus (HIV)-positive people ([WHO 2013](#_ENREF_222)). Even though Australia has a low rate of TB, with 4.7–6.5 cases per 100,000 population in 2010–12 ([Lumb et al. 2013](#_ENREF_123); [WHO 2013](#_ENREF_222)), the total number of TB cases increased by 33% between 1998 and 2008, with most new cases occurring in arrivals from countries where TB is endemic ([National Tuberculosis Advisory Committee 2012](#_ENREF_154)).

In Australia TB is a notifiable disease.National guidelines have been developed on the public health management of this disease ([CDNA 2013](#_ENREF_36)). TB continues to pose ongoing challenges due to an increasing incidence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant strains. A major concern articulated in the Australian Government TB policy is the entry into Australia of individuals infected with drug-resistant TB from Papua New Guinea via the Torres Strait ([Marais, Sorrell & Britton 2012](#_ENREF_127)).

TB is transmitted through respiratory droplets from persons with active pulmonary or laryngeal TB. In rare cases invasion of MTB may occur through mucous membranes or damaged skin. It most commonly affects the lungs but may affect almost any organ or system, including the lymph nodes, central nervous system, liver, bones, genitourinary tract, and gastrointestinal tract ([Cruz-Knight & Blake-Gumbs 2013](#_ENREF_44); [Garcia-Monco 2014](#_ENREF_71)). Extrapulmonary TB occurs in 10–42% of patients, depending on their ethnic background, age and immune status, as well as the presence or absence of underlying disease and the genotype of the MTB strain ([Zumla et al. 2013](#_ENREF_228)). Table 1 lists the clinical symptoms associated with the classic presentation of TB.

Table 1 Clinical presentations of TB

| **Site of infection** | **Clinical symptoms** |
| --- | --- |
| Pleural TB | Blood-tinged sputum producing chronic cough, pleurisy, chest pain. |
| TB lymphadenitis | Enlarged cervical or supraclavicular lymph nodes. |
| Tuberculous meningitis | Persistent or intermittent headache for 2–3 weeks; mental status changes, coma. |
| Head and neck TB | The presenting complaints can include lump in the neck, nasal obstruction, sore throat or discomfort, external nasal lesions and otitis media. |
| Skeletal TB | Clinical presentation includes localised pain associated with fever and weight loss. Spine is most common site (Pott disease). Back pain, stiffness, lower extremity paralysis (50%). |
| Tuberculous arthritis | Involves the joints. Hips and knees more commonly affected. Pain precedes radiographic changes. |
| Cutaneous TB | Lesions show a wide spectrum of morphology including tuberculous chancre, TB verrucosa cutis, lupus vulgaris, scrofuloderma, orificial TB, miliary TB, metastatic TB abscess, and most cases of papulonecrotic tuberculid. |
| Pericardial TB | Clinical features include cough, weight loss, fever, night sweats and anorexia. |
| Genitourinary TB | The kidneys are the most common site of infection causing flank pain, dysuria and frequent urination. Men may present with a painful scrotal mass, prostatitis, orchitis or epididymitis. In women the condition may mimic pelvic inflammatory disease. Causes 10% of sterility in women worldwide and 1% of women in industrialised countries. |
| Renal TB | Renal TB is usually a complication of a previous primary pulmonary infection. MTB form cortical granulomas, and on reactivation spread into the medulla, causing papillitis. Advanced disease leads to cortical scarring, and infundibular and pelvic strictures. The end result of diffuse disease is destruction, loss of function and calcification of the entire kidney. |
| Gastrointestinal TB | TB may infect any site along the gastrointestinal tract. TB can manifest as non-healing ulcers of the mouth or anus, difficulty swallowing, abdominal pain (e.g. peptic ulcer), malabsorption, painful diarrhoea or haematochezia. Can also affect the liver, spleen and pancreas. |
| Ocular TB | Ocular TB can affect nearly every ocular tissue. Clinical manifestations include vitritis, macular oedema, retinal periphlebitis, choroiditis uveitis, retinal vasculitis and serpiginous-like choroiditis. |
| TB in the breast | Breast TB is rare and can present as clinical suspicion of carcinoma due to the development of granulomas; it can also present as mastitis. At later stages it erodes through the skin, causing ulceration and discharging sinus tracts. |
| TB from joint replacement surgery | MTB prosthetic joint infection is most often caused by reactivation of prior tuberculous arthritis. |

Sources: Abbara & Davidson ([2011](#_ENREF_1)); Abes, Abes & Jamir ([2011](#_ENREF_3)); Al-Mezaine et al. ([2008](#_ENREF_7)); Al-Serhani ([2001](#_ENREF_8)); Bani-Hani et al. ([2005](#_ENREF_18)); Berbari et al. ([1998](#_ENREF_22)); Cruz-Knight & Blake-Gumbs ([2013](#_ENREF_44)); Kakkar et al. ([2000](#_ENREF_96)); Muttarak, ChiangMai & Lojanapiwat ([2005](#_ENREF_150)); Reuter et al. ([2006](#_ENREF_176))

Some people have a high risk of infection due to an increased likelihood of exposure to an infected individual ([CDNA 2013](#_ENREF_36)), such as:

* new arrivals and recently returned travellers from countries with a high TB incidence
* contacts of an active case within the past 5 years
* people living in overcrowded conditions, such as some Indigenous Australians in localised areas (e.g. Northern Territory, Queensland) or in institutions
* healthcare workers who serve or have served high-risk populations.

The fate of the mycobacteria in a newly infected individual is dependent on the person’s immune system. A healthy immune system may clear the bacterium or, alternatively, exposure can lead to latent TB or progress to primary active TB ([Cruz-Knight & Blake-Gumbs 2013](#_ENREF_44)). Most infections in humans are asymptomatic and latent, and can persist for a lifetime. In the healthy host, progression to active TB occurs in approximately 10% of those infected. For half of these patients this progression occurs within 2 years, and in the other half it can occur up to decades later ([CDNA 2013](#_ENREF_36); [Zumla et al. 2013](#_ENREF_228)). Once infected, some patients are more susceptible to progression to active TB than others ([CDNA 2013](#_ENREF_36)). These include:

* children younger than 5 years of age, adolescents and the elderly
* people who are malnourished
* people who are immunocompromised due to:
  + diseases such as HIV, diabetes and renal failure
  + immunomodulating therapies, such as corticosteroids, anti-TNF inhibitors and anti-cancer treatments.

Patients with a respiratory infection that is unresponsive to standard treatment should be suspected of having TB if they belong to one of these high-risk populations. Standardised TB treatment for an appropriate period of time will cure over 98% of drug-sensitive cases ([HKCS/BMRC 1987](#_ENREF_87)). Deaths from TB in Australia are usually due to co-morbidities or delays in diagnosis and treatment ([CDNA 2013](#_ENREF_36)). The success of treatment and the prevention of drug resistance and relapse relies heavily on the compliance of the healthcare provider in prescribing the right drug combination, dose and duration of treatment, as well as on patient adherence to treatment.

The aim of government policy is to prioritise screening of higher risk groups such as Aboriginal and Torres Strait Islander peoples and persons born overseas (including immigrants, students, healthcare workers), engage in regional TB control programs and ensure that there is a high standard of diagnosis and treatment ([National Tuberculosis Advisory Committee 2012](#_ENREF_154)).

#### Drug-resistant mycobacterial infections

MDR-TB[[2]](#footnote-2) and extensively drug-resistant TB[[3]](#footnote-3) are serious global public health problems ([Abubakar et al. 2013](#_ENREF_5)). In Australia MDR-TB occurs in 2–3% of cases and extensively drug-resistant TB is uncommon ([Lumb et al. 2013](#_ENREF_123)). Treatment of drug-resistant TB is difficult to manage, requires a long duration, requires the use of drugs that are less potent and more toxic, and may result in poor health outcomes.

Resistance to anti-TB drugs is the result of spontaneous mutations in the genome of MTB and is caused by inappropriate monotherapy and intermittent treatment with anti-TB drugs ([Abubakar et al. 2013](#_ENREF_5); [Lemos & Matos 2013](#_ENREF_117)). Resistance occurs at rates that are predictable for each drug, varying from 1 in every 102–4 bacilli for pyrazinamide to 1 in every 107–8 bacilli for rifampicin ([Lemos & Matos 2013](#_ENREF_117)).

Combination treatments can successfully prevent the emergence of resistance during the treatment of TB. Any MTB that becomes resistant to one drug can be killed by the other drug and vice versa ([Lemos & Matos 2013](#_ENREF_117); [Mitchison 2012](#_ENREF_144)).

#### Non-tuberculous mycobacterial infections

Non-tuberculous mycobacteria (NTM) are environmental mycobacteria, and do not include the MTB pathogens or *M. leprae* that causes Hansen's disease or leprosy ([Runyon 1959](#_ENREF_178)). Disease caused by NTM is not notifiable in Australia; hence, there is little information on the incidence or prevalence of NTM disease. Clinically significant pulmonary and extrapulmonary NTM cases represent approximately one-third of all NTM pulmonary isolates and two-thirds of all extrapulmonary isolates processed by laboratories in Queensland ([Thomson 2010](#_ENREF_201); [Thomson et al. 2013](#_ENREF_202)).

Table 2 lists the *Mycobacterium* species isolated in Queensland in 2005 and the proportion of pulmonary or extrapulmonary disease that was caused by each species. Of the isolates from pulmonary sites, most of the clinically significant disease was caused by *M. intracellulare*, *M. avium* and *M. kansasii*; whereas for non-pulmonary sites, most clinically significant disease was caused by *M. fortuitum*, *M. abscessus,* *M. chelonae,* *M. intracellulare*, *M. peregrinum* and *M. avium*.

Table 2 Proportion of mycobacterial isolates causing clinically significant and non-significant pulmonary and extrapulmonary disease in Queensland, 2005

| **Mycobacteria species** | **Significant pulmonary** | **Not significant pulmonary** | **Significant extrapulmonary** | **Not significant extrapulmonary** |
| --- | --- | --- | --- | --- |
| *M. intracellulare* | **16.2%** | 20.1% | **4.9%** | 3.5% |
| *M. avium* | **3.4%** | 5.7% | **4.2%** | 0.7% |
| *M. kansasii* | **2.0%** | 1.2% | – | – |
| *M. abscessus* | 1.4% | 3.4% | **6.3%** | 1.4% |
| *M. chelonae* | 0.6% | 1.8% | **5.6%** | 2.1% |
| *M. scrofulaceum* | 0.6% | 1.4% | 2.1% | 0.7% |
| *M. gordonae* | 0.4% | 3.3% | 0.7% | 1.4% |
| *M. fortuitum* | 0.2% | 3.5% | **16.1%** | 4.9% |
| *M. peregrinum* | – | 0.4% | **4.9%** | – |
| *M. ulcerans* | – | – | 2.8% | – |
| *M. haemophilum* | – | 0.2% | 0.7% | 1.4% |
| *M. smegmatis* | – | – | 0.7% |  |
| *M. szulgai* | – | – | 0.7% | – |
| *M. lentiflavum* | – | 1.0% | – | 0.7% |
| *M. asiaticum* | – | 0.6% | – | 0.7% |
| *M. simiae* | – | 0.4% | – | – |
| *M. mucogenicum* | – | 0.4% | – | 0.7% |
| *M. nonchromogenicum* | – | 0.2% | – | – |
| *M. marinum* | – | – | – | 0.7% |
| *M. asiaticum* | – | – | – | 0.7% |

Numbers in **bold** highlight the three most common pulmonary and extrapulmonary NTM species that were responsible for significant disease in 2005.

Source: Thomson ([2010](#_ENREF_201))

The incidence of pulmonary disease due to NTM has been increasing worldwide. Some of the reasons for this increase include greater awareness of NTM as pulmonary pathogens, the introduction of new technologies and improvements in existing methods, enabling better detection and more-accurate identification of NTM isolates. In addition, NTM is more prevalent in an ageing population.

NTM organisms originate from environmental sources such as food, other animals, soil or water. Pulmonary NTM infections are the most common and are usually caused by the MAC group. *M. kansasii*, *M. xenopi* and *M. malmoense* are the next most common causes, with their prevalence varying among American and European countries ([Borchardt & Rolston 2013](#_ENREF_29); [Martin-Casabona et al. 2004](#_ENREF_131)).

Skin and soft-tissue NTM infections, often originating from a cut or graze, manifest clinically as rashes, ulcers, nodules, granulomas, cellulitis or abscesses. NTM skeletal infections of bones, joints and tendons primarily occur following accidental trauma, surgery, puncture wounds or injections. These infections can be localised or multifocal, and can progress to septic arthritis, osteomyelitis and even bacteraemia. Disseminated NTM infections are almost exclusively limited to severely immunocompromised persons ([Borchardt & Rolston 2013](#_ENREF_29)).

#### Nucleic acid amplification test (NAAT) for active mycobacterial infection

###### In-house NAAT

Most in-house NAAT methods are polymerase chain reaction (PCR)-based. The PCR process amplifies DNA via a temperature-mediated DNA polymerase, using specific primers that are complementary to the ends of the targeted sequence. PCR is carried out with a series of alternating temperature steps or cycles: (1) 92–95 °C to denature the DNA so that the two strands separate, (2) a lower temperature, usually between 45 °C and 60 °C, to allow annealing of the primer sequences to the single-stranded DNA and (3) an amplification step at the optimal temperature for the DNA polymerase, usually 65 °C. PCR can be used to amplify targeted gene sequences that vary in length from 100 bases to over 20,000 bases. For the detection of DNA sequences specifically associated with MTB or NTM, the targeted sequence is usually small, around 100 bases, but may be as large as 500 bases.

A commonly occurring problem with PCR is that primers can bind to incorrect regions of the DNA, for example to a related gene from another bacterial species, resulting in unexpected non-specific products. Several modified PCR methods are used to overcome this problem.

Nested PCR involves two sets of primers used in two successive runs of PCR; the second set amplifies a secondary smaller target region within the first PCR product. Thus, the second region is only amplified if the first product was amplified from the intended target sequence and not from a non-specific sequence.

Real-time PCR is a quantitative method where the amplified product is detected as the reaction progresses. This method often uses fluorescent dyes to detect the PCR product. The number of cycles required and the quantity obtained of the product can be used to determine if the amplified product is due to the specific target. Products that require additional cycles and are slow to amplify are often non-specific.

Reverse transcription is used to detect and amplify RNA sequences using an enzyme called reverse transcriptase, which transcribes the RNA of interest into its DNA complement. Subsequently, the newly synthesised complementary DNA is amplified using traditional PCR. Reverse-transcription PCR can be combined with quantitative real-time PCR for quantification of RNA.

Multiplex PCR consists of multiple primer sets within a single PCR mixture to produce products of varying sizes that are specific to different DNA sequences. By targeting multiple genes at once, additional information may be gained from a single test run. Thus, one PCR run could be used to both identify MTB using an MTB-specific target and detect the presence of specific mutations that confer antibiotic resistance, such as the well-documented mutation in the *rpoB* gene that confers rifampicin resistance.

Loop-mediated isothermal amplification (LAMP) is an isothermal non-PCR-based amplification method in which isothermal amplification is carried out at a constant temperature. This method employs a DNA polymerase and four to six specially designed primers that recognise a total of six to eight distinct sequences on the target DNA (Figure 1a).




Figure 1 Principles of the LAMP method

(a) Primer design of the LAMP reaction (b) Starting structure producing step (c) Cycling amplification step

Source: Tomita et al. ([2008](#_ENREF_203))

LAMP is then initiated by the binding of an inner primer containing sequences of the sense and antisense strands of the target DNA. Strand displacement DNA synthesis is primed by an outer primer causing the release of a single-stranded DNA, which serves as a template for DNA synthesis that is primed by a second primer pair that hybridise to the end of the target to produce a stem–loop DNA structure (Figure 1b). In subsequent LAMP cycling, one inner primer hybridises to the loop on the product and initiates the displacement DNA synthesis (Figure 1c). This results in the accumulation of 109 copies of the target in less than an hour. LAMP is relatively new and less versatile than PCR, and the primer design is much more difficult than for PCR, requiring computer programs as it is subject to numerous constraints ([Torres et al. 2011](#_ENREF_204)). LAMP may also be combined with a reverse transcription step to allow the detection of RNA.

###### Commercial NAAT

The most widely used commercial NAAT for detection of MTB is the GeneXpert MTB/RIF assay (Xpert, Cepheid, Sunnyvale, CA, USA), which is endorsed by the World Health Organization (WHO) and has been approved by the TGA for use on patient material, regardless of the acid-fast bacilli (AFB) smear microscopy result.

The Xpert assay is a semi-quantitative, nested real-time PCR test that uses a cartridge containing all elements necessary for the reaction ([Association of Public Health Laboratories 2013](#_ENREF_12); [Lawn et al. 2013](#_ENREF_114)). The Xpert assay detects MTB and rifampicin resistance (considered to be a reliable proxy for MDR-TB) in sputum samples or concentrated sediments prepared from induced or expectorated sputa that are either AFB microscopy positive or negative. The Xpert assay system simplifies molecular testing by fully integrating and automating sample preparation, real-time PCR amplification and detection using a six-colour laser ([Association of Public Health Laboratories 2013](#_ENREF_12)).

The assay simultaneously detects MTB-complex and the genetic mutations associated with rifampicin resistance by amplifying an MTB-complex-specific 81-bp sequence from the core region of the *rpoB* gene. The assay is based on this region as it accounts for 95% of all known rifampicin-resistant mutations in MTB, and all known mutations in this region confer rifampicin resistance ([El-Hajj et al. 2001](#_ENREF_62); [Lawn et al. 2013](#_ENREF_114)). It then uses five differently coloured fluorogenic nucleic acid probes, which fluoresce only when bound to their target sequence. Each probe is highly specific and binds to a different segment of the amplified core region, as shown in Figure 2. If the amplified sequence differs from the target rifampicin-susceptible sequence by as little as a single nucleotide substitution, the probe will not bind ([El-Hajj et al. 2001](#_ENREF_62)). The assay also includes a sample-processing control probe, which will fluoresce even if the assay cannot detect any MTB in the sample, to distinguish between a true negative result and test failure ([El-Hajj et al. 2001](#_ENREF_62)).

Shows the hybridisation sites of the five Xpert fluorogenic probes. Changes in codon Ser531 and His526 (circled) account for more than 70% of the mutations in this region.

Figure 2 The 81-bp MTB-specific rifampicin-resistance determining region of the *rpoB* gene

The hybridisation sites of the five Xpert fluorogenic probes are shown. The single letter codes for the amino acids encoded by this region and the common single amino acid substitutions that confer rifampicin resistance are also shown. Changes in codon Ser531 and His526 account for more than 70% of the mutations in this region.

Sources: Adapted from Cepheid Xpert MTB/RIF brochure ([Cepheid](#_ENREF_37)), Casali et al. ([2014](#_ENREF_35)) and Rattan et al. ([1998](#_ENREF_175))

Thus, the interpretation of the Xpert NAAT results (assuming the sample-processing control probe is positive, indicating that the test has not failed) is as follows:

* negative for MTB if one or no probes are fluorescent
* positive for MTB if at least two of the five probes are fluorescent
* rifampicin-resistant MTB detected if two to four probes are fluorescent
* rifampicin-resistant MTB not detected if all five probes are fluorescent.

There are no commercially available kits for the detection of NTM listed on the Australian Register of Therapeutic Goods (ARTG). However, there are nine listed by the US Food and Drug Administration; three of these kits detect *M. avium*, one kit each detect *M. kansasii, M. gordonae, M. intracellulare*, and three kits are rapid diagnostic systems for mycobacteria[[4]](#footnote-4).

Recently, NAAT has also been used for diagnosis of TB from extrapulmonary specimens ([Lawn et al. 2013](#_ENREF_114)).

#### Intended purpose

NAAT is intended for use with specimens from untreated patients (i.e. < 3 days of anti-TB drug treatment) for whom there is a clinical suspicion of TB. As the number of bacilli reduces rapidly within days to 2 weeks after commencing appropriate TB treatment (providing the MTB is not drug resistant), MTB cannot be reliably detected in treated patients.

The applicant recommended that NAAT should only be performed in institutions proficient in the culture and identification of MTB. Transport and storage at 2–8 °C is important for this test, and samples should preferably be read within 24–48 hours (prolonged storage > 4 days has been reported to impact on results). Results can be provided to clinicians within 24–48 hours.

There are recognised guidelines for Australian mycobacteriology laboratories that specify the biosafety procedures, infrastructure, equipment and work practices required by the laboratory ([National Tuberculosis Advisory Committee 2006](#_ENREF_153)). Laboratories performing TB cultures must participate in a recognised quality assurance program.

#### Clinical need

The use of NAAT in the diagnosis and management of active TB infection is proposed to be an addition to the current clinical algorithm and does not substitute for any current test.

Both the Australian National Tuberculosis Advisory Committee ([National Tuberculosis Advisory Committee 2006](#_ENREF_153)) and the Association of Public Health Laboratories in the USA ([Association of Public Health Laboratories 2013](#_ENREF_12)) strongly recommend that all specimens received for NAAT also undergo both AFB microscopy (where possible) and culture and drug susceptibility testing (DST). This would occur regardless of the NAAT result confirming the presence or absence of MTB.

The rationale for this recommendation relates to the view that knowledge of the AFB microscopy result, in conjunction with a NAAT result, can better inform clinical decisions. For example, a NAAT-negative, AFB-positive specimen in conjunction with patient history and clinical presentation could contribute to ruling out MTB infection, and may suggest an NTM infection. Patients with HIV and pulmonary TB have a higher likelihood of being AFB microscopy negative ([de Albuquerque et al. 2014](#_ENREF_47); [Scherer et al. 2011](#_ENREF_181)), so a NAAT-positive result could be useful for managing TB in these patients.

Culturing the organism is still important, as a negative NAAT does not exclude the possibility of a positive culture. Additionally, a positive NAAT does not differentiate among the species of MTB or determine the presence of other *Mycobacterium* species ([Association of Public Health Laboratories 2013](#_ENREF_12)).

As the Xpert assay only determines the presence or absence of rifampicin resistance, all MTB isolates should receive additional DST using culture-based methods to determine the susceptibility patterns of other first- and second-line drugs used to treat TB ([Association of Public Health Laboratories 2013](#_ENREF_12)).

The applicant has proposed that patient outcomes will differ according to the pre-test probability of a patient having TB. Given the public health implications of active pulmonary TB, patients with a high pre-test probability of having TB (approximately 20% of those tested, of whom 50–70% will actually have TB) commence antibiotic treatment immediately. Of the remaining 80% of patients with a low pre-test probability of having TB and in whom treatment is delayed until culture results are available, only 5–10% will actually have TB. In this population the applicant has suggested that the use of NAAT is non-inferior to current practice.

When rifampicin-resistant MTB is detected by NAAT in patients who have already started treatment, clinicians are provided with information on whether the patient’s treatment is likely to be effective within a few days, and this can lead to a change in case management. There are theoretical public health benefits associated with reducing the infectiousness of the patient earlier. Currently, a change in the antibiotic regimen would be due to ongoing AFB tests (where they can be collected), indicating that a patient is either not responding to treatment or is waiting for the result of the culture and DST in 6–8 weeks. In this situation the applicant has suggested that the use of NAAT may be superior to current practice.

For patients whose pre-test probability of TB is low, the applicant has suggested that positive NAAT results would result in immediate treatment that would not normally have been indicated, given the patient’s TB risk assessment.

In patients suspected of having an NTM infection, NAAT is expected to be an additional test to those currently performed to diagnose NTM.

#### Existing tests for diagnosing *Mycobacterium* species

NAAT for mycobacteria is currently not listed on the MBS. However, some Australian diagnostic laboratories, such as Alfred Health[[5]](#footnote-5) and PathWest Pathology Services[[6]](#footnote-6), offer in-house NAAT (MTB PCR) for screening specimens from patients with suspected TB.

Currently, most testing for MTB occurs using both AFB smear microscopy and culture tests. Although they are two separate tests, they are usually performed at the same time using the same specimen. The results for these two tests are delivered at different times; AFB microscopy results are reported within 24–48 hours, whereas culture results are reported at 6–8 weeks.

AFB smear microscopy involves spreading a suitable specimen thinly onto a glass slide, treating it with an acid-fast stain (Ziehl-Neelsen (ZN), Kinyoun stain or auramine-rhodamine stain) and examining the stained slide under a microscope ([Lab Tests Online 2012](#_ENREF_110)). Results are typically available between several hours and 1 day after a sample is collected. AFB microscopy is ordered when:

* the patient has symptoms that suggest pulmonary or extrapulmonary TB
* the patient has a positive TB screening test and is at increased risk for active disease and/or has characteristic lung involvement as shown by X-ray
* an individual has been in close contact with a person who has been diagnosed with TB and has either symptoms or a condition that increases their risk of contracting the disease
* for monitoring purposes during treatment for TB
* an immunosuppressed patient is systemically unwell and they are screened for unusual infections such as mycobacteria and fungi.

Cultures are used to diagnose active MTB and NTB infections, to help determine whether the TB is confined to the lungs or has spread to other organs, to monitor the effectiveness of treatment, and to help determine when a patient is no longer infectious ([Lab Tests Online 2012](#_ENREF_110)). Traditionally, cultures have used semi-solid agar-based media and require 4–8 weeks for sufficient growth to obtain a diagnosis. However, newer liquid culture systems are approximately 10% more sensitive for detection of mycobacteria than semi-solid media, and can obtain results in days rather than weeks ([WHO 2007](#_ENREF_219)). One drawback is that liquid culture is more prone to contamination with other microorganisms ([WHO 2007](#_ENREF_219)).

DST is usually conducted in conjunction with a culture to determine the most effective antibiotics to treat the infection. The mycobacteria are grown in the presence of anti-TB drugs, either in liquid or semi-solid media, and compared with growth when the drug is absent. If growth of the MTB is detected in the presence of the anti-TB drug, it indicates drug resistance ([TBFacts.org](#_ENREF_194)). Liquid culture systems can reduce the delay for results to as little as 10 days instead of several weeks ([WHO 2007](#_ENREF_219)).

#### Marketing status of device

NAAT for the detection of mycobacteria may be an in-house assay or a commercial kit. In December 2010 the WHO endorsed the Xpert assay for the rapid and accurate detection of MTB and rifampicin-resistant MTB. This test was approved by the TGA in April 2013 and by the U.S. Food and Drug Administration in July 2013.

Summary of TGA approval[[7]](#footnote-7) for the IVD Class 3 GeneXpert MTB/RIF assay:

ARTG entry number: 207732

Sponsor: Cepheid Holdings Pty Ltd

Intended purpose: The GeneXpert MTB/RIF assay for use with the Cepheid GeneXpert system is a semi-quantitative, nested real-time PCR in-vitro diagnostic (IVD) test for the detection of:

* MTB-complex DNA in sputum samples or concentrated sediments prepared from induced or expectorated sputa that are either AFB smear positive or negative
* rifampicin-resistance associated mutations of the *rpoB* gene in samples from patients at risk for rifampicin resistance

The GeneXpert MTB/RIF assay is intended for use with specimens from untreated patients for whom there is clinical suspicion of TB.

No other commercially available NAATs for the detection of MTB and/or NTM are approved by the TGA.

An in-house NAAT for the detection of MTB is classified as a Class 3 IVD medical device by the TGA. IVDs are pathology tests and related instrumentation used to carry out testing on human samples, where the results are intended to assist in clinical diagnosis or in making decisions concerning clinical management. From 1 July 2014 all IVDs must comply with a set of essential principles for their quality, safety and performance. Laboratories that manufacture Classes 1–3 in-house IVD medical devices must comply with the requirements of Part 6A, Schedule 3, of the Regulations ([Therapeutic Goods Administration 2011](#_ENREF_196)).

To meet these requirements the laboratory must be accredited as a medical testing laboratory by either the National Association of Testing Authorities or a conformity assessment body determined suitable by the TGA, and meet the National Pathology Accreditation Advisory Council ([National Pathology Accreditation Advisory Council 2014](#_ENREF_152)) performance standard requirements for the development and use of in-house IVDs (Therapeutic Goods Administration 2012). The Guidelines for Australian mycobacteriology laboratories ([National Tuberculosis Advisory Committee 2006](#_ENREF_153)) also state that these requirements must be met.

#### Current reimbursement arrangements

Treatment for TB is provided free of charge to patients in Australia. Testing to confirm active mycobacterial infection is only covered if the patient is a public patient in a public hospital or if the test performed is listed on the MBS. Standard microbial testing for TB in people with signs and symptoms of active disease in Australia involves AFB microscopy and culture of suitable specimens, and these tests are listed on the MBS (Table 3).

Table 3 Current MBS item descriptors for diagnosing active mycobacterial infections

|  |
| --- |
| **Category 6 – PATHOLOGY SERVICES** |
| **69324**  Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of sputum, urine, or other body fluid or 1 operative or biopsy specimen, including (if performed):  (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or  (b) pathogen identification and antibiotic susceptibility testing;  including a service mentioned in item 69300  **Fee:** $43.00 **Benefit:** 75% = $32.25 85% = $36.55 |
| **69325**  A test described in item 69324 if rendered by a receiving approved pathology practitioner  (Item is subject to rule 18)  **Fee:** $43.00 **Benefit:** 75% = $32.25 85% = $36.55 |
| **69327**  Microscopy (with appropriate stains) and culture for mycobacteria - 2 specimens of sputum, urine, or other body fluid or 2 operative or biopsy specimens, including (if performed):  (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or  (b) pathogen identification and antibiotic susceptibility testing;  including a service mentioned in item 69300  **Fee:** $85.00 **Benefit:** 75% = $63.75 85% = $72.25 |
| **69328**  A test described in item 69327 if rendered by a receiving approved pathology practitioner  (Item is subject to rule 18)  **Fee:** $85.00 **Benefit:** 75% = $63.75 85% = $72.25 |
| **69330**  Microscopy (with appropriate stains) and culture for mycobacteria - 3 specimens of sputum, urine, or other body fluid or 3 operative or biopsy specimens, including (if performed):  (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or  (b) pathogen identification and antibiotic susceptibility testing;  including a service mentioned in item 69300  **Fee:** $128.00 **Benefit:** 75% = $96.00 85% = $108.80 |
| **69331**  A test described in item 69330 if rendered by a receiving approved pathology practitioner  (Item is subject to rule 18)  **Fee:** $128.00 **Benefit:** 75% = $96.00 85% = $108.80 |

Source: MBS Online. Available from URL: <http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Downloads-201407> (accessed 16 June 2014)

#### Proposal for public funding

The application did not provide a proposed MBS item descriptor.

Patients with signs and symptoms of active MTB, and patients suspected of having an NTM infection, are two different populations that require different NAATs and different MBS item descriptors. Suggested MBS item descriptors are listed in Table 4.

Table 4 Suggested MBS item descriptors

| **Category 6 – PATHOLOGY SERVICES** |
| --- |
| MBS item number  Nucleic acid amplification test for the detection of *Mycobacterium tuberculosis* complex in patients with signs and symptoms consistent with active tuberculosis.  **Fee:** To be advised |
| MBS item number  Nucleic acid amplification test for the detection of non-tuberculous mycobacteria species in patients with a compatible clinical disease.  **Fee:** To be advised |

NAAT to diagnose MTB infections should be conducted on both AFB microscopy positive and negative specimens and on all pulmonary and extrapulmonary specimen types.

NAAT to diagnose NTM infections should be able to detect the most common NTM species associated with pulmonary and extrapulmonary disease, as determined by the state Mycobacterium Reference Laboratories.

NAAT to diagnose NTM infections is intended to be conducted in tissues with granulomatous change in both AFB-positive and -negative specimens, where MTB is not a consideration or has been excluded by an MTB-specific NAAT.

***PASC advice is that there should be no limit on the number of tests per year per patient in the MBS item descriptor.***

There are a number of NAATs currently listed on the MBS. These range from detection of microbial nucleic acid (item 69494), with a Medicare fee of $28.85, to the amplification and determination of hepatitis C virus genotype (item 69491), with a Medicare fee of $206.20. The application reports that the New South Wales state reference laboratory charges $200 for TB PCR, which is billed to the patient. During the assessment NAAT costs in Australia were found to vary substantially, from $28.65 to $130 or perhaps more if confirmation testing is required. The Victorian reference laboratory[[8]](#footnote-8) indicated that an in-house NAAT costs $82 and the commercial Xpert kit $130. In this instance the costs are met primarily through the Victorian State Government (only private patients and non-Australian residents are billed for testing).

#### Consumer impact statement

No consumer responses were received during the public consultation period.

# Approach to assessment

## Objective

To determine whether there is sufficient evidence, in relation to safety, effectiveness and cost-effectiveness, to have NAAT listed on the MBS for the diagnosis of MTB in patients with the signs and symptoms of active TB, and NTM in patients suspected of having an NTM infection.

A systematic review (SR) of published medical literature was undertaken. Searches to identify relevant studies and reviews for the period between 1990 and June 2014 were conducted for the Cochrane Library, Current Contents, Embase, PubMed, Web of Science, Cinahl, Econlit and Scopus databases, as well as Australian and international health technology assessment (HTA) websites.

## Clinical pathway

The clinical management algorithms for patients with the signs and symptoms of active TB are shown in Figure 3 and Figure 4. The pathways underwent public consultation and incorporated both expert opinion and guidance from the Centers for Disease Control[[9]](#footnote-9). There is a view by experts that the major factor in the current clinical management of a patient with the signs and symptoms of active TB is the patient’s pre-test probability of having TB.

Figure 3 presents current and proposed clinical management algorithms for patients with the clinical signs and symptoms of active TB and for whom AFB microscopy can be done; that is, the patient can provide a sample for testing. This includes samples such as sputum, bronchoalveolar lavage, bronchial aspirates, gastric aspirates and stool for the diagnosis of pulmonary TB; and samples such as cerebrospinal fluid (CSF), urine, lymph node fine-needle aspirates (FNAs) or any other body fluid or tissue sample for the diagnosis of extrapulmonary TB. Currently, clinicians rely on the results of AFB microscopy, as well as whether the patient has a high or low pre-test probability that they will have active TB, as the basis to initiate or defer antibiotic treatment. NAAT is suggested as an adjunctive test that would be performed concurrently with AFB microscopy and culture.

Figure 4 presents current and proposed clinical management algorithms for patients who present with the clinical signs and symptoms of active TB and from whom it is not possible to obtain a specimen suitable for AFB microscopy. The only patients that could be identified to fit this profile were those for whom it was not possible to obtain a sample for any purpose. Due to the lack of a sample, the effectiveness of NAAT is not assessible in these patients. Thus, this algorithm could not be addressed in the assessment and will not be discussed further.

Figure 5 presents current and proposed clinical management algorithms for patients who are suspected of having an NTM infection. It should be noted that the NTM population eligible for NAAT has been expanded from the population specified in the protocol, in order to include patients presenting with specimens other than tissue biopsies, such as sputum specimens to be tested for MAC disease or blood samples for disseminated NTM. It should also be noted that histology is not able to differentiate between MTB and NTM infections and it is assumed that culture will also be performed. The expanded population base was necessary due to the insufficient evidence-base for NTM infections as a whole. The proposed use of NAAT will substitute for current testing.

For the current pathway: the specimen is collected and undergoes AFB smear microscopy, culture and DST. If histology indicative of MTB the patient starts treatment, if not the decision to commence or defer treatment is based on clinical judgement (pre-test probability and specimen diagnostic yield). Treatment is reviewed when culture and DST results become available. 
For the proposed pathway: the specimen is collected and undergoes AFB smear microscopy, NAAT, culture and DST. If NAAT is MTB-positive the patient starts treatment, if NAAT is MTB-negative, the decision to commence or defer treatment is based on clinical judgement (pre-test probability, AFB microscopy result and specimen diagnostic yield). Treatment is reviewed when culture and DST results become available.


Figure 3 Current clinical management of TB and proposed use of NAAT for active TB where AFB is obtained

AFB = acid-fast bacilli; DST = drug susceptibility testing; MTB = *Mycobacterium tuberculosis*; NAAT = nucleic acid amplification testing; TB = tuberculosis

The current and proposed clinical management pathways for the diagnosis of active TB where AFB microscopy is not able to be obtained are similar to that in figure 2 except instead of AFB microscopy result, the histopathology of the specimen is considered in the treatment decision. No patient populations were identified to fit this pathway.

Figure 4 Current clinical management and proposed algorithm with use of NAAT for active TB where AFB microscopy is not able to be obtained

AFB = acid-fast bacilli; DST = drug susceptibility testing; MTB = *Mycobacterium tuberculosis*; NAAT = nucleic acid amplification testing; TB = tuberculosis

For the current pathway: the specimen is collected and undergoes histopathology, AFB smear microscopy, culture and DST. If histology indicative of an NTM infection the patient starts treatment, if not treatment is deferred until the culture and DST results become available. 
For the proposed pathway: the specimen is collected and undergoes AFB smear microscopy, NAAT, culture and DST. If NAAT is NTM-positive the patient starts treatment, if NAAT is NTM-negative treatment is deferred until the culture and DST results become available.

Figure 5 Current clinical management algorithm and proposed algorithm with use of NAAT for patients who are suspected of having an NTM infection

AFB = acid-fast bacilli; DST = drug susceptibility testing; MTB = *Mycobacterium tuberculosis*; NAAT = nucleic acid amplification testing

## Comparator

Patients with the clinical signs and symptoms of active TB will receive NAAT in addition to AFB microscopy. Standard microbial testing in Australia for TB, in people with signs and symptoms of active disease, involves AFB microscopy and culture of suitable specimens. As both the intervention and comparator groups receive AFB testing, the main comparator for NAAT is culture alone.

The patient population suspected of having an NTM infection receive NAAT in addition to culture, and this may replace further testing such as additional biopsies. Therefore, the appropriate comparator in the identified population is current testing without NAAT.

## The reference standard

The accuracy of NAAT at determining the presence of MTB or NTM in a specimen will be determined using culture as the reference standard. The diagnostic accuracy of NAAT in determining the presence of rifampicin-resistant MTB in a specimen will also be determined using DST as the reference standard.

It is important to note that culture is an imperfect reference standard for the diagnosis of MTB and NTM. Not all patients who are clinically diagnosed as having TB or NTM infections (on the basis of histopathology, symptoms and response to drug therapy, as well as culture) will have received a positive culture result.

## Research questions

Outlined below are the clinical questions formulated according to the information provided in the protocol, which was revised and accepted by the Protocol Advisory Subcommittee (PASC) of the MSAC.

#### Research questions:

* What are the safety, effectiveness, and cost-effectiveness of NAAT versus NAAT plus AFB microscopy in diagnosing TB in patients who have signs and symptoms of TB?
* What are the safety, effectiveness, and cost-effectiveness of NAAT versus current testing in diagnosing NTM in patients suspected of having an NTM infection?

#### Subquestions (for a linked evidence approach):

Accuracy

* What is the accuracy of NAAT in the diagnosis of patients with suspected MTB, compared with AFB microscopy and culture?
* What is the accuracy of NAAT plus AFB microscopy in the diagnosis of patients with suspected MTB, compared with AFB microscopy alone?
* What is the accuracy of in-house NAAT compared with commercial NAAT in the diagnosis of patients with suspected MTB, using culture as the reference standard?
* What is the accuracy of NAAT in the detection of genetic mutations on the *rpoB* gene that are associated with rifampicin resistance?
* What is the accuracy of NAAT in the diagnosis of NTM in patients suspected of having an NTM infection, compared with culture?

Change in management

* Does AFB microscopy plus NAAT to determine the presence of MTB and rifampicin resistance change patient management, compared with management decisions made based on AFB microscopy alone, in patients with a high pre-test probability of active TB?
* Does AFB microscopy plus NAAT to determine the presence of MTB and rifampicin resistance change patient management, compared with management decisions made based on AFB microscopy alone, in patients with a low-pre-test probability of TB?
* Does NAAT plus culture change patient management, compared with culture plus other tests, in patients suspected of having an NTM infection?

Effectiveness of change in management

* To what extent does treating patients who have rifampicin-resistant MTB infections with alternative treatments result in better health outcomes for the patient and their contacts?
* What is the health impact of early versus delayed treatment of TB on the individual and their contacts?
* What adverse events (AEs) are associated with inappropriate antibiotic treatment for TB?

## Diagnostic assessment framework

This assessment uses the theoretical framework outlined in the MSAC *Guidelines for the assessment of diagnostic technologies* ([MSAC 2005](#_ENREF_148)).

This means that evidence of the clinical effectiveness of diagnosing MTB or NTB using NAAT requires either:

* evidence of the effectiveness of NAAT from high-quality comparative studies evaluating the use of NAAT and subsequent treatment, compared with culture plus DST and treatment (direct evidence). RCTs provide the highest quality evidence for this comparison; or, if this is not available:
* evidence of treatment effectiveness from high-quality comparative studies evaluating the change in management for TB, linked with applicable and high-quality evidence of the accuracy of NAAT to diagnose MTB or NTM, compared with culture plus DST. This is called ‘linked evidence’.

There was limited direct evidence available that met all the inclusion criteria that assessed the safety and effectiveness of NAAT in the diagnosis of MTB or NTB infections.

## Review of literature

#### Literature sources and search strategies

The medical literature was searched to identify relevant studies and reviews for the period between 1990 and June 2014. Searches were conducted for the databases described in Table 5. Search terms are described in Table 6 to Table 10.

Due to the large volume of evidence for the diagnostic accuracy of NAAT compared with culture, only studies published after 2005 that provided 2x2 data suitable for meta-analysis for both AFB microscopy and NAAT compared with culture, were included in the final analysis. Studies on the only commercial NAAT product (Xpert) available in Australia were published in 2006 onwards. In-house NAAT, on the other hand, was available before 2005. However, as there have been significant changes in laboratory practice over the past 10 years ([Boyle & Pai 2012](#_ENREF_31); [Moore, Guzman & Mikhail 2005](#_ENREF_146); [Nybo 2012](#_ENREF_161); [Public Health and Ambulatory Care 2012](#_ENREF_171)), it seemed reasonable to limit study eligibility to publications in the previous decade.

The diagnostic accuracy of in-house NAAT performed more than 10 years ago compared with culture was reported in two SRs. Pai et al. ([2004](#_ENREF_164)) reported that the pooled sensitivity in pleural fluid specimens was 71% (95%CI 63, 76; k=26), and Pai et al. ([2003](#_ENREF_165)) reported that the pooled sensitivity in CSF specimens was 76% (95%CI 57, 83; k=35). These values are much lower than that reported in this assessment for non-sputum specimens (90%; 95%CI 83, 94, k=44; see Figure 15). Thus, the inclusion of only those studies published after 2005 in the final analysis provided more-accurate data on the accuracy of NAAT as currently performed in the diagnostic laboratory.

An SR by Takwoingi et al. ([2013](#_ENREF_192)) showed that there was a > 2-fold discrepancy in the relative diagnostic odds ratio between non-comparative studies (that compared either the index test or the comparator with the reference standard) and comparative studies (that compared both the index test and the comparator with the reference standard). Thus, these studies provide the highest quality evidence available to assess the accuracy of NAAT and AFB microscopy compared with culture to diagnose MTB infections.

Table 5 Electronic databases searched

| Electronic database | Period covered |
| --- | --- |
| Cochrane Library – including, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, the Cochrane Central Register of Controlled Trials (CENTRAL), the Health Technology Assessment Database, the NHS Economic Evaluation Database | 1990 – 6/2014 |
| Current Contents | 1990 – 6/2014 |
| Embase | 1990 – 6/2014 |
| PubMed | 1990 – 6/2014 |
| Web of Science – including Science Citation Index Expanded and Conference Proceedings Citation Index- Science | 1990 – 6/2014 |
| Cinahl | 1990 – 6/2014 |
| Econlit | 1990 – 6/2014 |
| Scopus | 1990 – 6/2014 |

Table 6 Search terms used for NAAT for MTB (direct evidence, accuracy and change in management)

| Element of clinical question | Search terms |
| --- | --- |
| Population | (tuberculosis OR MTB OR MTB/RIF OR “tubercle bacillus” OR Tuberculosis [MeSH] OR Mycobacterium OR “M. africanum” OR “M. bovis” OR “M. microti” OR “M. canettii” OR “M. caprae” OR “M. pinnipedii” OR “M. mungi”) |
| Intervention | (Amplicor OR Amplified OR “Direct Test” OR “Direct Detection” OR TaqMan OR Xpert OR “nucleic acid amplification” OR NAAT OR “polymerase chain reaction” OR PCR OR “Nucleic Acid Amplification Techniques” [MeSH]) |
| Comparator (if applicable) | N/A |
| Outcomes (if applicable) | N/A |
| Limits | 1990 – June 2014; NOT (Other Animals NOT Humans) |

MeSH = Medical Subject Heading, based on a Medline/PubMed platform; N/A = not applicable

Table 7 Search terms used for NAAT for NTM (direct evidence, accuracy and change in management)

| **Element of clinical question** | **Search terms** |
| --- | --- |
| Population | (“mycobacterium nontuberculous” OR “Mycobacterium Infections, Nontuberculous” [MeSH] OR “environmental mycobacteria” OR “mycobacteria other than tuberculosis” OR MOTT OR NTM OR NTMB OR “M. abscessus” OR “M avium” OR “M. chelonae” OR “M. flavescens” OR “M. fortuitum” OR “M. genavense” OR “M. gordonae” OR “M. haemophilum” OR “M. intracellulare” OR “M. kansasii” OR “M. malmoense” OR “M. marinum” OR “M. peregrinum” OR “M. scrofulaceum” OR “M. simiae” OR “M. smegmatis” OR “M. szulgai” OR “M. terrae” OR “M. ulcerans” OR “M. xenopi”) |
| Intervention | (Amplicor OR Amplified OR “Direct Test” OR “Direct Detection” OR Xpert OR TaqMan OR “nucleic acid amplification” OR NAAT OR “polymerase chain reaction” OR PCR OR “Nucleic Acid Amplification Techniques” [MeSH]) |
| Comparator (if applicable) | N/A |
| Outcomes (if applicable) | N/A |
| Limits | 1990 – June 2014; NOT (Other Animals NOT Humans) |

MeSH = Medical Subject Heading, based on a Medline/PubMed platform; N/A = not applicable

Table 8 Search terms used for impact of early identification of drug resistance and alternative treatment

| **Element of clinical question** | **Search terms** |
| --- | --- |
| Population | (tuberculosis OR MTB OR MTB/RIF OR “tubercle bacillus” OR Tuberculosis [MeSH] OR Mycobacterium OR “M. africanum” OR “M. bovis” OR “M. microti” OR “M. canettii” OR “M. caprae” OR “M. pinnipedii” OR “M. mungi”) AND (“rpoB protein, Mycobacterium tuberculosis” [Supplementary Concept] OR rpoB OR resistant OR resistance OR “multidrug resistant” OR MDR OR “Drug resistance, Bacterial” [MeSH]) |
| Intervention | N/A |
| Comparator (if applicable) | (Rifampin [MeSH] OR rifampicin OR benemycin OR rimactan OR tubacin OR rifadin OR rimactane OR isoniazid) |
| Outcomes (if applicable) | (infectious OR contagious OR contacts OR delay OR “excess morbidity” OR “excess mortality” OR public health OR outbreak) |
| Limits | 1990 – June 2014; NOT (Other Animals NOT Humans) |

MeSH = Medical Subject Heading, based on a Medline/PubMed platform; N/A = not applicable

Table 9 Search terms used for impact of early versus delayed treatment for TB

| **Element of clinical question** | **Search terms** |
| --- | --- |
| Population | (tuberculosis OR MTB OR MTB/RIF OR “tubercle bacillus” OR Tuberculosis [MeSH] OR Mycobacterium OR “M. africanum” OR “M. bovis” OR “M. microti” OR “M. canettii” OR “M. caprae” OR “M. pinnipedii” OR “M. mungi”) |
| Intervention and comparator | (early OR delayed OR delay OR immediate OR timely OR speed OR expedited) AND (antibiotics OR drug OR treatment OR isoniazid OR rifampicin OR rifampin OR ethambutol OR myambutol OR pyrazinamide) |
| Outcomes (if applicable) | N/A |
| Limits | 1990 – June 2014; NOT (Other Animals NOT Humans) |

MeSH = Medical Subject Heading, based on a Medline/PubMed platform; N/A = not applicable

Table 10 Search terms used for impact of inappropriate antibiotic use

| **Element of clinical question** | **Search terms** |
| --- | --- |
| Population | (tuberculosis OR MTB OR MTB/RIF OR “tubercle bacillus” OR Tuberculosis [MeSH] OR Mycobacterium OR “M. africanum” OR “M. bovis” OR “M. microti” OR “M. canettii” OR “M. caprae” OR “M. pinnipedii” OR “M. mungi”) |
| Intervention | (antibiotics OR drug OR treatment OR isoniazid OR rifampicin OR rifampin OR ethambutol OR myambutol OR pyrazinamide) |
| Outcomes (if applicable) | (“adverse events” OR side-effects OR reaction\* OR “Drug-Related Side Effects and Adverse Reactions”[MeSH]) |
| Study type | “systematic review” OR “meta-analysis” |
| Limits | 1990 – June 2014; NOT (Other Animals NOT Humans) |

MeSH = Medical Subject Heading, based on a Medline/PubMed platform; N/A = not applicable

#### Selection criteria

In general, studies were excluded if they:

* did not address the research question;
* focused on latent TB (as NAAT for latent TB has already been assessed);
* did not provide information on the pre-specified target population (i.e. were focused on mycobacteria that cause Hansen’s disease (leprosy);
* did not address one of the pre-specified outcomes and/or provided inadequate data on these outcomes;
* were in a language other than English and were of a lower level of evidence than the included studies; or
* did not have an appropriate study design.

If the same data were duplicated in multiple articles, only results from the most comprehensive or most recent article were included.

Specified *a priori* patient subgroups of particular interest in the analysis included patients with high and low pre-test probabilities of having TB and patients with HIV.

#### Search results

The PRISMA flowcharts are shown in Figure 6, Figure 7, Figure 8, Figure 9 and Figure 10. These outline the study selection process and number of papers considered at each stage of the SR ([Liberati et al. 2009](#_ENREF_118)).

#### PRISMA flowcharts Source: [Liberati et al.](#_ENREF_80) ([2009](#_ENREF_118))

33,678 potential relevant studies were identified in the literature search, 3,684 of which were retrieved for more detailed evaluation. Of 1,240 potentially appropriate studies to be included in the systematic review, 1,146 were excluded with reasons such as incorrect PICO criteria, incorrect study design, unable to extract data, or could not retrieve article on time. In total 95 studies were included, 2 provided direct evidence, 17 reporting on change in management, and 79 on diagnostic accuracy.

Figure 6 Summary of the process used to identify and select studies investigating the use of NAAT to diagnose MTB (direct evidence, accuracy and change in management)

a Pre-2005 DA studies were not further evaluated for inclusion (see ‘Literature sources and search strategies’)

9,099 potential relevant studies were identified in the literature search, 320 of which were retrieved for more detailed evaluation. Of these, 308 were excluded with reasons such as incorrect PICO criteria, incorrect study design, unable to extract data, or could not retrieve article on time. In total 12 studies were included that reported on diagnostic accuracy of NAAT in detecting NTM infections.

Figure 7 Summary of the process used to identify and select studies investigating the use of NAAT to diagnose NTM (direct evidence, accuracy and change in management)

6,744 potential relevant studies were identified in the literature search, 280 of which were retrieved for more detailed evaluation. Of 31 potentially appropriate studies to be included in the systematic review, 28 were excluded with reasons such as incorrect PICO criteria, incorrect study design, unable to extract data, or could not retrieve article on time. In total 3 studies were included.

Figure 8 Summary of the process used to identify and select studies for the impact of early identification of drug resistance and alternative treatment

7,362 potential relevant studies were identified in the literature search, 663 of which were retrieved for more detailed evaluation. Of 25 potentially appropriate studies to be included in the systematic review, 22 were excluded with reasons such as incorrect PICO criteria, incorrect study design, unable to extract data, or could not retrieve article on time. In total 3 studies were included.

Figure 9 Summary of the process used to identify and select studies for the impact of early versus delayed treatment for TB

2,407 potential relevant studies were identified in the literature search, 76 of which were retrieved for more detailed evaluation. Of 10 potentially appropriate studies to be included in the systematic review, 7 were excluded because either higher level evidence was available or could not retrieve article on time. In total 3 studies were included.

Figure 10 Summary of the process used to identify and select studies for the impact of inappropriate antibiotic use

#### Data extraction and analysis

A profile of key characteristics was developed for each included study (see Appendix F). Each study profile provides the level of evidence, design and quality of the study, authors, publication year, location, criteria for including/excluding patients, study population characteristics, type of intervention, comparator intervention and/or reference standard (where relevant), and outcomes assessed. Studies that could not be retrieved or that met the inclusion criteria but contained insufficient or inadequate data for inclusion are listed in Appendix G. Definitions of all technical terms and abbreviations are provided in the Glossary (page 31). Descriptive statistics were extracted or calculated for all safety and effectiveness outcomes in the individual studies.

#### Assessing diagnostic accuracy

To assess the diagnostic accuracy of NAAT, studies were only included if they provided data that could be extracted into a classic 2×2 table (Table 11), in which the results of the index diagnostic test or the comparator were cross-classified against the results of the reference standard ([Armitage, Berry & Matthews 2002](#_ENREF_11); [Deeks 2001](#_ENREF_49)), and Bayes’ Theorem was applied:

Table 11 Diagnostic accuracy data extraction for NAAT

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| - | - | **Reference standard** | (culture ± DST)**-** | - |
| - | - | *Disease +* | *Disease –* | - |
| **Index test (NAAT)** | *Test +* | true positive | false positive | Total test positive |
| Or comparator (AFB) | *Test –* | false negative | true negative | Total test negative |
| - | - | Total with MTB or NTM | Total without MTB or NTM | - |

AFB = acid-fast bacilli; DST = drug susceptibility testing; MTB = *Mycobacterium tuberculosis*; NAAT = nucleic acid amplification testing; NTM = non-tuberculous mycobacteria

##### Primary measures

Test sensitivity was calculated as the proportion of people with MTB or NTM infections (as determined by the reference standard) who had a positive test result using AFB and/or NAAT:

Sensitivity (true positive rate) = number with true positive result / total with MTB or NTM infections

Test specificity was calculated as the proportion of people without infection (as determined by reference standard) who had a normal test result using AFB and/or NAAT:

Specificity (true negative rate) = number with true negative result / total without MTB or NTM infections

The 95%CI was calculated by exact binomial methods.

Positive and negative likelihood ratios (LR+ and LR–) were also reported. These ratios measure the probability of the test result in patients with MTB or NTM infections compared with those without.

LR+ = sensitivity / 1 – specificity

LR– = 1 – sensitivity / specificity

An LR of 1 means that the test does not provide any useful diagnostic information, whereas LR+ > 5 and LR– < 0.2 can suggest strong diagnostic ability ([MSAC 2005](#_ENREF_148)).

##### Summary measures

Diagnostic test accuracy meta-analysis was undertaken to assess the accuracy of NAAT compared with AFB microscopy in the diagnosis of MTB or NTM infections, compared with culture, using Stata version 12 ([Stata Corporation 2013](#_ENREF_188)). Only studies that provided raw (2×2) data were included. Summary receiver–operator characteristic (SROC) curves, forest plots and LR scattergrams were generated using the ‘midas’ command in Stata, which requires a minimum of four studies for analysis and calculates summary operating sensitivity and specificity (with confidence and prediction contours in SROC space). Heterogeneity was calculated using the formula I2 = 100% x (Q – df)/Q, where Q is Cochran's heterogeneity statistic and df is the degrees of freedom ([Higgins et al. 2003](#_ENREF_85)). Summary estimates for sensitivity, specificity, LR+ and LR– were also calculated. Confidence intervals were computed assuming asymptotic normality after a log transformation for variance parameters and for LR+ and LR–.

Subgroup analyses were performed for results according to specimen type, incidence of TB in the study population and the presence of an HIV infection.

Where meta-analysis could not be performed, the median (range) sensitivity and specificity values were calculated.

#### Appraisal of the evidence

Appraisal of the evidence was conducted in three stages:

Stage 1: Appraisal of the applicability and quality of individual studies included in the review (strength of the evidence).

Stage 2: Appraisal of the precision, size of effect and clinical importance of the results for primary outcomes in individual studies—used to determine the safety and effectiveness of the intervention.

Stage 3: Integration of this evidence for conclusions about the net clinical benefit of the intervention in the context of Australian clinical practice.

#### Stage 1: strength of the evidence

The evidence presented in the selected studies was assessed and classified using the dimensions of evidence defined by the National Health and Medical Research Council ([NHMRC 2000](#_ENREF_156)).

These dimensions (Table 12) consider important aspects of the evidence supporting a particular intervention and include three main domains: strength of the evidence, size of the effect and relevance of the evidence. The first domain is derived directly from the literature identified as informing a particular intervention; the last two each require expert clinical input as part of its determination.

Table 12 Evidence dimensions

|  |  |
| --- | --- |
| **Type of evidence** | **Definition** |
| Strength of the evidence:  Level  Quality  Statistical precision | The study design used, as an indicator of the degree to which bias has been eliminated by design a  The methods used by investigators to minimise bias within a study design  The *p*-value or, alternatively, the precision of the estimate of the effect. It reflects the degree of certainty about the existence of a true effect |
| Size of effect | The distance of the study estimate from the ‘null’ value and the inclusion of only clinically important effects in the confidence interval |
| Relevance of evidence | The usefulness of the evidence in clinical practice, particularly the appropriateness of the outcome measures used |

a See Table 13

The three sub-domains (level, quality and statistical precision) are collectively a measure of the strength of the evidence.

The ‘level of evidence’ reflects the effectiveness of a study design to answer a particular research question. Effectiveness is based on the probability that the design of the study has reduced or eliminated the impact of bias on the results. The NHMRC evidence hierarchy provides a ranking of various study designs (‘levels of evidence’) by the type of research question being addressed (Table 13).

Table 13 Designations of levels of evidence according to type of research question (including table notes)

|  |  |  |
| --- | --- | --- |
| **Level** | **Intervention a** | **Diagnostic accuracy b** |
| I c | A systematic review of level II studies | A systematic review of level II studies |
| II | A randomised controlled trial | A study of test accuracy with: an independent, blinded comparison with a valid reference standard d, among consecutive persons with a defined clinical presentation e |
| III-1 | A pseudo-randomised controlled trial  (i.e. alternate allocation or some other method) | A study of test accuracy with: an independent, blinded comparison with a valid reference standard d, among non-consecutive persons with a defined clinical presentation e |
| III-2 | A comparative study with concurrent controls:  ▪ non-randomised, experimental trial f  ▪ cohort study  ▪ case-control study  ▪ interrupted time series with a control group | A comparison with reference standard that does not meet the criteria required for level II and III-1 evidence |
| III-3 | A comparative study without concurrent controls:  ▪ historical control study  ▪ two or more single arm study g  ▪ interrupted time series without a parallel control group | Diagnostic case-control study e |
| IV | Case series with either post-test or pre-test/post-test outcomes | Study of diagnostic yield (no reference standard) h |

Source: Merlin, Weston & Tooher ([2009](#_ENREF_137))

Explanatory notes:

a Definitions of these study designs are provided on pages 7-8 in ‘How to use the evidence: assessment and application of scientific evidence’ ([NHMRC 2000](#_ENREF_156)) and in the accompanying Glossary.

b These levels of evidence apply only to studies assessing the accuracy of diagnostic or screening tests. To assess the overall effectiveness of a diagnostic test there also needs to be a consideration of the impact of the test on patient management and health outcomes ([MSAC 2005](#_ENREF_148); [Sackett & Haynes 2002](#_ENREF_179)). The evidence hierarchy given in the ‘Intervention’ column should be used when assessing the impact of a diagnostic test on health outcomes relative to an existing method of diagnosis/comparator test(s). The evidence hierarchy given in the ‘Screening’ column should be used when assessing the impact of a screening test on health outcomes relative to no screening or alternative screening methods.

c A systematic review will only be assigned a level of evidence as high as the studies it contains, excepting where those studies are of level II evidence. Systematic reviews of level II evidence provide more data than the individual studies and any meta-analyses will increase the precision of the overall results, reducing the likelihood that the results are affected by chance. Systematic reviews of lower level evidence present results of likely poor internal validity, and thus are rated on the likelihood that the results have been affected by bias rather than whether the systematic review itself is of good quality. Systematic review quality should be assessed separately. A systematic review should consist of at least two studies. In systematic reviews that include different study designs, the overall level of evidence should relate to each individual outcome/result, as different studies and study designs might contribute to each different outcome.

d The validity of the reference standard should be determined in the context of the disease under review. Criteria for determining the validity of the reference standard should be pre-specified. This can include the choice of the reference standard(s) and its timing in relation to the index test. The validity of the reference standard can be determined through quality appraisal of the study ([Whiting et al. 2003](#_ENREF_217)).

e Well-designed population based case-control studies (e.g. screening studies where test accuracy is assessed on all cases, with a random sample of controls) do capture a population with a representative spectrum of disease and thus fulfil the requirements for a valid assembly of patients. However, in some cases the population assembled is not representative of the use of the test in practice. In diagnostic case-control studies a selected sample of patients already known to have the disease is compared with a separate group of normal/healthy people known to be free of the disease. In this situation patients with borderline or mild expressions of the disease, and conditions mimicking the disease are excluded, which can lead to exaggeration of both sensitivity and specificity. This is called spectrum bias or spectrum effect because the spectrum of study participants will not be representative of patients seen in practice ([Mulherin & Miller 2002](#_ENREF_149)).

f This also includes controlled before-and-after (pre-test/post-test) studies, as well as adjusted indirect comparisons (i.e. use A vs B and B vs C, to determine A vs C with statistical adjustment for B).

g Comparing single arm studies i.e. case series from two studies. This would also include unadjusted indirect comparisons (i.e. use A vs B and B vs C, to determine A vs C but where there is no statistical adjustment for B).

h Studies of diagnostic yield provide the yield of diagnosed patients, as determined by an index test, without confirmation of the accuracy of this diagnosis by a reference standard. These may be the only alternative when there is no reliable reference standard.

Note A: Assessment of comparative harms/safety should occur according to the hierarchy presented for each of the research questions, with the proviso that this assessment occurs within the context of the topic being assessed. Some harms (and other outcomes) are rare and cannot feasibly be captured within RCTs, in which case lower levels of evidence may be the only type of evidence that is practically achievable; both physical and psychological harms may need to be addressed by different study designs; harms from diagnostic testing include the likelihood of false positive and false negative results; harms from screening include the likelihood of false alarm and false reassurance results.

Note B: When a level of evidence is attributed in the text of a document, it should also be framed according to its corresponding research question, e.g. level II intervention evidence; level IV diagnostic evidence; level III-2 prognostic evidence.

Note C: Each individual study that is attributed a ‘level of evidence’ should be rigorously appraised using validated or commonly used checklists or appraisal tools to ensure that factors other than study design have not affected the validity of the results.

Source: Hierarchies adapted and modified from: Bandolier editorial ([1999](#_ENREF_17)); NHMRC ([1999](#_ENREF_155)); Phillips et al. ([2001](#_ENREF_167)).

Individual studies assessing diagnostic effectiveness were graded according to pre-specified quality and applicability criteria ([MSAC 2005](#_ENREF_148)), as shown in Table 14.

Table 14 Grading system used to rank included studies

|  |  |  |
| --- | --- | --- |
| **Validity criteria** | **Description** | **Grading system** |
| Appropriate comparison | Did the study evaluate a direct comparison of the index test strategy versus the comparator test strategy? | C1 direct comparison  CX other comparison |
| Applicable population | Did the study evaluate the index test in a population that is representative of the subject characteristics (age and sex) and clinical setting (disease prevalence, disease severity, referral filter and sequence of tests) for the clinical indication of interest? | P1 applicable  P2 limited  P3 different population |
| Quality of study | Was the study designed to avoid bias?  High quality = no potential for bias based on pre-defined key quality criteria  Medium quality = some potential for bias in areas other than those pre-specified as key criteria  Poor quality = poor reference standard and/or potential for bias based on key pre-specified criteria | Q1 high quality  Q2 medium quality  Q3 poor reference standard  poor quality  or insufficient information |

The appraisal of intervention studies pertaining to treatment safety and effectiveness was undertaken using the Downs and Black ([1998](#_ENREF_57)) checklist, which was used for trials and cohort studies. Studies of diagnostic accuracy were assessed using the QUADAS-2 quality assessment tool ([Whiting et al. 2011](#_ENREF_218)), whereas SRs included in the last step of the linked analysis were assessed with the PRISMA checklist ([Liberati et al. 2009](#_ENREF_118)).

#### Stage 2: precision, size of effect and clinical importance

Statistical precision was determined using statistical principles. Small CIs and p-values give an indication as to the probability that the reported effect is real and not attributable to chance ([NHMRC 2000](#_ENREF_156)). Studies need to be appropriately powered to ensure that a real difference between groups will be detected in the statistical analysis.

For intervention studies it was important to assess whether statistically significant differences between patients receiving intervention and comparator were also clinically important. The size of the effect needed to be determined, as well as whether the 95%CI included only clinically important effects.

The outcomes being measured in this report were assessed as to whether they were appropriate and clinically relevant ([NHMRC 2000](#_ENREF_156)).

#### Stage 3: Assessment of the body of evidence

Appraisal of the body of evidence was conducted along the lines suggested by the NHMRC in their guidance on clinical practice guideline development ([NHMRC 2009](#_ENREF_157)). The five components considered essential by the NHMRC when judging the body of evidence are the:

* evidence-base—which includes the number of studies sorted by their methodological quality and relevance to patients
* consistency of the study results—whether the better quality studies had results of a similar magnitude and in the same direction i.e. homogenous or heterogeneous findings
* potential clinical impact—appraisal of the precision, size and clinical importance or relevance of the primary outcomes used to determine the safety and effectiveness of the test
* generalisability of the evidence to the target population
* applicability of the evidence—integration of this evidence for conclusions about the net clinical benefit of the intervention in the context of Australian clinical practice.

A matrix for assessing the body of evidence for each research question, according to the components above, was used for this assessment (Table 15).

Table 15 Body of evidence matrix

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Component** | **A**  **Excellent** | **B**  **Good** | **C**  **Satisfactory** | **D**  **Poor** |
| Evidence-base a | One or more level I studies with a low risk of bias or several level II studies with a low risk of bias | One or two level II studies with a low risk of bias, or an SR or several level III studies with a low risk of bias | One or two level III studies with a low risk of bias, or level I or II studies with a moderate risk of bias | Level IV studies, or level I to III studies/SRs with a high risk of bias |
| Consistency b | All studies consistent | Most studies consistent and inconsistency may be explained | Some inconsistency reflecting genuine uncertainty around clinical question | Evidence is inconsistent |
| Clinical impact | Very large | Substantial | Moderate | Slight or restricted |
| Generalisability | Population(s) studied in body of evidence are the same as target population | Population(s) studied in the body of evidence are similar to target population | Population(s) studied in body of evidence differ to target population for guideline but it is clinically sensible to apply this evidence to target population c | Population(s) studied in body of evidence differ from target population and it is hard to judge whether it is sensible to generalise to target population |
| Applicability | Directly applicable to Australian healthcare context | Applicable to Australian healthcare context with few caveats | Probably applicable to Australian healthcare context with some caveats | Not applicable to Australian healthcare context |

SR = systematic review; several = more than two studies

a Level of evidence determined from the NHMRC evidence hierarchy (see Table 13).

b If there is only one study, rank this component as ‘not applicable’.

c For example, results in adults that are clinically sensible to apply to children OR psychosocial outcomes for one cancer that may be applicable to patients with another cancer.

Source: Adapted from NHMRC ([2009](#_ENREF_157))

## Expert advice: Health Expert Standing Panel (HESP)

HESP has been established as a panel of the MSAC and is a pool of experts collated from various medical fields who are nominated by their associated professional body or by applicants. HESP members are engaged to provide practical, professional advice to evaluators that directly relates to each application and the service being proposed for the MBS. HESP members are not members of either MSAC or its subcommittees. Their role is limited to providing input and guidance to the assessment groups to ensure that the pathway is clinically relevant and takes into account consumer interests. HESP members’ advice is used to inform the deliberations that MSAC presents to the Federal Minister for Health.

# Results of assessment and discussion

## Is it safe?

| Summary—What is the safety of NAAT versus current testing in diagnosing MTB? |
| --- |
| No studies were identified assessing the safety of NAAT versus current testing in patients suspected of TB. To date, NAAT has been widely used without any safety concerns. |

Studies were screened to assess the safety of NAAT according to criteria outlined *a priori* in Box 1.

Box 1 PICO criteria for studies assessing the safety of NAAT in patients suspected of TB where AFB microscopy is obtained

|  |  |
| --- | --- |
| **Population** | Patients with clinical signs and symptoms of active TB whose specimen is suitable for AFB microscopy and culture, and who have had < 3 days of anti-TB treatment |
| **Intervention** | AFB microscopy and culture plus NAAT for the detection of MTB-complex DNA and genetic mutations on the *rpoB* gene associated with rifampicin resistance |
| **Comparators** | AFB microscopy and culture |
| **Outcomes** | AEs from testing procedures and subsequent treatments |
| **Publication type** | Randomised trials, cohort studies, case series or systematic reviews of these study designs |
| **Search period** | 1990 – May 2014 or inception of the database, if later than 1990 |
| **Language** | Non-English language articles were excluded unless they provided a higher level of evidence than the English language articles identified |

#### Safety of NAAT

No studies were identified that reported on the safety of NAAT (plus AFB microscopy and/or culture) compared with current testing (AFB microscopy, tissue biopsy and/or culture). As NAAT is usually conducted on the same samples used for other testing, no AEs were expected.

To date, NAAT has been widely used without any safety concerns. However, more patients will receive a false-positive NAAT than a false-positive AFB result. Therefore, more patients will receive treatment for a disease they do not have and will possibly have an adverse reaction to the anti-TB drugs until clinical unresponsiveness is noted or culture results become available.

## Is it effective?

## Direct evidence of the effectiveness of NAAT in the diagnosis of MTB

| Summary—Does NAAT improve health outcomes? Both studies assessing the direct health impact of NAAT were conducted in a setting with a high TB prevalence, and so the applicability to the Australian healthcare system is questionable.  A high-quality RCT reported no difference in morbidity outcomes at 2 and 6 months follow-up when NAAT and AFB microscopy were compared. However, a strong trend indicating fewer deaths in the NAAT group compared with the AFB microscopy group was observed at 2 months, but this trend was no longer apparent at 6 months. A historical control study of medium quality found no difference in the mortality rate at 2 months follow-up when comparing NAAT with no NAAT. However, both studies were likely to be confounded by high levels of treatment initiation based on clinical evidence in the comparator groups.  The difference in treatment initiation between groups in the study by Theron et al. (2014) is unlikely to be reflected in treatment initiation rates in Australia because NAAT is suggested to be used as an adjunct to AFB testing. The incremental impact of NAAT over current testing practice in Australia, and the impact on patient morbidity and mortality, cannot be estimated from this study. |
| --- |

Studies were included to assess the effectiveness of NAAT according to the criteria outlined *a priori* in Box 2.

Box 2 PICO criteria for identification of studies relevant to an assessment of effectiveness of NAAT for patients where AFB microscopy is obtained

|  |  |
| --- | --- |
| **Population** | Patients with clinical signs and symptoms of active TB whose specimen is suitable for AFB microscopy and culture, and who have had < 3 days of anti-TB treatment |
| **Intervention** | AFB microscopy and culture plus NAAT for the detection of MTB-complex DNA and genetic mutations on the *rpoB* gene associated with rifampicin resistance |
| **Comparators** | AFB microscopy and culture |
| **Outcomes** | Time to symptom resolution, quality of life, length of infectious period, number of contacts infected |
| **Publication type** | Randomised trials, cohort studies, case series or systematic reviews of these study designs |
| **Search period** | 1990 – June 2014 or inception of the database, if later than 1990 |
| **Language** | Non-English language articles were excluded unless they provided a higher level of evidence than the English language articles identified |

Two studies were included that assessed the direct health impact of NAAT on suspected TB patients ([Theron et al. 2014](#_ENREF_200); [Yoon et al. 2012](#_ENREF_225)). However, both studies were conducted in a high-prevalence African setting, and so applicability to the Australian healthcare system is questionable. In the absence of studies conducted in a more relevant setting, the study profiles of these two studies are summarised in Table 95 (Appendix F), and an overall summary of the body of evidence is presented in Table 16.

Table 16 Body of evidence matrix for studies reporting direct evidence on the effectiveness of NAAT in the diagnosis of MTB

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Component** | **A**  **Excellent** | **B**  **Good** | **C**  **Satisfactory** | **D**  **Poor** |
| Evidence-base a |  | One or two level II studies with a low risk of bias, or an SR or several level III studies with a low risk of bias |  |  |
| Consistency | All studies consistent |  |  |  |
| Clinical impact |  |  |  | Slight or restricted |
| Generalisability |  |  |  | Population(s) studied in body of evidence differ from target population and it is hard to judge whether it is sensible to generalise to target population |
| Applicability |  |  |  | Not applicable to Australian healthcare context |

a Level of evidence determined from the NHMRC evidence hierarchy (see Table 13)

Source: Adapted from NHMRC ([2009](#_ENREF_157))

One of the studies was a high-quality multicentre RCT (conducted in South Africa, Zimbabwe, Zambia and Tanzania) with 1,502 participants, who were either assigned to AFB microscopy plus culture (n=758) or Xpert plus culture (n=744). TB-related morbidity and mortality were reported in both groups ([Theron et al. 2014](#_ENREF_200)). The lack of AFB microscopy in the Xpert plus culture arm of the trial further limits the applicability of the findings to the proposed use of Xpert in Australia.

The second study of 477 participants was a historical control study of medium quality with some risk of bias, and was conducted in Uganda ([Yoon et al. 2012](#_ENREF_225)). This study included consecutive hospitalised Ugandan patients with suspected TB in two phases. In the baseline phase Xpert results were not reported to clinicians, whereas in the implementation phase the results were reported. Two-month mortality was reported and compared between groups.

#### Morbidity

Theron et al. ([2014](#_ENREF_200)) reported comparative morbidity outcomes after NAAT compared with AFB microscopy. In this study AFB microscopy and NAAT (Xpert) were done at point-of-care to assist same-day clinical decision-making and to improve patient retention and clinical outcomes. Thus, both the NAAT results in the intervention group and the AFB microscopy results in the comparator group were available on the same day as specimen collection. Additionally, only about half the patients who initiated treatment did so on the basis of a positive Xpert result. TB-related morbidity was graded using the TBscore (range 0–13) ([Wejse et al. 2008](#_ENREF_216)) and the Karnofsky performance score (KPS). The KPS subjectively rates the patient’s performance according to their ability to perform normal daily activities, ability to work, assistance needs, and disease-related symptoms on a scale from 0% to 100% ([Rudolf et al. 2013](#_ENREF_177)). Morbidity was measured at baseline and at 2 and 6 months. The results are shown in Table 17.

Table TB-related morbidity at recruitment, 2 months and 6 months, according to baseline culture status in patients given anti-TB treatment, per group

| **-** | **TBscore**  **NAAT (N=744)** | **TBscore**  **AFB (N=758)** | **p-value** | **KPS**  **NAAT (N=744)** | **KPS**  **AFB (N=758)** | **p-value** |
| --- | --- | --- | --- | --- | --- | --- |
| **Baseline** | - | - | - | - | - | - |
| Patients given treatment | Median (IQR)  5 (4–7) | Median (IQR)  5 (4–7) | 0.12 | Median (IQR)  70 (50–80) | Median (IQR)  70 (50–80) | 0.62 |
| * culture-positive group | n=168  5 (4–7) | n=153  5 (4–7) | 0.56 | n=168  70 (57.5–90) | n=153  70 (60–80) | 0.89 |
| * culture-negative or contaminated group | n=151  5 (4–7) | n=170  5 (4–6) | 0.08 | n=151  70 (50–80) | n=170  60 (50–80) | 0.59 |
| **2 months** | - | - | - | - | - | - |
| Patients given treatment | Median (IQR)  2 (0–3) | Median (IQR)  1 (0–3) | 0.39 | Median (IQR)  90 (80–90) | Median (IQR)  90 (80–90) | 0.91 |
| * culture-positive a | 2 (0.25–3) | 2 (0–3) | 0.85 | 90 (80–90) | 80 (70–90) | 0.23 |
| * culture-negative b | 1 (0–3) | 1 (0–7) | 0.37 | 90 (80–90) | 80 (70–90) | 0.23 |
| Per-patient change in score since recruitment in patients given treatment | Median (IQR)  4 (2–5) | Median (IQR)  3 (2–4) | 0.17 | Median (IQR)  10 (10–30) | Median (IQR)  20 (10–30) | 0.87 |
| * culture-positive | 3 (2–5) | 3 (2–4) | 0.20 | 10 (10–30) | 10 (0–22.5) | 0.59 |
| * culture-negative or contaminated | 4 (2.5–5) | 3 (2–4) | 0.28 | 20 (10–30) | 20 (10–30) | 0.96 |
| Patients with a > 25% decrease (for TBscore) or increase (for KPS) in score from baseline | n/N (%)  168/197 (85%) | n/N (%)  150/183 (82%) | 0.38 | n/N (%)  93/197 (47%) | n/N (%)  83/183 (45%) | 0.72 |
| * culture-positive | 89/108 (82%) | 66/87 (76%) | 0.26 | 46/108 (43%) | 32/87 (37%) | 0.41 |
| * culture-negative or contaminated | 79/88 (90%) | 84/96 (88%) | 0.63 | 47/88 (53%) | 51/96 (53%) | 0.97 |
| **6 months** | - | - | - | - | - | - |
| Patients given treatment | Median (IQR)  0 (0–3) | Median (IQR)  1 (0–3) | 0.20 | Median (IQR)  100 (90–100) | Median (IQR)  100 (90–100) | 0.81 |
| * culture-positive c | 1 (0–3) | 1 (0–3) | 0.35 | 100 (90–100) | 100 (90–100) | 0.85 |
| * culture-negative d | 0 (0–3) | 0 (0–2) | 0.80 | 100 (90–100) | 100 (90–100) | 0.87 |
| Per-patient change in score since recruitment in patients given treatment | Median (IQR)  4 (2–5) | Median (IQR)  4 (3–5) | 0.16 | Median (IQR)  30 (10–40) | Median (IQR)  30 (10–40) | 0.92 |
| * culture-positive | 4 (2.25–5) | 4 (3–5) | 0.35 | 30 (10–40) | 20 (10–40) | 0.44 |
| * culture-negative or contaminated | 4 (3–5.5) | 4 (3–5) | 0.38 | 40 (17.5–50) | 30 (20–40) | 0.53 |
| Patients with a > 25% decrease (for TBscore) or increase (for KPS) in score from baseline | n/N (%)  148/168 (88%) | n/N (%)  146/167 (87%) | 0.85 | n/N (%)  82/168 (49%) | n/N (%)  76/167 (46%) | 0.55 |
| * culture-positive | 85/97 (88%) | 70/81 (86%) | 0.81 | 42/97 (43%) | 32/81 (39%) | 0.61 |
| * culture-negative or contaminated | 62/71 (87%) | 76/86 (88%) | 0.84 | 40/71 (56%) | 44/86 (51%) | 0.52 |

AFB = acid-fast bacilli; KPS = Karnofsky performance score, 0–100% = with 0% being dead, < 40% = unable to care for self and requires equivalent of institutional or hospital care, 50–70% = unable to work but able to live at home and care for most personal needs, = 80–90% able to carry on normal activity and to work, 100% = being normal with no signs of disease; NAAT = nucleic acid amplification testing; TB = tuberculosis; TBscore = score 0–13 based on the 13 clinical indications, each contributing 1 point, normal values are scored as zero

a 87 (57%) of the AFB microscopy group vs 108 (64%) of 168 in the NAAT group were followed up within 2 weeks (p=0.170); of the patients who were not followed up within 2 weeks, 11 (17%) of 66 vs 6 (10%) of 60 had died (p=0.274), and 33 (50%) of 66 vs 36 (60%) of 60 were followed up > 2 weeks before/after the specified date (p=0.260).

b 96 (56%) of 170 of the AFB microscopy group vs 88 (58%) of 151 in the NAAT group were followed up within 2 weeks (p=0.74); of the patients who were not followed up within 2 weeks, 15 (20%) of 74 vs 8 (13%) of 63 had died (p=0.237), and 22 (30%) of 74 vs 21 (33%) of 63 were followed up > 2 weeks before/after the specified date (p=0.651).

c 81 (53%) of 153 of the AFB microscopy group vs 97 (58%) of 168 in the NAAT group were followed up within 2 weeks (p=0.39); of the patients who were not followed up within 2 weeks, 14 (19%) of 72 vs 14 (20%) of 71 had died (p=0.967), and 23 (32%) of 72 vs 23 (33%) of 71 were followed up > 2 weeks before/after the specified date (p=0.954).

d 86 (51%) of 170 of the AFB microscopy group vs 71 (47%) of 151 in the NAAT group were followed up within 2 weeks (p=0.52); of the patients who were not followed up within 2 weeks, 21 (25%) of 84 vs 14 (18%) of 80 had died (p=0.241), and 28 (33%) of 84 vs 28 (35%) of 80 were followed up > 2 weeks before/after the specified date (p=0.822).

Source: Theron et al. ([2014](#_ENREF_200))

TBscores at baseline and at 2 months and 6 months follow-up were similar in both groups (Table 17). When both tests were compared there were no differences reported in the median per-patient change in TBscore or KPS. The proportion of patients with a > 25% decrease in TBscore or KPS from recruitment to 2 and 6 months follow-up also did not differ.

#### Mortality

In the RCT by Theron et al. ([2014](#_ENREF_200)) mortality was reported after 2 and 6 months follow-up. A strong trend was observed indicating fewer deaths in the NAAT group at 2 months, but this did not quite reach statistical significance (Table 18 At 6 months there was no difference in the mortality rate between the two groups. The historical control study ([Yoon et al. 2012](#_ENREF_225)) only followed patients for a duration of 2 months after testing and found no difference between the two groups (Table 18).

Table 18 Mortality after NAAT versus no NAAT

| **Study** | **NAAT group** | **Comparator** | **Relative risk (95%CI), p-value** |
| --- | --- | --- | --- |
| **Deceased at 2 months** | - | - | - |
| Theron et al. ([2014](#_ENREF_200)) | 14/321 (4%) | 26/324 (8%) | 0.543 (0.29, 1.02), p=0.0538 |
| Yoon et al. ([2012](#_ENREF_225)) | 35/181 (19%) | 55/278 (20%) | 0.977 (0.67, 1.43), p=0.906 |
| **Deceased at 6 months** | - | - | - |
| Theron et al. ([2014](#_ENREF_200)) | 28/321 (9%) | 35/324 (11%) | 0.807 (0.50, 1.3), p=0.3737 |

Comparator for Theron et al. ([2014](#_ENREF_200)) was AFB microscopy

Comparator for Yoon et al. ([2012](#_ENREF_225)) was a historical control group

#### Discussion

There was little difference in the observed mortality and morbidity rates when the diagnosis of TB included the use of NAAT compared with no NAAT for patients in these two studies. The RCT showed a trend towards improved mortality rate with the use of NAAT at 2 months but this trend was not observed at 6 months. Both these studies were conducted in countries with a high prevalence of TB. The authors from both studies postulated various reasons for this general lack of effect on morbidity and/or mortality despite improved TB diagnosis and treatment initiation in the NAAT groups compared with the comparator groups. Theron et al. ([2014](#_ENREF_200)) suggested that the potential long-term epidemiological effect of NAAT was probably underestimated in their study because of high levels of treatment initiation in AFB-negative patients in the comparator group.

It should also be noted that while 112 NAAT-positive patients out of a total of 170 culture-positive (eventually treated) patients (66%) started treatment on the same day, the availability of same-day AFB microscopy results in the comparator group resulted in 67 AFB-positive patients out of 154 culture-positive (eventually treated) patients (44%) also starting treatment on the same day. This approximate 20% difference in treatment initiation between groups is unlikely to be reflected in treatment initiation rates in Australia because NAAT is suggested to be used as an adjunct to AFB testing. The incremental impact of NAAT over current testing practice in Australia, and the impact on patient morbidity and mortality, cannot be estimated from the study by Theron et al. (2014).

Yoon et al. ([2012](#_ENREF_225)) suggested that the lack of effect on 2-month mortality in their study may be due to several factors, including insufficient powering to detect small differences in mortality rates between groups, a significantly higher proportion of patients in the baseline phase receiving empiric TB treatment compared with the implementation phase, and more patients presenting with increased disease severity in the implementation phase than in the baseline phase. Thus, the authors concluded that the higher rates of empiric TB treatment in the baseline phase and sicker patients in the implementation phase may have attenuated the 2-month mortality in the implementation group.

Due to the limited evidence provided by these two studies, a linked evidence approach was taken to inform this assessment.

## Linked evidence of effectiveness of NAAT in the diagnosis of MTB

### Is it accurate?

| **Summary—What is the diagnostic accuracy of NAAT (with or without AFB microscopy) versus culture compared with AFB versus culture in the detection of MTB?** |
| --- |
| Diagnostic accuracy meta-analyses were conducted for multiple comparisons and the results are summarised below.  Culture as the reference standard  Even though culture is considered to be the ‘gold standard’ diagnostic test for TB, it is an imperfect reference standard because not all patients who receive a clinical diagnosis of TB based on other findings such as histopathology, clinical symptoms and responsiveness to anti-TB drugs will be culture-positive.  The pooled sensitivity and specificity of culture and NAAT using clinical diagnosis as a reference standard showed that:   * 24% of patients clinically diagnosed with TB had a false-negative culture result compared with 14% having a false-negative NAAT. * Thus, a large proportion of NAAT ‘false-positive’ patients (i.e. NAAT-positive, culture-negative) would be clinically diagnosed as having TB.   Therefore, NAAT is likely to be more effective at confirming the presence of an MTB infection than the meta-analysis using culture as the reference standard would suggest. |
| AFB microscopy plus NAAT compared with culture  The pooled sensitivity and specificity for AFB microscopy plus NAAT compared with culture was 94% (95%CI 91, 98) and 88% (95%CI 82, 92), respectively, and did not differ significantly to those for sputum and non-sputum specimens when analysed separately:   * 6% of patients will have a false-negative result and 12% of patients will have false-positive results.   The summary LR+ and LR– values for the ability of AFB plus NAAT to correctly diagnose the presence or absence of TB in patients when compared with culture suggest that:   * In sputum specimens AFB plus NAAT correctly identified most patients as either culture-positive or culture-negative. * In non-sputum specimens AFB plus NAAT correctly identified most patients who were culture-negative and showed strong diagnostic evidence for confirmation of culture-positive TB. |
| NAAT versus culture  Compared with culture the pooled sensitivity and specificity of NAAT for all specimens were 89% (95%CI 85, 92) and 94% (95%CI 91, 96), respectively, and did not differ significantly when sputum and non-sputum specimens were analysed separately:   * Overall, 11% of patients had false-negative results and 6% false-positive results.   The SROC curve showed some threshold effect, suggesting that in-house NAAT was less specific than commercial NAAT when compared with culture, especially in countries with a high incidence of TB and when testing non-sputum specimens.  The summary LR+ and LR– values for the ability of NAAT to correctly diagnose the presence or absence of TB in patients when compared with culture suggest that:   * Both in-house NAATs and the commercial Xpert NAAT had diagnostic value in confirming or excluding culture-positive disease. * Overall, patients with a positive NAAT result were likely to have culture-positive TB, whereas patients with a negative NAAT result were unlikely to be falsely negative.   In the context of interpreting NAAT results in conjunction with AFB findings:   * When specimens are AFB-positive, NAAT could confidently exclude the likelihood of culture-positive TB, but a positive NAAT result did not eliminate the possibility of being culture-negative. The explanation for this result is that culture is an imperfect reference standard. Culture in AFB-positive specimens likely resulted in misclassification of many of the 22% false-positive results seen for NAAT. * In AFB-negative specimens a positive NAAT result was likely to correctly confirm the presence of MTB. However, interpretation of a negative NAAT result is dependent on the type of specimen tested:   + In patients with AFB-negative sputum a negative NAAT indicated that the patient may not be culture-positive but it could not be ruled out.   + In patients with AFB-negative non-sputum specimens a negative NAAT result provided no additional useful information. This is likely due to the paucibacillary nature of AFB-negative specimens.   There was no difference in the diagnostic accuracy of NAAT compared with culture between HIV-positive and HIV-negative patients.  NAAT was both highly sensitive (93%; 95%CI 85, 97) and highly specific (98%; 95%CI 96, 99) compared with culture-based DST in identifying rifampicin-resistant MTB. |
| Comparison of NAAT, AFB microscopy and AFB plus NAAT using culture as the reference standard  AFB plus NAAT had the highest false-positive rate, at 12%, with NAAT at 6% and AFB at 2%:   * A false-positive result means a patient will receive treatment for a short time (until clinical unresponsiveness is noted or culture results are available) for a disease they do not have. |
| AFB microscopy had the highest false-negative rate, at 38%; NAAT and AFB plus NAAT were much lower at 11% and 6%m, respectively:   * The consequences of a false-negative result are much more severe, as the patient may remain untreated for a longer time period and could potentially spread the disease to more individuals. |

Studies were included to assess the accuracy of NAAT according to criteria outlined in Box 3.

Box 3 PICO criteria for identification of studies relevant to an assessment of the accuracy of NAAT

|  |  |
| --- | --- |
| **Population** | Patients with clinical signs and symptoms of active TB who have a specimen suitable for AFB microscopy and culture, and who have had < 3 days of anti-TB treatment |
| **Intervention** | NAAT with or without AFB microscopy for the detection of MTB-complex DNA and genetic mutations associated with anti-TB drug resistance |
| **Comparator** | AFB microscopy |
| **Reference standard** | Culture ± DST |
| **Outcomesa** | * Sensitivity * Specificity * Positive/negative predictive value * Level of agreement (concordance of data) * Diagnostic yield |
| **Publication type** | All study designs listed in the ‘Diagnostic accuracy’ column of Table 13 |
| **Search period** | 2005 – June 2014 |
| **Language** | Non-English language articles were excluded unless they provided a higher level of evidence than the English language articles identified |

a Due to the large volume of studies, included studies were limited to those that provided 2x2 data suitable for meta-analysis of sensitivity, specificity and likelihood ratios

Pre-specified subgroups for analysis included patients with a high pre-test probability of active TB (e.g. those from a country with high rates of TB) versus those with a low pre-test probability of TB. Although studies conducted in countries with a high incidence of TB were a good surrogate for patients with a high pre-test probability of having TB, there was no good surrogate for patients with a low pre-test probability of having TB. Many of the patients in those studies conducted in countries with a low incidence of TB were most likely recent immigrants from high-incidence countries. Those studies that used extrapulmonary specimens were a more appropriate surrogate for patients with a low pre-test probability of having TB, as the incidence of TB was lower in these patients.

A total of 79 studies provided data to assess the diagnostic accuracy of NAAT and AFB microscopy compared with culture in mixed pulmonary and/or extrapulmonary specimens from patients suspected of having an MTB infection. Culture methods included standard diagnostic laboratory procedures such as L-J or Ogawa solid media and/or liquid BACTEC media. Of these 79 studies, 20 (10 using an in-house NAAT and 10 using the commercial Xpert NAAT) provided data using mixed pulmonary and extrapulmonary specimens, 34 (21 in-house NAAT and 13 Xpert) using sputum specimens and 40 (29 in-house NAAT and 11 Xpert) using non-sputum specimens. Eight studies only provided data for the accuracy of NAAT compared with culture in patients with AFB-negative specimens. Eleven studies (1 in-house NAAT 10 Xpert) assessed the diagnostic accuracy of NAAT compared with culture to identify patients with drug-resistant MTB infections; 3 of the included studies only provided data for this outcome. The study profiles, patient characteristics and quality appraisal of these studies are listed in Table 96 (Appendix F) and the extracted 2x2 data are presented in Appendix C (Table 71 to Table 90). An overall summary of the body of evidence is presented in Table 19.

Table 19 Body of evidence matrix for studies reporting on the accuracy of AFB and NAAT compared with culture in diagnosing MTB infections

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Component** | **A**  **Excellent** | **B**  **Good** | **C**  **Satisfactory** | **D**  **Poor** |
| Evidence-base a | One or more level I studies with a low risk of bias or several level II studies with a low risk of bias |  |  |  |
| Consistency |  | Most studies consistent and inconsistency may be explained |  |  |
| Clinical impact |  | Substantial |  |  |
| Generalisability |  | Population(s) studied in the body of evidence are similar to target population |  |  |
| Applicability |  | Applicable to Australian healthcare context with few caveats |  |  |

a Level of evidence determined from the NHMRC evidence hierarchy (see Table 13).

Source: Adapted from NHMRC ([2009](#_ENREF_157))

The proportion of patients diagnosed with culture-positive MTB varied greatly among studies. In the 68 studies that compared the diagnostic accuracy of AFB microscopy and NAAT with culture in patients suspected of having TB, the proportion of patients from whom MTB could be cultured ranged from 1% to 81%, with a mean of 30%. The mean proportion of patients with culture-positive MTB infections was greater in countries with a high incidence of TB (> 100 cases per 100,000 people; 33%) than in those with intermediate (100–10 cases per 100,000 people; 29%) or low incidence (< 10 cases per 100,000 people; 24%) rates. As expected, the mean proportion of culture-positive specimens was greater in patients with AFB-positive specimens (80%, range 27–100%) than in AFB-negative specimens (19%, range 1–72%). The proportion of culture-positive specimens identified for all subgroups are listed in Table 93 (Appendix D).

#### Comparison of NAAT and culture, using clinical diagnosis as a reference standard

In order to compare the sensitivity and specificity of culture and NAAT, using clinical diagnosis as a reference standard, meta-analysis was conducted using data from 10 of the included studies that provided data using a clinical reference standard. The basis for a positive clinical diagnosis differed between studies but included some or all of the following: clinical findings, AFB microscopy, histology/cytology, chest radiographic findings, site-specific CT scan / MRI results, culture results and response to anti-TB drug therapy. The pooled sensitivity for culture versus clinical diagnosis was 76% (95%CI 54, 90) compared with 86% (95%CI 77, 92) for NAAT versus clinical diagnosis (Figure 11). This indicated that 24% of patients clinically diagnosed with TB will have a false-negative culture result compared with 14% having a false-negative NAAT (1 – sensitivity). This finding was consistent with the proportion of culture-positive cases reported in the *Tuberculosis notifications in Australia, 2010 Annual Report*[[10]](#footnote-10); 78% of all MTB cases were confirmed by culture.

Pooled sensitivity and specificity values with 95% CIs (respectively) for:
4 studies comparing culture with clinical diagnosis = 76% (54, 90) and 100% (100, 100)
8 studies comparing NAAT with clinical diagnosis = 86% (77, 92) and 98% (97, 99)
9 studies comparing NAAT with culture = 86% (79, 91) and 94% (88, 97)


Figure 11 Forest plot showing the pooled sensitivity and specificity values for culture compared with NAAT, using a clinical reference standard, and for NAAT compared with culture in the same subset of studies

CRS = clinical reference standard; K = the number of studies; NAAT = nucleic acid amplification testing

#### Meta-analysis of studies assessing the diagnostic accuracy of AFB plus NAAT compared with culture

Forest plots showing the sensitivity and specificity for the 38 studies that compared the diagnostic accuracy of AFB microscopy plus NAAT with culture in patients suspected of having TB are shown in Figure 43 and Figure 44 (Appendix D). A summary of meta-analysis of subgroups based on NAAT methodology, specimen type and incidence of TB in the country the study was conducted in is presented in Figure 12. AFB microscopy combined with NAAT was very sensitive (overall: 94%; 95%CI 91, 98) but the specificity was lower (88%; 95%CI 82, 92). Thus, 6% of patients will have a false-negative result for both AFB microscopy and NAAT, and 12% of patients (8% with sputum specimens and 17% with non-sputum specimens) will be falsely-positive for either AFB microscopy or NAAT.

Pooled sensitivity and specificity values with 95% CIs (respectively) for AFB microscopy plus NAAT versus culture:
all 38 studies = 94% (91, 96) and 88% (82, 92)
22 studies using in-house NAAT = 96% (92, 98) and 82% (70, 89)
16 studies using commercial NAAT = 91% (85, 94) and 94% (89, 97)
19 studies from high TB incidence countries = 94% (91, 96) and 79% (65, 88)
12 studies from medium TB incidence countries = 95% (89, 98) and 94% (90, 97)
7 studies from low TB incidence countries = 94% (80, 98) and 92% (79, 97)
18 studies testing sputum specimens = 94% (91, 96) and 83% (70, 91)
18 studies testing non-sputum specimens = 94% (91, 96) and 83% (70, 91)


Figure 12 Forest plot showing the pooled sensitivity and specificity values for AFB plus NAAT compared with culture for studies grouped according to the NAAT comparator, specimen type and incidence of TB in the country in which the study was conducted

The sensitivity and specificity values shown in green represent median (range) values as meta-analysis could not be performed with that subgroup.

Incidence of TB based on WHO estimates from 2012: high incidence = > 100 cases per 100,000 people; medium incidence = 10–100 cases per 100,000 people; low incidence = ≤ 10 cases per 100,000 people

K = the number of studies; NAAT = nucleic acid amplification testing; TB = tuberculosis

The LR scattergram in Figure 13 shows that the summary LR+ and LR– values for all studies investigating the ability of AFB microscopy plus NAAT to correctly identify patients with TB compared with culture were mostly within the green bands or the upper of the two left quadrants. This suggests that negative AFB and NAAT results correctly identified most patients who were culture-negative, and a positive result for either AFB or NAAT was more likely than not to indicate a culture-positive result. The reduced confidence in correctly diagnosing patients with culture-positive TB when AFB and NAAT were used together was due to the higher false-positive rate for the combined tests when compared with culture; 12% for AFB plus NAAT compared with 2% for AFB alone (Appendix E) and 6% for NAAT alone (Figure 15). As discussed above, culture is an imperfect reference standard and it is likely that many of the patients with apparent false-positive results actually have TB.

The summary LR+ and LR– values with 95% CIs (respectively) for AFB plus NAAT versus culture:
all specimens = 7.9 [5.2, 12.2] and 0.07 [0.05, 0.10]
all specimens using in-house NAAT = 5.2 [3.1, 8.7] and 0.05 [0.03, 0.10]
all specimens using commercial NAAT = 14.7 [8.1, 26.7] and 0.10 [0.06, 0.16]
sputum specimens = 11.9 [6.9, 20.8] and 0.06 [0.03, 0.14]
sputum specimens using in-house NAAT = 6.7 [4.0, 11.3] and 0.04 [0.01, 0.14]
sputum specimens using commercial NAAT = 25.4 [14.4, 44.7] and 0.12 [0.05, 0.28]
non-sputum specimens = 5.4 [3.0, 9.8] and 0.07 [0.05, 0.11]
non-sputum specimens using in-house NAAT = 2.3 [0.6, 8.3] and 0.01 [0.00, 0.26]
non-sputum specimens using commercial NAAT = 12.0 [5.0, 28.9] and 0.07 [0.04, 0.11]


Figure 13 LR scattergram for diagnosis of MTB infection by AFB plus NAAT compared with culture in studies using either in-house NAAT or commercial Xpert NAAT

AFB microscopy plus NAAT was most effective at confirming and excluding the presence of culture-positive disease in sputum specimens but could only confidently exclude culture-positive disease in non-sputum specimens (Figure 13B and C). When studies using either an in-house NAAT or the commercial NAAT in combination with AFB were analysed separately, the summary LR+ and LR– estimates for the AFB plus commercial NAAT were more effective at confirming the presence of culture-positive disease than AFB plus in-house NAAT for all specimen types. Furthermore, in non-sputum specimens a positive AFB or in-house NAAT result did not provide any useful information, most likely due to the 14% false-positive rate in this population. A negative AFB and commercial NAAT result was only able to confidently exclude the presence of culture-positive disease in non-sputum specimens.

The SROC curve shows no threshold effect when AFB microscopy is combined with either in-house NAAT or commercial NAAT (Figure 14). The SROC curves also show that when AFB microscopy plus NAAT was conducted in countries with a high incidence of TB, the results were less sensitive in sputum specimens and less specific in non-sputum specimens than when conducted in countries with an intermediate or low incidence of TB. The area under the curve (AUC) for AFB microscopy plus NAAT (0.97; 95%CI 0.95, 0.98) indicated that AFB plus NAAT performs well in predicting culture positivity (AUC > 0.9).




Figure 14 SROC curve for all studies investigating the sensitivity and specificity of AFB plus NAAT versus culture in the diagnosis of TB for all studies based on NAAT methodology (A), and for sputum (B) and non-sputum (C) specimens based on incidence of TB

AUC = area under curve; SROC = summary receiver–operator characteristic

#### Meta-analysis of studies assessing the diagnostic accuracy of NAAT compared with culture

Forest plots showing the sensitivity and specificity for the 68 studies that compared the diagnostic accuracy of NAAT with culture in patients suspected of having TB are shown in Figure 41 and Figure 42 (Appendix D). Although the sensitivity ranged from 6% to 100%, it was less variable than for AFB microscopy (Appendix E), with only 12/68 (18%) having a sensitivity below 70%. Meta-analysis showed that the overall pooled sensitivity for NAAT compared with culture was 89% (95%CI 85, 92). There were no significant differences in the pooled sensitivities for in-house compared with the commercial NAAT (Xpert) for any subgroup investigated; however, there was a slight trend suggesting that in-house NAATs were more sensitive than the commercial NAAT for most comparisons (Figure 15).

Pooled sensitivity and specificity values with 95% CIs (respectively) for NAAT versus culture:
all 68 studies = 89% (85, 92) and 94% (91, 96)
44 studies using in-house NAAT = 90% (83, 94) and 91% (85, 95)
24 studies using commercial NAAT = 86% (81, 90) and 97% (95, 98)
36 studies from high TB incidence countries = 89% (85, 92) and 88% (82, 92)
21 studies from medium TB incidence countries = 89% (84, 93) and 98% (95, 99)
11 studies from low TB incidence countries = 88% (77, 94) and 97% (90, 99)
30 studies testing sputum specimens = 89% (82, 94) and 95% (91, 96)
35 studies testing non-sputum specimens = 91% (83, 94) and 92% (84, 96)


Figure 15 Forest plot showing the pooled sensitivity and specificity values for NAAT compared with culture for studies grouped according to the NAAT comparator, specimen type and incidence of TB in the country in which the study was conducted

Incidence of TB based on WHO estimates from 2012: high incidence = > 100 cases per 100,000 people; medium incidence = 10–100 cases per 100,000 people; low incidence = ≤ 10 cases per 100,000 people

K = the number of studies; NAAT = nucleic acid amplification testing; TB = tuberculosis

There was greater variability in the specificity among studies, especially those that were conducted in countries with a high incidence of TB and that used in-house NAAT methodologies (Figure 42 in Appendix D). Meta-analysis of this subgroup showed that the pooled specificity was 79% (95%CI 67, 88), which was significantly lower than for the Xpert NAAT in these countries (96%; 95%CI 92, 96). In fact, the overall pooled specificity for all studies using in-house NAATs (91%; 95%CI 85, 95) was significantly lower than for those using the Xpert NAAT (97%; 95%CI 95, 98). Similar differences in the pooled estimates were seen for both the sputum and non-sputum subgroups, but the difference between in-house and commercial NAATs did not reach statistical significance in the non-sputum subgroup due to the wide CIs (Figure 15).

For specific non-sputum specimen types, the pooled specificity ranged from 90% to 97%, except for body fluids (such as synovial fluid and endometrial fluid), which had a pooled sensitivity of 69% (Figure 40 in Appendix D). It should be noted that although the pooled sensitivity of NAAT compared with culture was 97% for CSF specimens (compared with only 11% for AFB microscopy), the wide 95%CI (21, 100) indicated uncertainty in this estimate. As expected, the pooled specificity among different specimen types was much more varied, ranging from 71% for body fluids to 97% for both bronchial specimens and urine specimens.

Overall, there was no observed publication bias based on the effective sample size between studies (p=0.23; Figure 16). However, when the studies were separated according to the use of an in-house or commercial NAAT index test, the slope became significant (p=0.05 and 0.02, respectively). There was no observed publication bias for the most variable subgroup as the slope of the regression line for in-house NAAT studies conducted in high TB incidence countries was non-significant (p=0.30).

The regression line does not show significant publication bias (p=0.23)

Figure 16 Deek’s Funnel plot asymmetry test to assess publication bias for the diagnostic accuracy of NAAT compared with culture

Publication bias is assessed visually by using the inverse of the square root of the effective sample size (ESS) versus the log diagnostic odds ratio, which should have a symmetrical funnel shape when publication bias is absent ([Light & Pillemer 1984](#_ENREF_119)). A regression slope coefficient, weighting by ESS, with p<0.05 indicates significant asymmetry ([Deeks, Macaskill & Irwig 2005](#_ENREF_50)).

The LR scattergram in Figure 17 shows that the summary LR+ and LR– values for all studies investigating the ability of NAAT to correctly identify patients with and without TB, compared with culture, were mostly within the upper right quadrant of the graph (Figure 17A). Thus, a positive NAAT result was likely to correctly confirm the presence of MTB (as diagnosed by culture). As the summary estimates for exclusion were within the green shaded area close to the upper left quadrant, NAAT provided strong diagnostic evidence suggesting that patients who tested negative were more likely not to have culture-positive TB than to be falsely negative. Similar results were seen when studies that reported data for either sputum or non-sputum specimens were analysed separately (Figure 17B and C).

The summary LR+ and LR– values with 95% CIs (respectively) for NAAT versus culture:
all studies = 14.9 [9.7, 23.1] and 0.12 [0.08, 0.16]
all studies using in-house NAAT = 9.5 [5.5, 16.5] and 0.11 [0.07, 0.18]
all studies using commercial NAAT = 29.3 [18.4, 46.5] and 0.14, [0.10, 0.20]
sputum specimens = 17.8 [10.9, 29.0] and 0.11 [0.07, 0.19]
sputum specimens with in-house NAAT = 10.1 [6.0, 17.0] and 0.09 [0.04, 0.19]
sputum specimens with commercial NAAT = 32.5 [18.1, 58.5] and 0.18 [0.10, 0.31]
non-sputum specimens = 11.1 [5.5, 22.4] and 0.10 [0.06, 0.18]
non-sputum specimens with in-house NAAT = 7.6 [3.4, 17.0] and 0.11 [0.05, 0.24]
non-sputum specimens with commercial NAAT = 22.8 [8.8, 59.4] and 0.11 [0.06, 0.18]


Figure 17 LR scattergram for diagnosis of MTB infection by NAAT compared with culture in studies using either in-house NAAT or commercial Xpert NAAT

LR = likelihood ratio; NAAT = nucleic acid amplification testing

The summary LR estimate for in-house NAATs was close to the border between the upper and lower quadrants or just below it, whereas the summary value for commercial NAAT was clearly in the upper half of the graph. This indicated that a positive NAAT result using commercial NAAT could predict culture-positivity with greater confidence than using an in-house NAAT for all specimen types. The summary estimates were also mostly within the green band in the upper right quadrant of the graph, indicating that although a negative result was likely to indicate a negative culture result, it could not rule out culture-positivity. For sputum specimens the summary estimate for in-house NAAT was just within the upper left quadrant, indicating more confidence in the specimen also being culture-negative.

The SROC curve, which depicts the relative trade-off between true-positive and false-positive results, indicated that NAAT performs well in predicting culture positivity, with an AUC of 0.97 (95%CI 0.95, 0.98) for all specimen types, 0.96 (95%CI 0.94, 0.97) for sputum specimens and 0.89 (95%CI 0.86, 0.91) for non-sputum specimens. The SROC curve showed some threshold effect, suggesting that in-house NAAT was less specific than the commercial Xpert NAAT when compared with culture, especially in countries with a high incidence of TB and when testing non-sputum specimens (Figure 18).




Figure 18 SROC curve for all studies investigating the sensitivity and specificity of NAAT versus culture in the diagnosis of TB for studies based on NAAT methodology (A), specimen type (B) and incidence of TB (C)

Incidence of TB based on WHO estimates from 2012: high incidence = > 100 cases per 100,000 people; medium incidence = 10–100 cases per 100,000 people; low incidence = ≤ 10 cases per 100,000 people

AUC = area under curve; NAAT = nucleic acid amplification testing; SROC = summary receiver–operator characteristic; TB = tuberculosis

In summary, the sensitivity and specificity for in-house NAATs and the commercial Xpert NAAT, when compared with culture, did not differ significantly. Nevertheless, the Xpert NAAT showed a trend suggesting that it may be less sensitive than in-house NAATs, especially when testing sputum specimens (83% versus 92%; Figure 15). The summary LR values indicate that both in-house NAATs and the commercial Xpert NAAT have diagnostic value in confirming or excluding culture-positive disease. Patients with a positive commercial NAAT result were more likely to be culture-positive than those with a positive in-house NAAT result for all specimen types. Patients with a negative NAAT result in sputum specimens were more likely to be culture-negative than those with a negative Xpert NAAT result.

#### Meta-analysis of studies assessing the diagnostic accuracy of NAAT compared with culture in either AFB-positive or AFB-negative specimens

Forest plots showing the sensitivity and specificity from individual studies that compared NAAT with culture in either AFB-positive specimens or AFB-negative specimens from patients suspected of having TB are shown in Figure 45 and Figure 46 (Appendix D). Figure 19 shows the pooled sensitivity and specificity values for NAAT compared with culture for AFB-positive and AFB-negative specimens.

Among the 28 studies that reported data for AFB-positive specimens, the sensitivity was at least 94% in all but 5 studies (pooled value 99%; 95%CI 96, 100). However, the specificity was much more variable, ranging from 0% to 100% between studies (pooled value 78%; 95%CI 53, 92). Conversely, in the 39 studies that reported data for AFB-negative specimens, the sensitivity was highly variable between studies, with a pooled value of 80% (95%CI 69, 87). The specificity was at least 82% in the studies that were conducted in countries with a low or medium incidence of TB, but was highly variable (range 18–100%) in studies conducted in countries with a high incidence of TB, especially those using in-house NAAT. These observations are reflected in the 95%CIs of the pooled sensitivity and specificity values from subgroup analyses shown in Figure 19A and B.

The LR scattergram shows that the summary LR+ and LR– values for NAAT compared with culture in AFB-positive specimens were within the lower left quadrant, indicating that a negative NAAT result can confidently exclude the likelihood of an MTB infection (as determined by culture) in patients who had an AFB-positive sample (Figure 20). Unexpectedly, a positive NAAT result does not eliminate the possibility of AFB-positive patients not having a detectable MTB infection (i.e. being culture-negative). This can be explained because culture is an imperfect reference standard, which likely resulted in misclassification of many of the 22% false-positive results (1 – specificity) seen for NAAT when compared with culture in AFB-positive specimens (Figure 19). Therefore, NAAT is likely to be more effective at confirming the presence of an MTB infection in these patients than the LR scattergram suggests.

In AFB-negative specimens the overall summary LR+ and LR– values for NAAT compared with culture were in the upper right quadrant of the scattergram or within the green shaded bands, indicating that a positive NAAT result is likely to correctly confirm the presence of MTB. However, interpretation of a negative NAAT result is dependent on the type of specimen tested. In patients with AFB-negative sputum a negative NAAT indicated that the patient may not be culture-positive but it could not be ruled out (summary values are within the green shaded area; Figure 21). In patients with AFB-negative non-sputum specimens, a negative NAAT result provided no additional useful information. This is likely due to the paucibacillary nature of AFB-negative specimens. It should be noted that if few bacilli are present in the specimen, the possibility of a false-negative result would increase for all three tests.

A: Pooled sensitivity and specificity values with 95% CIs (respectively) for NAAT versus culture in AFB-positive specimens:
all 28 studies = 99% (96, 100) and 78% (53, 92)
16 studies using in-house NAAT = 98% (93, 100) and 65% (31, 88)
12 studies using commercial NAAT = 99% (95, 100) and 88% (67, 96)
13 studies from high TB incidence countries = 99% (93, 100) and 54% (21, 84)
9 studies from medium TB incidence countries = 98% (89, 99) and 76% (64, 85)
4 studies from low TB incidence countries = 98% (94, 100) and 97% (1, 100)
14 studies testing sputum specimens = 97% (89, 99) and 68% (41, 87)
11 studies testing non-sputum specimens = 100% (87, 100) and 56% (11, 93)
B: Pooled sensitivity and specificity values with 95% CIs (respectively) for AFB microscopy versus culture in AFB-negative specimens:
all 39 studies = 80% (69, 87) and 94% (88, 97)
23 studies using in-house NAAT = 85% (69, 94) and 85% (72, 93)
16 studies using commercial NAAT = 72% (62, 80) and 98% (96, 99)
20 studies from high TB incidence countries = 83% (69, 92) and 82% (66, 91)
12 studies from medium TB incidence countries = 79% (55, 92) and 97% (95, 99)
7 studies from low TB incidence countries = 70% (51, 84) and 99% (94, 100)
17 studies testing sputum specimens = 67% (45, 84) and 96% (90, 99)
19 studies testing non-sputum specimens = 86% (78, 91) and 86% (78, 91)


Figure 19 Forest plot showing the pooled sensitivity and specificity values for NAAT compared with culture for AFB-positive (A) and AFB-negative (B) specimens grouped according to NAAT methodology, specimen type and incidence of TB in the country in which the study was conducted

Green plots represent median (range) in groups for which meta-analysis could not be conducted.

Incidence of TB based on WHO estimates from 2012: high incidence = > 100 cases per 100,000 people; medium incidence = 10–100 cases per 100,000 people; low incidence = ≤ 10 cases per 100,000 people

K = the number of studies; NAAT = nucleic acid amplification testing; TB = tuberculosis




Figure 20 LR scattergram for diagnosis of MTB infection by NAAT compared with culture for AFB-positive specimens according to NAAT methodology

LR = likelihood ratio; NAAT = nucleic acid amplification testing

The SROC curve for studies investigating NAAT compared with culture in AFB-positive specimens showed no threshold effects based on commercial or in-house NAAT (Figure 22) or specimen type (not shown). However, for studies investigating NAAT compared with culture in AFB-negative specimens, a threshold effect was seen (Figure 23). In-house NAAT tended to be more sensitive and less specific than commercial NAAT when compared with culture. Similarly, NAAT compared with culture tended to be less sensitive and more specific when testing sputum specimens than for non-sputum specimens. The AUC for NAAT versus culture in AFB-positive (0.98; 95%CI 0.96, 0.99) and AFB-negative (0.93; 95%CI 0.91, 0.95) specimens indicated that the NAATs perform well in predicting culture positivity (AUC > 0.9) for both types of specimen.

The summary LR+ and LR– values with 95% CIs (respectively) for NAAT versus culture in AFB-negative specimens:
all studies = 13.4 [7.0, 25.6] and 0.22 [0.14, 0.33]
all studies using in-house NAAT = 5.8 [3.0, 11.3] and 0.17 [0.08, 0.37]
all studies using commercial NAAT = 43.1 [18.7, 99.4] and 0.29 [0.21, 0.40]
sputum specimens = 17.6 [6.2, 50.2] and 0.32 [0.16, 0.63]
non-sputum specimens = 8.1 [2.8, 23.7] and 0.16 [0.11, 0.24]


Figure 21 LR scattergram for diagnosis of MTB infection by NAAT compared with culture for AFB-negative specimens according to NAAT methodology

LR = likelihood ratio; NAAT = nucleic acid amplification testing




Figure 22 SROC curve for all studies investigating the sensitivity and specificity of NAAT versus culture in the diagnosis of TB for AFB-positive specimens based on NAAT methodology

AUC = area under curve; SROC = summary receiver–operator characteristic




Figure 23 SROC curve for all studies investigating the sensitivity and specificity of NAAT versus culture in the diagnosis of TB for AFB-negative specimens based on NAAT methodology (A) and specimen type (B)

AUC = area under curve; NAAT = nucleic acid amplification testing; SROC = summary receiver–operator characteristic

#### Comparison of AFB microscopy, NAAT and AFB plus NAAT, using culture as a reference standard

Using both AFB microscopy and NAAT to diagnose MTB infections was more sensitive than using either test alone for both sputum and non-sputum specimens (Figure 24); however, there was a corresponding decrease in specificity when the two tests were combined.

Pooled sensitivity and specificity values with 95% CIs (respectively) for all 68 studies using:
AFB microscopy versus culture = 62% (54, 69) and 98% (97, 99)
NAAT versus culture = 89% (85, 92) and 94% (91, 96)
AFB microscopy plus NAAT versus culture = 94% (91, 96) and 88% (82, 92)
Pooled sensitivity and specificity values with 95% CIs (respectively) for the 30 studies testing sputum specimens using:
AFB microscopy versus culture = 71% (59, 81) and 97% (95, 99) 
NAAT versus culture = 89% (82, 94) and 95% (91, 96)
AFB microscopy plus NAAT versus culture = 94% (91, 96) and 83% (70, 91)
Pooled sensitivity and specificity values with 95% CIs (respectively) for the 35 studies testing non-sputum specimens using:
AFB microscopy versus culture = 46% (37, 55) and 98% (97, 99)
NAAT versus culture = 91% (83, 94) and 92% (84, 96)
AFB microscopy plus NAAT versus culture = 94% (91, 96) and 83% (70, 91)


Figure 24 Forest plot showing the pooled sensitivity and specificity values for AFB, NAAT and AFB plus NAAT compared with culture according to specimen type

AFB = acid-fast bacilli; K = the number of studies; NAAT = nucleic acid amplification testing; TB = tuberculosis.

Overall, 38% of all patients (29% of those providing sputum specimens and 54% of those providing non-sputum specimens) had a false-negative AFB microscopy result but only 2–3% were falsely positive when compared with culture. For NAAT only 11% of patients (11% with sputum specimens and 9% with non-sputum specimens) had false-negative results and 6% (5% with sputum specimens and 8% with non-sputum specimens) false-positive results. When the two tests were combined, 5–6% of patients had a false-negative result and 12% (8% with sputum specimens and 17% with non-sputum specimens) were falsely positive. However, as not all patients with a clinical diagnosis of TB will be culture-positive, it is uncertain what proportion of these false-positive patients have been truly misdiagnosed.

The clinical impact of a higher false-positive rate will result in some patients receiving treatment for a disease they do not have, until clinical unresponsiveness is noted or culture results are available. The consequences of a false-negative result are much more severe, as the patient may remain untreated for a longer time period and could potentially spread the disease to more individuals in the community.

When the summary LR+ and LR– values were compared, some differences between the tests were observed. The LR scattergram in Figure 25 shows that the summary LR+ and LR– values for either AFB microscopy or NAAT are in the upper left quadrant. While AFB microscopy is only useful to confirm the presence of TB, NAAT also has some diagnostic value in identifying those without disease as it lies in the shaded area of this quadrant.

In contrast, when AFB microscopy and NAAT are combined the summary values are in the lower right quadrant, indicating that a negative result from both tests is a good indication that the patient will also be culture-negative for MTB. However, decreased certainty in a positive AFB microscopy or NAAT result correlating with a positive culture is due to the 22% false-positive NAAT rate for the AFB-positive population. As discussed above, culture is an imperfect reference standard; hence, many of these patients would receive a clinical diagnosis of TB.

The summary LR+ and LR– values with 95% CIs (respectively) for:
AFB versus culture = 31.8 [95% CI 21.2, 47.5] and 0.39 [95% CI 0.32, 0.47]
NAAT versus culture = 14.9 [9.7, 23.1] and 0.12 [0.08, 0.16]
AFB plus NAAT versus culture = 7.9 [5.2, 12.2] and 0.07 [0.05, 1.10]


Figure 25 LR scattergram for diagnosis of MTB infection by AFB (A), NAAT (B) and AFB plus NAAT (C) compared with culture in studies using either in-house NAAT or the commercial Xpert NAAT

AFB = acid-fast bacilli; LR = likelihood ratio; NAAT = nucleic acid amplification testing

#### Comparison of AFB microscopy and NAAT, using culture as a reference standard in HIV-positive and HIV-negative patients

Eight studies provided data to assess the diagnostic accuracy of NAAT and AFB microscopy compared with culture in HIV-positive patients suspected of having an MTB infection. Of these, 2 studies used in-house NAAT and 6 used commercial NAAT. Five of these studies were conducted in countries with a high incidence of TB and only 2 looked at the accuracy of NAAT in AFB-negative specimens (Figure 47 in Appendix D). Six studies provided data to assess the diagnostic accuracy of NAAT and AFB microscopy compared with culture in HIV-negative patients suspected of having an MTB infection, and all were conducted in countries with a high incidence of TB. Of these, 3 studies used in-house NAAT and 3 used commercial NAAT (Figure 48 in Appendix D). It should be noted that the *Tuberculosis notifications in Australia, 2010 Annual Report*[[11]](#footnote-11) stated that HIV and TB co-infection remains rare in Australia and is a relatively minor contributor to annual TB incidence, unlike in many other parts of the world.

The pooled sensitivity and specificity values for AFB microscopy or NAAT compared with culture in HIV-positive and -negative populations were compared with those for all included studies, which largely consisted of patients in whom their HIV status was unknown (Figure 26). There were no differences between the pooled values for the three population groups, indicating that HIV status does not affect the performance of either AFB microscopy or NAAT.

Pooled sensitivity and specificity values with 95% CIs (respectively) for AFB microscopy versus culture:
all 68 studies = 62% (54, 69) and 98% (97, 99)
7 studies in HIV-positive patients = 62% (49, 73) and 98% (96, 99)
36 studies from high TB incidence countries = 57% (44, 70) and 98% (97, 99)
6 high incidence, HIV-negative studies = 39% (28, 52) and 99% (96, 100)
4 high incidence, HIV-negative studies =47% (38, 57) and 98% (96, 99)
Pooled sensitivity and specificity values with 95% CIs (respectively) for NAAT versus culture:
all 68 studies = 89% (85, 92) and 94% (91, 96)
7 studies in HIV-positive patients = 92% (82, 96) and 95% (85, 99)
36 studies from high TB incidence countries = 89% (85, 92) and 88% (82, 92)
6 high incidence, HIV-negative studies = 89% (71, 97) and 88% (60, 98)
4 high incidence, HIV-negative studies =91% (71, 97) and 88% (83, 92)


Figure 26 Forest plot showing the pooled sensitivity and specificity values for AFB and NAAT compared with culture according to HIV status

AFB = acid-fast bacilli; High TB incidence = > 100 cases per 100,000 people based on WHO estimates from 2012; HIV = human immunodeficiency virus; K = the number of studies; NAAT = nucleic acid amplification testing; TB = tuberculosis

HIV-positive patients with pulmonary TB commonly produce AFB-negative sputum specimens ([de Albuquerque et al. 2014](#_ENREF_47); [Scherer et al. 2011](#_ENREF_181)). Thus, the difficulty associated with diagnosis of TB in HIV-positive patients is related to the reduced sensitivity of NAAT compared with culture in AFB-negative specimens. Figure 27 shows that 33% (1 – sensitivity) of AFB-negative sputum specimens will have a false-negative NAAT result when compared with culture; in contrast, only 3% of AFB-positive specimens will have a false-negative result. The difference in the pooled sensitivity for non-sputum specimens is more modest (14% and 0%, respectively) but still sufficient to be of some concern to clinicians.

Pooled sensitivity and specificity values with 95% CIs (respectively) for NAAT versus culture:
all 68 studies = 89% (85, 92) and 94% (91, 96)
28 studies testing AFB-positive specimens = 99% (96, 100) and 78% (53, 92)
39 studies testing AFB-negative specimens = 80% (69, 87) and 94% (88, 97)
all 30 studies testing sputum specimens = 89% (82, 94) and 95% (91, 96)
14 studies testing AFB-positive sputum specimens = 97% (89, 99) and 68% (41, 87)
17 studies testing AFB-negative sputum specimens = 67% (45, 84) and 96% (90, 99)
all 35 studies testing non-sputum specimens = 91% (83, 94) and 92% (84, 96)
11 studies testing AFB-positive non-sputum specimens = 100% (87, 100) and 56% (11, 93)
19 studies testing AFB-negative non-sputum specimens = 86% (78, 91) and 86% (78, 91)


Figure 27 Forest plot comparing the pooled sensitivity and specificity values for NAAT versus culture according to AFB result and specimen type in HIV-positive specimens

AFB = acid-fast bacilli; K = the number of studies

#### Meta-analysis of studies assessing the diagnostic accuracy of NAAT compared with culture-based DST in detecting drug-resistant MTB infections

Eleven studies provided data to assess the diagnostic accuracy of NAAT compared with culture-based DST in patients suspected of having TB who were later found to be culture-positive (Figure 28). The prevalence of rifampicin-resistant MTB strains in these studies ranged from 0% (in 3 studies) to 63% with a median of 4% and a mean of 12%. Only 1 study used an in-house NAAT (pyrosequencing of the *rpoB* gene); the other 10 studies used the Xpert NAAT. Two of the studies also compared the Xpert NAAT to DST for the detection of MDR-MTB. In these studies detection of mutations in the *rpoB* gene was considered a surrogate measure for detecting MDR.

Meta-analysis of these studies showed that NAAT is both highly sensitive (93%; 95%CI 85, 97) and highly specific (98%; 95%CI 96, 99) compared with DST in identifying rifampicin-resistant MTB. The utility of the Xpert NAAT as a surrogate for MDR-MTB cannot be evaluated in this assessment as only 2 studies met the inclusion criteria, with vastly differing sensitivity results.




Figure 28 Forest plot of the sensitivity and specificity of NAAT compared with culture-based DST to detect drug-resistant MTB infections

MDR = multidrug resistance; NAAT = nucleic acid amplification testing; RIF = rifampicin; TB = tuberculosis

### Does it change patient management?

| **Summary—Does NAAT change clinical management?** |
| --- |
| Seventeen relevant studies on change in management after NAAT were identified.  Not surprisingly, all studies were in agreement that the use of NAAT resulted in a quicker diagnosis of patients with TB, especially in those who were AFB-negative. Predictably, this also resulted in earlier treatment in NAAT-positive patients.  A historical control study of poor quality and a retrospective cohort study of medium quality reported that the median duration of unnecessary and/or over-treatment of TB was shorter in patients when NAAT was used to guide treatment decisions compared with those when NAAT was not available.  There were conflicting data on the likely impact of NAAT in the clinical setting. A retrospective cohort study of poor quality, conducted in the UK (medium TB incidence), concluded that clinician decision-making would be affected by NAAT results and that there would be significant clinical benefits from the use of NAAT in low-prevalence settings. Conversely, two cohort studies (one retrospective) of medium quality, conducted in Saudi Arabia (medium TB incidence) and Canada (low TB incidence), suggest that clinicians would be reluctant to change patient management based on the NAAT result. |

Studies were included to assess change in management following NAAT according to criteria outlined *a priori* in Box 4.

Box 4 PICO criteria for identification of studies relevant to an assessment of change in management following NAAT in patients able to have an AFB microscopy test

|  |  |
| --- | --- |
| **Population** | Patients with clinical signs and symptoms of active TB whose specimen is suitable for AFB microscopy and culture, and who have had < 3 days of anti-TB treatment  Subpopulations for analysis:   1. those with a high pre-test probability of active TB, e.g. come from a country with high rates of TB, versus those with a low pre-test probability of TB |
| **Intervention** | 1. AFB microscopy plus NAAT for the detection of MTB-complex DNA ± culture 2. NAAT for the detection of genetic mutations on the *rpoB* gene associated with rifampicin resistance |
| **Comparators** | 1. AFB microscopy ± culture 2. No NAAT for rifampicin resistance, ongoing AFB tests to determine if patient is responding to treatment |
| **Outcomes** | Time to diagnosis of TB or alternate condition, time to diagnosis of resistance, time to appropriate treatment, rate of treatment, duration of treatment, number of contacts required to be traced, number of contacts infected, rate of rifampicin resistance |
| **Study design** | Randomised trials, cohort studies, case series or systematic reviews of these study designs |
| **Search period** | 1990 – May 2014 or inception of the database if later than 1990 |
| **Language** | Studies in languages other than English were excluded unless they represented a higher level of evidence than that available in the English language evidence-base |

Seventeen studies reporting change in management outcomes due to NAAT were identified. Eight of these studies were conducted in developing countries with a high TB-prevalence (e.g. South-Africa, Uganda, Peru) and 8 studies were conducted in low-prevalence countries (e.g. USA, UK, Canada). The remaining study was conducted in a country with an intermediate TB burden (Korea). Only two studies used in-house NAATs and the remainder used commercial NAAT, of which 12 used the Xpert NAAT. The study profiles are summarised in Table 97 (Appendix F) and an overall summary of the body of evidence is presented in Table 20.

Table 20 Body of evidence matrix for studies reporting change in management outcomes due to NAAT

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Component** | **A**  **Excellent** | **B**  **Good** | **C**  **Satisfactory** | **D**  **Poor** |
| Evidence-base a |  | One or two level II studies with a low risk of bias, or an SR or several level III studies with a low risk of bias |  |  |
| Consistency |  | Most studies consistent and inconsistency may be explained |  |  |
| Clinical impact |  |  |  | Slight or restricted |
| Generalisability |  | Population(s) studied in the body of evidence are similar to target population |  |  |
| Applicability |  |  | Probably applicable to Australian healthcare context with some caveats |  |

SR = systematic review; several = more than two studies

a Level of evidence determined from the NHMRC evidence hierarchy (see Table 13).

Source: Adapted from NHMRC ([2009](#_ENREF_157))

#### Time to diagnosis and/or treatment

Fourteen studies reported data on time to TB diagnosis or anti-TB treatment after the intervention/comparator. Eight of these studies were conducted in countries with relatively high TB prevalence and 1 with intermediate TB prevalence (Table 97 in Appendix F). Median time to TB diagnosis and median time to therapy are shown in Table 21 and Table 22, respectively. It was shown that time to diagnosis is shorter with NAAT, compared with liquid and solid culture, and similar to AFB microscopy. Median time to therapy is also decreased with the use of NAAT (in these cases, Xpert) compared with other methods of diagnosis (especially culture), as shown in Table 22. These results correspond with those from two other studies: (1) a prospective cohort study by Sohn et al. ([2014](#_ENREF_186)), which stated that for five subjects in their study who had AFB-negative Xpert-positive results, treatment would have started a median of 12 days (IQR 4–23) earlier if results had been shared with the physicians, whereas treatment would have been only around 1 day sooner for AFB-positive cases; and (2) a Spanish retrospective cohort study by Buchelli Ramirez et al. ([2014](#_ENREF_32)), which reported that in the sputum AFB-negative group, Xpert-positive results allowed for an early treatment start. In this study treatment was brought forward by 26.1 ± 14.5 days, without waiting for culture results.

In addition to the median time to diagnosis and treatment data, a historical control study by Yoon et al. ([2012](#_ENREF_225)) reported that the proportion of TB patients diagnosed on day 1 using AFB microscopy was 55%, compared with 78% in patients diagnosed by AFB microscopy plus Xpert NAAT (p<0.001). The study by Theron et al. ([2014](#_ENREF_200)) showed that 44% (67/154) of culture-positive patients in a group that had AFB microscopy started treatment on the day of presentation, compared with 66% (122/170) in a group that had Xpert NAAT (p<0.0001). Furthermore, a medium-quality retrospective cohort study by Kwak et al. ([2013](#_ENREF_109)) reported that the median turnaround time for Xpert results in Korea was 0 days (IQR 0–1), which was significantly less than AFB microscopy with a turnaround time of 1 day (IQR 0–1), liquid or solid culture with 14 days (IQR 10.25–1.75) and 24 days (IQR 17–30) respectively, and DST with 78 days (IQR 65–96). Time to confirmation of results by a physician was also significantly shorter for Xpert results in this study, with a median of 6 (IQR 3–7) days, compared with 12 (IQR 7–19.25), 21 (IQR 7–19.25), 38.5 (IQR 25.75–50.25) and 90 (IQR 75.75–106) days for AFB microscopy, liquid culture, solid culture and DST, respectively. Median turnaround time (from sampling to reporting) was also reported in the retrospective study by Omrani et al. ([2014](#_ENREF_162)), which was 1 day for Xpert NAAT, 1 day for AFB microscopy (p>0.999) and 44 days for mycobacterial cultures (p<0.001). Laboratory processing times for AFB microscopy were 2.5 times as long as Xpert NAAT (23.2 hours, IQR 15.3–32.6 versus 9.1 hours, IQR 5.5–15.6, p<0.001), as stated by a cohort study done in the US ([Lippincott et al. 2014](#_ENREF_121)).

Table 21 Median time to TB diagnosis/detection using NAAT versus comparator

| **Study Country** | **Number of patients** | **Median time to TB diagnosis, NAAT (IQR)** | **Median time to TB diagnosis, comparator (IQR)** |
| --- | --- | --- | --- |
| Boehme et al. ([2010](#_ENREF_27))  Peru, South Africa, Uganda, Philippines | N=6648 | Xpert: 0 days (0–1) | AFB microscopy: 1 day (0–1)  Solid culture: 30 days (23–43)  Liquid culture: 16 days (13–21) |
| Sohn et al. ([2014](#_ENREF_186))  Canada | N=502 | Xpert: 25 hours (3–39) | AFB microscopy: 26 hours (25–51)  Culture: 516 hours, 22 days (336–720) |
| Van Rie et al. ([2013b](#_ENREF_213))  South Africa | N=344 | Xpert: 1 day (1–1) | AFB microscopy: 8 days (5–10)  Culture: 29 days (24–35) |
| Fan et al. ([2014](#_ENREF_65))  China | N=280 | NAAT (in-house): 0.5 day | Liquid culture: 28.2 days (15–50)  (p<0.001) |
| Yoon et al. ([2012](#_ENREF_225))  Uganda | Baseline N=157 Implementation (Xpert) N=105 | Xpert: 0 days (0–1), range 0–55 | AFB and/or microscopy: 1 day (0–26) |

AFB = acid-fast bacilli; NAAT = nucleic acid amplification test; Xpert = GeneXpert MTB/RIF assay

Table 22 Median time to therapy using GeneXpert versus comparator

| **Study** | **Number of patients** | **Median time in days to therapy, NAAT (IQR)** | **Median time in days to therapy, comparator (IQR)** | **p-value** |
| --- | --- | --- | --- | --- |
| Boehme et al. ([2010](#_ENREF_27))  Peru, South Africa, Uganda, Philippines | N=6648 | Xpert in AFB-negative, culture-positive TB: 5 (2–8) | AFB-negative, culture-positive TB (other methods): 56 (39–81) | - |
| Hanrahan et al. ([2013](#_ENREF_82))  South Africa | Xpert positive N=50 Empiric TB N=25 X-ray positive N=19 Culture positive N=20 | Those positive on Xpert: 0 | Empiric TB: 14 (5–35)  Suggestive chest X-ray: 14 (7–29)  Culture positive (Xpert negative): 144 (28–180) | - |
| Kwak et al. ([2013](#_ENREF_109))  Korea | Xpert N=43 No Xpert N=86 | Xpert: 7 (4–9) | No Xpert (culture and/or AFB): 21 (7–33.5) | <0.001 |
| Omrani et al. ([2014](#_ENREF_162))  Saudi Arabia | Xpert N=76 Comparator N=64 | Xpert: 0 | AFB microscopy: 0  Culture: 22 | >0.999  <0.001 |
| Theron et al. ([2014](#_ENREF_200))  South Africa | Microscopy N=758 Xpert N=744 | Xpert: 0 (0–3) | AFB microscopy: 1 (0–4) | 0.0004 |
| Van Rie et al. ([2013b](#_ENREF_213))  South Africa | N=344 | Xpert: 1 (1–1)  N=162 | Other methods a: 8 (1–42) |  |
| Van Rie et al. ([2013a](#_ENREF_212))  South Africa | N=160 | Xpert: 0 (0–0) | Other methods: 13 (10–20) | <0.001 |
| Yoon et al. ([2012](#_ENREF_225))  Uganda | Baseline N=157 Implementation (Xpert) N=105 | Xpert: 0 (0–2) | AFB microscopy: 1 (0–5) | 0.06 |

a Xpert-negative, culture-positive participants (N=10); six patients started treatment before the culture result was available.

AFB = acid-fast bacilli; IQR = interquartile range; MDR = multi-drug resistant; NAAT = nucleic acid amplification test; Xpert = GeneXpert MTB/RIF assay.

The RCT by Theron et al. ([2014](#_ENREF_200)) also reported the proportion of patients initiating TB treatment and the reasons for treatment initiations, as shown in Table 23 and Figure 29. The proportion of patients receiving treatment (regardless of reason of initiation) was higher in the Xpert group than in the AFB microscopy group during days 1–9. Furthermore, there were more culture-positive patients on treatment in the Xpert group, compared with the AFB microscopy group, until day 56.

Table 23 Proportion of patients initiating treatment based on AFB microscopy or NAAT results, by day

| **By day:** | **Positive AFB microscopy (%)** | **Positive NAAT (%)** |
| --- | --- | --- |
| 1 | 67/758 (9%) | 130/744 (17%) |
| 2 | 99/758 (13%) | 170/744 (23%) |
| 3 | 105/758 (14%) | 172/744 (23%) |
| 14 | 105/758 (14%) | 181/744 (24%) |
| 28 | 111/758 (15%) | 181/744 (24%) |
| 56 | 111/758 (15%) | 182/744 (24%) |

AFB = acid-fast bacilli; NAAT = nucleic acid amplification test

Source: Theron et al. ([2014](#_ENREF_200))

Graph showing an increase from approximately 17% of patients receiving treatment at day 1 to 24% being treated at day 56 based on NAAT result. The compared to 9% of patients at day 1 increasing to 15% pf patients at day 56 being treated based on AFB microscopy result.

Figure 29 Percentage of patients initiating treatment based on smear (AFB microscopy) or NAAT results, by day

Source: Theron et al. ([2014](#_ENREF_200))

Regarding antibiotic resistance detection, Boehme et al. ([2010](#_ENREF_27)) reported that the median time for rifampicin resistance results was 1 day (IQR 0–1) for the Xpert NAAT, compared with 20 days (IQR 10–26) for line probe assay and 106 days (IQR 30–124) for phenotypic susceptibility testing.

Time-related management results other than median time to diagnosis/treatment after Xpert NAAT were reported in three studies ([Lacroix et al. 2008](#_ENREF_111); [Marks et al. 2013](#_ENREF_129); [Taegtmeyer et al. 2008](#_ENREF_191)), all in low-prevalence countries The poor-quality retrospective cohort study by Lacroix et al. ([2008](#_ENREF_111)) showed that the average delay in TB diagnosis in a public health department in Quebec was decreased by the use of PCR (n=77) compared with no use of PCR (n=38), with a mean of 89.3 days (95%CI 76.4, 102.2) compared with 97.9 days (95%CI 74.2, 121.6; p=0.498), respectively. NAAT (MTD, Gen-Probe, San Diego, California) also significantly decreased the average time to final TB determination for all patients except for those with AFB-negative NAAT-positive culture-negative specimens versus patients with AFB-negative culture-negative (no NAAT) specimens in an unadjusted analysis by Marks et al. ([2013](#_ENREF_129)). Furthermore, this medium-quality retrospective cohort study, conducted in the USA, reported a multivariable analysis of time to determination of AFB-positive culture-positive patients, and found that a NAAT result reduced the time to TB diagnosis (adjusted hazard ratio = 2.3; 95%CI 1.4, 3.7). A different medium-quality retrospective cohort study (UK) used a INNO-LiPA RIF TB assay (Immunogenetics, Zwijndrecht, Belgium) and compared the mean time to identification of MTB and rifampicin resistance with AFB microscopy and/or mycobacterial culture ([Taegtmeyer et al. 2008](#_ENREF_191)). The mean time to detection of mycobacteria and rifampicin resistance was 8.8 ± 5.9 days with NAAT compared with 26.0 ± 10.9 days to identification (p=0.001) using culture (without NAAT). In this study, for all the AFB-positive samples, NAAT identified 86% of the samples within 2 weeks, compared with only 7% of samples using culture.

Thus, all studies were in agreement that the use of NAAT resulted in a quicker diagnosis of patients with TB, especially in those who were AFB-negative. Predictably, this also resulted in earlier treatment in NAAT-positive patients.

#### Impact on TB treatment

Unnecessary treatment and overtreatment for TB were reported in three studies. Forty-seven out of 143 patients without culture-positive TB were initially treated empirically pending culture results in the medium-quality cohort study by Davis et al. ([2014](#_ENREF_46)). Xpert results were negative in 45/47 (95.7%) of these patients, whereas 1 patient who was not treated had a positive result. Only 8 (18%) of these 45 patients were clinically diagnosed with culture-negative TB. In conclusion, 82% (37/45) of patients correctly classified by Xpert were over-treated for active TB. If Xpert had been used to guide initial treatment decisions, the median duration of overtreatment would have been 1 day (IQR 1–3) compared with 46 days (IQR 45–49), a median difference of 44 days (IQR 43–47). In this scenario 44 fewer patients would have started empirical TB treatment, and during the 13-month study period the total number of overtreatment days would have decreased by 95%, from 2,280 (95%CI 2,081, 2,479) to 111 (95%CI 0, 256) days.

Although these results were hypothetical, they correspond with results from a historical control study of poor quality by Guerra et al. ([2007](#_ENREF_78)), which reported a median duration of non-indicated TB treatment of 6 days for patients undergoing NAAT (MTD; Gen Probe, San Diego, CA) and 31 days for the non-NAAT group (p=0.002). Furthermore, a retrospective cohort study of medium quality by Marks et al. ([2013](#_ENREF_129)) reported culture-negative NAAT-negative patients had significantly fewer average days on outpatient medications, compared with those receiving no NAAT, with an average of 3 versus 57 days for AFB-positive culture-negative patients and 58 versus 100 days for AFB-negative culture-negative patients, respectively (p<0.05).

Conversely, a retrospective cohort study of medium quality from Saudi Arabia (mediun TB incidence of 15/100,000 people[[12]](#footnote-12)) reported a lack of change in overtreatment and patient management after NAAT in current clinical practice ([Omrani et al. 2014](#_ENREF_162)). Anti-TB therapy was not discontinued in any patients with negative Xpert results that started therapy empirically (n=8). Furthermore, Xpert was requested in only 54.3% (76/140) of patients and, overall, an Xpert-positive result was the reason for therapy initiation in just 12.1% (17/140) of patients. The authors concluded that physicians who are highly experienced in the diagnosis and treatment of TB underused the Xpert NAAT and it had only a limited impact on their decisions related to starting or stopping anti-TB therapy.

A cohort study of medium quality by Sohn et al. ([2014](#_ENREF_186)), conducted in Canada (low TB incidence of 4.6/100,000 people), also reported that the Xpert NAAT had no impact in preventing unnecessary TB treatment; however, in these patients species confirmation was done by existing NAAT in the clinical lab within a day of the positive AFB microscopy, and clinical suspicion in these cases was low.

NAAT had a clinical impact on management in 39% (20/51, 95%CI 27%, 53%) of patients in the retrospective cohort study of poor quality by Taegtmeyer et al. ([2008](#_ENREF_191)), conducted in the UK (medium TB incidence of 15/100,000 people). In 7 patients for whom there was uncertainty about TB diagnosis, TB was confirmed by NAAT and TB therapy continued. Three patients who had started empiric TB treatment were able to stop because of NAAT results, 2/4 patients with MRD-TB were identified by NAAT, and in 5 patients (previously treated) MDR-TB was excluded. In 3 patients the need for a hospital contact-tracing exercise was confirmed. The study further hypothesised that if NAAT had been used in the other 36 patients for whom it was indicated, it could have had a clinical impact on 8 of them (22%). If NAAT had been used in the 36 patients who were AFB-positive (not indicated by British guidelines), the results could have stopped unnecessary treatment in 14% (5/35, 95%CI 5%, 29%) of patients who did not have TB, provided rapid confirmation in 19 patients and excluded TB in a further 12 patients. The authors concluded that there were significant clinical benefits from the use of NAAT in low-prevalence settings.

### Does change in management improve patient outcomes?

| **Summary—Do alterations in clinical management and treatment options have an impact on the health outcomes of patients diagnosed with TB?** |
| --- |
| Early versus delayed treatment of TB  Two prospective cohort studies of poor quality reported that a delay in time to diagnosis, defined as the period from onset of any TB symptoms to the diagnosis of TB, was significantly associated with an increased risk of transmission of infection among contacts. A retrospective cohort study of poor quality, conducted in New Zealand, indicated that the time between development of symptoms and diagnosis was not significantly associated with the odds of achieving a favourable treatment outcome (i.e. cure or treatment completed).  Early identification of drug resistance  No studies were identified that met the PICO criteria. However, three cohort studies (two retrospective) of medium quality provided some evidence that patients with rifampicin-resistant TB who received a rifampicin-containing Category II treatment, before receiving the results of drug sensitivity testing, had slightly poorer health outcomes than those who did not.  Unnecessary antibiotic treatment  All TB patients are at risk of adverse health events (e.g. hepatitis) associated with first-line treatment. Two SRs, one of medium quality and one of poor quality, found that some but not all AEs as a consequence of patients with active TB receiving inappropriate antibiotic treatment (due to MTB resistance) may be avoided with appropriate treatment, to which the MTB strain is sensitive. One SR of good quality found that patients have a higher risk of developing multidrug-resistant TB (MDR-TB) if they receive inappropriate drug treatment. |

To answer the question whether a change in management leads to improved patient health outcomes, additional literature searches were done based on the PICO criteria outlined *a priori* in Table 24.

Table 24 PICO criteria for identification of studies relevant to an assessment of health outcomes following a change in management

|  | **Early versus delayed treatment of TB** | **Early identification of drug resistance** | **Unnecessary antibiotic treatment** |
| --- | --- | --- | --- |
| **Population** | Patients with clinical signs and symptoms of active TB and a low pre-test probability of active TB | Patients with clinical signs and symptoms of active TB and a high pre-test probability of active TB, who are identified at some point as having rifampicin resistance  Subgroups: those patients able to have an AFB microscopy, and those unable to have AFB microscopy | Patients with clinical signs and symptoms of active TB (true positives or false positives) |
| **Intervention** | Immediate treatment for TB, i.e. antibiotics | Early treatment with antibiotics, other than rifampicin | Treatment for TB with antibiotics |
| **Comparators** | Treatment for TB delayed 6–8 weeks (due to negative AFB result, negative NAAT result, or clinical judgement that patient does not have TB based on histology, until culture results received) | Standard treatment for active TB (including rifampicin), delayed treatment with alternative antibiotics | No treatment for TB |
| **Outcomes** | Time to symptom resolution, quality of life, length of infectious period, number of contacts infected | Time to symptom resolution, quality of life, length of infectious period, number of contacts infected | AEs from antibiotic treatment |
| **Study design** | Randomised trials, cohort studies, case series or systematic reviews of these study designs | Randomised trials, cohort studies, case series or systematic reviews of these study designs | Systematic reviews of randomised trials |
| **Search period** | 1990 – June 2014 or inception of the database if later than 1990 | 1990 – June 2014 or inception of the database if later than 1990 | 1990 – June 2014 or inception of the database if later than 1990 |
| **Language** | Studies in languages other than English will only be translated if they represent a higher level of evidence than that available in the English language evidence-base | Studies in languages other than English will only be translated if they represent a higher level of evidence than that available in the English language evidence-base | Studies in languages other than English will only be translated if they represent a higher level of evidence than that available in the English language evidence-base |

#### What health impact does early versus delayed treatment of TB have on the individual and their contacts?

Delay in treatment of TB resulting from failure to diagnose TB prior to the availability of culture results is likely to prolong the duration of symptoms in the patient, with a corresponding reduction of quality of life (QoL). In addition, treatment delay increases the duration of exposure for those individuals in contact with the patient, with a corresponding increase in the risk of transmission ([American Thoracic Society 1992](#_ENREF_9)).

None of the articles identified by the literature search to identify evidence regarding the health implications for both the patient and their contacts resulting from a delay of treatment of active TB of a duration consistent with the time required to obtain culture results (6–8 weeks) completely fulfilled the PICO criteria outlined in Table 24. However, three studies provided evidence of reasonable relevance to this section of the report. Ponticiello et al. ([2001](#_ENREF_169)) and Golub et al. ([2006](#_ENREF_76)) examined the effect of a delay in diagnosis of TB on the risk of infection among the close contacts of the patient, while van der Oest, Kelly & Hood ([2004](#_ENREF_210)) assessed the effect of delay on patients’ treatment outcomes. The study profiles are summarised in Table 98 (Appendix F) and an overall summary of the body of evidence is presented in Table 25.

Table 25 Body of evidence matrix for studies assessing the health impact of early versus delayed treatment of TB

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Component** | **A**  **Excellent** | **B**  **Good** | **C**  **Satisfactory** | **D**  **Poor** |
| Evidence-base a |  |  |  | Level IV studies, or level I to III studies/SRs with a high risk of bias |
| Consistency |  | Most studies consistent and inconsistency may be explained |  |  |
| Clinical impact |  |  |  | Slight or restricted |
| Generalisability |  | Population(s) studied in the body of evidence are similar to target population |  |  |
| Applicability |  | Applicable to Australian healthcare context with few caveats |  |  |

SR = systematic review

a Level of evidence determined from the NHMRC evidence hierarchy (see Table 13).

Source: Adapted from NHMRC ([2009](#_ENREF_157))

Ponticiello et al. ([2001](#_ENREF_169)) presented the results of a poor-quality prospective cohort study of TB patients and their close contacts to investigate sociodemographic and clinical risk factors for transmission of TB, including delay in diagnosis (Table 26). The study was conducted at a TB referral centre in Italy, and included patients with newly diagnosed pulmonary TB during the period January 1997 and December 1998, and their close contacts. Close contacts included the patient’s household and all other persons sharing the same indoor environment with the patient for prolonged periods. The applicability of this study is limited by the fact that the effect of extended delay to diagnosis was compared with a diagnostic delay of up to 1 month; the risk of transmission to contacts when treatment was initialised immediately upon development of symptoms was not reported. In addition, delay in diagnosis was defined as the period from onset of any TB symptoms to the diagnosis of TB, which includes both the patients’ delay in seeking medical attention (presumably as reported by the patient) as well as health-system delays in diagnosis and treatment initiation.

All the patients included in the study had AFB microscopy of sputum or bronchial specimens. The average delay in diagnosis of TB was 2.25 ± 1 month. In a multivariate logistic regression model, delay time to diagnosis was the only factor that remained significantly and independently associated with an increased risk of infection among contacts, as determined by positivity to the tuberculin skin test (p<0.0002). For patients with a diagnostic delay of 1.5 months the adjusted odds ratio for contacts infected / not infected, compared with a diagnostic delay of less than 1 month, was 4.2 (95%CI 1.3, 13.7), while with a diagnostic delay of 2 months this increased to 6.1 (95%CI 1.9, 19.6).

Golub et al. ([2006](#_ENREF_76)) performed a similar prospective cohort study of poor quality to determine the association between total treatment delay and TB transmission in patients with verified pulmonary TB reporting to the Maryland Department of Health and Mental Hygiene in the USA between June 2000 and November 2001 (Table 26). Total treatment delay was defined as the interval from first TB symptoms to initiation of treatment for TB. The median total treatment delay for US-born patients was 99 days, with 67% (36/54) of patients having delays ≥ 60 days. The probability of having infected contacts (tuberculin skin test positive) increased with longer delay in diagnosis; 38% of contacts of patients with a delay of ≥ 60 days had positive tuberculin skin tests compared with 25% of contacts with < 60 days’ delay (p=0.05). Although these results are not surprising, they reinforce the belief that quicker diagnosis of TB is of great benefit in reducing its spread to close contacts of infected individuals.

van der Oest, Kelly & Hood ([2004](#_ENREF_210)) performed a retrospective study of poor quality based on notified cases of TB among residents of the Waikato Health District, located in the North Island of New Zealand, from January 1992 to December 2001 (Table 26). Although the outcome measure used in the study—favourable treatment outcome (i.e. cure or treatment completion)—was not specified in the PICO, due to the paucity of relevant evidence on the health impact of treatment delay on the patient, this study was included. The definition of diagnostic delay was the time between development of symptoms and diagnosis. While 84.7% of patients were reported as having delayed diagnosis of over 4 weeks, the mean and standard deviation of the time to diagnosis were not provided. Of those patients for whom data were available, 79% successfully completed treatment. The results of a logistic regression model indicated that time between development of symptoms and diagnosis was not significantly associated with a favourable treatment outcome (OR=1.02; 95%CI 0.99, 1.04; p=0.15). As ‘favourable treatment outcome’ was poorly defined in this study, this result may simply reflect that the treatment completion rate, which may be influenced by many factors, appears to be unrelated to any treatment delays.

Table 26 Summary of studies assessing the health impact of early versus delayed treatment of TB on the individual and their contacts

| **Study** | **Definition of treatment delay** | **Results** |
| --- | --- | --- |
| **Effect on contacts** | **--** | **-** |
| Ponticiello et al. ([2001](#_ENREF_169))  Italy  N=90 source cases, 227 contacts | Delay defined as period from onset of any TB symptoms to diagnosis  Reference: delay to diagnosis ≤ 1 month | Prevalence of TST+ among contacts (all cases)  125/227 (45%: 39–51%)  18/125 (14%) developed active TB  % contacts TST+ by treatment delay  1 month 6/43 (14.0%) (reference)  1.5 months 15/37 (40.5%)  2 months 24/56 (42.9%)  2.5 months 13/23 (56.5%)  ORadj: TST+/TST– for long delay versus TST+/TST– for 1-month delay, (95%CI) a  1.5 months ORadj=4.2 (1.3, 13.7)  2 months ORadj=6.1 (1.9, 19.6)  2.5 months ORadj=7.5 (1.9, 30.3) |
| Golub et al. ([2006](#_ENREF_76))  USA  N=54 US-born patients, 310 contacts | Interval from first TB symptoms to initiation of treatment  Delay treated as dichotomous variable with cut-off of either 60 days or 90 days  Median total delay 99 days | Patients with treatment delay:  ≥ 60 days 36/54 (67%)  ≥ 90 days 30/54 (56%)  Contacts TST+ (delay 60 days) p=0.05 b  Delay < 60 days 18/71 (25%)  Delay ≥ 60 days 91/239 (38%)  Contacts TST+ (delay 90 days) p<0.01 b  Delay < 90 days 24/100 (24%)  Delay ≥ 90 days 85/210 (40%)  Total delay ≥ 90 days as predictor of TST + contacts (GEE multivariate model)  ORadj: 2.34 (95%CI 1.07, 5.12) p=0.03  TB cases among contacts  Delay 46–66 days 2/10  Delay ≥ 90 days 8/10 |
| **Clinical effect on patient** | **-** | **-** |
| Van der Oest, Kelly & Hood ([2004](#_ENREF_210))  New Zealand  N=244  Patients with documented length of delay=152 (62%) | Delay between development of symptoms and notification of the case | Favourable treatment outcome  OR: 1.02 (95%CI 0.99–1.04) p=0.15 |

CI = confidence interval; OR = odds ratio; ORadj = adjusted odds ratio; TST = tuberculin skin test

a Adjusted OR, determined from logistic regression

b Favourable treatment outcome as defined by the WHO: cure or treatment completed

c OR determined from logistic regression

In summary, 2 studies reported that a delay in time to diagnosis was significantly associated with an increased risk of transmission of infection among contacts. Although these results are not surprising, they reinforce the belief that quicker diagnosis of TB is of great benefit in reducing the spread of TB to close contacts of infected individuals. The lack of an effect on favourable treatment outcomes after earlier initiation of treatment found in a retrospective cohort study agrees with the findings of the 2 studies, providing direct evidence on the effect of including NAAT in clinical decision-making. Those 2 studies found that inclusion or exclusion of NAAT results had no effect on morbidity and mortality rates.

#### To what extent does treating patients who have rifampicin-resistant MTB infections with alternative treatments result in better health outcomes for the patient and their contacts?

The aim of this literature search was to determine the effectiveness of change in management due to rifampicin-resistance mutations being identified. This could impact mortality, time to symptom resolution, QoL, the length of the infectious period, or the number of contacts infected with TB. None of the articles found completely met the PICO criteria found in Table 24. However, 3 studies provided some evidence to answer part of the research question. The study profiles can be found in Table 99 (Appendix F) and an overall summary of the body of evidence is presented in Table 27.

Table 27 Body of evidence matrix for studies investigating the effect of change in management due to detection of drug resistant MTB

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Component** | **A**  **Excellent** | **B**  **Good** | **C**  **Satisfactory** | **D**  **Poor** |
| Evidence-base a |  |  |  | Level IV studies, or level I to III studies/SRs with a high risk of bias |
| Consistency b | All studies consistent |  |  |  |
| Clinical impact |  |  |  | Slight or restricted |
| Generalisability |  |  | Population(s) studied in body of evidence differ to target population for guideline but it is clinically sensible to apply this evidence to target population |  |
| Applicability |  | Applicable to Australian healthcare context with few caveats |  |  |

SR = systematic review

a Level of evidence determined from the NHMRC evidence hierarchy (see Table 13).

Source: Adapted from NHMRC ([2009](#_ENREF_157))

A study by Meyssonnier et al. ([2014](#_ENREF_138)) reported the outcomes of a retrospective cohort of rifampicin mono-resistant TB patients in France. At the time of TB diagnosis 83% (25/30) received rifampicin-containing regimens (Table 28). The remaining 5 patients did not receive rifampicin due to suspected resistance because of a previous treatment history or the first-line DST results from other countries or contacts. However, when DST results to first-line drugs were available in the study population, 3 patients did not have any modification of the rifampicin-containing regimen. Two of these patients were considered cured after 9 months of treatment and a 2-year follow-up (2 months of standard four-drug regimen and 7 months of rifampicin and isoniazid). The third patient died after 9 months of standard treatment, but also had a Kaposi sarcoma related to HIV co-infection. Of the patients receiving antibiotic treatment other than rifampicin, 13 (52%) received fluoroquinolone-containing regimens without aminoglycoside, 4 (16%) received amikacin-containing regimens without fluoroquinolone and 8 (32%) received both fluoroquinolones and amikacin.

Table 28 Association between treatment characteristics and health outcomes among rifampicin-resistant TB patients

| **Health outcomes** | **RIF containing regimen (n=3)** | **Antibiotics, other than RIF (n=25)** |
| --- | --- | --- |
| **Recovery** | 2 (67%) | 16 (64%) |
| **Lost to follow-up** | − | 3 (12%) |
| **Dead** | 1 (33%) | 3 (12%) |
| **Relapse** | − | 3 (12%) |

RIF = rifampicin

Source: Meyssonnier et al. ([2014](#_ENREF_138))

The second study, a Thai retrospective chart review by Lam et al. ([2014](#_ENREF_112)), identified that patients with rifampicin-resistant or MDR-TB who received rifampicin-containing Category II treatment (streptomycin, isoniazid, ethambutol, rifampicin, and pyrazinamide) before DST results had poorer treatment outcomes than those who received the treatment post-DST (Table 29). Patients who completed treatment and those who were cured of TB were considered to have successful outcomes; patients for whom treatment failed and those who defaulted or died were considered to have poor treatment outcomes. However, it was not reported which combination of antibiotic treatments the ‘no rifampicin’ group received (possibly variable).

Table 29 Association between treatment characteristics and poor treatment outcome among rifampicin-resistant and MDR-TB patients, Thailand 2004–08

| **Category II treatment** | **Poor outcome / total outcomes** | **Univariate OR [95%CI]** | **p-value** | **Multivariate OR [95%CI]** | **p-value** |
| --- | --- | --- | --- | --- | --- |
| **None** | 50/155 (32.3%) | Reference | - | Reference | - |
| **Pre-DST only** | 15/26 (57.7%) | 2.9 [1.2, 6.7] | 0.02 | 2.5 [1.1, 6.4] | 0.05 |
| **Post-DST / full treatment course** | 4/9 (44.4%) | 1.7 [0.4, 6.5] | 0.45 | 2.8 [0.7, 11.6] | 0.16 |

CI = confidence interval; DST = drug susceptibility testing; OR = odds ratio

Source: Lam et al. ([2014](#_ENREF_112))

The third study, a British cohort study by Drobniewski et al. ([2002](#_ENREF_58)), showed survival curves comparing MDR-TB patients treated with three drugs to which the bacterium was susceptible on DST results and those treated with fewer agents, also with demonstrable susceptibility. In the first group (n=62) the median survival period was 2,066 days or 5.66 years (95%CI 1336, 2515), and in the second group (n=13) this was 599 days or 1.64 years (95%CI 190, 969). Although this study did not meet the PICO criteria for inclusion, the authors reported that those who received appropriate treatment would have a longer median survival time and a lower chance of death, with an estimated risk ratio of 0.06 (95%CI 0.01, 0.23). Furthermore, those in whom culture results were available within 30 days were less likely to die, with a risk ratio of 0.23 (95%CI 0.06, 0.86), indicating the importance of accurate DST data in the clinical management of patients.

These 3 studies suggest that patients with rifampicin-resistant TB who receive rifampicin-containing anti-TB regimens have a slightly worse prognosis than those who receive other regimens. However, the reports are of limited applicability as they did not meet the PICO criteria.

#### What are the AEs associated with unnecessary antibiotic treatment?

A likely outcome of a change in first-line management of patients with active TB, specifically those who receive antibiotic treatment inappropriate for the genotype (and resistance) of the TB bacillus causing their disease, is the AEs and reactions associated with their antibiotic therapy. A literature search was conducted to identify evidence regarding the safety of first-line antibiotic treatment in patients with active TB. The PICO criteria for identification of the literature can be seen in Table 24. Evidence was sought for the first-line drugs isoniazid, rifampicin, ethambutol, myambutol and pyrazinamide. Due to the volume of articles identified, only the highest level of evidence is included here.

Three SRs were included ([Forget & Menzies 2006](#_ENREF_66); [Frydenberg & Graham 2009](#_ENREF_69); [van der Werf et al. 2012](#_ENREF_211)). Study profiles for the three SRs can be found in Table 100 in Appendix F, and an overall summary of the body of evidence is presented in Table 30.

Table 30 Body of evidence matrix for studies assessing the health impact of inappropriate antibiotic treatment

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Component** | **A**  **Excellent** | **B**  **Good** | **C**  **Satisfactory** | **D**  **Poor** |
| Evidence-base a | One or more level I studies with a low risk of bias or several level II studies with a low risk of bias |  |  |  |
| Consistency b | All studies consistent |  |  |  |
| Clinical impact |  |  | Moderate |  |
| Generalisability |  |  | Population(s) studied in body of evidence differ to target population for guideline but it is clinically sensible to apply this evidence to target population |  |
| Applicability |  | Applicable to Australian healthcare context with few caveats |  |  |

SR = systematic review; several = more than two studies

a Level of evidence determined from the NHMRC evidence hierarchy (see Table 13).

Source: Adapted from NHMRC ([2009](#_ENREF_157))

The review by Forget and Menzies ([2006](#_ENREF_66)), assessed as medium quality, searched only one database (Medline) and in addition sought relevant articles from the authors’ files and pearled references. While the review did not meet all criteria that define an SR, it nevertheless provided the best identified evidence across a range of first-line drugs for prophylactic treatment in patients of all ages with active TB and. A second review of medium quality assessed the toxicity of first-line drugs and prophylactic treatment in children with TB through literature identified in PubMed, EMBASE and the Cochrane Library Reference ([Frydenberg & Graham 2009](#_ENREF_69)). In addition, reference lists were hand-searched for relevant articles. The third relevant study identified assessed evidence of multidrug resistance following inappropriate TB treatment, and was of high quality ([van der Werf et al. 2012](#_ENREF_211)). This study conducted a broad systematic literature search and used clearly defined criteria for appropriate treatment regimens and multidrug resistance.

##### Adverse reactions to first-line TB therapy (all ages)

Forget and Menzies ([2006](#_ENREF_66)) reported on the serious adverse reactions associated with five first-line anti-TB drugs. Their results for isoniazid, rifampicin, pyrazinamide and ethambutol will be discussed here. The authors comment that the attribution of side effects to individual drugs is challenging as most patients are given multidrug regimens; however, if a temporal relationship between a drug and symptoms could be established, the symptoms were attributed to that drug. The authors of this review used the attribution made by the primary study authors. In some studies attribution of symptoms could only be made to the treatment regimen, and therefore the adverse reactions to multidrug TB regimens are also reported briefly here.

*Isoniazid*

Metabolism of isoniazid therapy is dependent on two pathways (direct and indirect) associated with different levels of activity in patients who have either high or low N-acetyltransferase activity (i.e. fast or slow acetylators). N-acetyltransferase activity is associated with race (90% of Asian, 45% of black, and 45% of white people are fast acetylators) and hepatic adverse reactions ([Mitchell et al. 1975](#_ENREF_142); [Mitchell et al. 1976](#_ENREF_143)). A summary of hepatic adverse reactions reported in 10 studies that administered isoniazid as chemoprophylaxis against TB is tabulated in Table 31.

Table 31 Summary of hepatic AEs to isoniazid from prospective and retrospective studies

| **Systematic review**  **Included studies** | **Total participants**  **(N)** | **Total cases**  **(N)** | **Adjusted rate per 1,000** | **Adjusted mortality per 1,000** |
| --- | --- | --- | --- | --- |
| Forget and Menzies ([2006](#_ENREF_66)) k=10 | 64,278 | 399 | 9.2 | 0.43 |

Forget and Menzies ([2006](#_ENREF_66)) found that there was heterogeneity between these 10 studies, although they did not provide a statistical summary. In particular, the definition of a hepatic AE varied between studies; for example, the definition of ‘hepatitis’ ranged from asymptomatic elevation in liver enzymes to clinical hepatitis. Study populations varied in the proportion of female participants (45.6% to 100% in studies that reported this factor) and in age. A prospective study in children (mean age 11 years) reported a low case rate of 11.6 per 1,000 when compared with a retrospective cohort study in which participants had a mean age of 76 years and reported a case rate of 49.9 per 1,000; however, both articles reported a mortality rate of zero.

Nine of the 10 studies reported completion/compliance rates at 12 months following initiation of treatment. Rates ranged from 16%/46% (completion/compliance at 6 months) in a retrospective cohort of 3,681 female patients who began therapy during pregnancy, to 95% completion in the prospective study of 434 children previously mentioned. The cohort of pregnant females also reported the highest adjusted mortality rate[[13]](#footnote-13) (1.18 per 1,000). Four of the 10 studies reported adjusted mortality rates of 0 per 1,000.

Incidence of hepatic AEs (adjusted rate per 1,000)[[14]](#footnote-14) ranged from 1.5 in an Asian cohort of 11,141 patients who were monitored through monthly interviews following a standardised protocol ([Nolan, Goldberg & Buskin 1999](#_ENREF_160)) to 79.6 in a US cohort of 1,000 for which cases were defined biochemically ([Byrd et al. 1979](#_ENREF_33)). In a US Public Health Service surveillance study involving 13,838 participants a more moderate incidence of 13.6 per 1,000 was reported ([Kopanoff, Snider & Caras 1978](#_ENREF_105)). This 1978 study reported that increasing age was a predominant factor for higher risk of developing isoniazid-related hepatitis.

*Other anti-TB drugs and regimens*

Forget and Menzies ([2006](#_ENREF_66)) reported incidence data for overall rates of side effects for patients on various anti-TB medications (Table 32). The authors report that populations, and in particular, definition of AEs showed heterogeneity between studies (no statistical measure given). Also reported was that older age was associated with the development of hepatitis, and skin rashes were more common in patients who were female, older, HIV infected or from Asia. Patients with chronic renal failure tend to have a higher incidence of adverse effects to an anti-TB regimen, in particular neuropsychiatric events.

Interestingly, more patients discontinued treatment on isoniazid mono-therapy (7%) when compared with rifampicin (2%), pyrazinamide (5%), ethambutol (0.2–0.3%) and streptomycin (3%). Patients on isoniazid also had more-elevated simple transaminases than those on the other drugs, but experienced hepatitis less often (0.4%) than rifampicin (1%) or pyrazinamide (1.5%). In children on TB mono-therapies, AEs occurred less often than in adults and tended to result in less morbidity; however, a large proportion of this data came from studies of prophylactic treatment.

Table 32 Incidence of AEs for drugs and regimens for first-line and prophylactic TB treatment

| **Drug / regimen** | **Discontinuation of treatment (overall)** | **Hepatitis** | **Simple elevation of transaminases** | **Dermato-logical** | **Gastro-intestinal** | **Hyper-sensitivity** | **Neuro-logical\*** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| INH | 7% | 0.4% | 11% | 1% | 2% | 0.1–17% | 1–3% |
| RIF | 2% | 1% | 3–9% | 0.5–3% | 1–8% | Yes | No |
| PZA | 5% | 1–5% | NA | 2–5% | 1% | NA | No |
| EMB | 0.2–0.3% | Rare | No | Rare | No | No | 0.2–0.3% |
| SM | 3% | No | No | 2% | No | Rare | Yes |
| RIF-PZA | 8% | 8% | 6% | 4% | 6% | 0.3% | 0.1–3% |
| PZA-Q | 67–88% | 18% | 4–88% | − | − | − | − |
| HR+ | 5% | 3% | 15% | 3% | 2% | 2% | 3–7% |
| HRZ+ | 4% | 3% | 22% | 12% | 12% | 1–4% | 7% |
| HRS+ | 6% | 2% | 3–51% | 11% | 16% | 1–4% | 14% |

Median rate given for values representing ≥ 4 studies; range given for values representing ≤ 3 studies

a Includes vestibular toxicity and optic neuritis

NA = not available; INH = isoniazid; Q = quinolone; RIF = rifampicin; PZA = pyrazinamide; EMB = ethambutol; SM = streptomycin; HR+ = regimens containing INH, RIF and any other drug, but not PZA or SM; HRZ+ = regimens containing INH, RIF, PZA and any other drug, but not SM; HRS+ = regimens containing INH, RIF and SM and any other drug

Source: Forget and Menzies ([2006](#_ENREF_66))

##### Adverse reactions in children (0–18 years)

A review by Frydenberg and Graham ([2009](#_ENREF_69)) was identified that discussed toxicity of first-line anti-TB regimens in children. On discussion of recommended doses for children, it was noted that the dosage level of isoniazid should depend on whether the child is a fast, intermediate or slow acetylator, as determined by the N-acetyltransferase 2 genotype. The slow acetylator genotype is associated with more AEs ([Possuelo et al. 2008](#_ENREF_170); [Tostmann et al. 2008](#_ENREF_206)). Once again, the attribution of side effects to individual drugs was found to be difficult when the majority of treatments are multidrug regimens. Incidence of AEs attributed to individual drugs are summarised in Table 33, stratified according to dose/regimen. In some cases the data from a number of studies using the same dose were combined. Reports of adverse reactions for mono-therapeutic use of rifampicin and pyrazinamide are scarce as they are most commonly used in multi-therapies. Furthermore, a large proportion of the included mono-therapy data in children comes from prophylactic use of anti-TB drugs.

The AEs reported in treatment trials of multidrug regimens in children are summarised in Table 34. For comparative studies the arm in which the AE occurred was not reported by Frydenberg and Graham ([2009](#_ENREF_69)). The AEs of two Indian trials assessing more serious forms of TB in children are shown in Table 35. One of the trials compared a treatment regimen containing streptomycin for more severe TB with a regimen without streptomycin for children with less-severe disease. A second trial treated children with tuberculous meningitis.

Table 33 Incidence of adverse reactions to TB drugs in children

| **Drug Adverse reaction** | **Drug regimen** | **Frequency (N participants)** | **Studies providing evidence (K)** |
| --- | --- | --- | --- |
| Isoniazide  *Hepatic reactions*  Severe hepatitis, hepatic failure  Transaminase elevation, subclinical  Jaundice  Discontinuation of therapy due to hepatoxicity  *Neurologic reactions*  Vitamin B6 deficiency  Clinical pyridoxine deficiency | < 10 mg/kg  Chemoprophylaxis (early months)  Chemoprophylaxis (9 months)  Chemoprophylaxis (3–4 months)  Chemoprophylaxis 10 mg/kg  Chemoprophylaxis 10 mg/kg  Chemoprophylaxis 10–20 mg/kg  Daily unspecified dose  Daily unspecified dose  Daily 3–15 mg/kg | Occasional (NR)  5–10%  6%  1.2%  1 case (1,451)  2 cases (1,451)  0 (> 6,000)  13%  0  0 | 2  5  1  1  4  4  3  1  1  2 |
| Rifampicin  *Hepatic reactions*  Hepatoxicity  Discontinuation due to transaminase elevation | Chemoprophylaxis  Chemoprophylaxis 10 mg/kg | 0 cases (25)  1 case (157) | 1  1 |
| Ethambutol  *Ocular reactions*  Possible ocular toxicity | 15–30 mg/kg | 2 cases (3,811) | 2 |

NR = not reported

Source: Frydenberg & Graham ([2009](#_ENREF_69))

Table 34 AEs reported in treatment trials for TB in children

| **Interventional regimen** | **Comparator** | **Adverse reaction** | **Cases (N)** | **Country (N participants)** |
| --- | --- | --- | --- | --- |
| Daily:  RIF 10 mg/kg  INH 10 mg/kg  PZA 25 mg/kg | Twice weekly:  RIF 15 mg/kg  INH 15 mg/kg  PZA 55 mg/kg | Significant side effect | 0 | South Africa (206) |
| Twice weekly:  RIF 10–15 mg/kg  INH 20–30 mg/kg  PZA 50–60 mg/kg | Daily:  RIF 10–15mg/kg  INH 10–15 mg/kg  PZA 20–30 mg/kg | Requiring modification of treatment  Initial vomiting  Mild joint pains | 0  6  2 | India  (76) |
| Daily for 9 months:  RIF 12 mg/kg  INH 6 mg/kg | Intermittent for 6 months:  RIF 12 mg/kg  INH 15 mg/kg  PZA 45 mg/kg | AEs | 0 | India  (NR) |
| RIF 10–15 mg/kg  INH 15 mg/kg | Various, all including:  RIF 10–15 mg/kg  INH 15 mg/kg | Transient hepatitis  Vomiting  Skin rash | 4  1  1 | India  (83) |
| RIF 10–12 mg/kg  INH 10–12 mg/kg  PZA 30–35 mg/kg | NA | Serious adverse effects  Temporary asymptomatic hyperuricaemia or transient elevation of transaminases | 0  11 | Greece  (36) |
| Twice weekly for 6 months:  RIF 10–20 mg/kg  INH 20–40 mg/kg  PZA 50–70 mg/kg | NA | Significant events interrupting treatment (vomiting, skin rash)  Events not requiring interruption of treatment (vomiting or abdominal pain)  Hepatitis, peripheral neuritis, joint pain | 2  9  0 | USA  (175) |
| Daily for 2 months:  RIF 10–15 mg/kg  INH 10–20 mg/kg  PZA 25–35 mg/kg  Then twice weekly for 4 months:  RIF 10–15 mg/kg  INH 10–20 mg/kg | NA | Rash  Jaundice  Deafness  Temporary allergy (desensitised by increasing doses) | 12  2  1  4 | Papua New Guinea  (639) |

INH = isoniazid; NA = not applicable, non-comparative study; PZA = pyrazinamide; RIF = rifampicin; SM = streptomycin

Source: Frydenberg & Graham ([2009](#_ENREF_69))

Table 35 AEs reported for treatment regimens for children with severe TB disease or TB meningitis

| **Interventional regimen** | **Comparator** | **Adverse reaction** | **Frequency—Intervention** | **Frequency—comparator** | **Country (N participants)** |
| --- | --- | --- | --- | --- | --- |
| Daily in intensive phase of more severe disease:  RIF, INH, PZA, EMB | Daily for less severe disease:  RIF, INH, PZA | Hepatoxicity | 2% | 1% | India  (323) |
| Children with TBM:  INH 20 mg/kg | Children with TBM:  INH 12 mg/kg | Jaundice | 39% | 12% | India  (NR) |

EMB = ethambutol; INH = isoniazid; PZA = pyrazinamide; RIF = rifampicin; TBM = tuberculous meningitis

Source: Frydenberg & Graham ([2009](#_ENREF_69))

##### Multidrug resistance after inappropriate TB treatment

An SR and meta-analysis by van der Werf et al. ([2012](#_ENREF_211)) assessed the risk of acquiring MDR-TB after taking inappropriate TB medication. A literature search for studies down to cohort level that assessed TB regimens as a risk factor for multidrug resistance identified no relevant articles, so the authors widened the selection criteria. Studies were included in which treatment was provided to non-MDR patients if drug resistance and genotype of the isolated TB bacilli were documented before treatment started. The definitions used by the authors for an appropriate treatment regimen and for MDR-TB are tabulated in Table 36 and Table 37, respectively. Four cohort studies were identified and included in the SR.

Table 36 Appropriate treatment regimens for TB patients with strains that have certain drug-resistance patterns

| **Drug-resistance pattern** | **Appropriate treatment regimen** |
| --- | --- |
| Pan susceptible | H-R and two other drugs in intensive phase and H-R in the continuation phase |
| H | H-R and two other drugs in intensive phase and H-R-E in the continuations phase a |
| Non-MDR-TB, R-susceptible | At least three drugs to which the strain is sensitive in the intensive and continuation phase b |
| Non-MDR-TB, R-resistant | At least four drugs to which the strain is sensitive in the intensive and continuation phase b |

a Based on World Health Organization guidelines ([WHO 2010](#_ENREF_221))

b Based on World Health Organization guidelines ([WHO 2008](#_ENREF_220))

H = isoniazid; MDR = multidrug resistance; R = rifampicin; E = ethambutol; TB = tuberculosis

Source: van der Werf et al. ([2012](#_ENREF_211))

Table 37 Definitions of MDR-TB, acquired MDR-TB, recurrence, relapse and reinfection

| **Type of TB** | **Definition** |
| --- | --- |
| MDR-TB | TB resistant to at least isoniazid and rifampicin |
| Acquired MDR-TB | A case with an initial strain susceptible to at least isoniazid or rifampicin that developed MDR-TB and has a genotyping pattern identical to the strain at diagnosis |
| Recurrence | A second episode of TB occurring after a first episode has been considered cured |
| Relapse | A second episode of TB occurring after a first episode has been considered cured with the same MTB strain as the first episode |

MDR = multidrug resistance; MTB = *Mycobacterium tuberculosis*; TB = tuberculosis

Source: van der Werf et al. ([2012](#_ENREF_211))

The populations of the four included studies were diagnosed with TB proven either by culture, new AFB-positive sputum (two AFB-positive sputum smears or one AFB-positive smear and an abnormal chest radiograph consistent with TB), AFB-positive sputum (at least one sputum sample reading > 10 bacilli/100 fields by direct microscopy), or by both sputum AFB microscopy and culture. Results from two of the four cohort studies were used in a fixed-effects model meta-analysis as they included patients in exposed (i.e. those who received an inappropriate treatment) and unexposed (i.e. those who received appropriate treatment) groups. As the exposed and unexposed groups were drawn from the same population, the studies potentially minimised population selection bias, although baseline differences were not assessed. In one study all patients were considered to have undergone inappropriate treatment as the continuation phase consisted of isoniazid and ethambutol and not isoniazid and rifampicin. In another cohort there were no events (i.e. the strain of TB at recurrence was different to the strain at initial infection), so neither of these latter two studies could be included in the meta-analysis. The applicability of the study cohorts to an Australian setting was low, as the studies were conducted either in areas where there is moderate to high prevalence of drug-resistant TB or in patients who had experienced a previous TB infection.

All studies performed DST before the start of treatment, as per the selection criteria of the review. The quality of the included studies was assessed to be moderate to high by van der Werf et al. ([2012](#_ENREF_211)); a summary of the data is presented in Table 38.

Table 38 Patients who acquired MDR-TB following appropriate or inappropriate TB treatment

| **Study reference**  **Country** | **Treatment appropriate based on DST** | **Non-MDR-TB patients treated (n)** | **Patients that failed treatment and acquired MDR-TB (n)** | **Patients with recurrence with acquired MDR-TB (n)** |
| --- | --- | --- | --- | --- |
| Sonnenberg et al. ([2001](#_ENREF_187))  South Africa | Yes  No | 294  29 | −  − | 0  0 |
| Quy et al. ([2003](#_ENREF_172))  Vietnam | Yes  No | 0  2,551 | 0  38 | 0  10 |
| Cox et al. ([2007](#_ENREF_43))  Uzbekistan | Yes  No | 240  74 | 1  9 | −  − |
| Matthys et al. ([2009](#_ENREF_134))  Russian Federation | Yes  No | 127  62 | 0  5 | −  − |

DST = drug susceptibility testing; MDR = multidrug resistance; TB = tuberculosis

Patients for whom it was unknown whether they acquired MDR-TB are not included as acquired MDR-TB

Source: van der Werf et al. ([2012](#_ENREF_211))

Patients included in the meta-analysis were shown to have a 27-fold increased risk of drug resistance if they received an inappropriate treatment regimen (RR=26.7, 95%CI 5.0, 141.7). When two patients for whom the strain of re-infection was not clear were excluded from the analysis, the risk was lower (RR=17.7, 95%CI 4.1, 77.6). Results are shown in Table 39. Heterogeneity was measured at 0.02 (df=1, p=0.88, I2=0%) using a Chi-squared analysis.

Table 39 Meta-analysis of two studies showing the risk ratio of inappropriate treatment and risk of developing multidrug-resistant TB

| **Study reference**  **Country** | **Inappropriate treatment**  **N events (total)** | **Appropriate treatment**  **N events (total)** | **Weight** | **Fixed RR IV (95%CI)** |
| --- | --- | --- | --- | --- |
| Cox et al. ([2007](#_ENREF_43)) | 9 (74) | 1 (240) | 66.4 | 29.19 (3.76, 226.62) |
| Matthys et al. ([2009](#_ENREF_134)) | 5 (62) | 0 (127) | 43.6 | 22.35 (1.26, 397.86) |
| Total (95%CI) | 14 (136) | 1 (367) | 100.0 | 26.68 (5.02, 141.70) |

RR = risk ratio

Source: van der Werf et al. ([2012](#_ENREF_211))

In summary, there are AEs and morbidity associated with anti-TB treatment. Patients who carry a resistant strain that can be identified by NAAT will possibly benefit from its early identification, followed by appropriate treatment. It should be noted that a patient receiving appropriate treatment for a resistant or non-resistant strain will still be at risk of adverse health events associated with that drug or regimen.

Data providing the evidence on AEs was non-comparative and came primarily from countries with high or medium incidence of TB, and therefore there is limited relevance in an Australian setting. Heterogeneity of reporting, dosing regimens and definitions of AEs (e.g. hepatitis) in studies makes it difficult to conduct a serious analysis of the data.

An important finding by van der Werf et al. ([2012](#_ENREF_211)) was that patients were found to be at higher risk of developing MDR-TB if they received inappropriate compared with appropriate treatment (RR=26.7, 95%CI 5.0, 141.7). Appropriate treatment was as defined according to WHO treatment guidelines for MDR-TB ([WHO 2008](#_ENREF_220)). Thus, from a public health perspective, earlier identification of drug resistant strains via NAAT could be beneficial in preventing inappropriate treatment and the further spread of MDR-TB.

The *Tuberculosis notifications in Australia, 2010 Annual Report*[[15]](#footnote-15) found that 12% of culture isolates with available DST results showed resistance to at least one of the standard first-line anti-TB agents. Resistance to isoniazid (no rifampicin resistance) was shown in 4.7% of isolates. Resistance to at least isoniazid and rifampicin (MDR-TB by definition) was reported in 3.5% of cases but half of these were from the Papua New Guinea – Torres Strait Islands cross-border region and the remainder from recent immigrants. Thus, drug resistance is currently not a serious problem in Australia. Appropriate treatment regimens would enable physicians to continue to contain or even reduce the spread of drug-resistant TB cases in Australia.

## Linked evidence of diagnostic effectiveness of NAAT in the diagnosis of NTM

Literature on NTM generally falls into four categories: MAC, which is associated with lung disease in immunocompromised patients; *M ulcerans*, which is associated with Buruli ulcer disease, a skin disorder endemic to certain regions of Africa but also identified in Australia (sometimes known as ‘Daintree ulcer’); *M avium* spp. paratuberculosis, a strain found predominately in animals, causing Johne’s disease, which is implicated in Crohn’s disease in humans; and the other less common mycobacteria, which form the fourth category.

Although there was a considerable body of literature about NTM, very little of it was relevant to the review. Many of the studies were case reports or outbreak investigations; most of the literature on Crohn’s disease compared the presence of mycobacteria in people with and without Crohn’s disease, rather than how it is diagnosed. Indeed, none of the literature on *M. avium* in Crohn’s disease was eligible for inclusion in the review. No direct evidence was found comparing NAAT with culture. Thus, a linked evidence approach was used. However, the studies that met the inclusion criteria only reported on diagnostic accuracy. No studies reporting on the effect of a change in management resulting from the use of NAAT were identified.

### Is it accurate?

| Summary—What is the diagnostic accuracy of NAAT versus culture in the diagnosis of NTM? |
| --- |
| Diagnostic accuracy meta-analyses were conducted for multiple comparisons and the results are summarised below. |
| Culture as the reference standard  It should be noted that culture is an imperfect reference standard. When compared with a clinical reference standard, only 46% (95%CI 27, 66) of those clinically diagnosed were culture-positive and only 31% (95%CI 4, 58) were AFB-positive.   * The median sensitivity of NTM-NAAT versus clinical diagnosis was 99% (range 98–99; k=2), indicating that many patients who are NTM-NAAT-positive and culture-negative would be diagnosed with clinical disease.   NAAT compared with culture  Meta-analysis was performed comparing two different NAATs with culture. NTM-NAAT detects NTMs in general by targeting either the 16S-23S rRNA sequence (k=3) or the gene encoding the 65-kDa heat shock protein (k=2); and MAC-NAAT specifically detects MAC strains (k=5).  The pooled sensitivity for NTM-NAAT compared with culture was 84% (95%CI 49, 97) and the specificity was 90% (95%CI 46, 99):   * 16% of patients had false-negative results and 10% of patients had false-positive results.   The pooled sensitivity for MAC-NAAT compared with culture was 59% (95%CI 35, 79) and the specificity was 100% (95%CI 99, 100):   * 41% of patients had false-negative results and no culture-negative patients had false-positive results. |
| The summary LR+ and LR– values for the ability of NAAT to correctly diagnose the presence or absence of NTM infections in patients when compared with culture suggest that:   * Patients with a positive MAC-NAAT result most likely had a culture-positive MAC infection, and patients with a negative result may or may not have had a culture-positive MAC infection. * Patients with a positive NTM-NAAT were more likely to have an infection than not, and patients with a negative result were more likely to not have an NTM infection than to be falsely negative.   The SROC curve shows some threshold effect, suggesting that MAC-NAAT may be more sensitive and less specific than NTM-NAAT when compared with culture:   * The AUC indicated that both NTM- and MAC-NAAT perform well in predicting culture positivity.   Overall, NAAT appears to be able to identify a larger proportion of patients with an NTM infection than either AFB microscopy or culture. However, only NTM-NAAT may be of any use in identifying those patients who do not have an NTM infection. Furthermore, these results should be viewed with caution due to the small number of studies included and the wide 95%CIs for many of the analyses. |

Studies were included to assess the accuracy of NAAT according to criteria outlined in Box 5.

Box 5 PICO criteria for direct evidence in patients with tissue biopsy consistent with NTM infection

| **Population** | Patients with tissue biopsy consistent with NTM infection |
| --- | --- |
| **Intervention** | Culture plus NAAT for the detection of non TB-mycobacteria (e.g. *Mycobacterium avium, M. kansasii, M. gordonae*, or *M. intracellulare*) |
| **Comparators** | Culture plus other tests, e.g. lung biopsy or skin biopsy if possible |
| **Outcomes** | Safety—adverse events from testing procedures and subsequent treatments  Direct effectiveness—time to symptom resolution, quality of life |
| **Study design** | Randomised trials, cohort studies, case series or systematic reviews of these study designs |
| **Search period** | 1990 – May 2014 or inception of the database if later than 1990 |
| **Language** | Studies in languages other than English will only be translated if they represent a higher level of evidence than that available in the English language evidence-base |

Note: The patient population was expanded to include all patients suspected of having an NTM infection.

Due to the paucity of evidence, variations from the PICO were necessary. The patient population for eligible studies was expanded to include any patients suspected of having an NTM infection. Although the protocol for this review stated that the reference standard should be AFB microscopy and culture, as so little evidence was found, studies with clinical reference standards (i.e. various combinations of clinical assessment and pathology results, but also response to treatment) were also included. Twelve studies conducted between 1997 and 2005 were identified that reported on the diagnostic accuracy of NAAT for the detection of NTM infections. The study profiles and the quality appraisal are summarised in Table 101 (Appendix F) and the extracted 2x2 data are presented in Table 91 and Table 92 (Appendix C). An overall summary of the body of evidence is presented in Table 40.

Table 40 Body of evidence matrix for studies reporting on the accuracy of NAAT in diagnosing NTM infections

| **Component** | **A**  **Excellent** | **B**  **Good** | **C**  **Satisfactory** | **D**  **Poor** |
| --- | --- | --- | --- | --- |
| Evidence-base a |  |  | One or two level III studies with a low risk of bias, or level I or II studies with a moderate risk of bias |  |
| Consistency b |  | Most studies consistent and inconsistency may be explained |  |  |
| Clinical impact |  |  |  | Slight or restricted |
| Generalisability |  |  | Population(s) studied in body of evidence differ to target population for guideline but it is clinically sensible to apply this evidence to target population |  |
| Applicability |  |  | Probably applicable to Australian healthcare context with some caveats |  |

a Level of evidence determined from the NHMRC evidence hierarchy (see Table 13).

Source: Adapted from NHMRC ([2009](#_ENREF_157))

Ten studies reported the diagnostic accuracy of NAAT compared with culture, but only 6 of these studies also compared AFB microscopy with culture (Table 101). Two of the studies also reported the diagnostic accuracy of NAAT and culture compared with a clinical reference standard. An additional two studies reported on the diagnostic accuracy of AFB, NAAT and culture compared with a clinical reference standard only (Table 101). Culture methods included standard diagnostic laboratory procedures, including L-J or Ogawa solid media and/or liquid BACTEC media. Four studies included respiratory specimens (3 of which included sputum specimens and 1 also included extrapulmonary specimens), 4 used blood and bone marrow specimens (all from HIV-positive patients) and 4 used tissue biopsy specimens (3 used archived formalin-fixed paraffin-embedded specimens).

The NAAT used in these studies could be separated into three distinct categories. Five studies used NAAT to detect NTMs in general (NTM-NAAT) by targeting either the 16S–23S rRNA sequence (k=3) or the gene encoding the 65-kDa heat shock protein (k=2). Six studies used NAAT to specifically detect MAC strains (MAC-NAAT), which included all 4 studies involving HIV-positive patients (1 of which only used a clinical reference standard). One study used NAAT to detect *M. ulcerans* in patients suspected of having Buruli ulcer by targeting IS*2404*, but only compared NAAT with a clinical reference standard (Table 101). However, many of these studies also identified patients (specimens) with MTB infections (Table 91 and Table 92). As MTB infections are much more common than NTM and would therefore affect the accuracy of NAAT in detecting NTM, MTB culture-positive specimens were excluded from the analysis wherever possible. MTB-positive results could not be excluded from the analysis for 2 studies that identified 6/46 ([Bogner et al. 1997](#_ENREF_28)) and 2/36 ([Mahaisavariya et al. 2005](#_ENREF_124)) positive cultures as MTB, and the study by Frevel et al. ([1999](#_ENREF_68)) did not report the number of MTB-positive cultures included in the analysis.

The prevalence of patients with culture-positive NTM infections varied between 4% and 67%, with 5 studies reporting NTM-positive cultures in less than 10% of the tested specimens. Only 2 studies reported a prevalence rate greater than 30%; these were 42% in the study investigating the presence of *M. ulcerans* in biopsy specimens from a suspected Buruli ulcer ([Phillips et al. 2005](#_ENREF_168)) and 67% in a study investigating the presence of MAC in blood and bone marrow aspirates from AIDS patients who were suspected of having disseminated mycobacterial infections ([Gamboa et al. 1997](#_ENREF_70)). The reason for this high rate of culture-positivity when compared with other studies looking at disseminated mycobacterial infections could not be determined. Studies using NTM-NAATs reported a mean prevalence of NTM-positive cultures of 13% (range 4–30) compared with 25% (range 9–67) for those using MAC-NAATs. As expected, the prevalence of culture-positive NTM was higher in AFB-positive specimens (36%) compared with AFB-negative specimens (21%; Table 41).

Table 41 Prevalence of NTM culture-positive specimens in the included studies

| **Specimen type** | **Number of studies** | **Prevalence of culture-positive NTM** |
| --- | --- | --- |
| All specimens across all studies | 7 | 14% [range 4–30] |
| NTM-NAAT vs culture studies | 5 | 13% [range 4–27] |
| MAC-NAAT vs culture studies | 5 | 25% [range 9–67] |
| AFB-positive specimens | 3 | 36% [range 11–60] |
| AFB-negative specimens | 5 | 18% [range 4–67] |

AFB = acid-fast bacilli; NTM = non-tuberculous mycobacteria; NTM-NAAT = NAAT designed to detect all NTMs; MAC-NAAT = NAAT designed to detect *M. avian* complex; NAAT = nucleic acid amplification testing

The sensitivity and specificity of AFB, NTM-NAAT, MAC-NAAT and culture compared with either culture or a clinical reference standard for the individual studies are shown in Figure 49 and Figure 50 (Appendix D), and the pooled values for various subgroups are shown in Figure 30.

When NTM-NAAT was compared with MAC-NAAT using culture as the reference standard, NTM-NAAT was more sensitive than MAC-NAAT (84%; 95%CI 49, 97 versus 59%; 95%CI 35, 79), but this difference did not reach statistical significance due to the wide CIs (Figure 30). The difference in sensitivity between MAC-NAAT and NTM-NAAT may be due to the restricted mycobacterial species detectable using MAC-NAATs. Two studies that used commercial MAC-NAATs ([Gamboa et al. 1997](#_ENREF_70); [Ninet et al. 1997](#_ENREF_159)) identified 13% (5/38) and 9% (6/68) culture-positive specimens, respectively, that grew NTMs not detectable by MAC-NAAT that could have been detected by NTM-NAAT. These specimens were treated as falsely negative in the analysis presented in this report. Conversely, 2 other studies included specimens with cultures positive for other NTMs as culture-negative results in the data presented ([Bogner et al. 1997](#_ENREF_28); [Tran et al. 2014](#_ENREF_207)). Thus, 4% (18/494) and 7% (25/361) of culture-negative specimens, respectively, were actually NTM culture-positive, thus overestimating the sensitivity of MAC-NAAT in the detection of patients with NTM infections in these 2 studies. The study by Matsumoto et al. ([1998](#_ENREF_133)) did not report the presence of any other NTMS.

Pooled sensitivity and specificity values with 95% CIs (respectively) for all specimens in:
5 studies comparing AFB microscopy to culture = 47% (24, 72) and 96% (68, 100)
2 studies comparing AFB microscopy to clinical diagnosis = 31% (4, 58) and 100% (95, 100)
5 studies comparing NTM-NAAT to culture =- 84% (49, 97) and 90% (46, 99)
5 studies comparing MAC-NAAT to culture =- 59% (35, 79) and 100% (99, 100)
4 studies comparing culture to clinical diagnosis = 46% (27, 66) and 100% (99, 100)
Pooled sensitivity and specificity values with 95% CIs (respectively) for MAC-NAAT versus culture in:
3 studies testing HIV-positive patients = 49% (10, 89) and 100% (99, 100)
2 studies where HIV status is negative or unknown = 69% (46, 92) and 99% (97, 100)


Figure 30 Forest plot showing the pooled sensitivity and specificity values for AFB and NAAT compared with culture or a clinical reference standard in diagnosing NTM infections in various types of specimens

Comparisons using culture as the reference standard are shown in blue and those using a clinical reference standard in red.

When there were 4 or more studies, pooled values were obtained using the ‘midas’ command in Stata; when there were less than 4 studies the pooled values were estimated using the ‘metan’ command.

AFB = acid-fast bacilli; CRS = clinical reference standard; NTM-NAAT = NAAT designed to detect all non-tuberculous mycobacteria; MAC-NAAT = NAAT designed to detect *M. avian* complex; NAAT = nucleic acid amplification testing

AFB microscopy was not very useful in identifying patients who did not have NTM infections. The pooled sensitivity for AFB microscopy versus culture was 47% (95%CI 24, 72), indicating that 53% of patients with a positive culture would have a false-negative result. When compared with a clinical diagnosis based on symptoms, histopathology and culture results, 77% of those diagnosed had a false-negative AFB result (pooled sensitivity 31%; 95%CI 4, 58). However, the pooled specificity was 97–100%, indicating that few patients would have a false-positive AFB result (Figure 30). The LR scattergram in Figure 31A shows that the summary LR+ and LR– estimates for AFB microscopy are in the upper right quadrant, indicating that patients with a positive AFB microscopy result are indeed very likely to have an NTM infection detectable by culture. However, a negative AFB result does not exclude the possibility of having an NTM infection and has no diagnostic value.

When comparing AFB microscopy with NTM-NAAT using culture as the reference standard, the pooled estimates suggested that NTM-NAAT was more sensitive (47% versus 84%; Figure 30), but this was not statistically significant as the CIs overlapped. There was a smaller difference in the pooled sensitivity for AFB microscopy compared with MAC-NAAT, with the CIs almost completely overlapping (47% versus 59%; Figure 30). Nevertheless, fewer patients would receive a false-negative result with NAAT compared with AFB microscopy, with up to 23% of NTM culture-positive patients being AFB-negative and NTM-NAAT-positive.

The summary LR+ and LR– values with 95% CIs (respectively) for:
AFB versus culture = 10.9 [1.7, 69.9] and 0.55 [0.36, 0.85]
NTM-NAAT versus culture = 8.5 [1.0, 68.52] and 0.18 [0.04, 0.72]
MAC-NAAT versus culture = 125.0 [48.4, 323.2] and 0.41 [0.23, 0.73]


Figure 31 LR scattergram for diagnosis of NTM infection by AFB microscopy (A) and NAAT (B) compared with culture

AFB = acid-fast bacilli; NTM-NAAT = NAAT designed to detect all non-tuberculous mycobacteria; MAC-NAAT = NAAT designed to detect *M. avian* complex; NAAT = nucleic acid amplification testing

NTM-NAAT was less specific than MAC-NAAT using culture as the reference standard (90%; 95%CI 46, 99 versus 100%; 95%CI 99, 100), but did not differ significantly to that for AFB microscopy (96%; 95%CI 68, 100). It should be noted that culture is an imperfect reference standard. When compared with a clinical reference standard, only 46% (95%CI 27, 66) of those clinically diagnosed were culture-positive, and only 31% (95%CI 4, 58) were AFB-positive. The median sensitivity for NTM-NAAT (99%, range 98–100, k=2; Figure 49) was higher than for culture and the specificity ranged from 87–100%. This suggested that most patients who were NTM-NAAT-positive and culture-negative probably had clinical disease.

In Figure 31, the LR scattergram showed that the summary LR+ and LR– values were in the top right quadrant, suggesting that a patient with a positive MAC-NAAT most likely had a MAC infection detectable by culture. However, a negative MAC-NAAT result does not eliminate the possibility of being culture-positive. On the other hand, the summary LR+ and LR– values for NTM-NAAT were within the green shaded areas, indicating that a patient with a positive NTM-NAAT is more likely to be culture-positive than not, and that a negative NTM-NAAT may be suggestive of not having a culture-positive infection. Thus, NAAT performed similarly to AFB microscopy in the ability to confirm the presence of culture-positive NTM infections, but NTM-NAAT was more likely to correctly predict the absence of disease.

The SROC curve, which depicts the relative trade-off between true-positive and false-positive results, shows a trend indicating that there may be a threshold effect between MAC and NTM-NAATs (Figure 32). The AUCs for NTM-NAAT (0.92; 95%CI 0.90, 0.94) and MAC-NAAT (1.00; 95%CI 0.98, 1.00) indicate that the NAATs perform well in predicting culture positivity (AUC > 0.9), whereas AFB microscopy (0.76; 95%CI 0.72, 0.79) performs only moderately (AUC 0.7–0.9). There was also a threshold effect between NTM-NAAT and MAC-NAAT indicating that NTM-NAAT is more sensitive and less specific.




Figure 32 SROC curve for all studies investigating the sensitivity and specificity of AFB and NAAT versus culture in the diagnosis of NTM

AUC = area under curve; SROC = summary receiver–operator characteristic; NTM-NAAT = NAAT designed to detect all non-tuberculous mycobacteria; MAC-NAAT = NAAT designed to detect *M. avian* complex; NAAT = nucleic acid amplification testing

Although the pooled sensitivity of the 3 MAC-NAAT studies that included HIV-positive patients was only 49% compared with 69% for the other 2 MAC-NAAT studies, this difference was not significant as the wide CIs almost completely overlapped (Figure 50 in Appendix D). Thus, there is no obvious difference in test performance in specimens from HIV-positive patients compared with those that are HIV-negative.

No conclusions could be reached about the accuracy of NAAT in the diagnosis of NTM in AFB-positive or -negative specimens. Not surprisingly, many specimens included in the analysis were AFB-negative (mean 16%, range 0-39), largely due to the paucibacillary nature of many specimen types tested for NTM infections. As a result, only 3 studies provided any data on AFB-positive specimens, 2 of which used NTM-NAAT and 1 MAC-NAAT. When these studies were compared with the 6 studies (3 NTM-NAAT and 3 MAC-NAAT) that provided data on AFB-negative specimens, the variability between studies was so great that no conclusions could be reached (Figure 50 in Appendix D).

Together, these results suggest that NAAT may be a better diagnostic test for diagnosing NTM infections than either AFB microscopy or culture. However, the results should be viewed with caution due to the small number of studies included and the wide 95%CIs for many of the analyses.

# Other relevant considerations

## TB in the Australian Indigenous population

#### High incidence of TB among Indigenous Australians

Although rates of TB in Australia are low, the absolute numbers of TB cases increased by 33% between 1998 and 2008, and specific subgroups such as indigenous Australians and immigrants have much higher rates than other Australians. The *Tuberculosis notifications in Australia, 2010 Annual Report*[[16]](#footnote-16) found that the incidence of TB in the Australian-born Indigenous population was 11 times higher than in the Australian-born non-Indigenous population (7.5 versus 0.7 per 100,000 people).

The *Strategic Plan for Control of Tuberculosis in Australia: 2011–2015*[[17]](#footnote-17) reported that rates of TB infection increase with age and transmission of TB to infants and children still occurs. Indigenous Australians also have higher rates of hospitalisation and mortality from TB than non-Indigenous Australians. Testing has shown that clustering of cases in households, and remote and town-camp communities occurs.

#### Addressing the problem

Strategies and policies such as *Closing the Gap*[[18]](#footnote-18) and *The Strategic Plan for Control of Tuberculosis in Australia: 2011–2015* are aimed at addressing the high Indigenous TB rates. Key priorities and actions for TB control that impact on Indigenous Australians include:

* reducing the disparities in TB rates among population sub-groups within Australia
* minimising the development of drug resistance within Australia
* ensuring the continued provision of safe, timely laboratory diagnosis of TB
* developing a strategy for awareness campaigns for primary care and organisations representing high-risk groups
* developing a national strategy for long-term assured supply of quality TB diagnostics and medications.

Skilled clinical and laboratory staff and universal access to rapid and reliable diagnosis and treatment for TB are critical for the success of these measures[[19]](#footnote-19). There are five state Mycobacterium Reference Laboratories in Australia, which provide basic TB diagnostic services (AFB microscopy and culture) as well as NAAT, DST, rapid molecular detection of drug resistance, and molecular epidemiological typing. These laboratories also provide specialised diagnostic services for the detection and characterisation of clinically significant NTM infections.

In providing these services, laboratories face increasing challenges such as the rising costs of providing a range of NAATs and compliance with progressively more stringent biosafety standards. Thus, the laboratories require the continued support of federal and state governments to remain an integral part of the nation’s TB control program. Currently, the cost of NAAT is mostly covered by state funding to the laboratories, but the availability of reimbursement for NAAT on the MBS would aid laboratories in maintaining the current high standard of the services provided. MBS reimbursement would also enable other public and private laboratories to offer NAAT in cooperation with the reference laboratories, which would provide training of laboratory personnel in mycobacterial diagnostics in both the public and private sectors. The broader availability of NAAT may result in more-rapid diagnosis and treatment of TB, leading to a further reduction in the spread of TB among close contacts in the community. This would benefit both the Indigenous and the immigrant populations.

#### Point-of-care NAAT for the detection of MTB and rifampicin resistance

Indigenous Australians who live in remote communities face specific challenges in being able to access healthcare initiatives such as TB control programs. Rapid diagnosis and treatment is essential to contain the spread of TB in these communities, especially to children and infants. Thus, point-of-care testing with same-day results offers easier access to diagnosis and more-rapid treatment initiation for people living in these isolated communities.

Xpert is the first fully automated NAAT developed for point-of-care diagnosis of MTB and rifampicin-resistant MTB, and was endorsed by the WHO in December 2010 ([WHO 2014](#_ENREF_223)). WHO stated that ‘Xpert testing should not be placed solely in centralized reference laboratories since patients gain the greatest benefit from the test when it is placed as close as possible to the point of care’. However, WHO also noted that certain conditions and infrastructure need to be available to ensure its efficient use. These include a stable and continuous electrical supply, an ambient temperature of 15–30 °C in the testing room, trained staff to perform the test, and biosafety precautions similar to those needed for direct AFB microscopy.

Three studies that met the inclusion criteria and looked at the use of Xpert in a point-of-care setting were included in this report. Only 1 of these studies provided any diagnostic accuracy data, reporting on the concordance between Xpert conducted by a nurse and by a trained laboratory technician. All 3 studies reported on differences in time to treatment initiation, with 2 studies also reporting health-related treatment outcomes.

A randomised, parallel-group, multicentre trial conducted by Theron et al. ([2014](#_ENREF_200)) randomised adults with symptoms suggestive of active TB from five primary healthcare facilities in South Africa, Zimbabwe, Zambia, and Tanzania to nurse-performed Xpert NAAT or sputum AFB microscopy at the clinic. In this study nurse-administered Xpert had substantial agreement with that done by a laboratory technician on a paired sputum specimen (κ=0·69; 95%CI 0·64, 0·74), and had a similar sensitivity and proportion of unusable results. The authors reported that nurse-administered Xpert detected 154 (83%) of 185 culture-positive patients, 112 of whom started treatment on the same day. However, as AFB microscopy was also done on site, the delay in treatment initiation in 91 (50%) of 182 culture-positive patients was only 1 day (IQR 0–4). Thus, it was not surprising that there were no significant differences in morbidity and mortality at either 2 months or 6 months follow-up between the two groups. Nevertheless, nurse-administered Xpert detected a larger proportion of culture-positive cases than AFB microscopy (83% versus 50%). Thus, more patients would start treatment immediately after Xpert than after AFB microscopy.

A cohort study by Van Rie et al. ([2013a](#_ENREF_212)) reported on the use of Xpert at a large primary care clinic in South Africa between April and October 2010. On presentation, two sputum samples were collected for AFB microscopy (and NAAT if the patient consented to participate in the study), and the patient was given a 5-day course of antibiotics if clinically indicated and asked to return within 5–7 days. Individuals returned to the clinic for their results after a median of 8 days (IQR 6–22). A third sputum sample was then collected and sent to a central laboratory for fluorescent AFB microscopy and liquid culture. The authors reported that patients who were Xpert-positive were started on anti-TB treatment on the same day as collection of the third sputum specimen in 15/16 cases, compared with a median delay of 13 days (IQR 7–27) for 38 patients diagnosed by chest X-ray and 34 days for 1 patient diagnosed by culture. Three patients were identified as AFB-positive and Xpert-negative (two were also culture-negative); however, none of them started treatment due to unsuccessful tracing.

A third study by Hanrahan et al. ([2013](#_ENREF_82)) was conducted between July and September 2011 at the same South African primary care clinic as the study by Van Rie et al. (2013a). In this study 96% (48/50) of Xpert-positive patients were started on treatment on the same day as presenting with symptoms (IQR 0–0), compared with a treatment delay of 14 days (IQR 7–29) for 18 Xpert-negative patients who were diagnosed by chest X-ray, 144 days (IQR 28–180) for 14 patients diagnosed by culture and 14 days (IQR 5–35) for those diagnosed empirically according to symptoms. However, at 6 months, treatment outcomes did not differ significantly between patients who were initially Xpert-positive or -negative (p=0.46). Among the 48 Xpert-positive cases started on treatment, 48% had a successful treatment outcome (i.e. 6-month treatment completion or cure) and 2% died. Among the 58 Xpert-negative patients started on treatment, 64% completed the treatment or were cured, and 2% died.

Thus, Xpert could be suitable for use in small regional hospitals and clinics in rural areas of Australia if suitable training of personnel was available. This would reduce the time between specimen collection and availability of test results for people living in remote communities, and may result in quicker treatment initiation. In addition, the early knowledge of rifampicin resistance may influence treatment decisions, ensuring that appropriate anti-TB drugs are given immediately. The linked evidence on patient outcomes due to a change in management indicated that there does not appear to be any advantage for patient health-related outcomes (e.g. cure) with early versus delayed treatment. However, early appropriate drug treatment reduced both the spread of TB to close contacts and the likelihood of developing drug resistance. Both of these are important public health outcomes essential for the control of TB in Australia.

# What are the economic considerations?

## Economic evaluation

#### Overview

A cost–utility analysis is presented to assess the cost-effectiveness of adding NAAT to AFB smear microscopy, and culture and sensitivity (C&S) testing in a population with clinical signs and symptoms of active TB. This is consistent with previously published economic evaluations of NAAT identified in the international literature. The economic model takes the form of a decision tree analysis, incorporating estimates of TB prevalence in the tested population, and AFB microscopy ± NAAT accuracy. The time horizon of the model is 20 months, chosen to capture all related costs and health outcomes in patients treated for TB ± MDR. Costs captured in the economic modelling include those of treatment, treating AEs, monitoring/management, hospitalisation and secondary transmissions. Outcomes were measured in quality-adjusted life years (QALYs), which were adjusted to capture disutility associated with treatment, and a further utility penalty was applied to account for decreased outcomes associated with active TB transmissions.

Four scenarios were considered in the economic analyses, based on the involvement of clinical judgment in initial treatment decisions (i.e. in determining the pre-test probability of TB). Various sensitivity analyses were also undertaken. The ICER of NAAT in the scenario thought to best reflect current practice (the ‘TB mixed scenario’) is $90,728/QALY. The incremental costs were observed to be driven largely by the cost of NAAT ($130). The ICER is most sensitive to decreases in the prevalence of TB in the tested population and in the specificity of NAAT, particularly in those with AFB-negative results and for rifampicin resistance.

### Population and setting for the economic evaluation

The PASC protocol listed three populations with suspected active mycobacterial infections that would be considered potentially eligible for MBS-funded NAAT. These are patients:

* with clinical signs and symptoms of active TB whose specimen is able to have AFB microscopy and C&S testing
* with clinical signs and symptoms of active TB whose specimen is not able to have AFB microscopy but who have C&S testing
* suspected of having an NTM infection who are able to have C&S testing.

NAAT is proposed to be undertaken as an additional test to existing test procedures in all these populations.

For patients suspected of TB the protocol indicates that initial treatment decisions are based on the clinical suspicion (pre-test probability) of TB, based on clinical judgement of the background epidemiology of the patient, presenting symptoms and imaging features. If TB is clinically suspected, patients are currently initiated on treatment irrespective of the AFB result. However, if the clinical suspicion of TB is deemed low, the decision to initiate treatment is based on AFB, if able to be performed. This is consistent with the current clinical management algorithm presented in Figure 3.

The introduction of NAAT is not expected to alter treatment initiation decisions in patients with a strong clinical suspicion of TB. However, as NAAT has the ability to identify mutations associated with rifampicin resistance, an appropriate MDR-TB treatment regimen may be initiated sooner in those identified with rifampicin resistance. In patients with a low clinical suspicion of TB, the PASC protocol considers that treatment decisions would be based on the NAAT result if AFB and NAAT are discordant. This is consistent with the proposed clinical management algorithm presented in Figure 3.

There is inadequate evidence available to demonstrate the effectiveness of NAAT in the second and third populations, and so economic evaluations for these populations would be inappropriate. Any health outcome difference incorporated into the model would not be evidence-based and therefore could only be speculative. Subsequently, a calculation of cost-effectiveness would be inappropriate as it would generate results that do not have an evidentiary basis. Any ICER would be subject to an unacceptable level of uncertainty and could be potentially misleading. However, a costing assessment has been undertaken of the financial implications for the MBS and Australian governments should the proposed listings for the second and third populations be accepted (see ‘Financial implications’)

The PASC protocol indicated that, due to possible differences in the accuracy of NAAT in patients with and without HIV, separate analyses should be presented (with the proposed structure of the decision analytic also considering HIV subgroups). However, as the clinical assessment found little difference in the accuracy between these populations (see ‘Comparison of AFB microscopy and NAAT, using culture as a reference standard in HIV-positive and HIV-negative patients’), and no evidence for change in management was identified, this subgroup has not been modelled separately. As all patients suspected of TB who are known to have an HIV infection would be considered to have a high clinical suspicion of TB, treatment is likely to be initiated on the basis of this suspicion. In this respect, the modelled scenario that best represents this population is that in which all patients are considered to have a high clinical suspicion of TB (see ‘Modelled economic evaluation’).

### Structure and rationale of the economic evaluation

#### Economic literature review

A literature search was conducted to identify published economic evaluations of NAAT for active TB infections (in those who can have an AFB) and to inform the structure of and inputs to the economic model (see Appendix H).

Five studies were identified that investigated the cost-effectiveness of NAAT in low-prevalence populations, as these are the most relevant to the Australian population (Table 42) ([Choi et al. 2013](#_ENREF_40); [Dowdy et al. 2003](#_ENREF_56); [Hughes et al. 2012](#_ENREF_89); [Millman et al. 2013](#_ENREF_140); [Rajalahti et al. 2004](#_ENREF_174)).

Table 42 Economic evaluations identified that investigate NAAT for active TB in low-prevalence countries

| Study | Setting | Results |
| --- | --- | --- |
| Millman et al. ([2013](#_ENREF_140)) | Decision tree analysis of adult inpatients in US hospital setting who have presumed TB and are in isolation until results of diagnostic tests (AFB compared with NAAT) become available. Differences in health outcomes were not anticipated, and so net costs were determined, which considered savings associated with the reduction in unnecessary hospitalisations and isolations. The cost implications of FPs and FNs were additionally considered as a cost penalty. | NAAT was associated with cost savings due to reduced hospital isolation and reduced overall length of stay. |
| Choi et al. ([2013](#_ENREF_40)) | Decision tree cost–utility analysis of individuals with suspected pulmonary TB in the USA. A single-year time horizon was used for mapping the decision analytic, after which extrapolation extended the time horizon to the life expectancy of the patients. Models are for HIV-negative and HIV-positive patients (considering different epidemiological and accuracy estimates, but same utility weights), and include outcomes of resistance mutation testing. Costs included lab testing, hospitalisation, isolation and treatment. Implications for FPs were considered. Multiple testing algorithms were modelled.  Algorithm 1 (no molecular testing) is relevant to comparator, with algorithms 3 and 5 relevant to proposed NAAT in Australia. Treatment may be initiated in AFB-negative, NAAT-negative if clinical suspicion is high (i.e. clinical diagnosis) (any algorithm) | Testing without NAAT was dominated by the strategies that included NAAT. |
| Hughes et al. ([2012](#_ENREF_89)) | Decision tree cost–utility analysis of NAAT for people with a clinical suspicion of TB in the UK setting. Time horizon chosen of 1 year. Model incorporates resistance testing and outcomes in FP and FNs. Costs include testing, treatment and follow-up outpatient consultations; isolation costs were not considered. The model did identify the number of people infected by unidentified TB, but attributed neither their costs nor outcomes into the results.  Strategies relevant to this model include #3: AFB and culture every time (for the comparator); and #11: AFB, NAAT and culture every time (for NAAT). | Strategy #11 was unlikely to be cost-effective compared with #3 (ICER £64,723). If secondary infections were incorporated fully into the model, the authors conclude that it could be conceivable that #11 would be optimal, as it was associated with the fewest secondary infections. |
| Rajalahti et al. ([2004](#_ENREF_174)) | Decision tree cost-effectiveness analysis of AFB and culture ± NAAT in patients with a clinical suspicion of TB in the Finnish setting. Effectiveness was measured in terms of correct treatment and isolation decisions. Costs included isolation, treatment, lab tests and inpatient/outpatient visits. Decision tree parameters populated based on observed data. | NAAT was associated with additional costs when applied in all patients, but cost savings were only in AFB-positive patients. |
| Dowdy et al. ([2003](#_ENREF_56)) | Decision tree cost-effectiveness analysis of NAAT in AFB-positive patients in the US setting. Effectiveness was measured in terms of ‘early exclusion of TB’. Costs included testing, isolation and treatment.  Unclear if all patients were subject to C&S testing. | NAAT was not considered cost-effective, as costs did not offset those of isolation and treatment averted. |

AFB = acid-fast bacilli; C&S = culture and sensitivity; FN = false negative; FP = false positive; HIV = human immunodeficiency virus; NAAT = nucleic acid amplification testing; TB = tuberculosis

All 5 studies were generally consistent in structure (decision tree) and time horizon (up to 1 year). Three of the studies considered the implications of false-positive and false-negative results, and most considered the cost of hospital isolation. However, the outcomes of the models varied; 2 studies ([Choi et al. 2013](#_ENREF_40); [Hughes et al. 2012](#_ENREF_89)) measured outcomes in terms of cost per QALY, whereas the other 3 investigated cost per correct treatment or isolation decision, or just costs as no change in outcomes were anticipated. The studies additionally varied in their results, with NAAT considered cost-effective in 3 studies and not cost-effective in 2.

None of the identified studies were conducted in the Australian setting. In Australia treatment initiation decisions take the clinical suspicion of TB into consideration. However, clinical suspicion was not considered in any of the studies identified, and therefore the applicability of the identified economic evaluations to the Australian context is uncertain. A modelled economic evaluation will be presented to determine the cost-effectiveness of NAAT (as an add-on test) in the population who can currently have an AFB.

#### Modelled economic evaluation

The structure of the economic model has been adapted from the cost–utility analyses identified in the literature search ([Choi et al. 2013](#_ENREF_40); [Hughes et al. 2012](#_ENREF_89)) to suit the local context. As clinical management in Australia differs depending on the clinical suspicion of TB, the model will be separated into patients with:

* a high clinical suspicion of TB (where treatment is initiated based on clinical suspicion)
* a low clinical suspicion of TB (where treatment decisions are initiated or delayed based on AFB ± NAAT results).

The benefit of NAAT in patients with high clinical suspicion of TB is to identify resistance mutations and initiate appropriate treatment for MDR earlier. In addition to earlier MDR treatment initiation, patients with low clinical suspicion of TB have additional benefits: NAAT may differentiate between TB and NTM infections (who would have been previously treated on the basis of the AFB results alone), and may reduce the delay in treating those with true TB who returned a negative AFB result (who would not have been treated without the availability of NAAT).

The model will take the form of a cost–utility analysis as this enables an assessment of NAAT in the context of the proposed benefits described above, in addition to quantifying the cost and outcome implications of false-positive and false-negative results (for the AFB microscopy ± NAAT alternatives).

A time horizon of 20 months was chosen, although this is longer than previously published cost–utility analyses, to capture all costs and outcomes associated with treatment for all patients, as treatment beyond 1 year is standard in patients with MDR-TB.

A summary of the structure of the economic model is presented in Table 43.

Table 43 Summary of the economic evaluation

|  |  |
| --- | --- |
| **Time horizon** | 20 months |
| **Outcomes** | QALYs |
| **Costs** | Australian dollars, 2014 prices |
| **Methods used to generate results** | Decision tree analysis |
| **Discount rate** | 5% costs and outcomes accrued beyond 1 year |
| **Software packages used** | Microsoft Excel |

QALY = quality-adjusted life-year

The structure of the decision tree is presented in Figure 33 (AFB model arm) and Figure 34 (AFB plus NAAT model arm).

Currently, patients with true TB are likely to be mixed across the populations that have a high or low clinical suspicion of TB. The prevalence of TB in each of these patient groups is likely to vary, as it would be expected that those with a high clinical suspicion of TB would have a higher prevalence than those with a low clinical suspicion of TB. These assumptions are used to inform the base-case scenario (‘TB mixed scenario’). However, given the influence of clinical judgement on the treatment management pathways, and the uncertainties associated with estimating the relative mix of patients across these groups (see ‘Prevalence of TB’), the influence of clinical judgment on the cost-effectiveness of NAAT will be explored through the addition of the following scenarios:

* TB low suspicion scenario: all patients (including all with true TB) are treated as though they have a low clinical suspicion of TB (i.e. clinical judgment is not used as a basis to initiate treatment)
* Perfect clinical judgment scenario: all patients with true TB are treated as though they have a high clinical suspicion of TB (i.e. clinical judgement is used as a basis to initiate treatment, and it is assumed that this has 100% sensitivity and specificity in identifying TB), and all patients without TB are treated as though they have a low clinical suspicion of TB (i.e. treatment initiation decisions are based on results of AFB ± NAAT)
* TB high suspicion scenario: all patients are treated as though they have a high clinical suspicion of TB (i.e. treatment is initiated in all patients on the basis of clinical judgment).

These additional scenarios are considered to be extreme cases. NAAT is expected to be most cost-effective in the TB low scenario, as it is associated with more benefits in those considered to have a low clinical suspicion of TB. In contrast, NAAT is also expected to be least cost-effective in the scenarios in which all patients with TB, and with or without TB, respectively, are managed as though they have a high clinical suspicion of TB. In these scenarios treatment initiation decisions are based on clinical judgement, with the benefit of NAAT restricted to identifying drug resistance to initiate an appropriate treatment earlier. In the perfect clinical judgement scenario all true TB-negative patients are treated as though they have a low clinical suspicion of TB, and so treatment decisions are based on the results of AFB ± NAAT and only false-positive patients will receive treatment (determined by the specificity of testing). The relative cost-effectiveness of NAAT between these extreme high and low scenarios is likely to be determined by the relative specificity of NAAT compared with AFB.

The cost-effectiveness of the TB mixed scenario, which is thought best to reflect current practice, is likely to lie between the extreme additional scenarios.

###### Model assumptions

* When AFB and NAAT are discordant, the treatment decision is based on NAAT (consistent with PASC protocol)
* C&S testing (the reference standard) is assumed to be 100% sensitive and specific, as all patients have C&S testing and at the end of 2 months all will have correct diagnosis (i.e. MDR-TB, TB or no TB)
* To simplify the model structure, rifampicin resistance is used as a surrogate marker of MDR-TB ([Lumb 2000](#_ENREF_122)), as the majority (37/40) of Australian bacteriologically confirmed cases in 2010 with rifampicin resistance were also MDR ([Lumb et al. 2013](#_ENREF_123))
* Once the decision to initiate or delay treatment has been made, the model assumes there will be no change in treatment until the results of C&S are available; this assumption may favour NAAT, as the earlier initiation of resistant drugs in the comparator arm would reduce the benefit of introducing NAAT
* Cost and utility penalties associated with the secondary transmission of TB are applied for each index case in the model, but the consequences (cost or health outcome) of further ongoing transmissions (e.g. tertiary transmissions and beyond) are not included in the base-case.

Patients with clinical signs and symptoms of active TB and who can have an AFB enter the model at the decision node. This figure presents the structure of the economic model for the decision to undergo AFB testing only (i.e. the comparator). Patients are split into those who have a high or low pre-test probability of TB. All patients who have a high pre-test probability of TB, irrespective of true TB status and AFB test results, initiate standard TB treatment. On the results of the culture and susceptibility testing, treatment is continued (for patients with true drug-susceptible TB), altered (for patients with drug-resistant TB) or stopped (for patients truly negative for TB).
Treatment initiation decisions in patients with a low pre-test probability are based on the results of AFB testing. Prevalence of TB in those considered having a low pre-test probability, prevalence of rifampicin resistance in those with TB and sensitivity and specificity parameters of AFB testing are used to estimate the proportion of patients who receive standard TB treatment or who defer treatment. On the results of the culture and susceptibility testing, treatment is initiated (for patients who with true TB ± drug-resistance in whom treatment was initially deferred), continued (for patients with true drug-susceptible TB who initiated treatment), altered (for patients with drug-resistant TB who initiated treatment) or stopped (for patients truly negative for TB who initiated treatment).

Figure 33 Decision analytic structure of the economic evaluation, comparator (AFB) model arm

AFB = acid-fast bacilli test; C = culture; High\_pretest = proportion of patients considered to have high clinical suspicion of TB; MDR = multidrug-resistant; RIF res = rifampicin resistant; RIF suscept = rifampicin susceptible; Rif\_res = prevalence of rifampicin resistance in TB; sensAFB = sensitivity of AFB for TB; specAFB = specificity of AFB for TB; S = susceptibility; TB = tuberculosis; TB\_high = prevalence of TB in high clinical suspicion population; TB\_low = prevalence of TB in low clinical suspicion population

Patients with clinical signs and symptoms of active TB and who can have an AFB enter the model at the decision node. This figure presents the structure of the economic model for the decision to undergo AFB + NAAT (i.e. the intervention). Patients are split into those who have a high or low pre-test probability of TB. All patients who have a high pre-test probability of TB, irrespective of true TB status and AFB + NAAT results, initiate TB treatment. The introduction of NAAT enables drug-resistance to be identified prior to treatment initiation, and so MDR therapy may be initiated, based on the prevalence of TB in those considered to have a high pre-test probability, prevalence of rifampicin resistance in those with TB and sensitivity and specificity parameters of NAAT in identifying TB and of identifying drug-resistance. On the results of the culture and susceptibility testing, treatment is continued (for patients with true drug-susceptible TB who initiated standard treatment, or patients with drug-resistant TB who initiated MDR treatment), altered (for patients with drug-resistant TB who initiated standard treatment, or patients with drug-susceptible TB who initiated MDR treatment) or stopped (for patients truly negative for TB). Improved outcomes are associated with the introduction of NAAT in patients with true MDR-TB who initiate MDR treatment, with detrimental outcomes associated with NAAT in patients in whom MDR treatment is falsely initiated.
Treatment initiation decisions in patients with a low pre-test probability are based on the results of AFB + NAAT. Prevalence of TB in those considered having a low pre-test probability, prevalence of rifampicin resistance in those with TB, sensitivity and specificity parameters of AFB testing and sensitivity and specificity parameters of NAAT for TB and for rifampicin resistance are used to estimate the proportion of patients who receive standard TB treatment, MDR-TB treatment or who defer treatment. On the results of the culture and susceptibility testing, treatment is initiated (for patients who with true TB ± drug-resistance in whom treatment was initially deferred), continued (for patients with true drug-susceptible TB who initiated standard treatment, or patients with drug-resistant TB who initiated MDR treatment), altered (for patients with drug-resistant TB who initiated standard treatment, or patients with drug-susceptible TB who initiated MDR treatment) or stopped (for patients truly negative for TB who initiated treatment). Improved outcomes are associated with the introduction of NAAT in patients with true MDR-TB who initiate MDR treatment or who defer treatment (when ineffective standard would have been initiated), patients with true drug-susceptible TB who would have deferred treatment based on AFB results or patients truly negative for TB who would have initiated treatment based on AFB results. Detrimental outcomes associated with NAAT resulted in patients in whom MDR treatment is falsely initiated, or standard treatment is initiated in MDR-TB or TB negative, or treatment is deferred in drug-susceptible TB.


Figure 34 Decision analytic structure of the economic evaluation, intervention (AFB plus NAAT) model arm

AFB = acid-fast bacilli test; C = culture; MDR = multidrug-resistant; NAAT = nucleic acid amplification test; R = resistance; RIF res = rifampicin resistant; RIF suscept = rifampicin susceptible; Rif\_res = prevalence of rifampicin resistance in TB; sensAFB = sensitivity of AFB for TB; sensNAAT\_AFBn = sensitivity of NAAT for TB in AFB-negative; sensNAAT\_AFBp = sensitivity of NAAT for TB in AFB-positive; sensNAAT\_rif\_res = sensitivity of NAAT for rifampicin resistance; specAFB = specificity of AFB for TB; specNAAT\_AFBn = specificity of NAAT for TB in AFB-negative; specNAAT\_AFBp = specificity of NAAT for TB in AFB-positive; specNAAT\_rif\_res = specificity of NAAT for rifampicin resistance; S = susceptibility; TB = tuberculosis; TB\_high = prevalence of TB in high clinical suspicion population; TB\_low = prevalence of TB in low clinical suspicion population

###### Implications for false-positive and false-negative results

The decision trees presented in Figure 33 and Figure 34 culminate in nine different categories according to whether a true or false result is initially concluded (referred to as ‘outcome states’). These are summarised in Table 44.

Table 44 Summary of decision tree outcome states in the economic evaluation

| True status | Treated status | Implication |
| --- | --- | --- |
| No TB | Untreated (TBTN) | Correct no treatment |
| No TB | Standard treatment (TBFP, TRN) | Standard treatment initiated, stop treatment on C&S results |
| No TB | MDR treatment (TBFP, FRP) | MDR treatment initiated, stop treatment on C&S results |
| TB | Untreated (TBFN) | No treatment initiated, begin standard treatment on C&S results |
| TB | Standard treatment (TBTP, TRN) | Correct standard treatment |
| TB | MDR treatment (TBTP, FRP) | MDR treatment initiated, switch to standard treatment on C&S results |
| MDR-TB | Untreated (TBFN) | No initial treatment initiated, begin MDR treatment on C&S results |
| MDR-TB | Standard treatment (TBTP, FRN) | Standard treatment initiated, switch to MDR treatment on C&S results |
| MDR-TB | MDR treatment (TBTP, TRP) | Correct MDR treatment |

C&S = culture and sensitivity; FRN = false resistance negative; FRP = false resistance positive; MDR = multidrug-resistant; TB = tuberculosis; TBFN = tuberculosis false negative; TBFP = tuberculosis false positive; TBTN = tuberculosis true negative; TBTP = tuberculosis true positive; TRN = true resistance negative; TRP = true resistance positive

*False-negative results (i.e. initially untreated TB (± MDR) or initial standard treatment in MDR-TB)*

As there was no indication from the clinical assessment that a treatment delay of up to 2 months leads to an increase in disease severity ([van der Oest, Kelly & Hood 2004](#_ENREF_210)), the economic modelling will assume treatment duration and QoL (from the time of correct diagnosis) as for those correctly treated. However, there is some indication that a delay in treatment leads to an increased risk of TB transmission ([Ponticiello et al. 2001](#_ENREF_169)). A cost and utility penalty are applied to account for the treatment costs and utility decrement associated with secondary infections; see ‘TB transmissions’ and Utility penalty for active TB transmissions’ for further details.

Treatment outcomes in MDR-TB patients treated initially with the standard regimen are assumed to be poorer than for those initially untreated, as treatment is ineffective and associated with AEs (i.e. outcomes equal to those untreated who then have a disutility associated with treatment applied).

*False-positive results (i.e. initial TB (± MDR) treatment in true-negative patients or MDR-TB treatment in susceptible TB)*

Patients that are truly negative for TB who undergo initial TB (± MDR) treatment are assumed to have the cost and disutility of 2 months of the applicable treatment applied. As these patients may have a range of alternative diagnoses that present with similar symptoms (associated with differing costs and outcomes), the delay to treatment for the alternative diagnosis is not considered in the assessment.

Patients with true susceptible TB that are treated initially with MDR regimen are assumed to be effectively treated but have poorer overall health outcomes than those treated with the standard regimen because of the increased AEs associated with MDR treatment.

### Inputs to the economic evaluation

***Prevalence***

###### Prevalence of TB

The prevalence of TB, defined as culture-positive, in studies included for the diagnostic accuracy of NAAT conducted in a low TB incidence country (k=11) was 24% (range 6−60%) (Table 93, Appendix D).

A reliable estimate for the prevalence of TB in the population with clinical signs and symptoms of active TB in Australia was not identified during the assessment, nor were estimates of the respective prevalences where that patient group is divided into those considered to have either a high or low clinical suspicion of TB. This introduces considerable uncertainty in the economic modelling, as the cost-effectiveness is likely to be sensitive to these variables.

Given the uncertainties in prevalence estimates identified, further information was provided by the applicant (an Australian pathology provider)[[20]](#footnote-20). It was estimated that 10−20% of patients would be considered to have a high clinical suspicion of TB, of which 50−70% would have TB. In those considered to have a low clinical suspicion of TB (the remaining 80−90% of patients) the prevalence is estimated to be in the range 5−10%. Using the upper limits of these estimates provides an overall prevalence estimate of 22% (Table 45). This value is reasonably similar to the prevalence of TB reported in the diagnostic accuracy studies conducted in low incidence countries (24%, Table 93, Appendix D), and so appears to have face validity.

It would be expected that the higher the proportion of patients with true TB that are treated based on clinical judgement, the less cost-effective NAAT will be, as there are fewer benefits of NAAT for patients managed this way; therefore, using the upper limit of these estimates is the conservative choice and will be used in the base-case analysis of the economic evaluation. However, it should be noted that if the overall prevalence of TB is an overestimate, the cost-effectiveness of NAAT may too be overestimated. Given that these are best-guess estimates, sensitivity analyses around these estimates will be presented.

Additional scenarios are presented to examine the extent to which treatment initiation decisions based on clinical suspicion affect the ICER. The base-case prevalence of 22% is maintained in these scenarios; however, all are managed as though they have either low or high clinical suspicion of TB, depending on the scenarios (Table 45).

Table 45 Prevalence estimates used in previously published economic evaluations of NAAT

| Scenario | Proportion high clinical suspicion A | Prevalence (high clinical suspicion)B | TB high clinical suspicion C (A × B) | Prevalence (low clinical suspicion) D | TB low clinical suspicion E ((1 − A) × D) | **Total (C + E)** |
| --- | --- | --- | --- | --- | --- | --- |
| TB mixed | 20% | 70% | 14% | 10% | 8% | 22% |
| TB low suspicion | 0% | 0% | 0% | 22% | 22% | 22% |
| Perfect clinical judgment | 22% | 100% | 22% | 0% | 0% | 22% |
| TB high suspicion | 100% | 22% | 22% | 0% | 0% | 22% |

NAAT = nucleic acid amplification testing; TB = tuberculosis

###### Prevalence of MDR-TB

The Australian Mycobacterium Reference Laboratory Network reported 1,051 bacteriologically confirmed cases of TB in 2010 ([Lumb et al. 2013](#_ENREF_123)). Results of susceptibility testing to first-line treatments were available for 1,050 cases (99.9%) and multidrug resistance was reported in 37 cases (3.5%). However, 16 patients with MDR-TB were Papua New Guinea nationals who accessed health services in the Torres Strait Protection Zone. The remaining 21 MDR-TB patients were people who lived in Australia. This represents 2.0% of the bacteriologically confirmed cases of TB. This estimate will be used as the base-case estimate for the prevalence of MDR-TB in TB cases in the economic analysis. An upper limit of 3.5% will be tested in sensitivity analyses, to reflect the proportion of MDR-TB in all bacteriologically confirmed cases of TB in 2010; a lower limit of 0.5% will be used, which reflects the lowest proportion observed by the Australian Mycobacterium Reference Laboratory Network since 1995 (Figure 35). This is consistent with proportions observed in Victoria during 2002–07 (0.6%–2.2%) ([Lavender, Brown & Johnson 2009](#_ENREF_113)).

The graph shows that the proportion of MDR-TB compared to all TB in patients living in Australia has fluctuated between 2001 and 2010, varying between 0.6% in 2005 and 2.0% in 2010.

Figure 35 Percentage of TB cases that exhibited multidrug resistance in Australia, 1995–2010

MDR-TB = multidrug-resistant tuberculosis; TSPZ = Torres Strait Protection Zone

Source: Figure 2, Lumb et al. ([2013](#_ENREF_123))

#### Test parameters

As NAAT is an add-on test, and as accuracy of NAAT differs by AFB result, accuracy estimates of NAAT used in the model are separated by AFB status.

Accuracy estimates used in the economic evaluation are based on the results of the meta-analyses of all patients, in all tissue types, as presented in the clinical assessment (Table 46). As accuracy estimates reported in studies that were conducted in low-incidence countries (Canada, France etc.) may be more applicable to the Australian context, these estimates will be used in the base-case analysis, with 95%CI tested in sensitivity analyses. Given that countries in a low-incidence setting form the minority of results for the accuracy of AFB (k=11) and NAAT by AFB status (k=4), sensitivity analyses will be presented using the results for these parameters from all studies included in the clinical assessment.

Table 46 Test parameters used in the economic evaluation

| Test | k | Sensitivity [95%CI] | Specificity [95%CI] | Source |
| --- | --- | --- | --- | --- |
| *Base case (low-incidence countries)* | *--* | *--* | *--* | *--* |
| AFB for TB | 11 | 56% [44, 68] | 98% [94, 100] | Figure 51 |
| NAAT in AFB+ for TB | 4 | 98% [94, 100] | 97% [1, 100] | Figure 51 |
| NAAT in AFB– for TB | 4 | 70% [51, 84] | 99% [94, 100] | Figure 51 |
| NAAT for rifampicin resistance | 8 | 92% [81, 97] | 99% [96, 100] | Figure 51 |
| *Sensitivity analyses (all countries)* | *-* | *-* | *-* | *-* |
| AFB for TB | 68 | 62% [54, 69] | 98% [97, 99] | Figure 51 |
| NAAT in AFB+ for TB | 25 | 99% [96, 100] | 78% [53, 92] | Figure 51 |
| NAAT in AFB– for TB | 39 | 80% [69, 87] | 94% [88, 97] | Figure 51 |
| NAAT for rifampicin resistance | 11 | 93% [85, 97] | 91% [78, 96] | Figure 51 |

AFB = acid-fast bacilli test; NAAT = nucleic acid amplification test; TB = tuberculosis

***Healthcare resources***

###### Test costs

The PASC protocol does not provide a proposed item fee for NAAT but indicates that the New South Wales (NSW) Mycobacterium Reference Laboratory charges $200 per NAAT, while that in Victoria charges $88. Both these laboratories were contacted during the assessment to confirm these costs and seek further information that may explain the differences in cost (e.g. commercial versus in-house, or if separate tests are conducted for resistance mutation testing). The Victorian laboratory indicated that an in-house NAAT costs $82 and that using the commercial Xpert kit is $130, met primarily through the Victorian State Government—only private patients & non-Australian residents are billed for testing[[21]](#footnote-21). It is unclear if the in-house PCR cost includes that of *rpoB* sequencing. This laboratory also indicated that rifampicin resistance mutations identified using Xpert are confirmed by in-house *rpoB* sequencing before results are released. These costs are assumed to be additional to the $130 test cost. No further information was provided by the NSW laboratory.

A search of pathology providers across the country indicated that at least two NSW public (bulk-billing) services[[22]](#footnote-22) bill ‘TB-PCR’ under MBS item 69494 ($28.65). It is unclear if this is indicative of the cost of NAAT for TB, or if it is used as a partial subsidy and the NSW State Government is responsible for the difference. A private pathology provider in Victoria charges $100.50 for ’*Mycobacterium* TB-PCR’ with no Medicare funding[[23]](#footnote-23).

The Mycobacterium Reference Laboratories in the other states (South Australia (SA), Western Australia (WA) and Queensland) were also contacted during the assessment to gather information regarding current NAAT use and costs. The laboratory in SA indicated that they conduct NAAT using the commercial Xpert kit at a cost of $70, which is currently funded by the SA State Government[[24]](#footnote-24). In WA, NAAT is conducted using either the Xpert kit or in-house real-time PCR (the choice of which depends on microscopy result, specimen type and clinical history), with an approximate cost of $40 per test, met predominantly by the laboratory and/or public health authorities[[25]](#footnote-25).

The applicant has indicated that they are charged approximately $100 by their state reference laboratory; however, the applicant assumes that this cost includes NAAT in addition to TB antigen and high-performance liquid chromatography testing, and so the approximate cost is not indicative of NAAT alone[[26]](#footnote-26).

In the absence of further information regarding NAAT costs, the base-case analysis assumes a test cost of $130 (based on the Victorian reference lab Xpert cost, as per advice from the Department of Health Policy Area). ICERs using alternative item fees for NAAT are presented in Appendix J.

As diagnostic AFB and C&S testing applies to all patients in both model arms, costs associated with these tests will not be considered.

###### Treatment costs

Costs were sourced for medications used commonly to treat susceptible TB and MDR-TB ([Street et al. 2012](#_ENREF_189)). Sources included the Pharmaceutical Benefits Schedule (PBS), where listed, and Chemist Warehouse, where not listed on the PBS. However, not all medications used in the treatment of TB are marketed for use in Australia, and so are only available through the Special Access Scheme. In these instances, and where costs could not be sourced alternatively, they were sourced from a public hospital pharmacy[[27]](#footnote-27). Some medications require co-administration with pyridoxine; these costs have been included in the analysis.

For the treatment of susceptible TB, the standard regimen consists of 2 months’ treatment with isoniazid, rifampicin, pyrazinamide and ethambutol (intensive phase), followed by a further 4 months with isoniazid and rifampicin (continuation phase). Daily doses are assumed based on the maximum dose per day ([Street et al. 2012](#_ENREF_189)).

For the treatment of MDR-TB it is assumed that the organism is resistant to isoniazid and rifampicin. The intensive phase of treatment consists of pyrazinamide, ethambutol, amikacin, moxifloxacin and prothionamide for 6 months, followed by 12 months of pyrazinamide, ethambutol, moxifloxacin and prothionamide ([Street et al. 2012](#_ENREF_189)). Amikacin is initially given intravenously via a peripherally inserted central catheter 5 days per week for the first 3 months and 3 days per week for the following 3 months ([Jenkins, Dedicoat & Cook 2013](#_ENREF_92)). A one-off catheterisation cost has been applied in the model to account for the insertion of the catheter (MBS item 13815, $85.25). After the initial hospitalisation period (see ‘Hospitalisation’), administration is assumed to occur in the home ([Jenkins, Dedicoat & Cook 2013](#_ENREF_92)) at a cost of $234 per administration ([Victoria State Government Department of Health 2014](#_ENREF_214)) (see Table 102, Appendix I).

Costs per month have been calculated and are presented in Table 47. These costs are assumed to apply each month while on treatment.

Table 47 Resource items associated with treatment of TB used in the economic evaluation

| Type of resource item | Natural unit of measurement | Unit cost | Source of unit cost | Cost per month |
| --- | --- | --- | --- | --- |
| **Medication (daily dose)** | **-** | **-** | **-** | **-** |
| Isoniazid (300mg) | 100mg tablet, 100 pack | $21.83 | PBS item 1554T | 3 tablets/day = 0.91 packs/month:  $19.93 |
| Rifampicin (600mg) | 300mg capsule, 100 pack | $147.98 | PBS item 1983J | 2 capsules/day = 0.61 packs/month:  $90.08 |
| Pyrazinamide (2000mg) | 500mg tablet, 100 pack | $77.00 | Public hospital pharmacy a | 4 tablets/day = 1.22 packs/month:  $93.75 |
| Ethambutol (1200mg) | 400mg tablet, 56 pack | $133.99 | Chemist Warehouse b | 3 tablets/day = 1.63 packs/month:  $218.48 |
| Amikacin (571mg) | 500mg/2 mL vial, 5 vial pack | $470.24 | Public hospital pharmacy a | 1.14 vials/day = 6.95 packs/month:  $3,269.07 |
| Moxifloxacin (400mg) | 400mg tablet, 5 pack | $72.99 | Chemist Warehouse d | 1 tablet/day = 6.09 packs/month:  $444.33 |
| Prothionamide (750mg) | 250mg tablet, 100 pack | $304.86 | Public hospital pharmacy a | 3 tablets/day = 0.91 packs/month:  $278.38 |
| **Associated costs** | **-** | **-** | **-** | **-** |
| Pyridoxine with isoniazid (25mg) | 25mg tablet, 100 pack | $7.99 | Chemist Warehouse e | 1 tablet/day = 0.30 packs/month:  $2.43 |
| Pyridoxine with prothionamide (300mg) | 100mg tablet, 50 pack | $11.02 | Chemist Warehouse f | 3 tablets/day = 1.83 packs/month:  $20.13 |
| Peripherally inserted central catheter (amikacin administration) | Insertion | $85.25 | MBS item 13815 | One-off cost (first-month only) |
| Amikacin administration | Per infusion | $234.00 | Victorian State Government ([2014](#_ENREF_214)) | Total administration cost for false-positive MDR results: $8,002  Total administration cost for true MDR-TB: $20,943  (see Table 102, Appendix I) |

a personal communication

b <http://www.chemistwarehouse.com.au/product.asp?id=61386&pname=Myambutol+400mg+Tablets+56> (accessed 12 September 2014)

c Assuming 1000mg dose 5 days per week for 3 months, and 1000mg dose 3 times per week for 3 months ([Jenkins, Dedicoat & Cook 2013](#_ENREF_92))

d <http://www.chemistwarehouse.com.au/product.asp?id=55677&pname=Avelox+400mg+Tablets+5> (accessed 12 September 2014)

e <http://www.chemistwarehouse.com.au/product.asp?id=7339&pname=Pyroxin+Tablets+25mg+100> (accessed 12 September 2014)

f <http://www.chemistwarehouse.com.au/product.asp?id=7340&pname=Pyroxin+Tablets+100mg+50> (accessed 12 September 2014)

The cost per month by treatment regimen (standard or MDR) and phase (intensive or continuing) is presented in Table 48.

Table 48 Cost per treatment regimen, per month

| Treatment regimen | Consists of | Cost per month |
| --- | --- | --- |
| Standard, IP | Isoniazid a, rifampicin, ethambutol, pyrazinamide | $425 |
| Standard, CP | Isoniazid a, rifampicin | $112 |
| MDR, IP | Ethambutol, pyrazinamide, amikacin, moxifloxacin, prothionamide a | $4,324 |
| MDR, CP | Ethambutol, pyrazinamide, moxifloxacin, prothionamide a | $1,055 |

a Co-administered with pyridoxine

CP = continuation phase; IP = intensive phase; MDR = multidrug-resistant

The total treatment course cost by outcome state is presented in Table 49.

Table 49 Total months in treatment and regimen costs, by outcome state

| True status | Treated status | No treatment | Standard (IP) (months) | Standard (CP) (months) | MDR  (IP) (months) | MDR  (CP) (months) | Treatment course cost a |
| --- | --- | --- | --- | --- | --- | --- | --- |
| No TB | Untreated | 20 | 0 | 0 | 0 | 0 | $0 |
| No TB | Standard treatment | 18 | 2 | 0 | 0 | 0 | $849 |
| No TB | MDR treatment | 18 | 0 | 0 | 2 | 0 | $16,735 |
| TB | Untreated | 14 | 2 | 4 | 0 | 0 | $1,299 |
| TB | Standard treatment | 14 | 2 | 4 | 0 | 0 | $1,299 |
| TB | MDR treatment | 12 | 2 | 4 | 2 | 0 | $18,035 |
| MDR-TB | Untreated | 2 | 0 | 0 | 6 | 12 | $59,232 |
| MDR-TB | Standard treatment | 0 | 2 | 0 | 6 | 12 | $60,081 |
| MDR-TB | MDR treatment | 2 | 0 | 0 | 6 | 12 | $59,332 |

a Calculated by multiplying the duration by the per-month treatment cost (including one-off cost for insertion of catheter for amikacin and administration costs). For example, the total treatment cost for untreated TB is equal to the sum of 6 months of no treatment (no cost), 2 months of standard intensive treatment (2 × $425) and 4 months of standard continuation treatment (4 × $112), which equals $1,299 (may not be exact due to rounding). Treatment costs are discounted at 5% per year when accrued beyond 1 year.

CP = continuation phase; IP = intensive phase; MDR = multidrug-resistant; TB tuberculosis

###### Costs of treating AEs associated with TB treatment.

The proportion of patients who experience an AE while on treatment is assumed to differ depending on the treatment regimen administered, as drugs commonly used in the treatment of MDR-TB are poorly tolerated ([Street et al. 2012](#_ENREF_189)). Francis et al. ([2014](#_ENREF_67)) conducted a retrospective case-control study of MDR-TB patients matched to susceptible TB patients for site of TB, HIV status, age and sex. AEs were reported for each group (Table 50); however, the severity and treatment of AEs were not reported.

The model assumes the same AE management for all patients who experience the same AE, with treatment decisions based on Victorian guidelines for the management of TB ([Street et al. 2012](#_ENREF_189)). Further, it is also assumed that AEs would be experienced while in the intensive phase of treatment, and so the costs of treating AEs (as per Table 50) are applied accordingly. For example:

* A false MDR-TB-positive patient (i.e. false-positive results for TB and resistance) is assumed to experience AEs related to MDR treatment, and so will have the cost ($34.29) applied
* As an MDR-TB patient on standard treatment (i.e. true-positive TB result, false-negative result for resistance) has 2 months of intensive standard treatment followed by the appropriate MDR regime, these patients are assumed to experience AEs associated with both standard and MDR treatment.

AEs that are managed by either altering doses or stopping treatment (i.e. temporary or permanent) have not been costed. These include hearing impairment, tinnitus and visual disturbances.

Table 50 Cost of treating AEs, by treatment regimen

| AE | Treatment | Proportion TB | Proportion MDR-TB | Treatment cost | Source | TB | MDR-TB |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Arthralgia | Ibuprofen | 1/48 (2%) | 0/16 (0%) | $14.87 | PBS 3192B | $0.31 | $0.00 |
| Hypothyroidism | Thyroxine | 0/48 (0%) | 1/16 (6%) | $29.66 | PBS 2175L | $0.00 | $1.85 |
| Nausea/vomiting | Cimetidine | 5/48 (10%) | 11/16 (69%) | $22.45 | PBS 1158Y | $2.34 | $15.43 |
| Psychiatric problems | Haloperidol | 0/48 (0%) | 7/16 (44%) | $16.24 | PBS 2761H | $0.00 | $7.11 |
| Rash/itch | Loratidine | 10/48 (21%) | 2/16 (13%) | $46.26 | PBS 4313B | $9.64 | $5.78 |
| Renal dysfunction | Replace electrolytes | 0/48 (0%) | 1/16 (6%) | $65.81 | PBS 3117C, 1841X, 5146W | $0.00 | $4.11 |
| **TOTAL** | - | - | - | - | - | **$12.29** | **$34.29** |

AE = adverse events; MDR = multidrug-resistant; TB = tuberculosis

###### TB management costs

Management of patients treated for TB is costed based on Victorian guidelines for the management of TB ([Street et al. 2012](#_ENREF_189)). The type of health resource item, frequency of use, and overall use and costs by outcome state are presented in Table 51.

###### Hospitalisation

Hospital isolation after diagnosis of TB is important to contain the spread of the disease. The costs associated with hospital isolation used in the economic evaluation are presented in Table 52. Francis et al. ([2014](#_ENREF_67)) report the proportion of Western Australian MDR-TB patients and susceptible TB controls (matched for site of TB, HIV status, age and sex) that were hospitalised during treatment and the mean total days in hospital. It was observed that significantly more patients with MDR-TB (100%) were hospitalised for an average of 26 days, compared with 35% of those with susceptible TB, who were hospitalised on average for 13 days (p<0.001). Sensitivity analyses will be conducted around these estimates.

To estimate the average cost of hospital isolation, National Hospital Costing Data have been used (Round 14, 2009–10) ([Australian Government Department of Health 2012](#_ENREF_13)). The average total cost per Respiratory Tuberculosis DRG (E76Z) in a public hospital was $14,230, including $904 for pharmacy costs. The average length of stay was 14.6 days. Excluding pharmacy costs (as these are costed elsewhere), the average cost per hospitalised day is $914[[28]](#footnote-28). A standardised growth rate of 2.6% is applied to estimate the cost in 2014 dollars ($1,039) ([Independent Hospital Pricing Authority 2014](#_ENREF_90)). These costs are applied to all patients with TB (± MDR) on diagnosis (immediate or delayed), as it is assumed that even if diagnosis is delayed, the same level of hospitalisation is applied for isolation and treatment once a contagion risk has been identified.

Table 51 Resource use associated with the management of TB used in the economic evaluation, by outcome state, discounted (where appropriate)

| Type of resource item | Frequency of use | Unit cost | Source of unit cost | No TB, unTx | No TB, Std | No TB, MDR | TB, unTx | TB,  Std | TB, MDR | MDR, unTx | MDR, Std | MDR, MDR |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Specialist attendance | At 2 weeks, then monthly for duration of treatment | $43.00 | MBS 105 | 0 | 3 | 3 | 7 | 7 | 9 | 19 | 21 | 19 |
| Visual acuity a | At baseline, and during specialist attendance, while on ethambutol | N/A | N/A | 0 | 4 | 4 | 4 | 4 | 4 | 20 | 22 | 20 |
| MC&S | At 2 weeks, then monthly for duration of treatment (MDR treatment: after 6 months, quarterly) | $43.00 | MBS 69324 | 0 | 3 | 3 | 7 | 7 | 9 | 11 | 13 | 11 |
| Chest X-ray | Quarterly | $47.15 | MBS 58503 | 0 | 0 | 0 | 2 | 2 | 3 | 6 | 7 | 6 |
| Full blood examination | Baseline | $16.95 | MBS 65070 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Erythrocyte sedimentation rate | Baseline | $7.85 | MBS 65060 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Liver function tests | Baseline (MDR: fortnightly for first month, monthly for duration) | $17.70 | MBS 66512 | 0 | 1 | 4 | 1 | 1 | 4 | 20 | 20 | 20 |
| Urea and electrolytes | Baseline (amikacin: at 2 weeks, then monthly for duration of treatment) | N/A b | N/A | 0 | 1 | 4 | 1 | 1 | 4 | 8 | 8 | 8 |
| Calcium and magnesium | Monthly while on amikacin | N/A b | N/A | 0 | 0 | 2 | 0 | 0 | 2 | 6 | 6 | 6 |
| Amikacin trough levels | At 2 weeks, then monthly for duration of amikacin treatment | $18.15 | MBS 66800 | 0 | 0 | 3 | 0 | 0 | 3 | 7 | 7 | 7 |
| Audiometry | Baseline and 2-monthly while on amikacin | $21.90 | MBS 11306 | 0 | 0 | 2 | 0 | 0 | 2 | 4 | 4 | 4 |
| Thyroid function tests | Quarterly while on prothionamide | $34.80 | MBS 66719 | 0 | 0 | 1 | 0 | 0 | 1 | 6 | 6 | 6 |
| **TOTAL** | - | - | - | **$0** | **$301** | **$487** | **$739** | **$739** | **$1,144** | **$2,334** | **$2,553** | **$2,346** |

a Costed as part of specialist attendance

b Ordered at same time as liver function tests, no additional cost as tests also listed in MBS item 66500

MC&S = AFB microscopy, culture and sensitivity; MDR = multidrud-resistant; Std = standard treatment; TB = tuberculosis; unTx = untreated

Table 52 Total cost of hospital isolation

| - | Susceptible TB | MDR-TB |
| --- | --- | --- |
| Proportion isolated | 35% | 100% |
| Days isolated (range) | 13 (2−41) | 26 (1−99) |
| Cost per day hospitalised | $1,039 | $1,039 |
| Total cost | $4,728 | $27,018 |

MDR-TB =multidrug-resistant tuberculosis; TB = tuberculosis

In patients with TB hospitalisation, costs are assumed to apply by true status. As there was no indication from the clinical evidence that a delay in diagnosis of 2 months leads to inferior outcomes such as longer treatment duration or hospitalisation, true-positive and false-negative TB patients are assumed to have the same hospitalisation costs applied (despite the accrual of costs at differing times).

For patients with a false TB diagnosis, duration of hospitalisation is assumed as for susceptible TB (as AFB microscopy after two weeks will likely be negative).

###### TB transmissions

The costs associated with TB transmission can be separated into those associated with (i) screening contacts and (ii) treatment of contacts identified with either latent or active TB. Consistent with evidence identified in the clinical assessment, patients in whom treatment is delayed are assumed to infect more contacts than those treated earlier ([Ponticiello et al. 2001](#_ENREF_169)).

Ponticiello et al. ([2001](#_ENREF_169)) report that the 90 TB patients enrolled in their study had 346 contacts screened (average 3.84 per patient). However, the study did not report the drug-resistance status of patients. It is unclear whether the number of contacts screened would be similar between patients with susceptible TB and MDR-TB. A retrospective analysis conducted in Canada ([Johnston et al. 2012](#_ENREF_95)) observed no significant difference in the median number of contacts screened per case of susceptible TB (cases: n=2,895; contacts: n=7,309) or MDR-TB (cases: n=28; contacts: n=89), with a median of 3 contacts per case reported (p=0.839). This is in contrast to a median of 6 contacts per case of MDR-TB (cases: n=16; contacts: n=727) and 3 per case of susceptible TB (cases: n=48; contacts: n=371) reported in the retrospective case-control study of Western Australian patients conducted by Francis et al. ([2014](#_ENREF_67)). The Australian data will be used in the base-case analysis of the economic evaluation.

Ponticiello et al. ([2001](#_ENREF_169)) observed that 6/43 (14%) contacts of cases with a delay to treatment of less than 1 month had a latent TB infection, and 24/56 (43%) contacts of cases with a delay of treatment of 2 months had latent TB. As this study did not report the drug-resistance status of patients, and as no evidence was identified in the clinical assessment for the effect of delayed treatment in MDR-TB, assumptions regarding latent MDR-TB transmission have been made in the modelling. The transmissibility of MDR-TB relative to susceptible TB has been reported to vary substantially—more infectious in some studies and less infectious in others ([Borrell & Gagneux 2009](#_ENREF_30)). A conservative approach is taken in the base-case analysis of the economic evaluation, which assumes a poor relative infectivity of MDR-TB (30%) ([Cohen & Murray 2004](#_ENREF_42)), as any overestimation of the transmissibility of MDR-TB will overestimate the costs of MDR-TB transmissions, disproportionately affecting the comparator. This is due to all patients with MDR-TB receiving ineffective treatment under current testing, and so remaining infectious, until the C&S results. This will be tested in the sensitivity analyses.

Ponticiello et al. ([2001](#_ENREF_169)) report that 18/125 (14%) contacts with a latent TB infection developed active TB during follow-up. This was not reported by the delay to treatment in the index case, but has been estimated. The delay in treatment of 2 months compared with less than 1 month resulted in approximately three (43% vs 14%) times more latent TB infections, and this has been used to estimate the relative proportion of active infections in those with a delay in treatment (Table 53). The relative infectivity coefficient assumed for latent TB transmissions with MDR is also assumed to apply to the transmission of active MDR infections.

Contacts of index patients are screened using the tuberculin skin test (Mantoux test), which is listed on the MBS under item 73811 ($11.20); this test is performed at time of exposure and repeated 2–3 months later. Treatment of latent susceptible TB is according to Victorian guidelines for the management of TB ([Street et al. 2012](#_ENREF_189)), and consists of 6 months’ isoniazid treatment (Table 47). Treatment guidelines for latent MDR-TB were not identified, so treatment is assumed to consist of 6 months’ moxifloxacin treatment, as per the most common treatment regimen reported of latent MDR-TB in a Victorian study conducted by Denholm et al. ([2012](#_ENREF_52)) (6 months’ fluoroquinolone) (Table 47). The cost of treating active infections includes treatment (and treatment of AEs), management and hospitalisations costs (Table 53).

The costs of baseline contact tracing only are assumed in contacts of false-positive TB patients.

Table 53 Total cost of identification and treatment of TB transmissions

| - | - | TB | MDR-TB | No TB | Delayed TB | Delayed MDR-TB |
| --- | --- | --- | --- | --- | --- | --- |
| A | Contacts ([Francis et al. 2014](#_ENREF_67)) | 3 | 6 | 3 | 3 | 6 |
| B | Tests per contact | 2 | 2 | 1 | 2 | 2 |
| C | Cost per TST (MBS item 73811) | $11.20 | $11.20 | $11.20 | $11.20 | $11.20 |
| D | Fitness (relative to DS-TB) | 1 | 0.30 a | 0 | 1 | 0.30 a |
| E | Proportion with latent infection ([Ponticiello et al. 2001](#_ENREF_169)) | (6/43) × D = 14% | (6/43) × D = 4% | 0 | (24/56) × D = 43% | (24/56) × D = 13% |
| F | No. of latent transmissions (A × E) | 0.42 | 0.25 | 0 | 1.29 | 0.77 |
| G | Latent infection regimen | Isoniazid | Moxifloxacin | N/A | Isoniazid | Moxifloxacin |
| H | Months of treatment | 6 | 6 | 0 | 6 | 6 |
| I | Cost per month of treatment (Table 47) | $22.37 b | $444.33 | 0 | $22.37 b | $444.33 |
| J | Treatment cost (G × H) | $134 | $2,666 | $0 | $134 | $2,666 |
| K | Proportion of latent TB patients who develop active TB ([Ponticiello et al. 2001](#_ENREF_169)) | 18/125 (14%) | 18/125 (14%) | 0 | 18/125 (14%) | 18/125 (14%) |
| L | By treatment delay | 25% c | 25% c | 0 | 75% d | 75% d |
| M | Proportion with active infection (D × K × L) | 4% | 1% | 0% | 11% | 3% |
| N | No. of active transmissions (F × M) | 0.015 | 0.003 | 0.000 | 0.140 | 0.025 |
| O | Treatment cost (Table 49) | $6,778 | $88,730 | $0 | $6,778 | $88,730 |
| - | **Cost penalty applied e** | **$224** | **$1,040** | **$34** | **$1,186** | **$4,422** |

a Cohen & Murray ([2004](#_ENREF_42))

b includes co-administration of pyridoxine

c 14%/(14% + 43%)

d 43%/(14% + 43%)

e (A × B × C) + (F × J) + (N × O)

DS-TB = drug-susceptible tuberculosis; MDR-TB = multidrug-resistant tuberculosis; TB = tuberculosis; TST = tuberculin skin test

###### Overall cost per outcome state

Total costs accrued over the 20-month time horizon, accounting for treatment, management, hospitalisation, transmissions and treatment of AEs, by outcome state, is presented in Table 54. These costs will be incorporated into the model in a stepped manner to view the effect of each on the resulting ICER.

It should be noted that these costs do not include the cost of NAAT, which applies to the intervention arm of the model only.

Table 54 Total costs, by outcome state, discounted (where appropriate)

| True status | Treated status | Treatment | AEs | Management | Hospitalisation | Transmissions | TOTAL |
| --- | --- | --- | --- | --- | --- | --- | --- |
| No TB | Untreated | $0 | $0 | $0 | $0 | $0 | $0 |
| No TB | Std treatment | $849 | $12 | $301 | $4,728 | $34 | $5,924 |
| No TB | MDR treatment | $16,735 | $34 | $487 | $4,728 | $34 | $22,018 |
| TB | Untreated | $1,299 | $12 | $739 | $4,728 | $1,186 | $7,965 |
| TB | Std treatment | $1,299 | $12 | $739 | $4,728 | $224 | $7,002 |
| TB | MDR treatment | $18,035 | $47 | $1,144 | $4,728 | $224 | $24,177 |
| MDR-TB | Untreated | $59,232 | $34 | $2,334 | $27,018 | $4,422 | $93,040 |
| MDR-TB | Std treatment | $60,081 | $47 | $2,553 | $27,018 | $4,422 | $94,121 |
| MDR-TB | MDR treatment | $59,332 | $34 | $2,346 | $27,018 | $1,040 | $89,771 |

Note: Costs associated with the correct treatment are highlighted.

AEs = adverse events; MDR = multidrug-resistant; Std = standard; TB = tuberculosis

***Utility values***

Utility values used in the previously published economic evaluations of NAAT are presented in Table 55.

The utility weights used in previously published cost–utility analyses of NAAT may be inappropriate to use in the current assessment, as a number of weights were found to be based on clinical opinion or assumptions, or could not be verified from the cited sources. To supplement these utility values, a search was conducted to identify studies that measure utility estimates in a TB population (see Appendix H). Six studies were identified that reported eliciting utility weights relevant to TB (Table 103, Appendix I).

Table 55 Utility values used in previously published economic evaluations of NAAT

| Study | Utility weight | Comment |
| --- | --- | --- |
| Choi et al. ([2013](#_ENREF_40)) | Complete health 1.0  First-line treatment (without TB) 0.9  MDR-TB treatment (without TB) 0.7  Treated active TB 0.85  Untreated active TB 0.7  Drug-related hepatotoxicity 0.8  Death 0 | Study refers to de Perio et al. ([2009](#_ENREF_48)), which refers to Tsevat et al. ([1988](#_ENREF_208)) for all utility weights  Tsevat et al. ([1988](#_ENREF_208)) states that values were assigned based on a consensus of internists and were assumed to be applicable to a US population |
| Hughes et al. ([2012](#_ENREF_89)) | General population 0.86 | EQ-5D weight elicited in general UK population ([Kind, Hardman & Macran 1999](#_ENREF_103)) |
| Hughes et al. (2012) | Decrement for active TB 0.39 | Study refers to Tan et al. ([2008](#_ENREF_193)), which cites Guo et al. ([2008](#_ENREF_79)) (Table 103, Appendix I), but utility weight cannot be verified from source |
| Hughes et al. (2012) | Decrement for treated active TB 0.1 | Study cites Khan et al. ([2002](#_ENREF_99)). Values were obtained from a panel of infectious-disease specialists with expertise in tuberculosis; utility weight cannot be verified from source |
| Hughes et al. (2012) | Decrement for toxicity with TB 0.25  Decrement for toxicity without TB 0.16 | Cites Holland et al. ([2009](#_ENREF_88)) in which the utility of treatment-limiting toxicity in TB is based on an assumption |

MDR-TB = multidrug-resistant tuberculosis; TB = tuberculosis

In the economic model, cases without TB are assumed to have a utility weight consistent with that of the general UK population (0.86), measured using the EQ-5D ([Kind, Hardman & Macran 1999](#_ENREF_103)). The utility weights reported in Jit et al. ([2011](#_ENREF_94)) (Table 103, Appendix I) are the most applicable to patients who have TB, as the study was conducted in the UK setting using the EQ-5D at diagnosis of TB (0.68) and after 2 months of treatment (0.81). These utilities are assumed in the model to apply to untreated and treated TB (± MDR). However, as the utilities were elicited after 2 months of standard treatment, this is assumed to apply to the continuation phase of treatment, and this estimate is assumed to not take into account disutility associated with treatment, including effects of AEs during the intensive phase.

To account for AEs associated with the intensive phase of treatment, in those with and without TB (i.e. false-positive patients), the utility weights for true-positive and false-positive treatment have a utility decrement applied. This decrement is estimated based on the utility decrement of toxicity with (0.22) or without (0.14) TB, adjusted[[29]](#footnote-29) from those used in Hughes et al. ([2012](#_ENREF_89)), and multiplied by the proportion of patients who experience AEs by MDR (81%) or standard (33%) treatment, as reported by Francis et al. ([2014](#_ENREF_67)). These utilities are assumed to apply for each month while in the intensive phase of treatment (duration of 2 months in standard treatment and 6 months in MDR treatment).

Utility values used in the economic evaluation are presented in Table 56.

Table 56 Utility values used in the economic evaluation

| Health state | Utility weight | QALYs accrued per month (utility weight/12) | Utility weight source/calculation |
| --- | --- | --- | --- |
| No TB or cured | 0.86 | 0.072 | Kind et al. ([1999](#_ENREF_103)) |
| No TB, standard treatment | 0.81 | 0.068 | 0.86 − (0.33 a × 0.14 b) |
| No TB, MDR treatment | 0.75 | 0.062 | 0.86 − (0.81 c × 0.14 b) |
| TB, untreated | 0.68 | 0.057 | Jit et al. ([2011](#_ENREF_94)) |
| TB, standard treatment (intensive phase) | 0.74 | 0.062 | 0.81 − (0.33 a × 0.22 d) |
| TB, MDR treatment (intensive phase) | 0.64 | 0.053 | 0.81 − (0.81 c × 0.22 d) |
| TB, treated (continuation phase) | 0.81 | 0.068 | Jit et al. ([2011](#_ENREF_94)) |
| MDR-TB, standard treatment (intensive phase) | 0.61 | 0.051 | 0.68 − (0.33 a × 0.22 d) |

a Proportion of patients who experience AEs with standard treatment, reported by Francis et al. ([2014](#_ENREF_67))

b Utility decrement of AEs related to TB treatment in patients without TB, as assumed in Hughes et al. ([2012](#_ENREF_89))

c Proportion of patients who experience AEs with MDR treatment, reported by Francis et al. ([2014](#_ENREF_67))

d Utility decrement of AEs related to TB treatment in true-positive patients, as assumed in Hughes et al. ([2012](#_ENREF_89))

AEs = adverse events; MDR = multidrug-resistant; TB = tuberculosis

###### Overall utility per outcome state

The overall utility accrued over the 20-month time horizon, accounting for time undiagnosed, time in each phase of treatment and time cured, by the decision tree outcome states is presented in Table 57.

Table 57 Overall utility, by outcome state, discounted (where appropriate)

| True status | Treated status | Untreated TB (months) | Standard (IP) (months) | MDR (IP) (months) | Treated TB (CP) (months) | No TB or cured (months) | Total QALYs a |
| --- | --- | --- | --- | --- | --- | --- | --- |
| No TB | Untreated | 0 | 0 | 0 | 0 | 20 | 1.406 |
| No TB | Standard treatment | 0 | 2 | 0 | 0 | 18 | 1.398 |
| No TB | MDR treatment | 0 | 0 | 2 | 0 | 18 | 1.387 |
| TB | Untreated | 2 | 2 | 0 | 4 | 12 | 1.339 |
| TB | Standard treatment | 0 | 2 | 0 | 4 | 14 | 1.369 |
| TB | MDR treatment | 0 | 2 | 2 | 4 | 12 | 1.332 |
| MDR-TB | Untreated | 2 | 0 | 6 | 12 | 0 | 1.216 |
| MDR-TB | Standard treatment | 0 | 2 | 6 | 12 | 0 | 1.204 |
| MDR-TB | MDR treatment | 0 | 0 | 6 | 12 | 2 | 1.245 |

Note: The outcomes associated with the correct treatment are highlighted.

a Calculated by multiplying the duration by the per-month utility weight. For example, the utility for untreated TB is equal to the sum of 2 months’ untreated TB (2 × 0.057), 2 months’ TB standard intensive phase (2 × 0.062), 4 months’ TB continuation phase (4 × 0.068) and 12 months’ cured (12 × 0.072), which equals 1.339 (figures not exact due to discounting of utilities accrued after 1 year and rounding)

CP = continuation phase; IP = intensive phase; MDR = multidrug-resistant; TB = tuberculosis

###### Utility penalty for active TB transmissions

To estimate the utility penalty for transmissions of active TB, it is assumed that these secondary patients receive the correct treatment according to the TB status of the index patient. For example, if an index patient had untreated MDR-TB, the secondary patient is assumed to have the 20-month utility of correctly treated MDR-TB. The utility difference between 20 months of no TB (1.406) and of correctly treated TB (± MDR) (1.369 or 1.245, respectively) is the penalty applied. The outcome-state utilities adjusted for TB transmissions are presented in Table 58. Results will be presented both with and without the inclusion of these utility penalties.

No utility penalty is applied for the transmission of latent TB.

Table 58 Outcome state utilities, adjusted for TB transmissions

| True status | Treated status | Index utility (Table 57) | Transmissions with active infection a | Utility penalty per transmission b | Weighted utility penalty c | Overall utility, adjusted for transmissions d |
| --- | --- | --- | --- | --- | --- | --- |
| No TB | Untreated | 1.406 | 0 | 0 | 0 | 1.406 |
| No TB | Standard treatment | 1.398 | 0 | 0 | 0 | 1.398 |
| No TB | MDR treatment | 1.387 | 0 | 0 | 0 | 1.387 |
| TB | Untreated | 1.339 | 0.33 | 0.037 | 0.012 | 1.327 |
| TB | Standard treatment | 1.369 | 0.11 | 0.037 | 0.004 | 1.365 |
| TB | MDR treatment | 1.332 | 0.11 | 0.037 | 0.004 | 1.328 |
| MDR-TB | Untreated | 1.216 | 0.20 | 0.161 | 0.031 | 1.184 |
| MDR-TB | Standard treatment | 1.204 | 0.20 | 0.161 | 0.031 | 1.172 |
| MDR-TB | MDR treatment | 1.245 | 0.06 | 0.161 | 0.010 | 1.235 |

Note: The outcomes associated with the correct treatment are highlighted.

a Row N, Table 53

b 20-month utility of no TB (untreated) − 20-month utility of correct TB (± MDR) treatment (Table 57)

c Transmissions with active infection × utility penalty

d Index utility − weighted utility penalty

### Outputs from the economic evaluation

The results of the economic evaluation are presented for four scenarios:

* TB mixed scenario: patients with true TB are spread across treatment populations based on high or low clinical suspicion of TB (best reflective of current practice)
* TB low-suspicion scenario: all patients (including all with true TB) are treated as though they have a low clinical suspicion of TB—that is, clinical judgment is not used as a basis to initiate treatment but, rather, treatment decisions are based on AFB ± NAAT
* Perfect clinical judgment scenario: all patients with true TB are treated as per high clinical suspicion—that is, clinical judgement has 100% sensitivity and specificity in identifying TB; and all patients without TB are treated as per low clinical suspicion—that is, treatment decisions are based on AFB ± NAAT
* TB high-suspicion scenario: all patients are treated as though they have a high clinical suspicion of TB—that is, treatment is initiated in all patients on the basis of clinical judgment.

The following summarises the results of the economic evaluation that will be presented:

* disaggregated by decision tree probabilities, incremental costs and incremental outcomes (TB mixed scenario only); the disaggregated results for additional scenarios are presented in Appendix I
* for the TB mixed scenario, the incremental cost-effectiveness is presented incorporating costs in a stepped manner (additional scenarios in Appendix I)
* incremental cost-effectiveness of each of the three additional scenarios
* sensitivity analyses.

#### Outcome-state probabilities

The results of the decision tree analysis are presented in Figure 55 (AFB model arm) and Figure 56 (AFB plus NAAT model arm), Appendix I. The probability at each decision tree terminal is derived from a composite of the prevalence of TB in the tested population, clinical suspicion and test accuracy parameters. The difference between the model arms is the incorporation of NAAT accuracy parameters into the intervention arm.

The proportion of patients managed per each outcome state, as derived from the decision tree analysis, is presented in Table 59.

Table 59 Outcome state probabilities, TB mixed scenario

| True status | Treated status | AFB | AFB + NAAT | Difference |
| --- | --- | --- | --- | --- |
| No TB | Untreated | 70.6% | 71.3% | 0.69% |
| No TB | Standard treatment | 7.4% | 6.7% | –0.70% |
| No TB | MDR treatment | 0.0% | 0.0% | 0.01% |
| TB | Untreated | 3.4% | 1.1% | –2.33% |
| TB | Standard treatment | 18.1% | 20.3% | 2.14% |
| TB | MDR treatment | 0.0% | 0.2% | 0.18% |
| MDR-TB | Untreated | 0.1% | 0.0% | –0.05% |
| MDR-TB | Standard treatment | 0.4% | 0.1% | –0.30% |
| MDR-TB | MDR treatment | 0.0% | 0.3% | 0.35% |
| **TOTAL** | **-** | **100%** | **100%** | **0%** |

Note: The probabilities associated with the correct treatment are highlighted.

AFB = acid-fast bacilli; MDR = multidrug-resistant; NAAT = nucleic acid amplification test; TB = tuberculosis

The highlighted rows in Table 59 reflect the relevant optimal treatment strategy. NAAT is associated with improvements in each of these strategies, due to improved sensitivity of NAAT in conjunction with AFB (fewer false-negative results) and the ability of NAAT to identify and treat MDR-TB earlier. A net reduction in false-positive results is also observed, due to false-positive results associated with NAAT in AFB true-negative patients being outweighed by AFB false-positive patients correctly identified using NAAT.

#### Incremental costs

The incremental cost of NAAT, broken down by the source of the cost, is presented in Table 60. NAAT is associated with an incremental cost ($85.11) that is largely driven by the cost of NAAT, offset by reduced costs associated with TB transmissions (due to the identification of MDR-TB and fewer false-negative results) and reduced hospitalisations (due to fewer patients with false-positive results who require hospital isolation).

Table 60 Breakdown of incremental costs, TB mixed scenario

| Cost | AFB | AFB + NAAT | Increment |
| --- | --- | --- | --- |
| Treatment | $607.05 | $631.19 | $24.14 |
| Treatment of AEs | $3.76 | $3.70 | –$0.06 |
| Management | $192.72 | $190.79 | –$1.93 |
| Hospitalisation | $1,490.04 | $1,457.36 | –$32.68 |
| TB transmissions | $103.40 | $69.04 | –$34.36 |
| NAAT cost | $0.00 | $130.00 | $130.00 |
| **TOTAL** | **$2,396.97** | **$2,482.08** | **$85.11** |

AEs = adverse events; AFB = acid-fast bacilli; NAAT = nucleic acid amplification test; TB = tuberculosis

#### Incremental QALYs

The incremental costs by outcome health state are derived from the product of the outcome-state probabilities (Table 59) and the overall utility, by outcome state as presented in Table 58. These are presented in Table 61. Overall NAAT is associated with a small incremental QALY gain (0.001), driven by a shift from initially untreated TB (or standard treatment in the case of MDR-TB) to correct treatment.

In part the small difference results from the assumption that the correct diagnosis is achieved in all patients after 2 months, and that this 2-month delay in treatment is not assumed to affect patient mortality rates or the severity of disease. Whereas a utility penalty has been applied for the transmission of active TB, none has been applied for the transmission of latent TB.

Table 61 Weighted utility by outcome state, TB mixed scenario

| True status | Treated status | AFB | AFB + NAAT | Increment |
| --- | --- | --- | --- | --- |
| No TB | Untreated | 0.992 | 1.002 | 0.010 |
| No TB | Standard treatment | 0.104 | 0.094 | –0.010 |
| No TB | MDR treatment | 0.000 | 0.000 | 0.000 |
| TB | Untreated | 0.046 | 0.015 | –0.031 |
| TB | Standard treatment | 0.248 | 0.277 | 0.029 |
| TB | MDR treatment | 0.000 | 0.002 | 0.002 |
| MDR-TB | Untreated | 0.001 | 0.000 | –0.001 |
| MDR-TB | Standard treatment | 0.004 | 0.001 | –0.004 |
| MDR-TB | MDR treatment | 0.000 | 0.004 | 0.004 |
| **TOTAL** | **-** | **1.395** | **1.396** | **0.001** |

Note: The outcomes associated with the correct treatment are highlighted.

AFB = acid-fast bacilli; MDR = multidrug-resistant; NAAT = nucleic acid amplification test; TB = tuberculosis

#### Incremental cost-effectiveness

The effect on the ICER of adding each additional group of costs is presented in Table 62 for the TB mixed scenario. Consistent with Table 60, the addition of transmissions and hospitalisation costs contribute most to the final ICER. The addition of the utility penalty for transmissions decreases the ICER further. This effect is consistently observed in the additional scenarios (Table 113, Appendix I).

Table 62 Stepped economic evaluation, TB mixed scenario

| Utilities considered | Costs included (NAAT cost applied in AFB + NAAT arm) | ICER |
| --- | --- | --- |
| Index patient utility | Treatment only | $188,307 |
| Index patient utility | Treatment and AEs | $188,238 |
| Index patient utility | Treatment, AEs and management | $185,882 |
| Index patient utility | Treatment, AEs, management and hospitalisation | $145,956 |
| Index patient utility | Treatment, AEs, management, hospitalisation and transmission | $103,978 |
| Index and secondary case utility | Treatment, AEs, management, hospitalisation and transmission | **$90,728** |

AEs = adverse events; ICER = incremental cost-effectiveness ratio

The incremental cost-effectiveness of NAAT in each of the additional scenarios is presented in Table 63.

Table 63 Incremental cost-effectiveness ratios for additional scenarios

| - | AFB | AFB + NAAT | Increment |
| --- | --- | --- | --- |
| **TB low scenario** | - | - | - |
| Costs | $2,105.43 | $2,148.83 | $43.39 |
| Outcomes | 1.394 | 1.396 | 0.002 |
| ICER | - | - | **$18,533** |
| **Perfect clinical judgment** | - | - | - |
| Costs | $2,016.20 | $2,119.79 | $103.59 |
| Outcomes | 1.397 | 1.397 | 0.0001 |
| ICER | - | - | **$724,423** |
| **TB high scenario** | - | - | - |
| Costs | $6,544.41 | $6,692.36 | $147.95 |
| Outcomes | 1.391 | 1.391 | 0.0001 |
| ICER | - | - | **$1,713,838** |

AFB = acid-fast bacilli; ICER = incremental cost-effectiveness ratio; NAAT = nucleic acid amplification test

NAAT is most cost-effective in the scenario in which all patients are managed as though they have a low clinical suspicion of TB. In this scenario, treatment decisions are driven by the results of AFB ± NAAT. The PASC protocol indicated that when AFB and NAAT results were discordant, treatment decisions would be based on NAAT, and so the introduction of NAAT in this scenario has the greatest ability to change patient management. NAAT is more sensitive than AFB, and this leads to improved management in patients with TB as there are fewer false-negative results. In patients without TB, change in patient management with NAAT occurs in two ways:

* in patients with an initial AFB (false)-positive result, NAAT may correctly identify no TB (i.e. NAAT may improve patient management), and decreases in the specificity of NAAT lead to the same treatment outcomes as if tested with AFB
* in patients with an initial AFB (true)-negative result, NAAT may falsely identify TB, and decreases in the specificity of NAAT lead to more false-positive results (i.e. NAAT leads to detrimental patient management).

Given that the pooled estimate of AFB specificity is high (98%), false-positive results are likely to be driven by the specificity of NAAT in AFB-negative results. As the pooled estimate for this parameter and that in AFB-positive results in low-incidence countries are also both high (99% and 97%, respectively), the net effect is a reduction in the number of false-positive results.

The cost-effectiveness of NAAT is least in the scenarios in which all patients (with TB, and with or without TB, respectively) are managed as though they have a high clinical suspicion of TB. In these scenarios treatment initiation decisions are based on clinical judgement, with the benefit of NAAT restricted to identifying drug resistance to initiate an appropriate treatment earlier. As the prevalence of MDR-TB in those with TB is approximately 2%, the benefits of NAAT are accrued in a very small proportion of the population tested (0.44%). As NAAT is associated with a net reduction in the number of false-positive results, the perfect clinical suspicion scenario, in which treatment initiation in true TB-negative patients is based on the results of AFB ± NAAT, is more cost-effective than the TB high scenario, in which all patients receive treatment.

Given that the TB mixed population is a combination of patients with high and low clinical suspicion of TB, it is unsurprising that the cost-effectiveness of NAAT lies between the respective estimates observed when all suspects are treated as though they have either a low or a high clinical suspicion of TB.

#### Sensitivity analyses

Sensitivity analyses for the base-case (TB mixed) scenario were conducted around a number of parameters included in the economic modelling (using 95%CI or plausible upper and lower limits). Analyses were presented in a tornado analysis (Figure 36). An additional sensitivity analysis was conducted using the test accuracy parameters for AFB and NAAT from all studies included in the clinical assessment (rather than those reported in studies conducted in a low-incidence setting only).

The tornado analysis indicates that the ICER is most sensitive to changes in the prevalence of TB in the tested population, the specificity of NAAT (ICERs exceeding $200,000 for the three NAAT specificity estimates) and the changes in the specificity of AFB.

There is considerable uncertainty in the prevalence of TB in the tested population (those with clinical signs and symptoms of TB). A best-guess estimate was applied in the model (22%) provided by the applicant. This estimate was similar to the prevalence of TB reported in the diagnostic accuracy of studies conducted in low-incidence countries (24%). A range of 10−30% was applied in the tornado analysis. Increasing the prevalence was observed to increase the cost-effectiveness of NAAT; therefore, conversely, decreasing the prevalence decreased the cost-effectiveness of NAAT, increasing the ICER to $967,000.

As previously described, NAAT may lead to an increase in false-positive results (and so false initiation of treatment) in those with an AFB-negative result based on the specificity of NAAT in AFB-negative patients, and the model is highly sensitive to this change. Any reduction in the specificity of this parameter (from 100%) increases the number of false-positive patients that receive detrimental treatment, leading to increases in cost and poorer quality of life. However, it should be noted that, as culture is an imperfect reference standard, some proportion of NAAT false-positive patients may truly have clinical disease (see ‘Comparison of NAAT and culture, using clinical diagnosis as a reference standard’).




Figure Tornado sensitivity analysis

AE = adverse event; AFB = acid-fast bacilli test; ICER = incremental cost-effectiveness ratio; LTBI = latent tuberculosis infection; MDR = multidrug-resistant; NAAT = nucleic acid amplification test; RIF = rifampicin; TB = tuberculosis

As false-positive rifampicin resistance (in patients without TB and those with susceptible TB) is driven only by the specificity of NAAT for rifampicin resistance; reductions in this parameter increase the number of patients falsely treated with a more costly and more toxic treatment regimen.

The model is sensitive to the 95%CI of the specificity of NAAT in AFB-positive results, but this is more reflective of the imprecision of the pooled estimate (95%CI 1, 100) rather than the model being highly sensitive to changes in this variable alone.

Increases in the specificity of AFB (from 98% to 100%) increase the ICER substantially (to $203,000). As NAAT may correctly identify no TB in patients with an initial AFB (false)-positive result, reducing AFB false-positive results reduces the benefits of NAAT; in contrast, reducing the specificity of AFB (to 94%) increases the number of AFB false-positive results, substantially increasing the benefits of NAAT (dominant ICER).

Other variables that the ICER was seen to be sensitive to include:

* the probability of hospitalisation with susceptible TB—decreasing from 35% to 0% increases the ICER by 50% due to the net reduction in false-positive results associated with the introduction of NAAT
* the infectivity of MDR-TB relative to susceptible TB—increasing the infectivity coefficient from 30% to 100% (i.e. assuming the same relative infectivity as susceptible TB) decreases the ICER to $4,000, due to an increase in the number of MDR-TB transmissions, which disproportionally affects the comparator (as AFB cannot identify drug resistance)
* the median number of contacts screened per susceptible TB case—increasing the number from 3 to 6 decreased the ICER by one-third, due to the net reduction in false-negative results associated with the introduction of NAAT.

An additional sensitivity analysis was conducted using the results of AFB and NAAT by AFB status from all studies included in the clinical assessment, rather than those from a low-incidence setting alone (values presented in Table 46). The ICER is extremely sensitive to these changes and is predominantly driven by the combined decrease in the pooled estimates of the specificity of NAAT in AFB-negative results (from 99% to 94%) and the specificity of NAAT for rifampicin resistance (from 99% to 91%) (Table 64).

Table 64 Sensitivity analysis using test accuracy results of AFB, NAAT from all studies identified in the systematic review

| - | AFB | AFB + NAAT | Increment |
| --- | --- | --- | --- |
| **Costs** | $2,392.55 | $3,045.78 | $653.23 |
| **Outcomes** | 1.395 | 1.396 | 0.00002 |
| **ICER** | - | - | **$30,009,858** |

AFB = acid-fast bacilli; ICER = incremental cost-effectiveness ratio; NAAT = nucleic acid amplification test

## Financial implications

A market-based approach is taken using MBS data to estimate the number of patients who accessed at least one of item of mycobacterial MC&S testing in 2009−13, and to project the expected number of patients who would be eligible for NAAT for TB and NTM (as requested) in 2015−19. One NAAT is assumed per eligible patient. As NAAT is not intended to replace current testing, the estimated net financial implication to the MBS is equal to the cost of the requested NAAT listings multiplied by the expected number of services.

### Data sources used in the financial analysis

The sources for data used in the financial analysis are presented in Table 65.

Table 65 Data sources used in the financial analysis

| Data | Source |
| --- | --- |
| Population eligible for NAAT | MBS data requested from the Department of Health relating to the number of patients who accessed at least one service from items 69324, 69325, 69327, 69328, 69330 or 69331 for the calendar years 2009−13.  These data are projected to estimate the number of patients eligible for NAAT during 2015−19. |
| Proportion of patients eligible for NAAT suspected of TB | Applicant estimate of mycobacterial infections tested suspected of TB (50%). The inverse is the estimate of mycobacterial infections tested that are suspected of NTM. |
| Cost of NAAT for TB | As per ‘Economic evaluation’ ($130) |
| Cost of NAAT for NTM | Victorian Mycobacterium Reference Laboratory price per NAAT for suspected *M. ulcerans* infections ($50) or generic region *Mycobacterium* PCR ($120) |
| Proportion of patients bulk-billed | MBS data requested from the Department of Health regarding the proportion of patients who accessed at least one service from items 69324, 69325, 69327, 69328, 69330 or 69331 for the calendar years 2009−13 who were bulk-billed. |

NAAT = nucleic acid amplification test; NTM = non-tuberculous mycobacteria; TB = tuberculosis

### Net financial implications to the MBS

The population eligible for NAAT is projected based on the number of patients who accessed mycobacterial MC&S testing (MBS items 69324, 69325, 69327, 69328, 69330 or 69331) each year during 2009−13 (Table 66). As these items are used to monitor the effectiveness of treatment and as this is not a proposed use of NAAT, the number of patients rather than the number of services has been used. This patient pool accounts for the population suspected of TB (who can or cannot have an AFB) and the population suspected of NTM.

Table 66 Number of patients who accessed MC&S services, 2009–13

| - | 2009 | 2010 | 2011 | 2012 | 2013 |
| --- | --- | --- | --- | --- | --- |
| No. patients who accessed at least one MC&S service | 28,188 | 27,853 | 30,213 | 32,857 | 34,302 |

MC&S = acid-fast bacilli microscopy, culture and sensitivity

A linear regression model fitted to the observed patient numbers (R2 = 0.92) was projected to 2019 (Figure 37 and Table 67). This approach may overestimate the eligible population for NAAT, as patients tested who are suspected of *M. leprae* may be included (but would not be eligible for NAAT) and, as these tests are used to monitor treatment effectiveness, patients may receive testing across multiple years for the same infection. Further, as the current MBS items are not restricted to patients with clinical signs and symptoms of a mycobacterial infection, and as HESP member feedback has indicated that testing may be ordered as part of the initial work-up of a chronic obstructive pulmonary disease or some renal diseases, this approach may further overestimate the eligible population. This will be tested in a sensitivity analysis.




Figure 37 Number of patients who accessed MC&S services, observed 2009–13 and projected 2014–19

MC&S = acid-fast bacilli microscopy, culture and sensitivity

Furthermore, it is proposed that use of NAAT may earlier identify TB and MDR-TB, enabling faster treatment and decreasing the number of secondary transmissions. Neither the potential decrease in the rate of increasing cases due to reduced transmissions, nor the potential savings on treatment costs due to decreased transmissions, is captured in the financial estimates.

As the MBS items for MC&S do not distinguish between TB and NTM, and do not distinguish between those who do and do not have an AFB test, these projected patient numbers cannot be separated into the three proposed populations with any degree of confidence. As NAAT costs differ between TB and NTM, the applicant has estimated that approximately 50% of the patients currently tested for mycobacterial infections are suspected of TB, and so 50% are suspected of NTM.

Generally, one NAAT is assumed per eligible patient. However, this approach may underestimate the estimated number of tests (and so costs) in circumstances in which multiple mycobacteria are suspected. For example, TB may be initially suspected with a pulmonary infection (and therefore be tested using TB NAAT), and then may also be tested using NAAT for *M. kansasii* and/or MAC. It is unclear how often this situation would occur—the applicant has made an estimate of approximately 30% of patients initially suspected of TB. This is used in the estimation of the financial implications associated with NAAT for NTM and will be tested in sensitivity analyses.

###### NAAT for TB

The cost per TB NAAT is as used in the economic modelling ($130); the financial implications of a range of test costs are presented in Appendix J. Over the past 5 years average bulk-billing rates for the current MC&S items ranged from 59% to 62%; the midpoint (60.5%) will be used in the analysis. It is assumed that the provider does not charge above the MBS fee, and so the patient contribution, in those not bulk-billed, is 15% of the proposed NAAT fee.

Of all patients suspected of a mycobacterial infection, it is assumed that 50% are suspected of having TB (based on applicant advice). This estimate is tested in sensitivity analyses. Applying this proportion to the projected eligible population estimates, 18,800 patients are estimated to be eligible for TB NAAT in the first year, increasing to 22,200 in the fifth. The total MBS fees associated with the introduction of NAAT for TB increase from $2.4 million to $2.9 million over the 5-year period, of which $2.1 million in year 1 to $2.5 million in year 5 are paid by the MBS. Safety net effects to the MBS have not been considered in these calculations, as MBS data relating to the proportion of patients eligible for the safety net are not available. Patient contributions are estimated to increase from $145,000 to $171,000 over the 5 years. This may be an overestimate as, due to the contagious nature of TB, state TB services may waive all patient fees associated with the investigation of TB.

Table 67 Number of patients eligible and cost of NAAT for TB

| - | 2015 | 2016 | 2017 | 2018 | 2019 |
| --- | --- | --- | --- | --- | --- |
| Projected no. of patients eligible for NAAT | 37,575 | 39,299 | 41,022 | 42,745 | 44,468 |
| *Population suspected of TB* | - | - | - | - | - |
| Proportion of patients suspected of TB | 50% | 50% | 50% | 50% | 50% |
| Number of patients suspected of TB | 18,788 | 19,650 | 20,511 | 21,373 | 22,234 |
| Proposed NAAT fee: | $130.00 | $130.00 | $130.00 | $130.00 | $130.00 |
| MBS benefit (85%) | $110.50 | $110.50 | $110.50 | $110.50 | $110.50 |
| Patient contribution (15%) | $19.50 | $19.50 | $19.50 | $19.50 | $19.50 |
| Proportion of patients bulk-billed | 61% | 61% | 61% | 61% | 61% |
| **MBS fees associated with TB listing:** | **$2,442,440** | **$2,554,500** | **$2,666,430** | **$2,778,490** | **$2,890,420** |
| MBS benefits payable (85%) | $2,076,074 | $2,171,325 | $2,266,466 | $2,361,717 | $2,456,857 |
| Patient co-payments a | $144,715 | $151,354 | $157,986 | $164,626 | $171,257 |

a Only payable by patients who are not bulk-billed

NAAT = nucleic acid amplification test; TB = tuberculosis

###### NAAT for NTM

The cost per NTM NAAT is assumed as per the Victorian Mycobacterium Reference Laboratory cost for *M. ulcerans* ($50). Sensitivity analysis will be conducted using the generic region *Mycobacterium* PCR test cost ($120) (also from the Victorian reference laboratory). Bulk-billing rates are assumed as per NAAT for TB.

Patients eligible for NAAT for NTM include those initially suspected of an NTM infection (i.e. 50% of all patients suspected of a mycobacterial infection) and those initially suspected of TB, who may also receive testing for NTM (30% of initial TB suspects). In year 1, 24,400 patients are considered eligible for NAAT for NTM, increasing to 28,900 in year 5.

The total MBS fees associated with the introduction of NAAT for NTM increase from $1.2 million to $1.4 million over the 5-year period, of which $1.0 million in year 1 to $1.2 million in year 5 are paid by the MBS. Safety net effects to the MBS have not been considered in these calculations. Patient contributions are estimated to increase from $72,400 to $85,600 over the 5 years.

Table 68 Number of patients eligible and cost of NAAT for NTM

| - | 2015 | 2016 | 2017 | 2018 | 2019 |
| --- | --- | --- | --- | --- | --- |
| Projected no. of patients eligible for NAAT | 37,575 | 39,299 | 41,022 | 42,745 | 44,468 |
| *Population suspected of NTM* | - | - | - | - | - |
| Proportion of patients suspected of NTM | 50% | 50% | 50% | 50% | 50% |
| Number of patients suspected of NTM | 18,788 | 19,650 | 20,511 | 21,373 | 22,234 |
| Proportion of initial TB suspects tested | 30% | 30% | 30% | 30% | 30% |
| Number of initial TB suspects tested | 5,636 | 5,895 | 6,153 | 6,412 | 6,670 |
| Total no. of patients tested for NTM | 24,424 | 25,545 | 26,664 | 27,785 | 28,904 |
| Proposed NAAT fee: | $50.00 | $50.00 | $50.00 | $50.00 | $50.00 |
| MBS benefit (85%) | $42.50 | $42.50 | $42.50 | $42.50 | $42.50 |
| Patient contribution (15%) | $7.50 | $7.50 | $7.50 | $7.50 | $7.50 |
| Proportion of patients bulk-billed | 61% | 61% | 61% | 61% | 61% |
| **MBS fees associated with NTM listing:** | **$1,221,220** | **$1,277,250** | **$1,333,215** | **$1,389,245** | **$1,445,210** |
| MBS benefits payable (85%) | $1,038,037 | $1,085,663 | $1,133,233 | $1,180,858 | $1,228,429 |
| Patient co-payments a | $72,357 | $75,677 | $78,993 | $82,313 | $85,629 |

a Only payable by patients who are not bulk-billed

NAAT = nucleic acid amplification test; NTM = non-tuberculous mycobacteria; TB = tuberculosis

The total MBS fees associated with the introduction of NAAT increase from $3.7 million to $4.3 million over the 5-year period, of which $3.1 million in year 1 to $3.7 million in year 5 are paid by the MBS. Patient contributions are estimated to increase from $217,000 to $257,000 over the 5 years (Table 69).

Table 69 Total cost of NAAT for requested listings

| - | 2015 | 2016 | 2017 | 2018 | 2019 |
| --- | --- | --- | --- | --- | --- |
| **MBS fees associated with NAAT listings:** | **$3,663,660** | **$3,831,750** | **$3,999,645** | **$4,167,735** | **$4,335,630** |
| MBS benefits payable (85%) | $3,114,111 | $3,256,988 | $3,399,698 | $3,542,575 | $3,685,286 |
| Patient co-payments a | $217,072 | $227,031 | $236,979 | $246,938 | $256,886 |

a Only payable by patients who are not bulk-billed

NAAT = nucleic acid amplification test

As described, the approach used to estimate the population suspected of having a mycobacterial infection may overestimate the population eligible for NAAT, as current MBS item numbers do not restrict testing to those with the clinical signs and symptoms of a mycobacterial infection.

As the implications of the Medicare Safety Net were not included in the analysis, the MBS benefits payable could be underestimated.

##### Uncertainty scenarios

Uncertainties flagged around estimates used in the financial analysis were tested in sensitivity analyses (Table 70).

The analyses were most sensitive to increases in the NAAT cost (TB or NTM), increasing the total cost of NAAT by more than 60%. The assumption that 25% of all patients currently tested are not eligible for NAAT (e.g. those who do not have clinical signs and symptoms of mycobacterial infection) decreased the total cost of NAAT by the same proportion (25%). Changes to variables that increased the proportion of patients tested for TB (relative to NTM), and increases in the proportion of patients initially suspected of TB tested for NTM, increased the total cost of NAAT slightly (16% and 3%, respectively).

Table 70 Sensitivity analyses

| - | 2015 | 2016 | 2017 | 2018 | 2019 |
| --- | --- | --- | --- | --- | --- |
| **Base-case** | - | - | - | - | - |
| Total cost of NAAT for TB | $2,442,440 | $2,554,500 | $2,666,430 | $2,778,490 | $2,890,420 |
| Total cost of NAAT for NTM | $1,221,220 | $1,277,250 | $1,333,215 | $1,389,245 | $1,445,210 |
| Total cost of NAAT | $3,663,660 | $3,831,750 | $3,999,645 | $4,167,735 | $4,335,630 |
| *Patients eligible for NAAT, 75% (base-case: 100%)* | - | - | - | - | - |
| Total cost of NAAT for TB | $1,831,830 | $1,915,810 | $1,999,920 | $2,083,900 | $2,167,880 |
| Total cost of NAAT for NTM | $915,915 | $957,905 | $999,960 | $1,041,950 | $1,083,940 |
| Total cost of NAAT | $2,747,745 | $2,873,715 | $2,999,880 | $3,125,850 | $3,251,820 |
| *Proportion of patients suspected of TB, 75% (base-case: 50%)* | - | - | - | - | - |
| Total cost of NAAT for TB | $3,663,530 | $3,831,620 | $3,999,710 | $4,167,670 | $4,335,630 |
| Total cost of NAAT for NTM | $892,415 | $933,360 | $974,305 | $1,015,185 | $1,056,115 |
| Total cost of NAAT | $4,555,945 | $4,764,980 | $4,974,015 | $5,182,855 | $5,391,745 |
| *Proportion of patients suspected of TB, 25% (base-case: 50%)* | - | - | - | - | - |
| Total cost of NAAT for TB | $1,221,220 | $1,277,250 | $1,333,280 | $1,389,180 | $1,445,210 |
| Total cost of NAAT for NTM | $1,549,960 | $1,621,075 | $1,692,190 | $1,763,240 | $1,834,305 |
| Total cost of NAAT | $2,771,180 | $2,898,325 | $3,025,470 | $3,152,420 | $3,279,515 |
| *Proportion of initial TB suspects tested for NTM, 20% (base-case: 30%)* | - | - | - | - | - |
| Total cost of NAAT for TB | $2,442,440 | $2,554,500 | $2,666,430 | $2,778,490 | $2,890,420 |
| Total cost of NAAT for NTM | $1,127,280 | $1,179,000 | $1,230,660 | $1,282,380 | $1,334,040 |
| Total cost of NAAT | $3,569,720 | $3,733,500 | $3,897,090 | $4,060,870 | $4,224,460 |
| *Proportion of initial TB suspects tested for NTM, 40% (base-case: 30%)* | - | - | - | - | - |
| Total cost of NAAT for TB | $2,442,440 | $2,554,500 | $2,666,430 | $2,778,490 | $2,890,420 |
| Total cost of NAAT for NTM | $1,315,160 | $1,375,500 | $1,435,770 | $1,496,110 | $1,556,380 |
| Total cost of NAAT | $3,757,600 | $3,930,000 | $4,102,200 | $4,274,600 | $4,446,800 |
| *Cost of NAAT for NTM, $120 (base-case: $50)* |  | - | - | - | - |
| Total cost of NAAT for TB | $2,442,440 | $2,554,500 | $2,666,430 | $2,778,490 | $2,890,420 |
| Total cost of NAAT for NTM | $2,930,928 | $3,065,400 | $3,199,716 | $3,334,188 | $3,468,504 |
| Total cost of NAAT | $5,373,368 | $5,619,900 | $5,866,146 | $6,112,678 | $6,358,924 |

NAAT = nucleic acid amplification test; NTM = non-tuberculous mycobacteria; TB = tuberculosis

### Other Australian healthcare system costs

Costs to the state and territory health systems

There is some indication that NAAT is currently being used (though perhaps not routinely) in the diagnosis of mycobacterial infections. Advice from one state Mycobacterium Reference Laboratory indicated that these costs are currently covered by the states for public patients, and so listing of NAAT will shift these costs from state health budgets to the federal health budget.

Costs to the private health insurer and/or patient

Patient contributions associated with the proposed NAAT listings are estimated to increase from $217,000 to $257,000 over a 5-year period.

Some testing may currently be funded privately. It is assumed that some of these costs will shift to the federal health budget (subject to the fee and patient contribution).

Total Australian healthcare system costs

Given that some shifting of costs from state health budgets to the federal health budget is anticipated with the proposed listings, the net societal costs of NAAT may be lower than those presented in Table 69.

# Conclusions

## Is NAAT safe?

There were no studies on the safety of NAAT compared with current testing (AFB microscopy, tissue biopsy and/or culture). As NAAT is usually conducted on the same samples used for other testing, and there is no need for resampling, no AEs were expected.

To date, NAAT has been widely used without any safety concerns. However, more patients will receive a false-positive NAAT than a false-positive AFB result. Therefore, more patients will receive treatment for a disease they do not have and will possibly have an adverse reaction to the anti-TB drugs until clinical unresponsiveness is noted or culture results become available.

## Is NAAT effective?

#### Direct evidence

Two studies were included that assessed the direct health impact of NAAT ([Theron et al. 2014](#_ENREF_200); [Yoon et al. 2012](#_ENREF_225)). Both studies were conducted in a high prevalence setting and applicability to the Australian healthcare system is therefore questionable. A high-quality RCT reported no difference in morbidity outcomes at 2 and 6 months follow-up when NAAT and AFB microscopy were compared. However, a strong trend indicating fewer deaths in the NAAT group compared with the AFB microscopy group was observed at 2 months, but this trend was no longer apparent at 6 months. A historical control study of medium quality found no difference in the mortality rate at 2 months follow-up when comparing NAAT with no NAAT.

The authors of both studies suggested that high rates of treatment initiation based on empiric evidence in the no-NAAT groups probably underestimated the morbidity and/or mortality rate in the NAAT groups. Yoon et al. ([2012](#_ENREF_225)) also suggested that sicker patients in the NAAT compared with the no-NAAT group contributed to this underestimation in their study.

#### Linked evidence

##### Is NAAT accurate in the diagnosis of MTB?

###### Comparison of NAAT and culture using clinical diagnosis as the reference standard

Culture is an imperfect reference standard as not all patients with a clinical diagnosis of TB (due to symptoms and response to anti-TB drugs) will be culture-positive. Meta-analysis to compare the sensitivity and specificity of culture and NAAT, using clinical diagnosis as a reference standard, indicated that 24% of patients clinically diagnosed with TB will have a false-negative culture result, compared with 14% having a false-negative NAAT. Thus, a large proportion of NAAT false-positive patients (i.e. NAAT-positive, culture-negative) would actually be clinically diagnosed as having TB. Therefore, NAAT is likely to be more effective at confirming the presence of an MTB infection than the meta-analysis using culture, as the reference standard would suggest.

###### AFB plus NAAT versus culture

Meta-analysis of studies investigating the diagnostic accuracy of AFB plus NAAT compared with culture showed that the overall pooled sensitivity (94%, 95%CI 91, 98) and specificity (88%, 95%CI 82, 92) values did not differ significantly to those for sputum and non-sputum specimens when analysed separately. Thus, 6% of patients will have a false-negative result, and 12% of patients (8% with sputum specimens and 17% with non-sputum specimens) will be false-positive.

The LR+ and LR– summary values for AFB microscopy plus NAAT compared with culture indicated that a negative AFB and NAAT result correctly identified most patients who were culture-negative and showed strong diagnostic evidence for confirmation of culture-positive TB. In sputum specimens, AFB plus NAAT correctly identified most patients as either culture-positive or culture-negative. As expected, the AUC for AFB microscopy plus NAAT, in both sputum and non-sputum specimens indicated that AFB plus NAAT performs well in predicting culture positivity.

###### NAAT versus culture

Meta-analysis of studies investigating the diagnostic accuracy of NAAT compared with culture showed that the pooled sensitivity (89%; 95%CI 85, 92) and specificity (94%; 95%CI 91, 96) values for all specimens did not differ significantly when sputum and non-sputum specimens were analysed separately. Consequently, 11% of patients (11% with sputum specimens and 9% with non-sputum specimens) will have false-negative results and 6% (5% with sputum specimens and 8% with non-sputum specimens) false-positive results when compared with culture results. The SROC curve showed some threshold effect, suggesting that in-house NAAT is less specific than commercial NAAT when compared with culture, especially in countries with a high incidence of TB and when testing non-sputum specimens. However, both in-house NAATs and the commercial Xpert NAAT have diagnostic value for confirming or excluding culture-positive disease. Overall, patients with a positive NAAT result are likely to have culture-positive TB, whereas patients with a negative NAAT result are unlikely to be falsely negative.

In AFB-positive specimens the overall pooled sensitivity (99%; 95%CI 96, 100) and specificity (78%; 95%CI 53, 92) values of NAAT compared with culture did not differ significantly between sputum and non-sputum specimens, but the CIs for specificity were very wide. In contrast, in AFB-negative specimens the pooled sensitivity and specificity values differed between sputum (sensitivity = 67%; 95%CI 45, 84, and specificity = 96%; 95%CI 90, 99) and non-sputum (sensitivity = 86%; 95%CI 78, 91, and specificity = 86%; 95%CI 78, 91) specimens, but the difference did not quite reach statistical significance.

The summary LR values showed that both in-house NAATs and the commercial Xpert NAAT have diagnostic value in confirming or excluding culture-positive disease. Overall, the ability of NAAT to correctly diagnose the presence or absence of TB in patients when compared with culture suggested that patients with a positive NAAT result most likely actually have culture-positive TB. Conversely, patients with a negative NAAT result were more likely not to have culture-positive TB than to be falsely negative.

In the context of interpreting NAAT results in conjunction with AFB findings, when patients are AFB-positive a negative NAAT result could confidently rule out culture-positive MTB being detected in that patient, but a positive NAAT result did not eliminate the possibility of AFB-positive patients not having a detectable MTB infection (i.e. being culture-negative). The reduced certainty in interpreting a positive NAAT result is due to culture being an imperfect reference standard, which likely resulted in misclassification of many of the 22% false-positive results seen for NAAT when compared with culture in AFB-positive specimens.

In patients with AFB-negative specimens a positive NAAT result is likely to correctly confirm the presence of culture-positive MTB. However, interpretation of a negative NAAT result is dependent on the type of specimen tested. In patients with AFB-negative sputum a negative NAAT indicated that the patient may not be culture-positive but it cannot be ruled out. In patients with AFB-negative non-sputum specimens a negative NAAT result provided no additional useful information. This is likely due to the paucibacillary nature of AFB-negative specimens. It should be noted that if few bacilli are present in the specimen, the possibility of a false-negative result would increase for all three tests.

Meta-analysis of studies investigating the diagnostic accuracy of NAAT compared with culture in HIV-positive and -negative patients showed that there was no difference in diagnostic accuracy among the three tests. However, as HIV-positive patients with pulmonary TB commonly produce AFB-negative sputum specimens ([de Albuquerque et al. 2014](#_ENREF_47); [Scherer et al. 2011](#_ENREF_181)), the difficulty associated with diagnosis of TB in HIV-positive patients is related to the reduced sensitivity of NAAT in AFB-negative compared with AFB-positive specimens.

###### AFB versus culture

Meta-analysis of studies investigating the diagnostic accuracy of AFB compared with culture showed that AFB microscopy was significantly more sensitive in identifying MTB in sputum (71%; 95%CI 59, 81) compared with non-sputum (46%; 95%CI 37, 55) specimens. Overall, 38% of all patients (29% with sputum specimens and 54% with non-sputum specimens) will have a false-negative AFB microscopy result, compared with only 2% with a false-positive result. The pooled specificity for AFB microscopy was 98% (95%CI 97, 99) for all specimens and was similar when sputum and non-sputum specimens were analysed separately. These results were confirmed by the SROC curve, which showed that there was a threshold effect based on specimen type, with sensitivity being higher in sputum specimens than non-sputum specimens.

For specific specimen types the pooled sensitivity for AFB microscopy compared with culture varied from 46% in urine to 62% in FNAs of lymph nodes. However, for CSF the pooled sensitivity was only 11%. Thus, AFB microscopy is not a useful tool for diagnosis of TB in CSF specimens. The pooled specificity was at least 94% in all specimen types.

The summary LR+ and LR– values for the ability of AFB microscopy to correctly diagnose the presence or absence of TB in patients when compared with culture suggest that patients with a positive AFB test result are most likely to actually have TB than not. However, patients with a negative test result may or may not have TB, indicating that AFB microscopy provides no useful information in these patients.

###### Comparison of AFB, NAAT and AFB plus NAAT using culture as the reference standard in HIV-positive patients

The pooled sensitivity and specificity values for AFB microscopy and/or NAAT compared with culture in HIV-positive and -negative populations were compared with those for all included studies, which largely consisted of patients in whom their HIV status was unknown. No differences between the pooled values for the three population groups were observed, indicating that HIV status does not affect the performance of either AFB microscopy or NAAT.

HIV-positive patients with pulmonary TB commonly produce AFB-negative sputum specimens ([de Albuquerque et al. 2014](#_ENREF_47); [Scherer et al. 2011](#_ENREF_181)). Thus, the difficulty associated with diagnosis of TB in HIV-positive patients is related to the reduced sensitivity of NAAT compared with culture in AFB-negative specimens, as discussed above.

###### NAAT versus culture-based DST

Meta-analysis of studies investigating the diagnostic accuracy of NAAT compared with culture-based DST showed that NAAT is both highly sensitive (93%; 95%CI 85, 97) and highly specific (98%; 95%CI 96, 99) compared with DST in identifying rifampicin-resistant MTB. Thus, NAAT could be used to inform appropriate treatment decisions, possibly avoiding side effects such as hepatitis from inappropriate use of rifampicin.

However, there was insufficient evidence to determine if NAAT could be used as a surrogate for the detection of MDR-MTB by detecting mutations in the *rpoB* gene that confer rifampicin resistance. Only 2 studies reported data for this comparison, with vastly different point estimates and enormous 95%CIs for sensitivity, and no conclusion could be reached.

##### Does it change patient management?

Fourteen studies reported results on time to TB diagnosis or anti-TB treatment after NAAT compared with AFB microscopy or culture, with 8 of these studies conducted in countries with a relatively high TB prevalence. It was shown that time to diagnosis was shorter with Xpert compared with liquid and solid culture, and similar to AFB microscopy. Median time to treatment was also decreased with the use of Xpert compared with other methods of diagnosis, especially culture. The proportion of TB patients diagnosed and initiating treatment on the day of presentation was higher when NAAT was used in addition to AFB microscopy. Furthermore, laboratory turnaround time was significantly shorter for Xpert and AFB microscopy, compared with culture. The median time for rifampicin-resistance detection was 1 day (IQR 0–1) for Xpert, compared with 20 days (IQR 10–26) for line probe assay and 106 days (IQR 30–124) for phenotypic susceptibility testing. Other time-related management results were reported in three studies conducted in low-prevalence countries, all reporting a decrease in time to identification of MTB infection when NAAT was used.

Thus, not surprisingly, all studies were in agreement that the use of NAAT resulted in a quicker diagnosis of patients with TB, especially in those who were AFB-negative. Predictably, this also resulted in earlier treatment in NAAT-positive patients.

Other changes in management were also reported. A historical control study of low quality and a retrospective cohort study of medium quality reported that the median duration of unnecessary and/or over-treatment of TB was shorter in patients when NAAT was used to guide treatment decisions compared with those when NAAT was not available. The retrospective cohort study also reported that culture-negative NAAT-negative patients had significantly fewer average days on outpatient medications compared with other groups.

There were conflicting data on the likely impact of NAAT in the clinical setting. A retrospective cohort study of low quality and a high risk of bias conducted in the UK (medium TB incidence; 15/100,000 people) reported that NAAT resulted in a change in management in 39% of patients. The authors concluded that there were significant clinical benefits from the use of NAAT in low-prevalence settings, with additional benefits when used with AFB-positive specimens ([Taegtmeyer et al. 2008](#_ENREF_191)).

On the other hand, a lack of change in management with no discontinuation of treatment after a negative Xpert result was reported in two cohort studies of medium quality, one retrospective and conducted in Saudi Arabia (medium TB incidence; 15/100,000 people) and the other conducted in Canada (low TB incidence; 4.6/100,000 people). Omrani et al. ([2014](#_ENREF_162)) concluded that physicians who are highly experienced in the diagnosis and treatment of TB underused the Xpert NAAT and it had only a limited impact on their decisions related to starting or stopping anti-TB therapy.

Thus, while there is no doubt that NAAT results would be available much faster than culture results and that patients could be started on anti-TB treatment much sooner, there was conflicting data on the likely impact of NAAT in the clinical setting.

##### Does change in management improve patient outcomes?

###### What health impact does early versus delayed treatment of TB have on the individual and their contacts?

Two prospective cohort studies, conducted in countries with a low incidence of TB (Italy and the USA), reported that a delay in time to diagnosis, defined as the period from onset of any TB symptoms to the initiation of anti-TB treatment, was significantly associated with an increased risk of transmission of infection among contacts. Although these results are not surprising, they reinforce the belief that quicker diagnosis of TB is of great benefit in reducing the spread of TB to the close contacts of infected individuals.

The results of a retrospective cohort study of poor quality, conducted in New Zealand, indicated that the time between development of symptoms and diagnosis was not significantly associated with the odds of achieving a favourable treatment outcome. As ‘favourable treatment outcome’ was poorly defined in this study, this result may simply reflect the treatment completion rate, which appears to be unrelated to any treatment delays.

###### To what extent does treating patients who have a rifampicin-resistant MTB infection with alternative treatments result in better health outcomes for the patient and their contacts?

No studies were identified that met all the PICO criteria. However, three cohort studies (two retrospective) of medium quality provided some evidence regarding the research question. These studies suggested that patients who received a rifampicin-containing Category II treatment before receiving the DST results had poorer treatment outcomes than those who did not.

###### What are the AEs associated with unnecessary antibiotic treatment?

All TB patients are at risk of adverse health events associated with first-line treatments, irrespective of their appropriateness. For example, the development of hepatitis was associated with the use of rifampicin and pyrazinamide, either separately or in combination (Table 32). Hepatitis occurred more often in older patients, and skin rashes were more common in patients who were female, older, HIV-infected or from Asia. Patients with chronic renal failure tended to have a higher incidence of AEs from anti-TB regimens, in particular neuropsychiatric events. Also, AEs occurred less often in children than in adults. However, data providing the evidence on AEs was non-comparative and came primarily from countries with high or medium incidences of TB, where patients may also have been sicker with co-morbidities or had poorer nutrition, limiting their relevance in an Australian setting. Nevertheless, two SRs, one of medium quality and one of poor quality, found that some but not all AEs as a consequence of patients with active TB receiving inappropriate antibiotic treatment (due to MTB resistance) may be avoided with appropriate treatment, to which the MTB strain is sensitive.

More importantly, from a public health perspective, one SR of good quality found that patients who received inappropriate treatment, as defined by the WHO treatment guidelines for MDR-TB ([WHO 2008](#_ENREF_220)), had a 27-fold increased risk of developing drug resistance than if they received an appropriate treatment regimen. Thus, earlier identification of drug-resistant strains via NAAT could be beneficial in preventing inappropriate treatment and the further spread of MDR-TB.

##### Overall conclusion with respect to comparative effectiveness

Comparison of AFB, NAAT, and AFB plus NAAT using culture as the reference standard showed that AFB plus NAAT (the testing strategy proposed in the application) has the highest false-positive rate, at 12%, with NAAT alone at 6% and AFB alone at 2%. A false-positive result means that a patient will receive treatment for a short time (until clinical unresponsiveness is noted or culture results are available) for a disease they do not have. However, as culture is an imperfect reference standard, a large proportion of these false-positive patients may actually have clinical disease. AFB microscopy alone has the highest false-negative rate, at 38%, with NAAT alone and AFB plus NAAT being much lower at 11% and 6%, respectively. The consequences of a false-negative result are much more severe, as the patient may remain untreated for a longer time period and could potentially spread the disease to more individuals in the community.

The results of the meta-analyses presented in this report suggest that NAAT would be a useful addition to AFB microscopy and culture in the diagnosis of both pulmonary and extrapulmonary TB. Patients with a positive AFB test result or a positive NAAT are most likely to have culture-positive TB, and it becomes almost certain if both tests are positive. No useful information can be obtained directly from a negative AFB result, as these patients may or may not have TB. A negative NAAT result should be interpreted with reference to the AFB result—a negative NAAT result in a patient who was AFB-positive almost completely eliminates the likelihood of being MTB culture-positive. Conversely, a negative NAAT result in a patient who was AFB-negative does not eliminate the possibility of having culture-positive disease.

The use of NAAT enables quicker diagnosis and treatment of patients with TB, especially in those who are NAAT-positive and AFB-negative. It also reduces the duration of unnecessary and/or over-treatment for TB, especially in those patients who are NAAT-negative and AFB-positive.

The accuracy of NAAT compared with culture-based DST indicates that NAAT can accurately identify patients with rifampicin-resistant MTB. Thus, NAAT could be used to inform the best type of antibacterial treatment of TB patients. This would help avoid side effects such as hepatitis from inappropriate use of rifampicin, and earlier appropriate treatment for rifampicin resistance would also reduce the risk of developing MDR-TB.

##### Is NAAT accurate in the diagnosis of NTM?

Culture is an imperfect reference standard, and meta-analysis of studies investigating the diagnostic accuracy of NAAT, AFB microscopy and culture using a clinical reference standard suggested that most patients who were NAAT-positive and culture-negative may have had clinical disease. Overall, NAAT appears to be able to identify a larger proportion of patients with an NTM infection than either AFB microscopy or culture. Additionally, the diagnostic accuracy results for NTM-NAAT and MAC-NAAT should be viewed with caution due to the small number of studies included and the wide 95%CIs for many of the analyses.

NAAT to detect NTM could be separated into three distinct categories: NAAT to detect NTMs in general (NTM-NAAT), NAAT to specifically detect *M. avian* complex (MAC) strains (MAC-NAAT), and NAAT to detect *M. ulcerans* in patients suspected of having Buruli ulcer. The pooled sensitivity and specificity values for NTM-NAAT compared with culture indicated that 24% of culture-positive patients would have false-negative results, but only 2% of culture-negative patients would have false-positive results. For MAC-NAAT compared with culture, 41% of culture-positive patients would have false-negative results and no culture-negative patient would have false-positive results. The summary LR+ and LR– values for the ability of MAC-NAAT to correctly diagnose the presence or absence of NTM infections in patients when compared with culture suggest that patients with a positive NAAT result are likely to actually have an infection, but patients with a negative NAAT result may or may not have an NTM infection. Conversely, patients with a negative NTM-NAAT are more likely to not have an NTM infection than to have one, but whether patients with a positive result actually have an infection is less certain. The SROC curve shows some threshold effect, suggesting that MAC-NAAT may be more sensitive and less specific than NTM-NAAT when compared with culture. Nevertheless, the AUC indicated that both NTM-NAAT and MAC-NAAT perform well in predicting culture positivity.

AFB microscopy was not very useful in identifying patients who do not have NTM infections when compared with culture. The pooled sensitivity values indicated that 53% of culture-positive patients and 69% of patients with a positive clinical diagnosis received a false-negative AFB result. The LR scattergram indicated that patients with a positive AFB test result were most likely to actually have an NTM infection, but patients with a negative test result may or may not have an NTM infection (AFB microscopy provides no useful information in these patients). The SROC AUC also indicated that AFB microscopy performed only moderately well in predicting culture positivity.

## Is NAAT cost-effective?

The base-case ICER for NAAT (the TB mixed scenario) is $90,728/QALY. The addition of NAAT leads to more patients initially receiving the correct treatment, due to improved sensitivity of NAAT in conjunction with AFB and the ability to identify MDR-TB. The incremental cost of NAAT is driven predominantly by the cost of testing, offset by reduced TB transmissions and hospitalisation costs. The incremental QALY gain is driven by the shift of TB patients from being initially untreated (or having standard treatment in the case of MDR-TB) to receiving correct treatment.

The cost-effectiveness of NAAT is affected by the extent of use of clinical judgement in initial treatment decisions. In the extreme scenario, in which clinical judgment is not exerted (i.e. treatment initiation decisions are based on the results of testing), NAAT is most cost-effective due to improved sensitivity in conjunction with AFB, thereby reducing the number of patients who would have been untreated on the basis of AFB results alone. However, in the scenarios in which clinical judgement perfectly identifies TB or in which clinical judgment is used as the basis to treat all patients, the benefits of NAAT are restricted to identifying rifampicin resistance, and so are accrued in a very small proportion of the population tested (2% of 22% = 0.44%).

Substantial uncertainty surrounds a number of variables included in the economic modelling, in particular the prevalence of TB in the tested population. The ICER is most sensitive to changes in this variable; for example, decreasing the estimated prevalence in the tested population from 22% to 10% increases the ICER to $967,000.

The ICER is also sensitive to decreases in the specificity of NAAT, particularly in AFB-negative results (e.g. using the lower limit of the 95%CI increases the ICER to $450,000) and for rifampicin resistance (e.g. using the lower limit of the 95%CI increases the ICER to $253,000). Any decrease in these specificities (from 100%) increases the number of false-positive patients that receive poorly tolerated treatment, leading to increases in cost and poorer quality of life. However, as culture is an imperfect reference standard for diagnosis of TB, some proportion of NAAT false-positive patients may truly have clinical disease, and so the uncertainty in the ICER associated with reductions in the specificity in AFB-negative results may be an overestimate.

## Costing

Given the uncertainties in estimating the eligible population, the financial implications of introducing NAAT are uncertain. However, as NAAT is proposed to be used as an add-on test, net costs to the MBS are implied. Estimates presented in the assessment ($3.7 million to $4.3 million over the 5-year period) are likely to represent the upper limits of proposed use, as all assumptions regarding the eligible population are likely to be overestimated. The financial implications are most sensitive to changes in the cost per test. While benefits associated with reduced transmissions may be expected, these have not been quantified.

As NAAT is currently being used (the extent of which is uncertain), some shifting of costs from the states to the federal health budget is anticipated, and so the net financial implications to the Australian healthcare system are likely to be less than the net cost of introducing NAAT to the MBS.

**Appendix A Health Expert Standing Panel and Assessment Group**

#### Health Expert Standing Panel (HESP)

Member Expertise or affiliation

Jim Black Associate Professor, Nossal Institute for Global Health, Melbourne School of Population and Global Health

#### Assessment group

**AHTA, University of Adelaide, South Australia**

Name Position

Judy Morona Senior Research Officer

Arlene Vogan Health Economist

Sharon Kessels Research Officer

Debra Gum Senior Research Officer

Joanne Milverton Research Officer

Jacci Parsons Team Leader (Medical HTA)

Skye Newton Team Leader (Medical HTA)

Camille Schubert Senior Health Economist

Tracy Merlin Managing Director

**Noted conflicts of interest**

There were no conflicts of interest.

# Appendix B Search strategies

#### HTA websites

|  |  |  |
| --- | --- | --- |
| INTERNATIONAL | - | |
| International Network of Agencies for Health Technology Assessment | <http://www.inahta.org/> | |
| AUSTRALIA | - | |
| Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP-S) | <http://www.surgeons.org/for-health-professionals/audits-and-surgical-research/asernip-s/> | |
| Centre for Clinical Effectiveness, Monash University | <http://www.monashhealth.org/page/Health_Professionals/CCE/> | |
| Centre for Health Economics, Monash University | <http://www.buseco.monash.edu.au/centres/che/> | |
| AUSTRIA | - | |
| Institute of Technology Assessment / HTA unit | <http://www.oeaw.ac.at/ita> | |
| CANADA | - | |
| Institut National d’Excellence en Santé et en Services Sociaux (INESSS) | <http://www.inesss.qc.ca/en/publications/publications>/ | |
| Alberta Heritage Foundation for Medical Research (AHFMR) | [http://www.ahfmr.ab.ca/publications.html](http://www.ahfmr.ab.ca/) | |
| Alberta Institute of Health Economics | <http://www.ihe.ca/> | |
| The Canadian Agency for Drugs And Technologies in Health (CADTH) | <http://www.cadth.ca/index.php/en/> | |
| The Canadian Association for Health Services and Policy Research (CAHSPR) | <http://www.cahspr.ca/> | |
| Centre for Health Economics and Policy Analysis (CHEPA), McMaster University | [http://www.chepa.org](http://www.chepa.org/) | |
| |  |  | | --- | --- | | Health Utilities Index (HUI), McMaster University | <http://www.fhs.mcmaster.ca/hug/index.htm> |   Centre for Health Services and Policy Research (CHSPR), University of British Columbia | [http://www.chspr.ubc.ca](http://www.chspr.ubc.ca/) | |
| Institute for Clinical and Evaluative Studies (ICES) | [http://www.ices.on.ca](http://www.ices.on.ca/) | |
| Saskatchewan Health Quality Council (Canada) | [http://www.hqc.sk.ca](http://www.hqc.sk.ca/) | |
| DENMARK | - | |
| Danish National Institute Of Public Health | <http://www.si-folkesundhed.dk/?lang=en> | |
| FINLAND | - | |
| Finnish National Institute for Health and Welfare | <http://www.thl.fi/en/web/thlfi-en/> | |
| FRANCE | - | |
| L’Agence Nationale d’Accréditation et d’Evaluation en Santé (ANAES) | <http://www.anaes.fr/> | |
| GERMANY |  | |
| German Institute for Medical Documentation and Information (DIMDI) / HTA | <http://www.dimdi.de/static/en/index.html> | |
| Institute for Quality and Efficiency in Health Care (IQWiG) | [http://www.iqwig.de](http://www.iqwig.de/) | |
| THE NETHERLANDS |  | |
| Health Council of the Netherlands Gezondheidsraad | <http://www.gezondheidsraad.nl/en/> | |
| Institute for Medical Technology Assessment (Netherlands) | <http://www.imta.nl/> |
| NEW ZEALAND | <http://www.otago.ac.nz/christchurch/research/nzhta/> | |
| New Zealand Health Technology Assessment (NZHTA) |  | |
| NORWAY | [http://www.kunnskapssenteret.no](http://www.kunnskapssenteret.no/) | |
| Norwegian Knowledge Centre for the Health Services |  | |
| SPAIN |  | |
| Agencia de Evaluación de Tecnologias Sanitarias, Instituto de Salud “Carlos III”I/Health Technology Assessment Agency (AETS) | <http://www.isciii.es/> | |
| Andalusian Agency for Health Technology Assessment (Spain) | <http://www.juntadeandalucia.es/> | |
| Catalan Agency for Health Technology Assessment (CAHTA) | [http://www.gencat.cat](http://www.gencat.cat/) | |
| SWEDEN |  | |
| Center for Medical Technology Assessment, Linköping University | <http://www.cmt.liu.se/?l=en&sc=true> | |
| Swedish Council on Technology Assessment in Health Care (SBU) | <http://www.sbu.se/en/> | |
| SWITZERLAND |  | |
| Swiss Network on Health Technology Assessment (SNHTA) | <http://www.snhta.ch/> | |
| UNITED KINGDOM | - | |
| National institute for Health Research, Health Technology Assessment Programme | <http://www.hta.ac.uk/> | |
| NHS Quality Improvement Scotland | <http://www.nhshealthquality.org/> | |
| National Institute for Clinical Excellence (NICE) | <http://www.nice.org.uk/> | |
| The European International Network on New and Changing Health Technologies | <http://www.euroscan.bham.ac.uk/> | |
| University of York NHS Centre for Reviews and Dissemination (NHS CRD) | <http://www.york.ac.uk/inst/crd/> | |
| UNITED STATES |  | |
| Agency for Healthcare Research and Quality (AHRQ) | [http://www.ahrq.gov/clinic/techix.htm](http://www.ahrq.gov/) | |
| Harvard School of Public Health | <http://www.hsph.harvard.edu/> | |
| Institute for Clinical and Economic Review (ICER) | <http://www.icer-review.org/> | |
| Institute for Clinical Systems Improvement (ICSI) | [http://www.icsi.org](http://www.icsi.org/) | |
| Minnesota Department of Health (US) | <http://www.health.state.mn.us/> | |
| National Information Centre of Health Services Research and Health Care Technology (US) | <http://www.nlm.nih.gov/nichsr/nichsr.html> | |
| Oregon Health Resources Commission (US) | <http://www.oregon.gov/oha/OHPR/HRC/Pages/index.aspx> | |
| Office of Health Technology Assessment Archive (US) | <http://ota.fas.org/> | |
| U.S. Blue Cross/ Blue Shield Association Technology Evaluation Center (Tec) | <http://www.bcbs.com/blueresources/tec/> | |
| Veteran’s Affairs Research and Development Technology Assessment Program (US) | <http://www.research.va.gov/default.cfm> | |

#### Additional sources of literature

|  |  |
| --- | --- |
| Source | Location |
| Internet | - |
| NHMRC- National Health and Medical Research Council (Australia) | <http://www.nhmrc.gov.au/> |
| US Department of Health and Human Services (reports and publications) | <http://www.hhs.gov/> |
| New York Academy of Medicine Grey Literature Report | <http://www.greylit.org/> |
| Trip database | [http://www.tripdatabase.com](http://www.tripdatabase.com/) |
| Current Controlled Trials metaRegister | <http://controlled-trials.com/> |
| National Library of Medicine Health Services/Technology Assessment Text | <http://text.nlm.nih.gov/> |
| U.K. National Research Register | <http://www.nihr.ac.uk/Pages/NRRArchive.aspx> |
| Google Scholar | <http://scholar.google.com/> |
| Australian and New Zealand Clinical Trials Registry | [www.anzctr.org.au](http://www.anzctr.org.au/) |
| World Health Organization | <http://www.who.int/en/> |
| Pearling | - |
| All included articles will have their reference lists searched for additional relevant source material | - |
| ***Guidelines search (last step linked evidence)*** | - |
| Guidelines International Network (G-I-N) | <http://www.g-i-n.net/> |
| NHMRC Clinical Guidelines Portal | [http://www.clinicalguidelines.gov.au](http://www.clinicalguidelines.gov.au/) |

#### Additional databases searched for economic evaluations

|  |  |
| --- | --- |
| **Electronic database** | **Time period** |
| Database of Abstracts of Reviews of Effects or Reviews of Effects (DARE) | to 19 May 2014 |
| Health Technology Assessment database | to 19 May 2014 |
| NHS Economic Evaluation Database (NHS EED) | to 19 May 2014 |

# 

# Appendix C Diagnostic accuracy 2x2 data from included studies

Table 71 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in mixed specimens

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Maurya et al. ([2011b](#_ENREF_136))  India | Level III-1  Low risk of bias | BACTEC culture | N=328 extrapulmonary specimens  n=37  n=291 | AFB (ZN)  IS*6110* PCR  AFB + NAAT  AFB +ve: IS*6110* PCR  AFB –ve: IS*6110* PCR | 23 140 140  23  117 | 14 63 71  6  57 | 128 11 11  0  11 | 163 114 106  8  106 | 20/479 specimens had contaminated cultures and were excluded from analysis |
| Fan et al. ([2014](#_ENREF_65))  China | Level III-1  Low risk of bias | MGIT liquid culture | N=200 respiratory samples | AFB –ve: SAT-TB PCR | 57 | 6 | 4 | 133 | None reported |
| Kim et al. ([2008](#_ENREF_102))  Korea | Level III-2  Low risk of bias | Ogawa media culture | N=2,973 specimens | AFB (FL + ZN)  IS*6110* PCR  AFB + NAAT | 118 142 148 | 2 56 56 | 79 55 49 | 2,774 2,720 2,720 | None reported |
| Deshmukh et al. ([2013](#_ENREF_55))  India | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=463 specimens -  n=111  n=352  N= 436 non-sputum  -  n=105  n=331 | AFB (ZN)  IS*6110* PCR  AFB + NAAT  AFB +ve: IS*6110* PCR  AFB –ve: IS*6110* PCR  AFB (ZN)  IS*6110* PCR  AFB + NAAT  AFB +ve: IS*6110* PCR  AFB –ve: IS*6110* PCR | 96 165 165  96  69  91 152 152  91  61 | 15 75 75  15  60  14 72 72  14  58 | 88 19 19  0  19  79 18 18  0  18 | 264 204 204  0  204  152 194 194  0  194 | 3/466 cultures grew NTM and were excluded from analysis |
| Deshmukh et al. ([2013](#_ENREF_55))  India | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=423 extrapulmonary  -  n=103  n=320 | AFB (ZN)  IS*6110* PCR  AFB + NAAT  AFB +ve: IS*6110* PCR  AFB –ve: IS*6110* PCR | 89 147 147  89  58 | 14 70 70  14  56 | 76 18 18  0  18 | 244 188 188  0  188 | - |
| Ben Kahla et al. ([2011](#_ENREF_21))  Tunisia | Level III-2  Low risk of bias | L-J culture | N=316 specimens -  n=60  n=256 | All: AFB (FL)  IS*6110* PCR  AFB + NAAT  AFB +ve: IS*6110* PCR  AFB –ve: IS*6110* PCR | 50 48 51  47  1 | 10 6 14  2  4 | 5 7 4  3  4 | 251 249 247  8  247 | 23/333 sputum samples were contaminated and not included in analysis |
| Therese, Jayanthi & Madhavan ([2005](#_ENREF_197))  India | Level III-2  Low risk of bias | L-J culture | N=280 extrapulmonary clinical samples  n=9  n=271 | AFB (ZN)  IS*6110* PCR  AFB + NAAT  AFB +ve: IS*6110* PCR  AFB –ve: IS*6110* PCR | 8 13 13  8  5 | 1 115 116  0  115 | 6 1 1  0  1 | 265 151 150  1  150 | None reported |
| Jiang et al. ([2012](#_ENREF_93))  China | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=235 mixed samples -  n=60  n=175  N=28 extrapulmonary  -  n=9  n=19 | AFB (ZN)  16S qRT-PCR  AFB + NAAT  AFB +ve: 16S qRT-PCR  AFB –ve: 16S qRT-PCR  AFB (ZN)  16S qRT-PCR  AFB + NAAT  AFB +ve: 16S qRT-PCR  AFB –ve: 16S qRT-PCR | 28 34 34  28  6  4 6 6  4  2 | 32 25 49  8  17  5 4 6  3  1 | 8 2 2  0  2  2 0 0  0  0 | 167 174 150  24  150  17 18 16  2  16 | None reported |
| Makeshkumar, Madhavan & Narayanan ([2014](#_ENREF_125))  India | Level III-2  Low risk of bias | L-J culture | N=178 extrapulmonary specimens | AFB (ZN)  IS*6110* PCR | 6 4 | 4 44 | 0 2 | 168 128 | None reported |
| Gholoobi et al. ([2014](#_ENREF_75))  Iran | Level III-2  Low risk of bias | L-J culture | N=30 mixed specimens | AFB (ZN)  16S-23S PCR  *rpoB* PCR  IS*6110* PCR | 9 8 5 7 | 3 4 0 0 | 3 4 7 5 | 15 15 18 18 | None reported |
| Ani et al. ([2009](#_ENREF_10))  Nigeria | Level III-2  Low risk of bias | L-J slope culture | N=40 mixed specimens from children  N=30 non-sputum samples | AFB –ve: IS*6110* PCR | 4  0 | 18  12 | 0  0 | 18  18 | None reported |
| Halse et al. ([2010](#_ENREF_81))  USA | Level III-2  Some risk of bias | MGIT and/or L-J culture | N=1,309 specimens   -  n=267  n=1,042  N=1,196 pulmonary   -  n=248  n=948  N=113 extrapulmonary   -  n=19  n=94 | AFB (ZN)  IS*6110 rpoB* qPCR  AFB + NAAT  AFB +ve: IS*6110 rpoB* qPCR  AFB –ve: IS*6110 rpoB* qPCR  AFB (ZN)  IS*6110 rpoB* qPCR  AFB + NAAT  AFB +ve: IS*6110 rpoB* qPCR  AFB –ve: IS*6110 rpoB* qPCR  AFB (ZN)  IS*6110 rpoB* qPCR  AFB + NAAT  AFB +ve: IS*6110 rpoB* qPCR  AFB –ve: IS*6110 rpoB* qPCR | 225 253 254  224  29  211 235 236  210  25  14 18 18  14  4 | 42 1 43  0  1  37 1 38  0  1  5 0 5  0  0 | 45 17 16  1  16  38 14 13  1  13  7 3 3  0  3 | 997 1,038 996  42  996  910 946 909  37  909  87 92 87  5  87 | 7/1,316 specimens had no PCR result  Inconclusive PCR: (not reproducible) 5 respiratory specimens 2 non-respiratory  Indeterminate PCR: (PCR inhibition) 3 respiratory specimens |
| Drouillon et al. ([2009](#_ENREF_59))  France and Italy | Level III-2  Some risk of bias | MGIT and/or L-J culture | N=607 specimens  N=548 pulmonary  N=59 extrapulmonary | AFB (ZN + FL)  qRT-PCR  AFB (ZN + FL)  qRT-PCR  AFB (ZN + FL)  qRT-PCR | 61 115  60 105  1 10 | 0 13  0 11  0 2 | 70 16  59 14  11 2 | 476 463  429 418  47 45 | 1/633 specimen was culture contaminated, 12/633 were PCR-2 inhibited, 13/633 were positive NTM and excluded from analysis |
| Shukla et al. ([2011](#_ENREF_184))  India | Level III-2  Some risk of bias | L-J culture | N=140 specimens  -  n=40  n=100  N=86 pulmonary  -  n=40  n=46  N=54 extrapulmonary | AFB (ZN)  IS*6110* nPCR  AFB + NAAT  AFB +ve: IS*6110* nPCR  AFB –ve: IS*6110* nPCR  AFB (ZN)  IS*6110* nPCR  AFB + NAAT  AFB +ve: IS*6110* nPCR  AFB –ve: IS*6110* nPCR  AFB –ve: IS*6110* nPCR | 38 46 48  36  10  38 44 46  36  8  2 | 2 58 60  0  58  2 20 22  0  20  38 | 10 2 0  2  0  8 2 0  2  0  0 | 90 34 32  2  32  38 20 18  2  18  14 | Not reported |
| Drouillon et al. ([2007](#_ENREF_60))  France | Level III-2  Some risk of bias | MGIT or Coletsos slants | N=168 pulmonary specimens | AFB  IS*6110* qPCR | 11 20 | 0 9 | 21 12 | 136 127 | 11/179 cultures were contaminated and excluded from analysis |
| Sharma et al. ([2012](#_ENREF_182))  India | Level III-2  Some risk of bias | MGIT and/or L-J culture | N=80 extrapulmonary specimens  n=79 | AFB (ZN)  M-PCR  AFB + NAAT  AFB –ve M-PCR | 1 3 3  2 | 0 63 63  63 | 2 0 0  0 | 77 14 14  14 | None reported |

AFB = acid-fast bacilli; FL = fluorescent; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; NAAT = nucleic acid amplification test; NTM = non-tuberculous mycobacteria; nPCR = nested PCR; PCR = polymerase chain reaction; qPCR = quantitative (real-time) PCR; qRT-PCR = quantitative (real-time) reverse transcription PCR; ZN = Ziehl-Neelsen

Table 72 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in mixed specimens

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Park et al. ([2013](#_ENREF_166))  Korea | Level III-1  Low risk of bias | Liquid and/or solid culture | N=320 pulmonary specimens  n=26  n=294 | AFB  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert | 13 19 22  10  9 | 13 6 19  0  6 | 10 4 1  3  1 | 284 291 278  13  278 | None reported |
| Tortoli et al. ([2012](#_ENREF_205))  Italy | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=1,413 extrapulmonary samples | AFB (FL)  Xpert | 98 188 | 12 32 | 140 50 | 1163 1143 | 61/1,493 specimens grew NTM  17/1,493 had indeterminate Xpert results and were excluded from analysis |
| Bates et al. ([2013](#_ENREF_19))  Zambia | Level III-2  Low risk of bias | MGIT culture | N=930 mixed pulmonary specimens from children | AFB (FL)  Xpert | 15 42 | 43 16 | 30 7 | 842 865 | None reported |
| Al-Ateah et al. ([2012](#_ENREF_6))  Kingdom of Saudi Arabia | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=239 specimens  -  n=43  n=196  N=183 non-sputum  -  n=12  n=171  N=67 extrapulmonary   -  n=7  n=60 | AFB (FL)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert  AFB (FL)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert  AFB (FL)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert | 41 58 59  41  17  10 21 22  10  11  6 16 17  6  10 | 1 0 1  0  0  1 0 1  0  0  0 0 0  0  0 | 20 4 3  1  3  13 3 2  1  2  11 2 1  1  1 | 177 177 176  1  176  159 159 158  1  158  50 49 49  0  49 | None reported |
| Malbruny et al. ([2011](#_ENREF_126))  France | Level III-2  Low risk of bias | MGIT and Coletsos slants | N=180 specimens  -  n=17  n=163 | AFB (FL)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert | 15 29 29  15  14 | 2 2 4  0  2 | 16 2 2  0  2 | 147 147 145  2  145 | None reported |
| Malbruny et al. ([2011](#_ENREF_126))  France | Level III-2  Low risk of bias | MGIT and Coletsos slants | N=162 non-sputum  -  n=13  n=149  N=89 extrapulmonary   -  n=5  n=84 | AFB (FL)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert  AFB (FL)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert | 11 24 24  11  13  4 12 12  4  8 | 2 2 4  0  2  1 2 3  0  2 | 15 2 2  0  2  10 2 2  0  2 | 134 134 132  2  132  74 73 72  1  72 | - |
| Balcells et al. ([2012](#_ENREF_16))  Chile | Level III-2  Low risk of bias | Solid L-J and liquid media culture | N=160 HIV+ sputum or mouthwash specimens | HIV+ AFB (ZN)  Xpert | 8 11 | 2 1 | 4 1 | 146 147 | Repeated Xpert MTB/RIF assays were performed for patients who had discordant results |
| Teo et al. ([2011](#_ENREF_195))  Singapore | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=153 specimens  -  n=58  n=95  N= 122 pulmonary  -  n=52  n=70  N=31 extrapulmonary   -  n=6  n=25 | AFB (FL)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert  : AFB (FL)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert  AFB (FL)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert | 47 70 70  47  23  43 56 56  43  13  4 14 14  4  10 | 11 8 14  5  3  9 5 11  3  2  2 3 3  2  1 | 30 7 7  0  7  19 6 6  0  6  11 1 1  0  1 | 65 68 62  6  62  51 55 49  6  49  14 13 13  0  13 | 9/162 respiratory specimens gave invalid GeneXpert results |
| Ioannidis et al. ([2011](#_ENREF_91))  Greece | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=92 AFB -ve mixed specimens | AFB –ve: Xpert | 19 | 5 | 3 | 65 | 12/105 cultures were contaminated  1/105 had invalid Xpert result |
| Deggim et al. ([2013](#_ENREF_51))  Switzerland | Level III-2  Low risk of bias | MGIT 960 liquid and Middlebrook 7H11 culture | N=77 mixed specimens -   n=19  n=58 | AFB (FL)  Xpert  AFB + NAAT  AFB +ve Xpert  AFB –ve Xpert | 14 15 15  14  1 | 5 2 7  0  2 | 4 3 3  0  3 | 54 57 52  5  52 | 2/79 had invalid Xpert results |
| Zeka, Tasbakan & Cavusoglu ([2011](#_ENREF_227))  Turkey | Level III-2  Some risk of bias | MB/BacT liquid and/or L-J culture | N=429 mixed specimens  n=32  n=397 | AFB (FL)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert | 31 71 71  31  40 | 1 6 7  0  6 | 58 18 18  0  18 | 339 334 333  1  333 | None reported |
| Marlowe et al. ([2011](#_ENREF_130))  USA | Level III-2  Some risk of bias | Culture | N=216 pulmonary specimens  n=126  n=90 | AFB  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert | 87 116 118  85  31 | 39 4 39  4  0 | 43 14 12  2  12 | 47 82 47  35  47 | 1/217 bronchial specimen was found to be PCR inhibitory and was excluded from analysis |
| Moure, Martin & Alcaide ([2012](#_ENREF_147))  Spain | Level III-2  Some risk of bias | MGIT and/or L-J culture | N=147 AFB –ve extrapulmonary specimens | AFB –ve: Xpert | 63 | 0 | 45 | 39 | 2/149 specimens had Xpert indeterminate results |

AFB = acid-fast bacilli; FL = fluorescent; HIV = human immunodeficiency virus; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; NAAT = nucleic acid amplification test; NTM = non-tuberculous mycobacteria; TB = tuberculosis; Xpert = GeneXpert MTB/RIF NAAT; ZN = Ziehl-Neelsen

Table 73 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in sputum

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Davis et al. ([2009](#_ENREF_45))  Uganda | Level II  Low risk of bias | L-J Middlebrook and MGIT cultures | N=100 sputum samples  -  n=63  n=37 | AFB (ZN)  *secA1* PCR  AFB + NAAT  AFB +ve: *secA1* PCR  AFB –ve *secA1* PCR | 55 62  63  54  8 | 8 6  11  3  3 | 8 1  0  1  0 | 29 31  26  5  26 | 27/127 AFB microscopy results not recorded and excluded from analysis |
| Mashta et al. ([2011](#_ENREF_132))  India | Level III-1  Low risk of bias | L-J liquid medium culture | N=463 sputum samples  -  n=228  n=235 | AFB (MB)  IS*6110* -*devR* PCR  AFB + NAAT  AFB +ve IS*6110* -devR PCR  AFB –ve IS*6110* -devR PCR | 148 69 157  60  9 | 80 71 115  32  35 | 44 123 39  88  39 | 191 200 152  48  152 | Contaminated samples (4%) were identified and patients were called to collect a second sample |
| Nakiyingi et al. ([2012](#_ENREF_151))  Uganda | Level III-1  Some risk of bias | L-J liquid medium culture | N=181 patients with AFB –ve sputum samples | AFB –ve IS*6110* PCR | 48 | 75 | 16 | 42 | 5/205 cultures were contaminated  19/205 PCR results were unavailable |
| Ekrami et al. ([2011](#_ENREF_61))  Iran | Level III-1 Some risk of bias | L-J solid medium culture | N=152 sputum samples | AFB (ZN)  IS*6110* PCR  IS*6110* nPCR) | 90 78 94 | 6 8 6 | 16 28 12 | 40 38 40 | None reported |
| Chakravorty et al. ([2006](#_ENREF_39))  India | Level III-2  Low risk of bias | L-J solid medium culture | N=506 sputum samples from 506 patients | USP AFB (ZN)  *devR* PCR  IS*6110* PCR | 273 269 272 | 39 52 65 | 0 4 1 | 194 181 168 | None reported |
| Michelon et al. ([2011](#_ENREF_139))  Brazil | Level III-2  Low risk of bias | Culture | N=469 sputum specimens  N=295 induced sputum specimens  N=174 spontaneous sputum specimens | AFB  IS*6110* PCR  AFB + NAAT  AFB  IS*6110* PCR  AFB + NAAT  AFB  IS*6110* PCR  AFB + NAAT | 62 65 75  55 51 60  7 14 15 | 7 7 12  5 5 10  2 2 2 | 14 10 1  6 9 1  8 1 0 | 386 387 381  229 230 224  157 157 157 | 4/476 (3 induced and 1 spontaneous) specimens were PCR inhibitory 3/479 (induced) gave indeterminate results |
| Jiang et al. ([2012](#_ENREF_93))  China | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=207 sputum samples  -  n=51  n=156 | AFB (ZN)  16S qRT-PCR  AFB + NAAT  AFB +ve: 16S qRT-PCR  AFB –ve: 16S qRT-PCR | 24 28 28  24  4 | 27 21 43  5  16 | 6 2 2  0  2 | 150 156 134  22  134 | None reported |
| Suzuki et al. ([2006](#_ENREF_190))  Japan | Level III-2  Low risk of bias | MGIT culture | N=138 sputum specimens  n=55  n=83 | : AFB  *dnaJ* PCR-ICA  AFB + NAAT  AFB +ve: *dnaJ* PCR-ICA  AFB –ve: *dnaJ* PCR-ICA | 53 41 57  39  1 | 2 5 5  2  3 | 20 32 16  14  19 | 63 60 60  0  60 | None reported |
| El Khechine et al. ([2009](#_ENREF_63))  France | Level III-2  Low risk of bias | BACTEC 9000 liquid culture | N=134 sputum samples  N=134 stool samples | AFB (ZN)  IS*6110* qPCR  AFB + NAAT | 13 18 18 | 2 10 10 | 7 0 0 | 112 106 106 | None reported |
| George, Mony & Kenneth ([2011](#_ENREF_73))  India | Level III-2  Low risk of bias | MGIT and/or L-J medium culture | N=71 sputum samples  -  n=33  n=38 | AFB (FL)  LAMP  AFB + NAAT  AFB +ve: LAMP  AFB –ve: LAMP | 32 31 32  29  2 | 1 2 3  2  0 | 7 8 7  1  7 | 31 30 29  1  29 | 7/78 samples showed contamination for both L-J and MGIT cultures and were omitted from analysis |
| Deshmukh et al. 2013  India | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=27 sputum specimens | AFB (ZN)  IS*6110* PCR  AFB + NAAT | 5 13 13 | 1 3 3 | 9 1 1 | 12 10 10 | None reported |
| Ani et al. ([2009](#_ENREF_10))  Nigeria | Level III-2  Low risk of bias | L-J slope culture | N=10 sputum specimens from children | AFB –ve IS*6110* PCR | 4 | 0 | 6 | 0 | None reported |
| Chakravorty et al. ([2005](#_ENREF_38))  India | Level III-2  Some risk of bias | L-J solid medium culture | N=571 samples from 571 patients | direct AFB (ZN)  USP AFB (ZN)  IS*6110* PCR | 322 225 325 | 21 18 70 | 6 103 3 | 222 225 173 | None reported |
| Santos et al. ([2006](#_ENREF_180))  Brazil | Level III-2  Some risk of bias | L-J medium culture | N=214 sputum samples   -  n=46  n=168 | AFB (direct)  AFB (conc.)  IS*6110* PCR  AFB (conc.) + NAAT  AFB +ve: IS*6110* PCR  AFB –ve: IS*6110* PCR | 14 17 38 38  17  21 | 1 4 24 26  2  22 | 30 27 6 6  5  1 | 169 166 146 144  22  124 | 4/218 samples were excluded due to contamination of culture tubes |
| Lee, Chen & Peng ([2009](#_ENREF_116))  Taiwan | Level III-2  Some risk of bias | Culture (not specified) | N=150 sputum samples | AFB  LAMP | 30 32 | 9 7 | 4 2 | 107 109 | None reported |
| de Albuquerque et al. ([2014](#_ENREF_47))  Brazil | Level III-2  Some risk of bias | L-J solid medium and 7H9 broth culture | N=140 sputum specimens from 140 HIV+ patients | HIV+ AFB (ZN)  IS*6110* qPCR | 37 41 | 0 1 | 10 6 | 93 92 | None reported |
| Marchi et al. ([2008](#_ENREF_128))  Brazil | Level III-2  Some risk of bias | L-J-MTBAC culture | N=117 sputum specimens | AFB (ZN)  IS*6110* PCR | 3 3 | 0 0 | 3 3 | 111 111 | None reported |
| Ereqat et al. ([2011](#_ENREF_64))  Palestine | Level III-2  Some risk of bias | Culture | N=95 samples from 84 patients  n=13  n=82 | AFB (ZN)  IS*6110* PCR  AFB + NAAT  AFB +ve: IS*6110* PCR  AFB –ve: IS*6110* PCR | 7 10 10  7  3 | 6 20 20  6  14 | 4 1 1  0  1 | 78 64 64  0  64 | None reported |
| Shukla et al. ([2011](#_ENREF_184))  India | Level III-2  Some risk of bias | L-J culture | N=40 AFB +ve sputum specimens | AFB +ve: IS*6110* nPCR | 36 | 0 | 2 | 2 | None reported |
| Gomez et al. ([2011](#_ENREF_77))  Southern Texas (USA) and Mexico | Level III-2  Some risk of bias | MGIT liquid medium and L-J solid medium culture | N=150 patients  -  n=101  n=49 | AFB  *RD1* qPCR  IS*1081* qPCR  IS*6110* qPCR  AFB + NAAT (IS*6110* qPCR)  AFB +ve: IS*6110* qPCR  AFB –ve: IS*6110* qPCR | 99  102 102 104  107  96  8 | 2  0 0 0  2  0  0 | 8  5 5 3  0  3  0 | 41  43 43 43  41  2  41 | 32 had contaminated MGIT |
| Haldar et al. ([2007](#_ENREF_80))  India | Level III-2 Some risk of bias | 7H9 liquid media culture | N=148 sputum samples | Direct AFB (ZN)  USP AFB (ZN)  *devR* FL-PCR   *devR* Gel-PCR  IS*6110* FL-PCR  IS*6110* Gel-PCR | 24 85  111 109 110 102 | 2 2  2 5  4 3 | 96 35  9 11 10 18 | 26 26  26 23 24 25 | None reported |

AFB = acid-fast bacilli; FL = fluorescent; HIV = human immunodeficiency virus; LAMP = loop-mediated isothermal amplification; L-J = Lowenstein-Jensen; MB = methylene blue; MGIT = Mycobacterium Growth Indicator Tubes; NAAT = nucleic acid amplification test; nPCR = nested PCR; PCR = polymerase chain reaction; PCR-ICA = PCR-immunochromatographic assay; qPCR = quantitative (real-time) PCR; qRT-PCR = quantitative (real-time) reverse transcription PCR; USP = universal sample processing; ZN = Ziehl-Neelsen

Table 74 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in sputum

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Rachow et al. ([2011](#_ENREF_173))  Tanzania | Level II  Low risk of bias | MGIT and/or L-J media culture | N=249 sputum samples  -  n=51  n=198 | AFB (ZN)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert | 51 61 62  50  11 | 0 8 8  0  8 | 18 8 7  1  7 | 180 172 172  0  172 | 43/292 were Xpert indeterminate and excluded from final analysis |
| Walusimbi et al. ([2013](#_ENREF_215))  Uganda | Level III-1  Low risk of bias | MGIT and/or L-J culture | N=369 AFB –ve HIV+ sputum specimens with valid results | HIV+ AFB –ve Xpert | 21 | 16 | 22 | 310 | 57/430 specimens had contaminated cultures  19/430 had invalid Xpert results |
| Carriquiry et al. ([2012](#_ENREF_34))  Peru | Level III-1  Low risk of bias | MGIT and/or L-J media culture | N=131 HIV+ patients  -  n=34  n=97 | HIV+ AFB (ZN)  Xpert  AFB + NAAT  AFB +ve: Xpert  ABF –ve: Xpert | 31 44 44  31  13 | 3 2 4  1  1 | 14 1 1  0  1 | 83 84 82  2  82 | 1 culture was contaminated  2 Xpert results were invalid and repeated |
| Nicol et al. ([2011](#_ENREF_158))  South Africa | Level III-2  Low risk of bias | MGIT culture | N=452 children with at least one induced sputum sample | AFB (FL)  Xpert | 27 52 | 0 6 | 43 18 | 382 376 | None reported |
| Zar et al. ([2013](#_ENREF_226))  South Africa | Level III-2  Low risk of bias | MGIT culture | N=384 children with at least one induced sputum sample | AFB (FL)  Xpert | 4 13 | 1 3 | 26 17 | 353 351 | None reported |
| Kurbatova et al. ([2013](#_ENREF_108))  Russia | Level III-2  Low risk of bias | MGIT and/or L-J media culture | N=228 specimens | AFB (direct)  AFB (FL)  Xpert (direct)  Xpert (conc.) | 65 93  102 103 | 3 12  17 16 | 44 16  5 6 | 124 114  104 111 | 2/238 culture results were missing 8/238 had Indeterminate Xpert results |
| Bates et al. ([2013](#_ENREF_19))  Zambia | Level III-2  Low risk of bias | MGIT culture | N=142 sputum specimens from children | AFB (FL)  Xpert | 3 9 | 7 2 | 7 1 | 125 130 | None reported |
| Helb et al. ([2010](#_ENREF_84))  Vietnam | Level III-2  Low risk of bias | MGIT and/or L-J media culture | N=107 patients  -  n=29  n=78 | AFB  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert | 29 67 67  29  38 | 0 0 0  0  0 | 53 15 15  0  15 | 25 25 25  0  25 | None reported |
| Al-Ateah et al. ([2012](#_ENREF_6))  Kingdom of Saudi Arabia | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=56 sputum specimens  -  n=31  n=25 | AFB (FL)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert | 31 37 37  31  6 | 0 0 0  0  0 | 7 1 1  0  1 | 18 18 18  0  18 | None reported |
| Malbruny et al. ([2011](#_ENREF_126))  France | Level III-2  Low risk of bias | MGIT and Coletsos slants | N=18 sputum specimens  -  n=14 | AFB (FL)  Xpert  AFB + NAAT  AFB –ve: Xpert | 4 5 5  1 | 0 0 0  0 | 1 0 0  0 | 13 13 13  13 | None reported |
| Hanrahan et al. ([2014](#_ENREF_83))  South Africa | Level III-2  Some risk of bias | MGIT media culture | N=2,082 patients | AFB  Xpert | 186  299 | 10  47 | 186  107 | 1,472  1,638 | None reported |
| Theron et al. ([2012](#_ENREF_199))  South Africa | Level III-2  Some risk of bias | MGIT medium culture | N=480 sputum samples  -  n=286   -  n=130 | AFB (FL)  Xpert  AFB + NAAT  HIV –ve: AFB (FL)  Xpert  AFB + NAAT  HIV +ve: AFB (FL)  Xpert  AFB + NAAT | 102 115 122  65 68 72  26 35 37 | 3 15 17  2 10 10  1 4 5 | 47 34 27  19 16 12  24 15 13 | 328 316 314  200 193 192  79 76  75 | None reported |
| Sohn et al. ([2014](#_ENREF_186))  Canada | Level III-2  Some risk of bias | Liquid culture | N=435 sputum samples  -  n=11  n=424 | AFB (FL)  Xpert  AFB + NAAT  AFB +ve: Xpert  AFB –ve: Xpert | 7 11 12  6  5 | 4 1 5  0  1 | 17 13 12  1  12 | 407 410 406  4  405 | 1/436 invalid Xpert result |

AFB = acid-fast bacilli; FL = fluorescent; HIV = human immunodeficiency virus; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; Xpert = GeneXpert MTB/RIF NAAT; ZN = Ziehl-Neelsen

Table 75 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in bronchoalveolar lavage, bronchial aspirates and washings

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Min et al. ([2010](#_ENREF_141))  Korea | Level III-2  Low risk of bias | Ogawa medium culture | N=136 bronchial aspirates | AFB stain (ZN)  *senX3-regX3* qPCR | 20  39 | 1  1 | 45  26 | 70  70 | None reported |
| Deshmukh et al. 2013  India | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=13 BAL specimens | AFB (ZN)  IS*6110* PCR  AFB + NAAT | 2 5 5 | 0 2 2 | 3 0 0 | 8 6 6 | None reported |
| Kibiki et al. ([2007](#_ENREF_101))  Tanzania | Level III-2  Some risk of bias | L-J culture | N=116 BAL samples | HIV+ AFB (ZN)  IS*6110* PCR | 16  27 | 1  42 | 12  1 | 87  46 | 4/120 specimens were contaminated (1 AFB +ve and 3 AFB –ve) |

AFB = acid-fast bacilli; BAL = bronchoalveolar lavage; HIV = human immunodeficiency virus; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; NAAT = nucleic acid amplification test; PCR = polymerase chain reaction; qPCR = quantitative (real-time) PCR; ZN = Ziehl-Neelsen

Table 76 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in bronchoalveolar lavage, bronchial aspirates and washings

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Theron et al. ([2013](#_ENREF_198))  South Africa | Level III-2  Low risk of bias | MGIT medium culture | N=154 BAL specimens   n=135  n=84 -  n=46 | AFB (FL)  Xpert AFB –ve: Xpert  HIV– AFB (FL)  Xpert HIV– AFB –ve Xpert  HIV+ AFB (FL)  Xpert  HIV+ AFB –ve Xpert | 15 25 9  7 12 5  4 6 1 | 1 5 4  0 3 3  1 2 1 | 12 2 2  5 0 0  3 2 7 | 126 122 120  72 69 69  37 34 34 | 1/156 specimens had contaminated cultures 1/156 had Xpert error and was excluded from the analysis |
| Al-Ateah et al. ([2012](#_ENREF_6))  Kingdom of Saudi Arabia | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=116 BAL specimens  n=111 | AFB (FL)  Xpert  AFB –ve: Xpert | 4 5  1 | 1 0  0 | 2 1  1 | 109 110  109 | None reported |
| Malbruny et al. ([2011](#_ENREF_126))  France | Level III-2  Low risk of bias | MGIT and Coletsos slants | N=40 specimens 31 bronchial aspirates 9 BAL  n=35 | AFB (FL)  Xpert  AFB + NAAT  AFB –ve: Xpert | 4 7 7  3 | 1 0 1  0 | 3 0 0  0 | 32 33 32  32 | None reported |

AFB = acid-fast bacilli; BAL = bronchoalveolar lavage; FL = fluorescent; HIV = human immunodeficiency virus; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; NAAT = nucleic acid amplification test; Xpert = GeneXpert MTB/RIF NAAT

Table 77 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in gastric aspirates

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bates et al. ([2013](#_ENREF_19))  Zambia | Level III-2  Low risk of bias | MGIT culture | N=788 gastric aspirates from children | AFB (FL)  Xpert | 12 33 | 23 5 | 36 15 | 717 735 | None reported |
| Malbruny et al. ([2011](#_ENREF_126))  France | Level III-2  Low risk of bias | MGIT and Coletsos slants | N=33 gastric aspirates  -  n=30 | AFB (FL)  Xpert  AFB + NAAT  AFB –ve: Xpert | 3 5 5  2 | 0 0 0  0 | 2 0 0  0 | 28 28 28  28 | None reported |
| Moure, Martin & Alcaide ([2012](#_ENREF_147))  Spain | Level III-2  Some risk of bias | MGIT and/or L-J culture | N=6 gastric aspirates | AFB –ve: Xpert | 2 | 0 | 1 | 3 | 2/8 specimens had an Xpert indeterminate result |

AFB = acid-fast bacilli; FL = fluorescent; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; NAAT = nucleic acid amplification test; Xpert = GeneXpert MTB/RIF NAAT

Table 78 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in stools

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| El Khechine et al. ([2009](#_ENREF_63))  France | Level III-2  Low risk of bias | L-J for stools | N=134 stool samples | AFB (ZN)  IS*6110* qPCR  AFB + NAAT | 9 13 13 | 0 11 11 | 4 0 0 | 121 110 110 | None reported |

AFB = acid-fast bacilli; L-J = Lowenstein-Jensen; NAAT = nucleic acid amplification test; qPCR = quantitative (real-time) polymerase chain reaction; ZN = Ziehl-Neelsen

Table 79 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in cerebrospinal fluid

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bhigjee et al. ([2007](#_ENREF_25))  South Africa | Level III-2  Low risk of bias | 7H11 medium culture and MGIT culture | N=126 CSF specimens from 68 patients | AFB –ve: IS*6110-MPB64* PCR  qPCR | 18 18 | 9 16 | 2 2 | 97 90 | None reported |
| Deshmukh et al. 2013  India | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=60 CSF specimens | AFB (ZN)  IS*6110* PCR  AFB + NAAT | 2 10 10 | 0 19 19 | 12 4 4 | 46 27 27 | None reported |
| Desai et al. ([2006](#_ENREF_54))  India | Level III-2  Low risk of bias | L-J culture | N=30 CSF specimens | AFB (ZN)  IS*6110* PCR | 1  8 | 0  12 | 19  0 | 22  10 | None reported |
| Makeshkumar, Madhavan & Narayanan ([2014](#_ENREF_125))  India | Level III-2  Low risk of bias | L-J culture | N=25 CSF specimens | AFB –ve: IS*6110* PCR | 0 | 9 | 0 | 16 | None reported |
| Ani et al. ([2009](#_ENREF_10))  Nigeria | Level III-2  Low risk of bias | L-J slope culture | N=5 CSF specimens from children | AFB –ve IS*6110* PCR | 0 | 0 | 0 | 5 | None reported |
| Therese, Jayanthi & Madhavan ([2005](#_ENREF_197))  India | Level III-2  Some risk of bias | L-J culture | N=120 CSF specimens  -  n=119 | AFB (ZN)  IS*6110* PCR  AFB + NAAT  AFB –ve: IS*6110* PCR | 1 1 1  0 | 0 37 37  37 | 0 0 0  0 | 119 82 82  82 | None reported |
| Baveja et al. ([2009](#_ENREF_20))  India | Level III-2  Some risk of bias | L-J and BACTEC culture | N=100 CSF specimens from children | AFB (ZN)  *MPB64* PCR | 2 22 | 0 0 | 20 0 | 78 78 | None reported |
| Shukla et al. ([2011](#_ENREF_184))  India | Level III-2  Some risk of bias | L-J culture | N=16 CSF specimens | AFB –ve: IS*6110* nPCR | 0 | 12 | 0 | 4 | None reported |

AFB = acid-fast bacilli; CSF = cerebrospinal fluid; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; NAAT = nucleic acid amplification test; nPCR = nested PCR; PCR = polymerase chain reaction; qPCR = quantitative (real-time) PCR; ZN = Ziehl-Neelsen

Table 80 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in cerebrospinal fluid

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Malbruny et al. ([2011](#_ENREF_126))  France | Level III-2  Low risk of bias | MGIT and Coletsos slants | N=15 CSF specimens | AFB –ve: Xpert | 1 | 0 | 0 | 14 | None reported |
| Al-Ateah et al. ([2012](#_ENREF_6))  Kingdom of Saudi Arabia | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=14 CSF specimens | AFB –ve: Xpert | 0 | 0 | 0 | 14 | None reported |
| Moure, Martin & Alcaide ([2012](#_ENREF_147))  Spain | Level III-2  Some risk of bias | MGIT and/or L-J culture | N=14 CSF specimens | AFB –ve: Xpert | 2 | 0 | 0 | 12 | None reported |

AFB = acid-fast bacilli; CSF = cerebrospinal fluid; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; Xpert = GeneXpert MTB/RIF NAAT

Table 81 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in body fluids

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Maurya et al. ([2011a](#_ENREF_135))  India | Level III-1  Low risk of bias | BACTEC culture | N=102 pleural effusions  -  n=17  n=85 | AFB (ZN)  IS*6110* PCR  AFB + NAAT  AFB +ve IS*6110* PCR  AFB –ve IS*6110* PCR | 15 45 45  15  30 | 2 17 18  1  16 | 32 2 2  0  2 | 53 38 37  1  37 | None reported |
| Singh et al. ([2006](#_ENREF_185))  India | Level III-1  Low risk of bias | L-J culture | N=85 bone-marrow aspirates | AFB –ve *MPB64* PCR | 1 | 18 | 0 | 66 | None reported |
| Bhanu et al. ([2005](#_ENREF_24))  India | Level III-1  Low risk of bias | L-J culture | N=16 endometrial aspirates | AFB (ZN)  *mpt64* PCR | 0 0 | 1 1 | 0 8 | 15 7 | 1 negative PCR included in analysis was found to be inhibitory |
| Makeshkumar, Madhavan & Narayanan ([2014](#_ENREF_125))  India | Level III-2  Low risk of bias | L-J culture | N=119 CSF specimens  59 ascetic fluid, 54 pleural fluid, 6 synovial fluid | AFB (ZN)  IS*6110* PCR | 1 0 | 0 28 | 0 1 | 118 90 | None reported |
| Deshmukh et al. 2013  India | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=52 body fluid specimens | AFB (ZN)  IS*6110* PCR  AFB + NAAT | 3 12 12 | 0 7 7 | 13 4 4 | 36 29 29 | None reported |
| Ani et al. ([2009](#_ENREF_10))  Nigeria | Level III-2  Low risk of bias | L-J slope culture | N=25 fluid specimens from children  11 gastric wash  5 ascitic fluid  9 pleural effusions | AFB –ve IS*6110* PCR | 12 | 0 | 0 | 13 | None reported |
| Therese, Jayanthi & Madhavan ([2005](#_ENREF_197))  India | Level III-2  Some risk of bias | L-J culture | N=107 specimens 104 peritoneal and 3 pericardial  n=106 | AFB (ZN)  IS*6110* PCR  AFB + NAAT  AFB –ve: IS*6110* PCR | 1 2 2  1 | 0 64 64  64 | 2 1 1  1 | 104 40 40  40 | None reported |
| Bhanothu, Theophilus & Rozati ([2014](#_ENREF_23))  India | Level III-2  Some risk of bias | L-J culture | N=11 pelvic fluids | AFB (ZN)  *TCR4* PCR  AFB + NAAT | 7 11 11 | 0 0 0 | 0 0 0 | 4 0 0 | None reported |

AFB = acid-fast bacilli; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; M-PCR = multiplex PCR; NAAT = nucleic acid amplification test; PCR = polymerase chain reaction; ZN = Ziehl-Neelsen

Table 82 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in body fluids

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Al-Ateah et al. ([2012](#_ENREF_6))  Kingdom of Saudi Arabia | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=22 specimens  13 pleural fluids  3 pericardial fluids  2 synovial fluids 4 abdominal aspirates | AFB –ve: Xpert | 3 | 0 | 0 | 19 | None reported |
| Malbruny et al. ([2011](#_ENREF_126))  France | Level III-2  Low risk of bias | MGIT and Coletsos slants | N=20 specimens  5 joint fluid 12 pleural fluid 3 peritoneal fluid | AFB –ve: Xpert | 4 | 0 | 2 | 14 | None reported |
| Moure, Martin & Alcaide ([2012](#_ENREF_147))  Spain | Level III-2  Some risk of bias | MGIT and/or L-J culture | N=44 specimens  31 pleural fluid 7 joint fluid 3 ascitic fluid 3 pericardial fluid | AFB –ve: Xpert | 13 | 0 | 22 | 9 | None reported |

AFB = acid-fast bacilli; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; Xpert = GeneXpert MTB/RIF NAAT

Table 83 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in fine-needle aspirates

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Makeshkumar, Madhavan & Narayanan ([2014](#_ENREF_125))  India | Level III-2  Low risk of bias | L-J culture | N=12 FNA specimens | AFB (ZN)  IS*6110* PCR | 2 1 | 3 3 | 0 1 | 7 7 | None reported |
| Derese et al. ([2012](#_ENREF_53))  Ethiopia | Level III-2  Some risk of bias | L-J culture | N=134 FNAs from lymph nodes | n=101 AFB (ZN)  n=124 IS*6110* nPCR | 8 21 | 5 8 | 27 29 | 61 66 | None reported |
| Pahwa et al. ([2005](#_ENREF_163))  India | Level III-2  Some risk of bias | L-J medium culture | N=55 FNAs | AFB (ZN + FL)  *MPB64* PCR | 14 17 | 5 5 | 5 1 | 31 32 | None reported |
| Mittal et al. ([2011](#_ENREF_145))  India | Level III-2  Some risk of bias | L-J culture | N=50 lymph node FNAs | AFB (ZN) IS*6110* PCR  AFB + NAAT | 22 27 30 | 2 3 3 | 8 3 1 | 18 17 16 | None reported |
| Therese, Jayanthi & Madhavan ([2005](#_ENREF_197))  India | Level III-2  Some risk of bias | L-J culture | N=44 lymph node FNA specimens  n=38 | AFB (ZN)  IS*6110* PCR  AFB + NAAT  AFB –ve: IS*6110* PCR | 5 9 9  4 | 1 10 11  10 | 4 0 0  0 | 34 25 24  24 | None reported |

AFB = acid-fast bacilli; FL = fluorescent; FNA = fine-needle aspirate; L-J = Lowenstein-Jensen; NAAT = nucleic acid amplification test; nPCR = nested PCRPCR = polymerase chain reaction; ZN = Ziehl-Neelsen

Table 84 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in fine-needle aspirates

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Van Rie et al. ([2013b](#_ENREF_213))  South Africa | Level III-2  Low risk of bias | MGIT culture | N=344 FNA specimens | HIV+ AFB (FL)  Xpert  AFB + NAAT | 59 139 140 | 5 23 23 | 87 10 9 | 188 172 172 | 8/373 cultures were contaminated or non-interpretable 4/373 were NTM 5/373 had invalid Xpert results and were excluded from analysis |
| Ablanedo-Terrazas et al. ([2014](#_ENREF_4))  Mexico | Level III-2  Low risk of bias | MGIT 960 liquid culture | N=68 lymph node FNAs | HIV+ AFB (ZN)  Xpert  AFB + NAAT | 12 15 15 | 4 0 4 | 3 0 0 | 49 53 49 | No invalid Xpert results were obtained |
| Ligthelm et al. ([2011](#_ENREF_120))  South Africa | Level III-2  Low risk of bias | MGIT 960 liquid culture | N=48 lymph node FNAs | AFB (ZN)  AFB (FL)  Xpert  AFB + NAAT | 12 22 28 29 | 0 1 3 2 | 17 7 1 0 | 19 18 16 17 | No invalid Xpert results were obtained |
| Malbruny et al. ([2011](#_ENREF_126))  France | Level III-2  Low risk of bias | MGIT and Coletsos slants | N=23 lymph nodes  -  n=20 | AFB (FL)  Xpert  AFB + NAAT  AFB –ve: Xpert | 3 6 6  3 | 0 0 0  0 | 3 0 0  0 | 17 17 17  17 | None reported |
| Biadglegne et al. ([2014](#_ENREF_26))  Ethiopia and Germany | Level III-2  Some risk of bias | L-J and Gottsacker culture | N=213 FNAs from lymph nodes  n=12  n=201 | AFB (FL)  Xpert  AFB + NAAT  AFB +ve Xpert  AFB –ve Xpert | 11 29 29  11  18 | 1 56 56  1  55 | 20 2 2  0  2 | 181 126 126  0  126 | 11/231 cultures were contaminated 8/231 Xpert results were indeterminate and excluded from analysis |
| Moure, Martin & Alcaide ([2012](#_ENREF_147))  Spain | Level III-2  Some risk of bias | MGIT and/or L-J culture | N=38 lymph nodes | AFB –ve: Xpert | 24 | 0 | 10 | 4 | None reported |
| Al-Ateah et al. ([2012](#_ENREF_6))  Kingdom of Saudi Arabia | Level III-2  Some risk of bias | MGIT and/or L-J culture | N=5 FNAs | AFB (FL)  Xpert | 2 2 | 1 0 | 0 0 | 2 3 | None reported |

AFB = acid-fast bacilli; FL = fluorescent; FNA = fine-needle aspirate; HIV = human immunodeficiency virus; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; NAAT = nucleic acid amplification test; NTM = non-tuberculous mycobacteria; Xpert = GeneXpert MTB/RIF NAAT; ZN = Ziehl-Neelsen

Table 85 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in abscesses/pus

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Deshmukh et al. 2013  India | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=94 pus specimens | AFB (ZN)  IS*6110* PCR  AFB + NAAT | 43 53 53 | 5 15 15 | 12 2 2 | 34 24 24 | None reported |
| Makeshkumar, Madhavan & Narayanan ([2014](#_ENREF_125))  India | Level III-2  Low risk of bias | L-J culture | N=7 pus specimens | AFB (ZN)  IS*6110* PCR | 1 1 | 0 2 | 0 0 | 6 4 | None reported |

AFB = acid-fast bacilli; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; NAAT = nucleic acid amplification test; PCR = polymerase chain reaction; ZN = Ziehl-Neelsen

Table 86 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in abscesses/pus

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Al-Ateah et al. ([2012](#_ENREF_6))  Kingdom of Saudi Arabia | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=10 abscess aspirates  n=8 | AFB (FL)  Xpert  AFB –ve: Xpert | 2 3  1 | 0 0  0 | 1 0  0 | 7 7  7 | None reported |
| Moure, Martin & Alcaide ([2012](#_ENREF_147))  Spain | Level III-2  Some risk of bias | MGIT and/or L-J culture | N=19 abscess aspirates | AFB –ve: Xpert | 13 | 0 | 4 | 2 | None reported |

AFB = acid-fast bacilli; FL = fluorescent; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; Xpert = GeneXpert MTB/RIF NAAT

Table 87 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in urine

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Deshmukh et al. 2013  India | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=53 urine specimens | AFB (ZN)  IS*6110* PCR  AFB + NAAT | 4 15 15 | 2 9 9 | 16 5 5 | 31 24 24 | None reported |
| Makeshkumar, Madhavan & Narayanan ([2014](#_ENREF_125))  India | Level III-2  Low risk of bias | L-J culture | N=8 urine specimens | AFB (ZN)  IS*6110* PCR | 2 2 | 1 2 | 0 0 | 5 4 | Not reported |
| Khosravi et al. ([2010](#_ENREF_100))  Iran | Level III-2  Some risk of bias | L-J culture | N=200 urine samples | AFB (ZN)  IS*6110* nPCR | 4 10 | 0 0 | 6 0 | 190 190 | None reported |
| Ghaleb, Afifi & El-Gohary ([2013](#_ENREF_74))  Egypt | Level III-2  Some risk of bias | BACTEC 12B and/or L-J culture | N=100 urine samples  -  n=99 | AFB (ZN)  IS*6110* PCR  AFB + NAAT  AFB –ve IS*6110* PCR | 1 3 3  2 | 0 3 3  3 | 0 0 0  0 | 99 94 94  94 | None reported |
| Khan, Cheema & Khan ([2013](#_ENREF_98))  Egypt | Level III-2  Some risk of bias | L-J culture | N=50 urine samples | AFB (ZN)  PCR | 11 16 | 2 2 | 8 3 | 29 29 | None reported |

AFB = acid-fast bacilli; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; NAAT = nucleic acid amplification test; nPCR = nested PCR; PCR = polymerase chain reaction; ZN = Ziehl-Neelsen

Table 88 Diagnostic accuracy of in-house NAAT compared with AFB microscopy and culture in tissue biopsies

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bhanu et al. ([2005](#_ENREF_24))  India | Level III-1  Low risk of bias | L-J culture | N=14 endometrial biopsies | AFB (ZN)  *mpt64* PCR | 1 1 | 0 7 | 0 0 | 13 6 | 3 negative PCR included in analysis were found to be inhibitory |
| Deshmukh et al. 2013  India | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=164 tissue specimens | AFB (ZN)  IS*6110* PCR  AFB + NAAT | 37 57 57 | 7 3 3 | 23 3 3 | 97 84 84 | None reported |
| Sharma et al. ([2013](#_ENREF_183))  India | Level III-2  Low risk of bias | L-J culture | N=50 endoscopic ileocaecal biopsies | AFB (ZN)  M-PCR | 1 2 | 1 0 | 0 29 | 47 19 | None reported |
| Shukla et al. ([2011](#_ENREF_184))  India | Level III-2  Some risk of bias | L-J culture | N=38 endometrial biopsies | AFB –ve: IS*6110* nPCR | 2 | 26 | 0 | 10 | None reported |
| Bhanothu, Theophilus & Rozati ([2014](#_ENREF_23))  India | Level III-2  Some risk of bias | L-J culture | N=191 endometrial or ovarian biopsies  n=37  n=154 | AFB (ZN)  *TCR4* PCR  AFB + NAAT  AFB +ve: TCR4 PCR  AFB –ve: *TCR4* PCR | 37 77 77  37  40 | 0 80 80  0  80 | 41 1 1  0  1 | 113 33 33  0  33 | None reported |
| Therese, Jayanthi & Madhavan ([2005](#_ENREF_197))  India | Level III-2  Some risk of bias | L-J culture | N=9 tissue biopsies  -  n=8 | AFB (ZN)  IS*6110* PCR  AFB + NAAT  AFB –ve: IS*6110* PCR | 1 1 1  0 | 0 4 4  4 | 0 0 0  0 | 8 4 4  4 | None reported |
| Keys et al. ([2012](#_ENREF_97))  Australia | Level III-2  Some risk of bias | Culture | N=5 pleural biopsies from children | AFB  PCR  AFB + NAAT | 1 3 | 0 2 | 2 0 | 2 0 | 1/6 specimens had an inconclusive PCR result |

AFB = acid-fast bacilli; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; M-PCR = multiplex PCR; NAAT = nucleic acid amplification test; nPCR = nested PCR; PCR = polymerase chain reaction; ZN = Ziehl-Neelsen

Table 89 Diagnostic accuracy of Xpert NAAT compared with AFB microscopy and culture in tissue biopsies

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Al-Atteah et al. ([2012](#_ENREF_6))  Kingdom of Saudi Arabia | Level III-2  Low risk of bias | MGIT and/or L-J culture | N=16 tissue biopsies | AFB (FL)  Xpert | 2 8 | 0 0 | 6 1 | 8 7 | None reported |
| Malbruny et al. ([2011](#_ENREF_126))  France | Level III-2  Low risk of bias | MGIT and Coletsos slants | N=6 vertebral biopsies | AFB (FL)  Xpert  AFB + NAAT | 1 1 1 | 0 0 0 | 0 0 0 | 5 5 5 | None reported |
| Moure, Martin & Alcaide ([2012](#_ENREF_147))  Spain | Level III-2  Some risk of bias | MGIT and/or L-J culture | N=20 tissue biopsies | AFB –ve: Xpert | 5 | 0 | 7 | 8 | None reported |

AFB = acid-fast bacilli; FL = fluorescent; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; NAAT = nucleic acid amplification test; Xpert = GeneXpert MTB/RIF NAAT

Table 90 Diagnostic accuracy of NAAT compared with drug sensitivity testing for the detection of drug-resistant MTB infections

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Inconclusive results** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Carriquiry et al. ([2012](#_ENREF_34))  Peru | Level III-1  Low risk of bias | DST | N= 39 culture-positive sputum samples | Xpert RIF | 6 | 3 | 0 | 30 | None reported |
| Vadwai et al. ([2011](#_ENREF_209))  India | Level III-2  Low risk of bias | DST with MGIT SIRE | N=125 culture-positive extrapulmonary specimens | Xpert RIF | 39 | 5 | 1 | 80 | None reported |
| Kurbatova et al. ([2013](#_ENREF_108))  Russia | Level III-2  Low risk of bias | DST | N=99 culture-positive Xpert-valid sputum specimens | Xpert (conc) vs L-J or MGIT Xpert (conc) vs L-J DST Xpert (conc) vs MGIT DST | 57 45 55 | 1 2 2 | 5 5 1 | 38 30 40 | 10/109 specimens had invalid Xpert RIF results 2/109 specimens had contaminated MGIT DST 25/109 specimens had contaminated L-J DST |
| Bates et al. ([2013](#_ENREF_19))  Zambia | Level III-2  Low risk of bias | DST with MGIT SIRE | N=52 culture-positive gastric lavage specimens | RIF resistance  Xpert RIF  Multi- drug resistance  Xpert RIF | 2  2 | 1  1 | 0  0 | 49  49 | 6/788 specimens were contaminated and excluded from analysis |
| Lee et al. ([2013](#_ENREF_115))  Korea | Level III-2  Low risk of bias | DST on Ogawa medium | N=35 culture-positive Xpert-positive bronchoscopy samples | Xpert RIF | 2 | 0 | 0 | 33 | None reported |
| Ioannidis et al. ([2011](#_ENREF_91))  Greece | Level III-2  Low risk of bias | GenoType MTBDRplus and confirmed by DST | N=32 culture-positive, GeneXpert-valid mixed samples | Xpert RIF | 3 | 1 | 0 | 28 | None reported |
| Hillemann et al. ([2011](#_ENREF_86))  Germany | Level III-2  Low risk of bias | DST | N=29 culture-positive non-respiratory specimens | Xpert RIF | 0 | 1 | 0 | 28 | 3/29 culture-positive specimens by Xpert NAAT had an indeterminate RIF resistance result |
| Theron et al. ([2013](#_ENREF_198))  South Africa | Level III-2  Low risk of bias | DST with MGIT SIRE | N=27 culture-positive BAL samples | RIF resistance  Xpert RIF  MDR  Xpert RIF | 1  1 | 3  3 | 0  0 | 23  23 | None reported |
| Deggim et al. ([2013](#_ENREF_51))  Switzerland | Level III-2  Low risk of bias | BACTEC MGIT 960 | N=18 culture-positive mixed specimens | Xpert RIF | 0 | 2 | 0 | 16 | None reported |
| Sohn et al. ([2014](#_ENREF_186))  Canada | Level III-2  Some risk of bias | DST | N=501 culture-positive sputum samples | Xpert RIF | 1 | 1 | 0 | 499 | 1/502 specimens had contaminated cultures 44/502 had invalid Xpert results and were repeated |
| Halse et al. ([2010](#_ENREF_81))  USA | Level III-2  Some risk of bias | DST | N=143 culture-positive mixed specimens | *rpoB* pyrosequencing | 2 | 1 | 1 | 139 | None reported |
| Marlowe et al. ([2011](#_ENREF_130))  USA | Level III-2  Some risk of bias | DST | N=130 culture-positive respiratory specimens | Xpert RIF | 0 | 3 | 0 | 127 | None reported |
| Zeka, Tasbakan & Cavusoglu ([2011](#_ENREF_227))  Turkey | Level III-2  Some risk of bias | DST | N=89 culture-positive mixed specimens  N=58 pulmonary N=31 extrapulmonary | RIF resistance  Xpert RIF  MDR  Xpert RIF | 1  1 | 0  0 | 0  4 | 88  84 | None reported |
| Biadglegne et al. ([2014](#_ENREF_26))  Ethiopia and Germany | Level III-2  Some risk of bias | BacT/Alert 3D DST | N=32 culture-positive FNA samples | Xpert RIF | 2 | 1 | 0 | 29 | None reported |

BAL = bronchoalveolar lavage; DST = drug susceptibility testing; FNA = fine-needle aspirate; L-J = Lowenstein-Jensen; MDR = multidrug-resistant; MGIT = Mycobacterium Growth Indicator Tubes; RIF = rifampicin

Table 91 Diagnostic accuracy of NAAT and AFB microscopy using culture as the reference standard for diagnosis of NTM

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Notes** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Abdalla et al. ([2009](#_ENREF_2))  Brazil | Level II  High risk of bias | L-J culture | N=27 FFPE skin biopsy MTB culture-negative specimens | AFB –ve In-house NTM-NAAT | 1 | 13 | 0 | 13 | Culture not performed on 3/34 specimens  4/34 were MTB C+ |
| Bogner et al. ([1997](#_ENREF_28))  Germany | Level III-1  Low risk of bias | BACTEC 12B and/or L-J culture | N=540 blood specimens | HIV+ In-house MAC-NAAT | 12 | 2 | 34 | 492 | Only MAC-positive and MAC-negative results considered  Results include 6 MTB and 18 non-MAC NTM C+ specimens |
| Mahaisavariya et al. ([2005](#_ENREF_124))  Thailand | Level III-1  High risk of bias | Culture | N=131 tissue biopsies  5 n=41  6 n=90 | AFB  In-house NTM-NAAT  AFB +ve In-house MTM-NAAT  AFB –ve In-house MTM-NAAT | 15  16  7  9 | 26  31  5  26 | 21  20  8  12 | 69  64  21  43 | 11/131 specimens had no culture results and were included as culture-negative  Results includes 2 MTB C+ specimens |
| Kox et al. ([1997](#_ENREF_106))  The Netherlands | Level III-2  Low risk of bias | Culture | N=238 MTB culture-negative specimens  n=53  n=185 | AFB (ZN)  In-house NTM-NAAT  AFB +ve In-house NTM-NAAT  AFB –ve In-house NTM-NAAT | 32 37  31  6 | 22 27  17  10 | 7 2  1  1 | 177 172  4  168 | 21/259 specimens were MTB C+ |
| Matsumoto et al. ([1998](#_ENREF_133))  Japan | Level III-2  Low risk of bias | Ogawa culture | N=139 MTB culture-negative bronchial washings  n=133 | AFB (ZN)  Comm MAC-NAAT  AFB –ve Comm MAC-NAAT | 4 10  6 | 2 1  1 | 8 2  2 | 125 126  124 | 2/141 specimens were MTB C+ |
| Choi et al. ([2012](#_ENREF_41))  Korea | Level III-2  Some risk of bias | MGIT culture | N=467 respiratory specimens that were MTB culture-negative | AFB (FL)  Comm NTM-NAAT | 6  29 | 0  0 | 36  13 | 425  453 | 64/531 specimens from patients suspected of MTB infections |
| Tran et al. ([2014](#_ENREF_207))  USA | Level III-2  Some risk of bias | BACTEC MGIT 960 culture | N=456 respiratory specimens  n=179  n=277 | AFB (ZN)  In-house MAC-NAAT  AFB +ve In-house MAC-NAAT  AFB –ve In-house MAC-NAAT | 67 57  54  3 | 112 2  0  2 | 29 39  13  26 | 248 358  112  246 | 8/464 specimens had inconclusive or indeterminate PCR results  25/360 MAC culture-negative specimens grew other NTMs and 101/360 grew MTB but were included as culture-negative in the analysis |
| Gamboa et al. ([1997](#_ENREF_70))  Spain | Level III-2  Some risk of bias | BACTEC 13A culture | N=101 specimens  N=91 blood specimens  N=10 BM specimens | HIV+, AFB –ve  Comm MAC-NAAT  Comm MAC-NAAT  Comm MAC-NAAT | 57  56  1 | 0  0  0 | 11  10  1 | 33  25  8 | 30/121 blood specimens were MTB culture-positive  5/15 BM specimens were MTB C+  6/11 false-negative specimens were non-MAC NTM C+ |
| Ninet et al. ([1997](#_ENREF_159))  Switzerland | Level III-2  High risk of bias | BACTEC 13A culture | N=195 MTB culture-negative blood specimens | HIV+ Comm MAC-NAAT | 14 | 0 | 24 | 157 | 6/201 were MTB C+  4/24 false-negative specimens were non-MAC NTM C+ |
| Frevel et al. ([1999](#_ENREF_68))  Germany | Level III-2  High risk of bias | Culture | N=69 FFPE samples | In-house NTM-NAAT | 5 | 14 | 0 | 50 | Only NTM results considered  MTB culture result unknown |

AFB = acid-fast bacilli; BM = bone marrow; C+ = culture positive; Comm = commercial; FFPE = formalin fixed, paraffin embedded; FL = fluorescent; HIV = human immunodeficiency virus; MTB = *Mycobacterium tuberculosis*; NAAT = nucleic acid amplification test; NTM = non-tuberculous mycobacteria; PCR = polymerase chain reaction; ZN = Ziehl-Neelsen

Table 92 Diagnostic accuracy of NAAT, AFB microscopy and culture using a clinical reference standard for diagnosis of NTM

| **Study**  **Country** | **Evidence level and risk of bias** | **Reference standard** | **Population**  **Samples** | **Tests** | **True-positive results** | **False-positive results** | **False-negative results** | **True-negative results** | **Notes** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Abdalla et al. ([2009](#_ENREF_2))  Brazil | Level II  High risk of bias | CRS | N=27 FFPE skin biopsy MTB culture-negative specimens | AFB –ve In-house NTM-NAAT  Culture | 12 1 | 2 0 | 0 11 | 13 15 | Culture not performed on 3/34 specimens  4/34 were MTB culture-positive |
| Phillips et al. ([2005](#_ENREF_168))  Ghana | Level III-2  Low risk of bias | CRS | Biopsy specimens  N=65  N=70  N=65 | AFB (ZN)  In-house MU-NAAT  Culture | 23  59  27 | 0  0  0 | 32  1  28 | 10  10  10 | 5/70 specimens did not have microscopy and culture results and were excluded from the analysis |
| Kox et al. ([1997](#_ENREF_106))  The Netherlands | Level III-2  Some risk of bias | CRS | N=238 MTB culture-negative specimens | In-house NTM-NAAT  Culture | 74 38 | 5 0 | 2 37 | 157 162 | 21/259 specimens were MTB culture-positive |
| Gazzola et al. ([2008](#_ENREF_72))  Italy | Level III-2  Some risk of bias | CRS | N=110 MTB culture-negative specimens  N=67 blood specimens  N=43 BM specimens | HIV+ MAC-NAAT  Culture  MAC-NAAT  Culture  MAC-NAAT + culture  AFB  MAC-NAAT  Culture  MAC-NAAT + culture | 10 13  6 10 10  1 4 3 6 | 1 0  0 0 0  0 1 0 1 | 8 9  5 5 1  6 3 4 1 | 91 92  56 56 56  36 35 36 35 | 4/71 blood specimens were MTB culture-positive  3/46 BM specimens were MTB culture-positive |

AFB = acid-fast bacilli; BM = bone marrow; Comm = commercial; CRS = clinical reference standard; FFPE = formalin fixed, paraffin embedded; HIV = human immunodeficiency virus; MTB = *Mycobacterium tuberculosis*; MU = *M. ulcerans*; NAAT = nucleic acid amplification test; NTM = non-tuberculous mycobacteria; PCR = polymerase chain reaction

# Appendix D Analysis of diagnostic accuracy data

Table 93 Prevalence of MTB culture-positive patients in included studies

| **-** | **Overall [range]** | **> 100 [range]** | **100–10 [range]** | **< 10 [range]** |
| --- | --- | --- | --- | --- |
| **All studies** | - | - | - | - |
| **All NAAT**  Overall k=68  AFB +ve k=28  AFB –ve k=39  HIV+ k=7  HIV+, AFB –ve k=2  HIV– k=6  HIV–, AFB +ve k=4  HIV–, AFB –ve k=5 | -  30% [1–81]  80% [27–100]  19% [1–72]  30% [16–42]  15% [12–19]  38% [8–77]  75% [27–100]  29% [6–50] | -  33% [2–81]  81% [27–100]  18% [1–50]  30% [16–42]  15% [12–19]  38% [8–77]  75% [27–100]  29% [6–50] | -  29% [1–71]  82% [47–98]  23% [2–72]  30% [22–34]  -  -  -  - | -  24% [6–60]  72% [54–88]  15% [4-48]  -  -  -  -  - |
| **In-house NAAT**  Overall k=44  AFB +ve k=16  AFB –ve k=23 | -  32% [1–81]  80% [47–100]  17% [1-44] | -  36% [2–81]  86% [65–100]  20% [1–44] | -  29% [1–71]  74% [47–98]  13% [2–31] | -  24% [12–60]  69% [54–84]  5% [4–5] |
| **Xpert**  Overall k=24  AFB +ve k=12  AFB –ve k=16 | -  27% [5–77]  78% [27–100]  23% [1–72] | -  27% [5–77]  67% [27–100]  14% [1–50] | -  29% [8–50]  92% [64–98]  37% [10-72] | -  24% [6–60]  74% [64–88]  18% [4–48] |
| **Sputum specimens** | - | - | - | - |
| **All NAAT**  Overall k=30  AFB +ve k=14  AFB –ve k=16  HIV+ k=3  HIV+, AFB +ve k=1  HIV– k=2  HIV–, AFB +ve k=1  HIV–, AFB –ve k=1 | -  37% [5–81]  76% [27–100]  25% [4–100]  35% [34–38]  12%  42% [8–77]  27%  50% | -  42% [7–81]  78% [27–100]  34% [9–100]  38% (k=1)  12%  42% [8–77]  27%  50% | -  38% [5–71]  80% [47–100]  24% [4–56]  34% [34–34]  -  -  -  - | -  15% [6–28]  59% [54–64]  5% [4–6]  -  -  -  -  - |
| **In-house NAAT**  Overall k=18  AFB +ve k=9  AFB –ve k=10 | -  41% [5–81]  76% [47–98]  26% [4–100] | -  58% [41–81]  85% [65–95]  40% [20–100] | -  34% [1–71]  72% [47–98]  14% [4–24] | -  13% [12–15]  54% (k=1)  5% (k=1) |
| **Xpert**  Overall k=12  AFB +ve k=5  AFB –ve k=7 | -  32% [6–77]  76% [27–100]  23% [4–56] | -  26% [7–77]  64% [27–100]  23% [9–50] | -  49% [34–68]  96% [91–100]  42% [28–56] | -  17% [6–28]  64% (k=1)  5% [4–6] |
| **Non-sputum specimens** | - | - | - | - |
| **All NAAT**  Overall k=35  AFB +ve k=11  AFB –ve k=19  HIV+ k=4  HIV+, AFB –ve k=1  HIV– k=3  HIV–, AFB +ve k=2  HIV–, AFB –ve k=3 | -  27% [1–67]  80% [44–100]  18% [0–72]  26% [16–42]  19%  34% [14–46]  94% [88–100]  24% [6–38] | -  29% [2–67]  86% [62–100]  14% [0–44]  27% [16–42]  19%]  34% [14–46]  94% [88–100]  24% [6–38] | -  24% [1–48]  68% [44–92]  32% [2–72]  30% [22–34]  -  -  -  - | -  23% [10–60]  79% [74–85]  9% [7–10]  -  -  -  -  - |
| **In-house NAAT**  Overall k=25  AFB +ve k=8  AFB –ve k=13 | -  27% [1–67]  79% [44–100]  15% [0–44] | -  29% [2–67]  86% [62–100]  15% [0–44] | -  21% [1–40]  44% (k=1)  19% [2–32] | -  27% [10–60]  74% (k=1)  7% (k=1) |
| **Xpert**  Overall k=10  AFB +ve k=4  AFB –ve k=6 | -  26% [6–60]  84% [67–92]  24% [1–72] | -  28% [6–60]  92% (k=1)  6% [1–10] | -  28% [13–48]  76% [67–85]  41% [8–72] | -  16% [16–16]  92% (k=1)  10% (k=1) |

AFB = acid-fast bacilli; HIV = human immunodeficiency virus; MTB = *Mycobacterium tuberculosis*; NAAT = nucleic acid amplification test; Xpert = GeneXpert MTB/RIF NAAT

Forest plot showing the sensitivity and specificity with 95% CIs for individual studies
reported as: Author, Year, Country, Incidence of TB, SENSITIVITY, SPECIFICITY
Studies from Low Incidence countries
In-house NAAT
Halse, 2010, USA, 3.6, 83% [78, 88], 95% [95, 97]
Keys, 2012, Australia, 6.5, 33% [1, 91], 100% [16, 100]
Ereqat , 2011, Palestine, 7.6, 64% [31. 89], 93% [85. 97]
Drouillon, 2009, France-Italy, 6.7-8.2, 47% [38, 55], 100% [99, 100]
Drouillon, 2007, France, 8.2, 34% [19, 53], 100% [97, 100]
El Khechine , 2009, France, 8.2, 67% [48, 82], 99% [97, 100]
Commercial NAAT
Marlowe, 2011, USA, 3.6, 67% [58, 85], 55% [44, 65]
Sohn, 2014, Canada, 4.6, 29% [13, 51], 99% [98, 100]
Deggim, 2013, Switzerland, 6, 78% [52, 94], 92% [81, 97]
Tortoli, 2012, Italy, 6.7, 41% [35, 48], 99% [98, 99]
Malbruny, 2011, France, 8.2, 48% [30, 67], 99% [95, 100]
Studies from Medium Incidence countries
In-house NAAT
Ghaleb , 2013, Egypt, 17, 100% [3,100], 100% [96,100]
Khan, 2013, Egypt, 17, 58% [33, 80], 94% [79, 99]
Suzuki, 2006, Japan, 19, 73% [61, 82], 97% [89, 100]
Ekrami , 2011, Iran, 21, 85% [77, 91], 87% [74, 95]
Gholoobi, 2014, Iran, 21, 75% [43, 95], 83% [59, 96]
Khosravi , 2010, Iran, 21, 40% [12, 74], 100% [98, 100]
Jiang, 2012, China, 73, 93% [86, 97], 95% [84, 99]
Gomez, 2011, Mexico, 23, 91% [80, 97], 96% [93, 98]
Ben Kahla, 2011, Tunisia, 31, 79% [64, 89], 100% [96, 100]
de Albuquerque , 2014, Brazil, 46, 50% [12, 88], 100% [97, 100]
Marchi, 2008, Brazil, 46, 82% [71, 90], 98% [96, 99]
Michelon , 2011, Brazil, 46, 39% [24, 55], 98% [94, 99]
Santos, 2006, Brazil, 46, 88% [73, 97], 82% [86, 96]
Lee, 2009, Taiwan, 68, 78% [61, 90], 84% [78, 89]
Commercial NAAT
Al-Atteah, 2012, Saudi Arabia, 15, 67% [54, 79], 99% [97, 100]
Balcells, 2008, Chile, 16, 67% [35, 90], 99% [95, 100]
Zeka, 2011, Turkey, 22, 35% [25, 46], 100% [98, 100]
Ablanedo-Terrazas , 2014, Mexico, 23, 80% [52, 96], 92% [82, 98]
Teo, 2011, Singapore, 50, 61% [49, 72], 86% [76, 93]
Kurbatova , 2013, Russia, 91, 85% [77, 91], 90% [84, 95]
Carriquiry , 2012, Peru, 95, 69% [53, 82], 97% [90, 99]


Figure 38 Forest plot of the sensitivity and specificity of AFB microscopy compared with culture, grouped according to use of in-house or commercial NAAT, for studies conducted in countries with low and medium incidence of TB

Incidence of TB based on WHO estimates from 2012: low incidence = ≤ 10 cases per 100,000 people; medium incidence = 10–100 cases per 100,000 people

AFB = acid-fast bacilli; NAAT = nucleic acid amplification test; TB = tuberculosis

Forest plot showing the sensitivity and specificity with 95% CIs for individual studies
Reported as: Author, Year, Country, Incidence of TB, SENSITIVITY, SPECIFICITY
Studies from High Incidence countries
In-house NAAT
Kim, 2008, Korea, 108, 60% [53, 67], 100% [100, 100
Min, 2010, Korea, 108, 31% [20, 43], 99% [92, 100
Baveja , 2009, India, 176, 9% [1. 29], 100% [95. 100
Bhanothu , 2014, India, 176, 52% [41, 63], 100% [97, 100
Bhanu, 2005, India, 176, 100% [3, 100], 97% [82, 100
Chakravorty , 2005, India, 176, 98% [96, 98], 91% [87, 95
Chakravorty , 2006, India, 176, 100% [99, 100], 83% [78, 88
Desai, 2006, India, 176, 5% [0, 25], 100% [85, 100
Deshmukh, 2013, India, 176, 52% [45, 60], 95% [91, 97
George, 2011, India, 176, 82% [66, 92], 97% [84, 100
Halder, 2007, India, 176, 20% [13, 28], 93% [76, 99
Makeshkumar , 2014, India, 176, 100% [54, 100], 98% [94, 99
Mashta, 2011, India, 176, 77% [70, 83], 70% [65, 76
Maurya , 2011a, India, 176, 32% [19, 47], 96% [87, 100
Maurya, 2011b, India, 176, 15% [10, 22], 92% [87, 96
Mittal, 2011, India, 176, 73% [54, 88], 90% [68, 99
Pahwa, 2005, India, 176, 74% [49, 91], 86% [71, 95
Sharma, 2012, India, 176, 33% [1, 91], 100% [95,100
Sharma, 2013, India, 176, 100% [3, 100], 98% [89, 100
Shukla, 2011, India, 176, 79% [65, 90], 98% [92, 100
Therese , 2005, India, 176, 57% [29, 82], 100% [98, 100
Davis, 2008, Uganda, 179, 87% [77, 94], 78% [62, 90
Derese , 2012, Ethiopia, 247, 23% [10, 40], 92% [83, 97
Kibiki, 2013, Tanzania, 295, 57% [37, 76], 99% [94, 100
Commercial NAAT
Park, 2013, Korea, 108, 57% [34, 77], 96% [93, 98
Helb, 2010, Vietnam, 147, 35% [25, 47], 100% [86, 100
Biadglegne, 2014, Ethiopia, 247, 35% [19, 55], 99% [97, 100
Rachow, 2011, Tanzania, 295, 74% [62, 84], 100% [98, 100
Bates, 2013, Zambia, 427, 33% [20, 49], 95% [94, 96
Hanrahan , 2014, South Africa, 1,003, 50% [45, 55], 99% [99, 100
Ligthelm , 2011, South Africa, 1,003, 76% [56, 90], 95% [74, 100
Nicol, 2011, South Africa, 1,003, 39% [27, 51], 100% [99, 100
Theron, 2012, South Africa, 1,003, 68% [60,76], 99% [97, 100
Theron, 2013, South Africa, 1,003, 50% [35, 75], 99% [96, 100
Van Rie, 2013, South Africa, 1,003, 40% [32, 49], 97% [94, 99
Zar, 2013, South Africa, 1,003, 13% [4, 31], 100% [98, 100
COMBINED (figures 39 and 40), , , 62% [54, 69], 98% [97, 99
Heterogeneity, , , , I2 = 94.1 [93.3, 95.0], I2 = 96.3 [95.9, 96.8


Figure 39 Forest plot of the sensitivity and specificity of AFB microscopy compared with culture, grouped according to use of in-house or commercial NAAT, for studies conducted in countries with high incidence of TB

Incidence of TB based on WHO estimates from 2012: high incidence = > 100 cases per 100,000 people. The combined values are for all studies in both Figures 38 and 39

AFB = acid-fast bacilli; NAAT = nucleic acid amplification test; TB = tuberculosis

Table 94 Pooled sensitivity and specificity of AFB and NAAT in non-sputum specimens compared with extrapulmonary specimens

| **-** | **Non-sputum**  **Sensitivity [95%CI]** | **Non-sputum**  **Specificity [95%CI]** | **Extrapulmonary**  **Sensitivity [95%CI]** | **Extrapulmonary**  **Specificity [95%CI]** |
| --- | --- | --- | --- | --- |
| **AFB**  All NAAT  In-house NAAT  Commercial NAAT  AFB (ZN)  AFB (FL) | -  46% [37, 55] k=35  46% [34, 59] k=25  46% [35, 57] k=10  46% [34, 59] k=26  46% [35, 57] k=10 | -  98% [97, 99] k=35  98% [96, 99] k=25  99% [98, 99] k=10  98% [96, 99] k=26  96% [90, 99] k=10 | -  44% [33, 55] k=29  43% [29, 58] k=21  48% [34, 63] k=8  46% [31, 61] k=21  42% [32, 53] k=7 | -  98% [96, 99] k=29  98% [96, 99] k=21  91% [81, 96] k=8  98% [95, 99] k=21  99% [97, 99] k=7 |
| **NAAT**  All NAAT  In-house NAAT  Commercial NAAT | -  91% [83, 94] k=35  91% [79, 96] k=25  90% [83, 94] k=10 | -  92% [84, 96] k=35  88% [75, 95] k=25  96% [90, 99] k=10 | -  91% [83, 96] k=29  91% [78, 97] k=21  90% [83, 94] k=8 | -  89% [79, 95] k=29  86% [70, 95] k=21  92% [85, 96] k=8 |
| **AFB + NAAT**  All NAAT  In-house NAAT  Commercial NAAT | -  94% [91, 96] k=18  100% [87, 100] k=11  94% [90, 96] k=7 | -  83% [70, 91] k=18  56% [11, 93] k=11  92% [82, 97] k=7 | -  94% [91, 96] k=17  93% [87, 96] k=10  94% [91, 97] k=7 | -  81% [68, 90] k=17  70% [49, 85] k=10  91% [81, 96] k=7 |

AFB = acid-fast bacilli; CI = confidence interval; FL = fluorescent staining; NAAT = nucleic acid amplification test; TB = tuberculosis; ZN = Ziehl-Neelsen staining

Pooled sensitivity and specificity values with 95% CIs (respectively) for AFB microscopy versus culture:
35 studies testing non-sputum specimens = 46% (37, 55) and 98% (97, 99)
6 studies testing BAL/bronchial aspirates = 48% (35, 61) and 99% (97, 100)
11 studies testing FNA specimens = 62% (45, 76) and 94% (89, 97)
8 studies testing tissue biopsies = 52% (42, 62) and 99% (91, 100)
5 studies testing urine samples = 46% (24, 71) and 99% (89, 100)
6 studies testing body fluids = 59% (17, 91) and 100% (93, 100)
4 studies testing CSF = 11% (5, 22) and 100% (100, 100)
Pooled sensitivity and specificity values with 95% CIs (respectively) for NAAT versus culture:
35 studies testing non-sputum specimens = 91% (83, 94) and 92% (84, 96)
6 studies testing BAL/bronchial aspirates = 90% (70, 97) and 97% (80, 100)
11 studies testing FNA specimens = 93% (81, 98) and 88% (79, 93)
8 studies testing tissue biopsies = 96% (71, 100) and 92% (26, 100)
5 studies testing urine samples = 92% (67, 99) and 97% (79, 100)
6 studies testing body fluids = 69% (9, 98) and 71% (53, 84)
4 studies testing CSF = 97% (21, 100) and 83% (31, 98)


Figure 40 Forest plot showing the pooled sensitivity and specificity values for AFB, NAAT and AFB plus NAAT compared with culture, according to specimen type

AFB = acid-fast bacilli; BAL = bronchoalveolar lavage; CSF = cerebrospinal fluid; FNA = fine-needle aspirate; NAAT = nucleic acid amplification test

Forest plot showing the sensitivity and specificity with 95% CIs for individual studies
Reported as: Author, Year, Country, Incidence of TB, SENSITIVITY, SPECIFICITY
Studies from Low Incidence countries
In-house NAAT
Halse, 2010, USA, 3.6, 94% [90, 96], 100% [99, 100]
Keys, 2012, Australia, 6.5, 100% [29, 100], 0% [0, 84]
Ereqat , 2011, Palestine, 7.6, 91% [59. 100], 76% [66. 85]
Drouillon, 2009, France-Italy, 6.7-8.2, 88% [81, 93], 97% [95, 99]
Drouillon, 2007, France, 8.2, 63% [44, 79], 93% [88, 97]
El Khechine , 2009, France, 8.2, 100% [89, 100], 91% [87, 94]
Commercial NAAT
Marlowe, 2011, USA, 3.6, 89% [83, 94], 95% [89, 99]
Sohn, 2014, Canada, 4.6, 46% [26, 67], 100% [99, 100]
Deggim, 2013, Switzerland, 6, 83% [59, 96], 97% [88, 100]
Tortoli, 2012, Italy, 6.7, 79% [73, 84], 97% [96, 98]
Malbruny, 2011, France, 8.2, 94% [79, 99], 99% [95, 100]
Studies from Medium Incidence countries
In-house NAAT
Ghaleb , 2013, Egypt, 17, 100% [29,100], 97% [91,99]
Khan, 2013, Egypt, 17, 84% [60, 97], 94% [79, 99]
Suzuki, 2006, Japan, 19, 56% [44, 68], 92% [83, 97]
Ekrami , 2011, Iran, 21, 74% [64, 82], 83% [69, 92]
Gholoobi, 2014, Iran, 21, 58% [28, 85], 100% [81, 100]
Khosravi , 2010, Iran, 21, 100% [69, 100], 100% [98, 100]
Jiang, 2012, China, 73, 97% [92, 99], 100% [92, 100]
Gomez, 2011, Mexico, 23, 87% [76, 95], 98% [95, 99]
Ben Kahla, 2011, Tunisia, 31, 87% [74, 95], 99% [94, 100]
de Albuquerque , 2014, Brazil, 46, 50% [12, 88], 100% [97, 100]
Marchi, 2008, Brazil, 46, 87% [77, 93], 98% [96, 99]
Michelon , 2011, Brazil, 46, 86% [73, 95], 86% [80, 91]
Santos, 2006, Brazil, 46, 94% [80, 99], 94% [88, 98]
Lee, 2009, Taiwan, 68, 94% [81, 99], 87% [82, 92]
Commercial NAAT
Al-Atteah, 2012, Saudi Arabia, 15, 94% [84, 98, 100% [98, 100]
Balcells, 2008, Chile, 16, 92% [62, 100], 99% [96, 100]
Zeka, 2011, Turkey, 22, 80% [70, 88], 98% [96, 99]
Ablanedo-Terrazas , 2014, Mexico, 23, 100% [78, 100], 100% [93, 100]
Teo, 2011, Singapore, 50, 91% [82, 96], 89% [80, 95]
Kurbatova , 2013, Russia, 91, 94% [88, 98], 87% [80, 93]
Carriquiry , 2012, Peru, 95, 98% [88, 100], 98% [92, 100]


Figure 41 Forest plot of the sensitivity and specificity of NAAT compared with culture, grouped according to use of in-house or commercial NAAT, for studies conducted in countries with low and medium incidence of TB

Incidence of TB based on WHO estimates from 2012: low incidence = ≤ 10 cases per 100,000 people; medium incidence = 10–100 cases per 100,000 people

NAAT = nucleic acid amplification test; TB = tuberculosis

Forest plot showing the sensitivity and specificity with 95% CIs for individual studies
Reported as: Author, Year, Country, Incidence of TB, SENSITIVITY, SPECIFICITY
Studies from High Incidence countries
In-house NAAT
Kim, 2008, Korea, 108, 72% [65, 78], 98% [97, 98
Min, 2010, Korea, 108, 60% [47, 72], 99% [92, 100
Baveja , 2009, India, 176, 100% [85. 100], 100% [95. 100
Bhanothu , 2014, India, 176, 99% [94, 100], 29% [21, 39
Bhanu, 2005, India, 176, 11% [0, 48], 62% [38, 82
Chakravorty , 2005, India, 176, 99% [97, 100], 71% [65, 77
Chakravorty , 2006, India, 176, 100% [98, 100], 72% [66, 78
Desai, 2006, India, 176, 100% [63, 100], 45% [24, 68
Deshmukh, 2013, India, 176, 90% [84, 94], 73% [68, 78
George, 2011, India, 176, 79% [64, 91], 94% [79, 99
Halder, 2007, India, 176, 92% [85, 96], 86% [67, 96
Makeshkumar , 2014, India, 176, 67% [22, 96], 74% [67, 81
Mashta, 2011, India, 176, 36% [29, 43], 74% [68, 79
Maurya , 2011a, India, 176, 96% [85, 99], 69% [55, 81
Maurya, 2011b, India, 176, 93% [87, 96], 64% [57, 71
Mittal, 2011, India, 176, 90% [73, 98], 85% [62, 97
Pahwa, 2005, India, 176, 94% [73, 100], 86% [71, 95
Sharma, 2012, India, 176, 100% [29, 100], 18% [10, 29
Sharma, 2013, India, 176, 6% [1, 21], 100% [82, 100
Shukla, 2011, India, 176, 96% [86, 99], 37% [27, 48
Therese , 2005, India, 176, 93% [66, 100], 57% [51, 63
Davis, 2008, Uganda, 179, 98% [91, 100], 84% [68, 94
Derese , 2012, Ethiopia, 247, 42% [28, 97], 89% [80, 95
Kibiki, 2013, Tanzania, 295, 96% [82, 100], 52% [41, 63
Commercial NAAT
Park, 2013, Korea, 108, 83% [61, 95], 98% [96, 99
Helb, 2010, Vietnam, 147, 82% [72, 89], 100% [86, 100
Biadglegne, 2014, Ethiopia, 247, 94% [79, 99], 70% [62, 76
Rachow, 2011, Tanzania, 295, 88% [78, 95], 96% [91, 98
Bates, 2013, Zambia, 427, 86% [73, 94], 98% [97, 99
Hanrahan , 2014, South Africa, 1,003, 74% [69, 78], 97% [96, 98
Ligthelm , 2011, South Africa, 1,003, 97% [82, 100], 84% [60, 97
Nicol, 2011, South Africa, 1,003, 74% [62, 84], 98% [97, 99
Theron, 2012, South Africa, 1,003, 77% [70, 84], 95% [93, 97
Theron, 2013, South Africa, 1,003, 93% [76, 99], 96% [91, 99
Van Rie, 2013, South Africa, 1,003, 93% [88, 97], 88% [83, 92
Zar, 2013, South Africa, 1,003, 43% [25, 63], 99% [98, 100
COMBINED , , , , 89% [85, 92], 94% [91, 96
Heterogeneity, , , , , I2 = 94.0 [93.1, 94.9], I2 = 98.2 [98.0, 98.4


Figure 42 Forest plot of the sensitivity and specificity of NAAT compared with culture, grouped according to use of in-house or commercial NAAT, for studies conducted in countries with high incidence of TB

Incidence of TB based on WHO estimates from 2012: high incidence = > 100 cases per 100,000 people. The combined values are for all studies in both Figures 41 and 42.

NAAT = nucleic acid amplification test; TB = tuberculosis

Forest plot showing the sensitivity and specificity with 95% CIs for individual studies
reported as: Author, Year, Country, Incidence of TB, SENSITIVITY, SPECIFICITY
Studies from Low Incidence countries
In-house NAAT
Halse, 2010, USA, 3.6, 94% [91, 97], 96% [94, 97]
Ereqat , 2011, Palestine, 7.6, 100% [94, 100], 70% [53, 84]
El Khechine , 2009, France, 8.2, 100% [89. 100], 91% [87. 94]
Commercial NAAT
Marlowe, 2011, USA, 3.6, 91% [84, 95], 55% [44, 65]
Sohn, 2014, Canada, 4.6, 50% [29, 71], 99% [97, 100]
Deggim, 2013, Switzerland, 6, 83% [59, 96], 88% [77, 95]
Malbruny, 2011, France, 8.2, 94% [79, 99], 97% [93, 99]
Studies from Medium Incidence countries
In-house NAAT
Ghaleb , 2013, Egypt, 17, 100% [29,100], 97% [91, 99]
Suzuki, 2006, Japan, 19, 78% [67, 87], 92% [83, 97]
Gomez, 2011, Mexico, 23, 100% [97, 100], 95% [84, 99]
Ben Kahla, 2011, Tunisia, 31, 93% [82, 98], 95% [91, 97]
Michelon , 2011, Brazil, 46, 99% [93, 100], 97% [95, 98]
Santos, 2006, Brazil, 46, 86% [73, 95], 85% [78, 90]
Jiang, 2012, China, 73, 94% [81, 99], 75% [69, 81]
Commercial NAAT
Al-Atteah, 2012, Saudi Arabia, 15, 95% [87, 99], 99% [97, 100]
Zeka, 2011, Turkey, 22, 80% [70, 88], 98% [96, 99]
Ablanedo-Terrazas , 2014, Mexico, 23, 100% [78, 100], 92% [82, 98]
Teo, 2011, Singapore, 50, 91% [82, 96], 82% [71, 90]
Carriquiry , 2012, Peru, 95, 98% [88, 100], 95% [89, 99]


Figure 43 Forest plot of the sensitivity and specificity of AFB plus NAAT compared with culture, grouped according to use of in-house or commercial NAAT, for studies conducted in countries with low and medium incidence of TB

Incidence of TB based on WHO estimates from 2012: low incidence = ≤ 10 cases per 100,000 people; medium incidence = 10–100 cases per 100,000 people

AFB = acid-fast bacilli; NAAT = nucleic acid amplification test; TB = tuberculosis

Reported as: Author, Year, Country, Incidence of TB, SENSITIVITY, SPECIFICITY
Studies from High Incidence countries
In-house NAAT
Kim, 2008, Korea, 108, 75% [68, 81], 98% [97, 98]
Bhanothu , 2014, India, 176, 99% [94, 100], 29% [21, 39]
Deshmukh, 2013, India, 176, 90% [84, 94], 73% [68, 78]
George, 2011, India, 176, 82% [66, 92], 91% [75, 98]
Mashta, 2011, India, 176, 80% [74, 85], 57% [51, 63]
Maurya , 2011a, India, 176, 96% [85, 99], 67% [53, 79]
Maurya, 2011b, India, 176, 93% [87, 96], 60% [52, 67]
Mittal, 2011, India, 176, 97% [83, 100], 84% [60, 97]
Sharma, 2012, India, 176, 100% [29, 100], 18% [10, 29]
Shukla, 2011, India, 176, 100% [93, 100], 35% [25, 45]
Therese , 2005, India, 176, 93% [66, 100], 56% [50, 62]
Davis, 2008, Uganda, 179, 100% [94, 100], 70% [53, 84]
Commercial NAAT
Park, 2013, Korea, 108, 9% [78, 100], 94% [90, 96]
Helb, 2010, Vietnam, 147, 82% [72, 89], 100% [86, 100]
Biadglegne, 2014, Ethiopia, 247, 94% [79, 99], 69% [62, 76]
Rachow, 2011, Tanzania, 295, 90% [80, 95], 96% [91, 98]
Van Rie, 2013, South Africa, 1,003, 94% [89, 97], 88% [83, 92]
Theron, 2012, South Africa, 1,003, 82% [75, 88], 95% [92, 97]
Ligthelm , 2011, South Africa, 1,003, 100% [83, 100], 89% [67, 99]
COMBINED , , , , 94% [91, 96], 88% [82, 92]
Heterogeneity, , , , I2 = 87.3 [84.3, 90.3], I2 = 98.1 [97.9, 98.4]


Figure 44 Forest plot of the sensitivity and specificity of AFB plus NAAT compared with culture, grouped according to use of in-house or commercial NAAT, for studies conducted in countries with high incidence of TB

Incidence of TB based on WHO estimates from 2012: high incidence = > 100 cases per 100,000 people. The combined values are for all studies in both Figures 43 and 44.

AFB = acid-fast bacilli; NAAT = nucleic acid amplification test; TB = tuberculosis

Forest plot showing the sensitivity and specificity with 95% CIs for individual studies
Reported as: Author, Year, Country, Incidence of TB, SENSITIVITY, SPECIFICITY
Studies from Low Incidence countries
In-house NAAT
Halse, 2010, USA, 3.6, 100% [98, 100], 100% [92, 100]
Ereqat , 2011, Palestine, 7.6, 100% [59. 100], 0% [0, 46]
Commercial NAAT
Marlowe, 2011, USA, 3.6, 98% [92, 100], 90% [76, 97]
Sohn, 2014, Canada, 4.6, 86% [42, 100], 100% [40, 100]
Deggim, 2013, Switzerland, 6, 100% [77, 100], 100% [48, 100]
Malbruny, 2011, France, 8.2, 100% [78, 100], 100% [16, 100]
Studies from Medium Incidence countries
In-house NAAT
Suzuki, 2006, Japan, 19, 74% [60,85], 0% [0, 84]
Gomez, 2011, Mexico, 23, 97% [91, 99], 100% [16, 100]
Ben Kahla, 2011, Tunisia, 31, 94% [83, 99], 80% [44, 97]
Santos, 2006, Brazil, 46, 77% [55, 92], 92% [73, 99]
Jiang, 2012, China, 73, 100% [88, 100], 73% [54, 87]
Commercial NAAT
Al-Atteah, 2012, Saudi Arabia, 15, 98% [87, 100], 100% [3, 100]
Zeka, 2011, Turkey, 22, 100% [89, 100], 100% [3, 100]
Teo, 2011, Singapore, 50, 100% [92, 100], 55% [23, 83]
Carriquiry , 2012, Peru, 95, 100% [89, 100], 67% [9, 99]
Studies from High Incidence countries
In-house NAAT
Bhanothu , 2014, India, 176, 100% [92,100], Not calculable
Deshmukh, 2013, India, 176, 100% [96, 100], 0% [0, 22]
George, 2011, India, 176, 97% [83, 100], 33% [1, 91]
Mashta, 2011, India, 176, 41% [33, 49], 60% [48, 71]
Maurya , 2011a, India, 176, 100% [78, 100], 50% [1, 99]
Maurya, 2011b, India, 176, 100% [91, 100], 56% [30, 80]
Shukla, 2011, India, 176, 95% [82, 99], 100% [16, 100]
Therese , 2005, India, 176, 100% [63, 100], 100% [3, 100]
Davis, 2008, Uganda, 179, 98% 92, 100], 63% [24, 91]
Commercial NAAT
Park, 2013, Korea, 108, 77% [45, 95], 100% [75, 100]
Helb, 2010, Vietnam, 147, 100% [88, 100], Not calculable
Biadglegne, 2014, Ethiopia, 247, 100% [72, 100], 0% [0, 98]
Rachow, 2011, Tanzania, 295, 98% [ 90, 100], Not calculable
COMBINED , , , , 99% [96, 100], 78% [53, 92]
Heterogeneity, , , , I2 = 96.9 [96.3, 97.4], I2 = 87.2 [83.6, 90.8]


Figure 45 Forest plot of the sensitivity and specificity of NAAT compared with culture in AFB-positive specimens, grouped according to type of NAAT and incidence of TB

Incidence of TB based on WHO estimates from 2012: low incidence = ≤ 10 cases per 100,000 people; medium incidence = 10–100 cases per 100,000 people; high incidence = > 100 cases per 100,000 people

AFB = acid-fast bacilli; NAAT = nucleic acid amplification test; TB = tuberculosis

Forest plot showing the sensitivity and specificity with 95% CIs for individual studies
Reported as: Author, Year, Country, Incidence of TB, SENSITIVITY, SPECIFICITY
Studies from Low Incidence countries
In-house NAAT
Halse, 2010, USA, 3.6, 64% [49. 78], 100% [99, 100]
Ereqat , 2011, Palestine, 7.6, 75% [19, 99], 82% [72. 90]
Commercial NAAT
Marlowe, 2011, USA, 3.6, 72% [56, 85], 100% [92, 100]
Ioaninidis, 2011, Greece, 4.5, 86% [65, 97], 93% [84, 98]
Sohn, 2014, Canada, 4.6, 29% [10, 56], 100% [99, 100]
Deggim, 2013, Switzerland, 6, 25% [1, 81], 96% [87, 100]
Malbruny, 2011, France, 8.2, 88% [62, 98], 99% [95, 100]
Studies from Medium Incidence countries
In-house NAAT
Ghaleb , 2013, Egypt, 17, 100% [16, 100], 97% [91, 99]
Suzuki, 2006, Japan, 19, 5% [0, 25], 95% [87, 99]
Gomez, 2011, Mexico, 23, 100% [63, 100], 100% [91, 100]
Ben Kahla, 2011, Tunisia, 31, 20% [1, 72], 98% [96, 100]
Santos, 2006, Brazil, 46, 95% [84, 98], 85% [78, 90]
Fan, 2014, China, 73, 93% [84, 98], 96% [91, 98]
Jiang, 2012, China, 73, 75% [35, 97], 90% [84, 94]
Commercial NAAT
Moure, 2012, Spain, 14, 58% [48, 68], 100% [91,100]
Al-Atteah, 2012, Saudi Arabia, 15, 85% [62, 97], 100% [98, 100]
Zeka, 2011, Turkey, 22, 69% [55, 80], 98% [96, 99]
Teo, 2011, Singapore, 50, 77% [58, 90], 95% [87, 99]
Carriquiry , 2012, Peru, 95, 93% [65, 100], 99% [93, 100]
Studies from High Incidence countries
In-house NAAT
Ani, 2009, Nigeria, 108, 100% [40, 100], 50% [33, 67]
Bhanothu , 2014, India, 176, 98% [88, 100], 29% [21, 39]
Deshmukh, 2013, India, 176, 78% [68,86], 77% [72, 82]
George, 2011, India, 176, 22% [3, 60], 100% [88, 100]
Mashta, 2011, India, 176, 19% [9, 33], 81% [75, 87]
Maurya , 2011a, India, 176, 94% [79, 99], 70% [56, 82]
Maurya, 2011b, India, 176, 91% [85, 96], 65% [57, 72]
Nakiyingi, 2012, Uganda, 179, 75% [63, 85], 36% [27, 45]
Sharma, 2012, India, 176, 100% [16, 100], 18% [10, 29]
Shukla, 2011, India, 176, 100% [69, 100], 36% [26, 46]
Singh, 2006, India, 176, 100% [3, 100], 79% [68, 87]
Therese , 2005, India, 176, 83% [36, 100], 57% [50, 63]
Davis, 2008, Uganda, 179, 100% 63, 100], 90% [73, 98]
Bhigjee , 2012, South Africa, 1,003, 90% [68, 99], 85% [77, 91]
Commercial NAAT
Park, 2013, Korea, 108, 90% [55, 100], 98% [95, 99]
Helb, 2010, Vietnam, 147, 72% [58, 83], 100% [86, 100]
Walusimbi, 2013, Uganda, 179, 49% [33, 65], 95% [92, 97]
Biadglegne, 2014, Ethiopia, 247, 90% [68, 99], 70% [62, 76]
Rachow, 2011, Tanzania, 295, 61% [36, 83], 95% [91, 98]
Theron, 2013, South Africa, 1,003, 50% [1, 99], 100% [97, 100]
COMBINED , , , , 80% [69, 87], 94% [88, 97]
Herterogeneity, , , , I2 = 88.7 [86.2, 91.3], I2 = 98.2 [97.9, 98.4]


Figure 46 Forest plot of the sensitivity and specificity of NAAT compared with culture in AFB-negative specimens, grouped according to use of in-house or commercial NAAT and incidence of TB

Incidence of TB based on WHO estimates from 2012: low incidence = ≤ 10 cases per 100,000 people; medium incidence = 10–100 cases per 100,000 people; high incidence = > 100 cases per 100,000 people

AFB = acid-fast bacilli; NAAT = nucleic acid amplification test; TB = tuberculosis

Forest plot showing the sensitivity and specificity with 95% CIs for individual studies
Reported as: Author, Year, Country, Incidence of TB, Specimen, NAAT, SENSITIVITY, SPECIFICITY
AFB
Ablanedo-Terrazas, 2014, Mexico, 23, FNA, Xpert, 80% [52. 96], 92% [82. 98
de Albuquerque , 2014, Brazil, 46, sputum, in-house, 79% [64, 89], 100% [96, 100
Carriquiry , 2012, Peru, 295, sputum, Xpert, 69% [53, 82], 97% [90, 99
Kibiki, 2013, Tanzania, 295, BAL, in-house, 57% [37, 76], 99% [94, 100
Theron, 2012, South Africa, 1,003, sputum, Xpert, 52% [37, 66], 99% [93, 100
Theron, 2013, South Africa, 1,003, BAL, Xpert, 57% [18, 90], 97% [86, 100
Van Rie, 2013, South Africa, 1,003, FNA, Xpert, 40% [32, 49], 97% [94, 99
Combined, , , , , , 62% [49, 73], 98% [96, 99
Heterogeneity, , , , , , I2 = 82.9 [71.2, 94.6], I2 = 52.7 [12.3, 93.0
NAAT
Ablanedo-Terrazas, 2014, Mexico, 23, FNA, Xpert, 100% [78, 100], 100% [93, 100
de Albuquerque , 2014, Brazil, 46, sputum, in-house, 87% [70, 95], 99% [94, 100
Carriquiry , 2012, Peru, 295, sputum, Xpert, 98% [88, 100], 98% [92, 100
Kibiki, 2013, Tanzania, 295, BAL, in-house, 96% [82 100], 52% [41, 63
Theron, 2012, South Africa, 1,003, sputum, Xpert, 70% [55, 82], 95% [88, 99
Theron, 2013, South Africa, 1,003, BAL, Xpert, 75% [35, 97], 94% [81, 99
Van Rie, 2013, South Africa, 1,003, FNA, Xpert, 93% [88, 97],  88% [83, 92
Combined, , , , , , 92% [82, 96], 95% [85, 99
Heterogeneity, , , , , , I2 = 88.4 [81.3, 95.6], I2 = 97.5 [96.5, 98.5
AFB + NAAT
Ablanedo-Terrazas, 2014, Mexico, 23, FNA, Xpert, 100% [78, 100], 92% [82, 98
Van Rie, 2013, South Africa, 1,003, FNA, Xpert, 94% [89, 97], 88% [83, 92
AFB -ve specimens
Walusimbi , 2013, Uganda, 179, sputum, Xpert, 49% [33, 65], 95% [92, 97
Theron, 2013, South Africa, 1,003, BAL, Xpert, 13% [0, 53], 97% [85, 100


Figure 47 Forest plot of the sensitivity and specificity of AFB and/or NAAT compared with culture in HIV-positive patients suspected of having TB

Incidence of TB based on WHO estimates from 2012

AFB = acid-fast bacilli; BAL = bronchoalveolar lavage; FNA = fine-needle aspirate; NAAT = nucleic acid amplification test; TB = tuberculosis

Forest plot showing the sensitivity and specificity with 95% CIs for individual studies
Author, Year, Country, Incidence of TB, Specimen, NAAT, SENSITIVITY, SPECIFICITY
AFB, 
Helb, 2010, Vietnam, 147, sputum, Xpert, 35% [25. 47], 100% [86. 100]
Bhanothu, 2014, India, 176, biopsies/fluids, In-house, 52% [41, 63], 100% [97, 100]
Deshmukh, 2013, India, 176, mixed, In-house, 52% [45, 60], 95% [91, 97]
Maurya, 2011a, India, 176, pleural fluid, In-house, 32% [19, 47], 96% [87, 100]
Theron, 2013, South Africa, 1,003, BAL, Xpert, 58% [28, 85], 100% [95, 100]
Zar, 2013, South Africa, 1,003, sputum, Xpert, 13% [4, 31], 100% [98, 100]
Combined, , , , , , , 39% [28, 52], 99% [96, 100]
Heterogeneity , , , , , , , I2 = 79.9 [64.4, 95.4], I2 = 81.4 [67.2, 95.6]
NAAT
Helb, 2010, Vietnam, 147, sputum, Xpert, 82% [72, 89], 100% [86, 100]
Bhanothu, 2014, India, 176, biopsies/fluids, in-house, 99% [94, 100], 29% [21, 39]
Deshmukh, 2013, India, 176, mixed, in-house, 90% [85, 94], 73% [68, 78]
Maurya, 2011a, India, 176, pleural fluid, in-house, 96% [85, 99], 69% [55, 81]
Theron, 2013, South Africa, 1,003, BAL, Xpert, 100% [74, 100], 96% [88, 99]
Zar, 2013, South Africa, 1,003, sputum, Xpert, 43% [25, 63], 99% [98, 100]
Combined, , , , , , , 89% [71, 97], 88% [60, 98]
Heterogeneity , , , , , , , I2 = 96.7 [95.1, 98.2], I2 = 98.4 [97.8, 99.0]
AFB + NAAT
Helb, 2010, Vietnam, 147, sputum, Xpert, 82% [72, 89], 100% [86, 100]
Bhanothu, 2014, India, 176, biopsies/fluids, in-house, 99% [94, 100], 29% [21, 39]
Deshmukh, 2013, India, 176, mixed, in-house, 90% 84, 94], 73% [68, 78]
Maurya, 2011a, India, 176, pleural fluid, in-house, 96% [85, 99], 67% [53, 79]
Combined, , , , , , , 92% [83, 97], 71% [38, 90, ]
Heterogeneity , , , , , , , I2 = 82.6 [66.2, 99.0], I2 = 96.4 [94.1, 98.6]
AFB +ve specimens
Helb, 2010, Vietnam, 147, sputum, Xpert, 100% [88, 100], Not calculable
Bhanothu, 2014, India, 176, biopsies/fluids, in-house, 100% [92, 100], Not calculable
Deshmukh, 2013, India, 176, mixed, in-house, 100% [96, 100], 0% [0, 22]
Maurya, 2011a, India, 176, pleural fluid, in-house, 100% [78, 100], 50% [1, 99]
AFB -ve specimens
Helb, 2010, Vietnam, 147, sputum, Xpert, 72% [58, 83], 100% [86, 100]
Bhanothu, 2014, India, 176, biopsies/fluids, in-house, 98% [88, 100], 29% [21, 39]
Deshmukh, 2013, India, 176, mixed, in-house, 78% [68, 85], 77% [72, 82]
Maurya, 2011a, India, 176, pleural fluid, in-house, 94% 79, 99], 70% [56, 82]
Theron, 2013, South Africa, 1,003, BAL, Xpert, 100% [48, 100], 96% [88, 99]
Combined, , , , , , , 87% [71, 95], 83% [49, 96]
Heterogeneity , , , , , , , I2 = 86.55 [76.1, 97.0], I2 = 97.4 [96.1, 98.6]


Figure 48 Forest plot of the sensitivity and specificity of AFB and/or NAAT compared with culture in HIV-negative patients suspected of having TB

Incidence of TB based on WHO estimates from 2012

AFB = acid-fast bacilli; BAL = bronchoalveolar lavage; HIV = human immunodeficiency virus; NAAT = nucleic acid amplification test; TB = tuberculosis

Forest plot showing the sensitivity and specificity with 95% CIs for individual studies
Reported as: Author, Year, Country, Incidence of TB, NAAT, SENSITIVITY, SPECIFICITY
All specimens
AFB versus culture
Kox, 1997, Netherlands, 6.3, NTM, 82% [66, 92], 89% [84, 93
Choi, 2012, Korea, 108, NTM, 14% [5, 29], 100% [99, 100
Mahaisavariya, 2005, Thailand, 119, NTM, 42% [26, 59], 73% [62, 82
Tran, 2014, USA, 3.6, MAC, 70% [60, 79], 69% [64, 74
Matsumoto , 1998, Japan, 19, MAC, 33% [10. 65], 98% [94. 100
Combined, , , , , 47% [24, 72], 96% [68, 100
Heterogeneity, , , , , I2 = 93.5 [89.3, 97.6], I2 = 98.2 [97.4, 99.0
AFB versus CRS
Gazzola, 2008, Italy, 6.7, MAC, 14% [0, 58], 100% [90, 100
Phillips, 2005, Ghana, 72, MU, 42% [29, 56], 100% [69, 100
*Estimated combined, , , , 31% [4, 58], 100% [95, 100
NAAT versus culture
NTM-NAAT
Frevel, 1999, Germany, 5.6, NTM, 100% [48, 100], 78% [66, 87
Kox, 1997, Netherlands, 6.3, NTM, 95% [83, 99], 86% [81, 91
Abdalla, 2009, Brazil, 46, NTM, 100% [3, 100], 50% [30, 70
Choi, 2012, Korea, 108, NTM, 69% [53, 82], 100% [99, 100
Mahaisavariya, 2005, Thailand, 119, NTM, 44% [28, 62], 67% [57, 77
Combined, , , , , 84% [49, 97], 90% [46, 99
Heterogeneity, , , , , I2 = 85.0 [73.0, 97.0], I2 = 96.6 [94.8, 98.4
MAC-NAAT
Tran, 2014, USA, 3.6, MAC, 59% [49, 69], 99% [98, 100
Bogner (HIV+), 1997, Germany, 5.6, MAC, 26% [14, 41], 100% [99, 100
Ninet (HIV+), 1997, Switzerland, 6, MAC, 37% [22, 54], 100% [98, 100
Gamboa (HIV+), 1997, Spain, 14, MAC, 84% [73, 92], 100% [89,100
Matsumoto , 1998, Japan, 19, MAC, 83% [52, 98], 99% [96, 100
Combined, , , , , 59% [35, 79], 100% 99, 100
Heterogeneity, , , , , I2 = 91.7 [86.0, 97.3], I2 = 20.7 [0.0, 88.7
NAAT versus CRS
Abdalla, 2009, Brazil, 46, NTM, 100% [74, 100], 87% [60, 98
Phillips, 2005, Ghana, 72, NTM, 98% [91, 100], 100% [69, 100
Gazzola (HIV+), 2008, Italy, 6.7, MAC, 56% [31, 78], 99% [94, 100
Kox, 1997, Netherlands, 6.3, MU, 97% [91, 100], 97% [93, 99


Figure 49 Forest plot of the sensitivity and specificity of AFB and NAAT compared with culture or a clinical reference standard in diagnosing NTM infections

a Estimated pooled values were obtained using the metan command in Stata 12.1

Incidence of TB based on WHO estimates from 2012

AFB = acid-fast bacilli; CRS = clinical reference standard; HIV = human immunodeficiency virus; MAC = *Mycobacterium avium* complex; NAAT = nucleic acid amplification test; NTM = non-tuberculous mycobacteria

Forest plot showing the sensitivity and specificity with 95% CIs for individual studies
Reported as: Author, Year, Country, Incidence of TB, NAAT, SENSITIVITY, SPECIFICITY
All specimens
Culture versus CRS
Abdalla, 2009, Brazil, 46, NTM, 8% [0, 38], 100% [78, 100]
Phillips, 2005, Ghana, 72, NTM, 49% [35, 63], 100% [69, 100]
Gazzola (HIV+), 2008, Italy, 6.7, MAC, 59% [36, 79], 100% [94, 100]
Kox, 1997, Netherlands, 6.3, MU, 51% [39, 62], 100% [97, 100]
*Estimated Combined, , , , 46% [27, 66], 100% [97, 100]
MAC-NAAT versus culture by HIV status
HIV-positive
Bogner, 1997, Germany, 5.6, MAC, 26% [14, 41], 100% [99,100]
Ninet, 1997, Switzerland, 6, MAC, 37% [22, 54], 100% [98, 100]
Gamboa, 1997, Spain, 14, MAC, 84% [73, 92], 100% [89, 100]
*Estimated combined, , , , 49% [10, 89], 100% [99, 100]
HIV-negative or unknown
Tran, 2014, USA, 3.6, MAC, 59% [49, 69], 99% [98, 100]
Matsumoto (HIV-), 1998, Japan, 19, MAC, 83% [52, 98], 99% [96, 100]
*Estimated combined , , , , 69% [46, 92], 99% [97, 100]
AFB-positive specimens
NAAT versus culture
Mahaisavariya, 2005, Thailand, 119, NTM, 47% [21, 73], 81% [61, 93]
Kox, 1997, Netherlands, 6.3, NTM, 97% [84, 100], 19% [5, 42]
Tran, 2014, USA, 3.6, MAC, 81% [69, 89], 100% [97, 100]
AFB-negative specimens
NAAT versus culture
Kox, 1997, Netherlands, 6.3, NTM, 86% [42, 100], 94% [90, 97]
Abdalla, 2009, Brazil, 46, NTM, 100% [3, 100], 50% [30, 70]
Mahaisavariya, 2005, Thailand, 119, NTM, 43% [22, 66], 62% [50, 74]
*Estimated combined, , , , 75% [39, 100], 70% [41, 98]
Tran, 2014, USA, 3.6, MAC, 10% [2, 27], 99% [97, 100]
Gamboa (HIV+), 1997, Spain, 14, MAC, 84% [73, 92], 100% [89, 100]
Matsumoto , 1998, Japan, 19, MAC, 75% [35, 97], 99% [96, 100]
*Estmated combined, , , , , 56% [1, 100], 99% [98, 100]


Figure 50 Forest plot of the sensitivity and specificity of culture compared with a clinical reference standard and subgroup analysis of NAAT compared with culture, based on HIV and AFB status

a Estimated pooled values were obtained using the metan command in STATA 12.1

Incidence of TB based on WHO estimates from 2012

AFB = acid-fast bacilli; CRS = clinical reference standard; HIV = human immunodeficiency virus; MAC = *Mycobacterium avium* complex; NAAT = nucleic acid amplification test; NTM = non-tuberculous mycobacteria.

# Appendix E Meta-analysis of studies assessing the diagnostic accuracy of AFB compared with culture

Of the 68 studies that compared the diagnostic accuracy of AFB microscopy to culture in patients suspected of having TB, 39 performed AFB microscopy using ZN staining, 23 used fluorescent stains such as auramine, 2 used alternative stains and 3 did not report the method used. Interestingly, 18/24 (75%) studies comparing AFB microscopy and the Xpert assay used fluorescent staining, whereas 34/44 (77%) of studies using in-house NAAT methods used ZN staining. Forest plots showing the sensitivity and specificity for these studies are shown in Figure 38 and Figure 39 (Appendix D). The sensitivity varied greatly between studies, ranging from 5% to 100% with a pooled sensitivity of 62% (95%CI 54, 69). There was less variability in the specificity, which was above 80% in all but 3 studies, with a pooled value of 98% (95%CI 97, 99). The proportion of culture-positive specimens that were AFB-positive is higher in these studies than that reported in the *Tuberculosis notifications in Australia, 2010 Annual Report* [[30]](#footnote-30), which reported that, of all MTB cases confirmed by culture, only 47% were AFB-positive.

Subgroup analysis was undertaken to determine the effects of AFB methodology, specimen type, incidence of TB in the country in which the study was conducted, and use of in-house or commercial NAAT index test on the accuracy of AFB microscopy (Figure 51). There was a significant difference in sensitivity between studies investigating diagnostic accuracy in patients who provided sputum samples (71%; 95%CI 59, 81) compared with those that provided non-sputum samples (46%; 95%CI 37, 55), as the 95%CIs did not overlap. Non-sputum specimens included patients suspected of having either pulmonary TB (e.g. bronchial aspirates) or extrapulmonary TB (e.g. synovial fluid or tissue biopsy). Analysis of extrapulmonary specimens alone showed that the sensitivity and specificity of AFB compared with culture did not differ markedly from those for non-sputum samples (Table 94 in Appendix D). For some specific specimen types there were sufficient studies for separate analysis (Figure 40 in Appendix D). The pooled sensitivity for AFB microscopy compared with culture varied from 46% in urine to 62% in FNAs of lymph nodes. However, for CSF the pooled sensitivity was only 11%. Thus, AFB microscopy is not a useful tool for diagnosis of TB in CSF specimens. The pooled specificity was at least 94% in all specimen types.

There was an overall 11% difference in sensitivity of AFB microscopy compared with culture, favouring studies that used an in-house NAAT over those that used the commercial Xpert NAAT, which was not statistically significant. However, this difference was entirely due to the type of specimen tested. In studies that used sputum samples, AFB microscopy was 24% more sensitive compared with culture when an in-house NAAT was used as the index test instead of a commercial NAAT. Conversely, there was no difference in sensitivity in studies that used non-sputum samples (Figure 51).

The reason for this is unclear, although there is likely to be some publication bias, as indicated by the significant asymmetry when comparing the effective sample size between studies (Figure 52). This asymmetry was no longer significant (p>0.05) when the studies were separated according to AFB methodology, NAAT methodology or specimen type (data not shown). Other variables that may influence publication bias include funding, conflict of interest, prejudice against an observed association and sponsorship, but the effects of these parameters were not tested.

Pooled sensitivity and specificity values with 95% CIs (respectively) for AFB microscopy versus culture:
all 68 studies = 62% (54, 69) and 98% (97, 99)
44 studies using in-house NAAT = 66% (55, 76) and 98% (96, 99)
24 studies using commercial NAAT = 55% (46, 63) and 98% (97, 99)
39 studies using AFB ZN staining = 63% (50, 74) and 98% (96, 99)
23 studies using AFB FL staining = 59% (49, 68) and 98% (97, 99)
36 studies from high TB incidence countries = 57% (44, 70) and 98% (97, 99)
21 studies from medium TB incidence countries = 73% (64, 80) and 97% (95, 99)
11 studies from low TB incidence countries = 56% (44, 68) and 98% (94, 100)
30 studies testing sputum specimens = 71% (59, 81) and 97% (95, 99)
35 studies testing non-sputum specimens = 46% (37, 55) and 98% (97, 99)


Figure 51 Forest plot showing the pooled sensitivity and specificity values for AFB microscopy compared with culture for studies grouped according to NAAT comparator, AFB methodology and incidence of TB in the country in which the study was conducted

Incidence of TB based on WHO estimates from 2012: high incidence = > 100 cases per 100,000 people; medium incidence = 10–100 cases per 100,000 people; low incidence = ≤ 10 cases per 100,000 people

FL = fluorescent staining; K = the number of studies; NAAT = nucleic acid amplification testing; TB = tuberculosis; ZN = Ziehl-Neelsen staining




Figure 52 Deek’s Funnel plot asymmetry test to assess publication bias for the diagnostic accuracy of AFB microscopy compared with culture

Publication bias is assessed visually by using the inverse of the square root of the effective sample size versus the diagnostic log odds ratio, which should have a symmetrical funnel shape when publication bias is absent ([Light & Pillemer 1984](#_ENREF_119)). A regression slope coefficient, weighting by ESS, with p<0.05 indicates significant asymmetry ([Deeks, Macaskill & Irwig 2005](#_ENREF_50)).

There was little to no difference in sensitivity and specificity between studies conducted in high-TB-incidence countries compared with low-incidence countries. The anomaly seen for medium-incidence countries was likely due to chance, given the variability between studies, as seen in Figure 38 and Figure 39 (Appendix D).

LR scattergrams plot LR+ against LR– where the likelihood of correctly identifying patients with MTB infections (as diagnosed by culture) increases along the x-axis and the likelihood of correctly eliminating the presence of MTB decreases along the y-axis. The summary LR+ and LR– values for studies investigating the ability of AFB microscopy to correctly diagnose patients with or without TB, compared with culture, were within the upper right quadrant of the graph (Figure 53). This quadrant represents LR+ and LR– values that suggest that AFB microscopy is likely to correctly confirm the presence of MTB, but a negative test result does not eliminate the likelihood of a positive culture result in patients suspected of having TB. The observed difference in sensitivity of AFB microscopy compared with culture in sputum and non-sputum specimens did not affect the clinical utility of the AFB test. The LRs for both sputum (LR+ 27.0 [95% CI 15.9, 45.6]; LR– 0.29 [95%CI 0.20, 0.43] and non-sputum (LR+ 23.3 [95%CI 13.7, 39.7]; LR– 0.55 [95%CI 0.47, 0.65] specimens were also in the same upper right quadrant. Thus, AFB microscopy is useful for those patients with a positive AFB test result as it identifies those patients as having TB and requiring immediate treatment. However, the clinician gains no further knowledge if a patient has a negative AFB test result, as this patient may still have TB.




Figure 53 LR scattergram for diagnosis of MTB infection by AFB microscopy compared with culture in studies using in-house NAAT or the Xpert NAAT

LR = likelihood ratio; NAAT = nucleic acid amplification testing

The SROC curve, which depicts the relative trade-off between true-positive and false-positive results, indicated that AFB microscopy performs well in predicting culture positivity, with an AUC of 0.94 (95%CI 0.92, 0.96). There was no threshold effect based on the AFB staining methodology, suggesting that it does not impact on the sensitivity or specificity of AFB microscopy when compared with culture (Figure 54). This lack of threshold effect suggests that the observed differences in sensitivity between studies using in-house NAATs (which favoured ZN staining) and commercial NAATs (which favoured fluorescent staining) were due to other differences that have not been identified. However, there was a threshold effect based on specimen type, with sensitivity being higher when sputum specimens were tested (Figure 54).




Figure 54 SROC curve for all studies investigating the sensitivity and specificity of AFB microscopy versus culture in the diagnosis of TB

AFB = acid-fast bacilli; AUC = area under curve; FL = fluorescent staining; SROC = summary receiver–operator characteristic; NAAT = nucleic acid amplification testing; ZN = Ziehl-Neelsen staining

# Appendix F Study profiles of studies included in the assessment

Table 95 Study profiles of included studies providing direct evidence on the effectiveness of NAAT on patients suspected of having TB

| **Study setting** | **Study design Quality appraisal** | **Study population** | **Selection criteria** | **Intervention** | **Comparator** | **Outcomes** |
| --- | --- | --- | --- | --- | --- | --- |
| Theron et al. ([2014](#_ENREF_200))  University of Cape Town, South Africa  Conducted at:  Five primary healthcare facilities in areas with a high HIV prevalence in South Africa, Zimbabwe and Tanzania | Randomised controlled trial (multicentre)  Level: II  Quality: 23/26  Low risk of bias | N=1,502  Median age: 37 years (IQR 30–46), 643 (43%) females, 895 (60%) HIV infected  758 assigned to AFB microscopy  744 assigned to Xpert MTB/RIF | Inclusion:  > 17 years of age, one or more symptoms of pulmonary TB (according to WHO criteria), able to provide sputum specimens, no anti-TB treatment in past 60 days  Exclusion:  Not reported | Xpert MTB/RIF on sputum specimen by nurse who received a 1-day training session | AFB microscopy on sputum specimen Positive if any smear revealed AFB over 100 fields (1000x for light microscopy and 400x for fluorescence microscopy) | TB-related morbidity after 2 and 6 months (using TBscore and Karnofsky performance score)  Mortality at 6-month follow-up  Failure rates |
| Yoon et al. ([2012](#_ENREF_225))  Division of Pulmonary and Critical care Medicine, San Francisco General Hospital, University of San Francisco, San Francisco, California, USA  Conducted at:  Mulago Hospital, Kampala, Uganda | Historical cohort study  Level: III-3  Quality: 18.5/26  Some risk of bias | N=477/525 included  Median age: 33 years (IQR 27–40), 229 (48%) female, 362 (76%) HIV infected | Inclusion:  Consecutive adults > 17 years of age admitted to hospital with cough > 2 weeks but < 6 months duration and provided consent  Exclusion:  Receiving TB treatment at the time of enrolment, no available culture results, no NAAT on implementation phase, death within 3 days of hospital admission | GeneXpert MTB/RIF, sputum AFB microscopy and mycobacterial culture | Same tests, but in comparator group Xpert results were not reported to clinicians or used for patient management | 2-month mortality |

IQR = interquartile range; NAAT = nucleic acid amplification test; TB = tuberculosis; WHO = World Health Organization

Table 96 Study profiles of included studies on diagnostic accuracy

| **Study**  **Country** | **Study design**  **Quality appraisal** | **Study population** | **Inclusion criteria / exclusion criteria** | **Sample preparation** | **Intervention** | **Comparator** | **Reference standard** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Ablanedo-Terrazas et al. ([2014](#_ENREF_4))  Mexico | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=68 lymph node FNAs from HIV+ patients  Median age 29 years (IQR 24–35.5) | Inclusion  Consecutive HIV+ patients, aged over 16 years, with palpable lymph nodes  Exclusion  Patients receiving treatment for TB during the previous 3 months | The tissue was homogenised before use | The Xpert MTB/RIF assay was performed following the manufacturer’s instructions | AFB microscopy with ZN staining | MGIT 960 and L-J culture for growth detection |
| Al-Ateah et al. ([2012](#_ENREF_6))  Kingdom of Saudi Arabia | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=239 specimens from 234 patients  Age and HIV status not reported  n=172 respiratory:  56 sputum  116 BAL  n=67 non-respiratory:  16 tissue biopsies  14 CSF  5 FNA  10 abscess aspirates  13 pleural fluids   3 pericardial fluids   2 synovial fluids  4 abdominal aspirates | Inclusion  All clinically suspected TB samples received during the study period  Exclusion  None | NALC-NaOH processing  Tissues and biopsies were ground with a small amount of sterile saline with a tissue grinder and then processed like other specimens | The treated specimen sample was transferred to the Xpert MTB/RIF cartridge and the test was run in the GeneXpert instrument | AFB smears were prepared, fixed and stained with AUR stain, then visualised with fluorescent microscopy  The suspected positive slides were confirmed by ZN stain | L-J medium was inoculated with 0.5 mL of dissolved specimen solution incubated at 37 °C for 8 weeks and examined weekly  0.5 mL was also added to liquid medium in MGITs and incubated in an automated MGIT 960 system™ at 37 °C for 6 weeks |
| Ani et al. ([2009](#_ENREF_10))  Nigeria | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=40 specimens from 40 children suspected of having TB  Age and HIV status not reported  10 sputum  11 gastric wash  5 CSF  5 ascitic fluid  9 pleural effusions | Inclusion  Specimens collected at the Jos University Teaching Hospital Jos, Nigeria  Exclusion  None stated | Sputum specimens were decontaminated and centrifuged for sedimentation of mycobacteria | PCR of a 123-base pair target DNA sequence from IS*6110* specific for MTB-complex | ZN AFB microscopy | Duplicate L-J slopes were cultured |
| Balcells et al. ([2012](#_ENREF_16))  Chile | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=160 HIV+ patients  Mean age 37.4 years (range 19–65)  81 had two sputum samples  53 had one sputum sample  26 provided mouth wash sample | Inclusion  Adults (aged > 18 years) with confirmed HIV infection and suspicion of pulmonary TB  They had to have cough (> 10 days), bloody sputum, pneumonia unresponsive to previous antibiotics, fever (> 10 days), abnormal CXR or weight loss  Exclusion  Empiric anti-TB treatment initiated > 7 days before enrolment | When two sputum samples were collected, a mixture of both was subjected to testing  The sputum samples were processed with NALC-NaOH, followed by centrifugation | Xpert MTB/RIF was performed according to manufacturer’s instructions  Repeated Xpert MTB/RIF assays were performed for patients who had discordant results (AFB-negative with positive Xpert MTB/RIF or vice versa) | Uncontaminated sputum samples and mouthwash were subjected to microscopy with ZN staining | Culture on solid L-J and MGIT liquid medium  Cultures were performed for all the samples, irrespective of rapid test results |
| Bates et al. ([2013](#_ENREF_19))  Zambia | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=930 specimens from children aged 15 years or younger  Median age 24 months (IQR 12–74)  279 (30%) HIV+  142 sputum samples 788 gastric aspirates | Inclusion  Any new child inpatient with a primary or secondary diagnosis of suspected TB  Exclusion  Patients who were deemed to have a poor prognosis or if parents or guardians refused consent | After AFB microscopy sample was taken, samples were homogenised and digested in NALC-NaOH and concentrated  The resulting suspension was used for culture and Xpert MTB/RIF | The concentrated sample was added to the Xpert MTB/RIF sample reagent in a 1:3 ratio and 2 mL of this mixture was added to the Xpert MTB/RIF cartridge and run in the machine in accordance with manufacturer’s instructions | Fluorescent AFB microscopy (AUR) was done directly on all samples | 1 MGIT tube was inoculated with 0.5 mL concentrated sample and incubated in the BACTEC 960 system for up to 42 days  DST was done on MTB-positive cultures with the BACTEC MGIT 960 SIRE kit |
| Baveja et al. ([2009](#_ENREF_20))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ?  Applicability: C1, P2 | N=100 CSF specimens from children strongly suspected of TB meningitis  Aged 6 months to 12 years  HIV status not reported | Inclusion  Children who were presumptively diagnosed with TB meningitis by a set of predetermined criteria  Exclusion  Patients who were deemed to have a poor prognosis or if parents or guardians refused consent | CSF samples were not pre-treated | PCR amplification was carried out using primers targeting the *MPB64* gene | CSF smear was stained with ZN stain and examined under a microscope | L-J culture and BACTEC medium were inoculated for growth |
| Ben Kahla et al. ([2011](#_ENREF_21))  Tunisia | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=333 specimens from 234 patients  Age and HIV status not reported  n=218 pulmonary (sputum, bronchial wash and gastric lavage)  n=115 extra-pulmonary (pleural fluid, joint fluid, pus, cerebrospinal fluid, tissue biopsy, urine, peritoneal fluid and sperm) | Inclusion  Specimens sent by hospital units to the laboratory for routine diagnosis of TB from December 2007 to September 2008 with sufficient volume to perform all diagnostic tests  Exclusion  None stated | Pulmonary samples, synovial fluids and pus were liquefied using NALC-NaOH method  The remaining samples were directly concentrated by centrifugation | PCR of a 580-bp sequence in the IS*6110* insertion sequence specific for MTB-complex | AFB microscopy was performed from the centrifugation pellets and stained with AUR  All positive and doubtful smears were confirmed by ZN technique | Culture was performed onto L-J and/or Coletsos media  All isolates were identified to species level using conventional techniques |
| Bhanothu, Theophilus & Rozati ([2014](#_ENREF_23))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ?  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=202 specimens from HIV– patients  Mean age 28.5 ± 4.5 years  n=123 endometrial tissue biopsies n=68 ovarian tissue biopsies n=11 pelvic aspirated fluids | Inclusion  Infertile women highly suspected of having FGTB  Exclusion  Older than 40 years of age, normal abdominal and vaginal examinations, pregnant and nursing women, severe psychiatric dysfunctions, endocrine problems, sexual disorders, autoimmune disorders, pulmonary or HIV co-infections, diabetes, malnutrition, hypertension, male infertility and ovulation abnormality | Not described | MTB-specific PCR method using primers to detect the *TCR4* gene | AFB smears were stained with ZN stain | Cultures were grown on L-J medium |
| Bhanu et al. ([2005](#_ENREF_24))  India | Level III-1:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ☺  Flow and timing ☺  Applicability: C1, P2 | N=18 specimens  Aged 20–40 years  HIV status not reported  16 endometrial aspirates 14 endometrial biopsies | Inclusion  Infertile women with laparoscopic findings suggestive of possible GUTB  Exclusion  None stated | The samples were decontaminated in NaOH employing modified Hank’s flocculation method | PCR of a 123-base pair target DNA sequence from IS*6110* specific for MTB-complex | ZN AFB microscopy | Growth on L-J medium culture was monitored for 8 weeks and the mycobacterial species identified in positive cultures |
| Bhigjee et al. ([2007](#_ENREF_25))  South Africa | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=126 CSF specimens from 68 patients  Mean age 32.2 ±10 years  48/57 patients were HIV+  HIV status for 11 patients unknown | Inclusion  Patients suspected to have neuro TB on clinical grounds  They were all AFB-negative | CSF was collected in three consecutive lots of approximately 10 mL: (1) lumbar CSF, (2) thoracic and cervical CSF and (3) CSF at the base of the brain  From each specimen of 10 mL of CSF, 5 mL were used for AFB microscopy and culture | PCR and qPCR using primers targeting IS*6110* and the *MPB64* gene | AFB, fluorescent microscopy, after AUR staining | Culture on 7H 11 agar and in mycobacterial indicator growth tubes  These specimens were cultured at 37 °C for 6 weeks and examined weekly for growth |
| Biadglegne et al. ([2014](#_ENREF_26))  Ethiopia and Germany | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=231 FNA samples from lymph nodes  Age and HIV status not reported | Inclusion  Patients with enlarged lymph nodes who were not responding to a 2-week course of broad spectrum antibiotics and clinically suspected for TB lymphadenitis  Exclusion  None stated | Specimens were decontaminated using NALC-NaOH method and centrifuged for sedimentation of mycobacteria | The treated specimen sample was transferred to the Xpert MTB/RIF cartridge and the test was run in the GeneXpert instrument | AUR AFB microscopy | L-J and Gottsacker slants were inoculated, incubated at 37 °C for 12 weeks and examined weekly  BacT/Alert bottles were inoculated, supplemented with antibiotics and then incubated in an automated BacT/Alert 3D System |
| Carriquiry et al. ([2012](#_ENREF_34))  Peru | Level III-1:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ☺  Flow and timing ☺  Applicability: C1, P2 | N=131 HIV+ patients (each two sputum samples)  Median age 35 years (IQR 29–42) | Inclusion  Adults (> 17 years of age) with HIV, and a high suspicion of TB  Exclusion  Received > two doses of TB treatment, failure to provide a second sputum sample | Sputum was decontaminated using NALC-NaOH method | Sample was transferred to the Xpert MTB/RIF cartridge  The cartridge was closed and placed into the GeneXpert System for analysis | Microscopy with ZN staining | Two slopes of L-J culture were inoculated  For MGIT, 0.5-mL sputum pellets were inoculated into liquid medium  DST was performed using the L-J proportional method |
| Chakravorty et al. ([2006](#_ENREF_39))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=506 sputum samples from 506 patients  Age and HIV status not reported | Inclusion:  Patients visiting TB centres for the diagnosis of pulmonary TB  Exclusion  Patients already receiving anti-tubercular treatment | Universal sample processing method, which involves homogenisation and decontamination of specimens by treatment with Universal Sample Processing solution  The sample was centrifuged, the sediment was resuspended and then used | PCR assay amplified a 308-bp region of the *devR* gene  An additional PCR assay targeting the repetitive IS*6110* sequence was also carried out | USP AFB microscopy with ZN staining | Culture was on L-J slopes  Cultures were confirmed to be MTB by the niacin test or by devR PCR |
| Chakravorty et al. ([2005](#_ENREF_38))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ?  Applicability: C1, P2 | N=571 sputum samples from 571 patients  Age and HIV status not reported | Inclusion:  Patients with fever, cough, expectoration of sputum, haemoptysis, pain, dyspnoea, weight loss, night sweats, general weakness, positive CXR, mantoux status and any past history of TB  Exclusion  Receiving anti-tubercular treatment | Universal sample processing method (homogenisation and decontamination of specimens by treatment with Universal Sample Processing solution)  A subset of 325 samples was also processed by the NALC-NaOH method, centrifuged and the sediments were used for AFB microscopy and culture | The isolated DNAs were used for IS*6110*-specific PCRs | USP AFB microscopy with ZN staining | Each sputum sample was decontaminated and inoculated onto L-J medium |
| Davis et al. ([2009](#_ENREF_45))  Uganda | Level II:  A comparison against independent, blinded reference standard among consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ☺  Flow and timing ☹  Applicability: C1, P2 | N=127 sputum samples from 101 outpatients and 26 inpatients  Outpatients median age 28 years (IQR 24–35)  Inpatients median age 33 years (IQR 28–42)  58/126 (46%) patients were HIV+ | Inclusion:  Prospectively enrolled outpatients and inpatients aged > 18 years with suspected TB  Exclusion  Receiving anti-tubercular treatment | Sputum samples obtained from outpatients were processed using dithiothreitol Specimens obtained from inpatients underwent processing using NALC-NaOH  Samples were stored frozen | PCR assay targeting the MTB *secA1* gene  Two PCRs for each sample were performed in separate capillary tubes | Sputum specimens were examined with direct ZN microscopy on the day of enrolment | Decontaminated sputum was inoculated on L-J media before freezing  Frozen samples were cultures using Middlebrook 7H11 agar plates and in MIGT  Cultures were considered to be negative if no growth was identified after 8 weeks |
| de Albuquerque et al. ([2014](#_ENREF_47))  Brazil | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=140 sputum specimens from 140 HIV+ patients  Mean age 37.1 ± 9.9 years | Inclusion  Age ≥ 18 years, HIV infected, clinical suspicion of pulmonary TB  Exclusion  Receiving anti-tubercular treatment, unable to provide sputum samples | Sputum decontamination was undertaken using the NaOH-N-acetyl-L-cysteine method | qPCR: target IS*6110* PCR amplification was performed in triplicate | ZN-stained smears | L-J solid medium and 7H9 broth culture  The culture was considered positive when at least one of the media presented mycobacterial growth |
| Deggim et al. ([2013](#_ENREF_51))  Switzerland | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ?  Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=79 mixed specimens  Age and HIV status not reported  71 respiratory including sputum, BAL 8 non-respiratory including ascetic fluid, pleural fluid, biopsy tissue | Inclusion  All clinical specimens received to urgently confirm or rule out TB in newly identified suspect cases  Exclusion  None stated | After Xpert, the remaining sample was decontaminated with NALC-NaOH and centrifuged for sedimentation of mycobacteria | The Xpert MTB/RIF assay was performed following the manufacturer’s instructions for respiratory specimens Non-respiratory specimens were tested similarly | AFB microscopy with AUR staining Positive results were confirmed by ZN staining | MGIT 960 liquid and Middlebrook 7H11 culture media for growth detection  DST was performed using the BACTEC MGIT 960 system |
| Derese et al. ([2012](#_ENREF_53))  Ethiopia | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ?  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=134 FNA samples from lymph nodes  Mean age 28.6 ± 12.7 years  HIV status not reported | Inclusion  Retrospective study on previously collected FNA specimens stored at  –80 °C to diagnose lymphadenitis TB  Exclusion  None stated | Specimens were decontaminated using NALC-NaOH method and centrifuged for sedimentation of mycobacteria | PCR was performed using IS*1081* primers | AFB microscopy with ZN staining | Four L-J medium (two with glycerol and two with pyruvate) slopes were incubated and examined weekly for 8 consecutive weeks |
| Desai et al. ([2006](#_ENREF_54))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality:  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=30 CSF samples  Age and HIV status not reported | Inclusion  In-house patients with a provisional diagnosis of tuberculous meningitis and had 2 mL of CSF available for study | Sample split in two The first 1-mL portion was centrifuged and used for AFB microscopy and culture, and the second 1-mL portion was stored at −20 °C and used for DNA extraction and PCR | PCR targeting IS*6110* was performed | ZN-stained smears | L-J solid medium |
| Deshmukh et al. ([2013](#_ENREF_55))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality:  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ?  Applicability: C1, P2 | N=466 HIV– patients eligible and 463 included in final analysis  Mean age 33 ± 21 years  n=40 pulmonary:  27 sputum  13 BAL  n=423 extrapulmonary:  60 CSF  52 body fluids  164 tissues  94 pus  53 urine | Inclusion  Suspected of TB with clinical history available and sufficient volume to perform all diagnostic tests  Exclusion  If above criteria were not met | The specimens were equally divided into two parts and assigned to the molecular technologist in the molecular diagnostic laboratory for the PCR test, and to the technologist in the mycobacteriology laboratory for AFB microscopy and culture | Specimens from sterile sites were processed first followed by those obtained from non-sterile sites, which were decontaminated using the NALC-NaOH method, in order of AFB scanty  PCR was performed using IS*6110* primer sequences | ZN staining | Culture was by both solid medium (L-J) and liquid medium (MGIT)  Positive cultures were confirmed for MTB species using the p-nitrobenzoic acid assay |
| Drouillon et al. ([2009](#_ENREF_59))  France and Italy | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P1 | N=633 specimens (357 from Paris, 100 from Parma and 176 from Rome)  Age and HIV status not reported  n=548 pulmonary:   417 sputum  46 gastric fluids  68 bronchial aspirates  17 bronchial washes  n=59 extrapulmonary:  3 CSF  11 pleural fluids  4 peritoneal fluids  1 pericardial fluid  4 tissue biopsies  12 lymph node  punctures  11 urine   5 pus  2 semen  6 stool | A prospective multicentre study that tested both pulmonary and extrapulmonary specimens from patients with suspected TB  Inclusion  Untreated, at-risk patients who, on the basis of their physicians’ initial assessments, were suspected of having active TB  Exclusion  Patients currently receiving anti-TB therapy for more than 6 days or who had completed treatment less than 12 months before the date of enrolment | When necessary, all specimens were decontaminated using the NALC-NaOH procedure | qRT-PCR, which uses the intercalation activating fluorescence DNA probe to emit enhanced fluorescence by binding to a complementary sequence targeting 16S rRNA | AFB microscopy was performed using both AUR and ZN staining | Culture was performed in either liquid (MGIT, BacT/Alert) or solid (L-J and/or Coletsos) medium, with incubation up to 63 days for liquid media and 3 months for solid media at 37 °C  Mycobacteria isolated from culture were characterised by molecular assays |
| Drouillon et al. ([2007](#_ENREF_60))  France | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ?  Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=179 pulmonary specimens (sputa and gastric fluids) were collected from 100 patients  Age and HIV status not reported | Inclusion  Consecutive, non-selected patients with suspected TB between April and October 2004  Exclusion  None stated | A minimum of 2 mL of pulmonary specimen was collected  Some was used directly for the DNA extraction  The remainder was decontaminated using NALC-NaOH solution | qPCR was performed to amplify and detect the IS*6110* sequence | Method not specified | Culture was performed using MGIT liquid media and Coletsos slants |
| Ekrami et al. ([2011](#_ENREF_61))  Iran | Level III-1:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ?  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=152 sputum samples  Age and HIV status not reported | Inclusion  Patients who were suspected of having pulmonary TB  Exclusion  Not reported | Processed according to standard routine diagnostic procedures using the NALC-NaOH method | PCR and nPCR  Purified DNA was amplified using primers specific to IS*6110* and two specific pairs of external and internal primers for this bacterium | ZN-stained AFB microscopy | L-J solid medium culture |
| El Khechine et al. ([2009](#_ENREF_63))  France | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=134 patients each with one sputum and one stool sample  Mean age 37 ± 15 years  HIV status not reported | Inclusion  Sputum specimens and stool specimens collected from patients suspected of having pulmonary TB  Exclusion  Not reported | Respiratory tract specimens were digested and decontaminated using the NALC-NaOH method  Stool specimens were filtered using a faecal specimen filtration vial kit | qPCR amplification and detection of IS*6110* | Direct ZN-stained microscopy of sputum or filtered stool | Decontaminated sputum was inoculated into a BACTEC 9000 bottle and incubated in an automated BACTEC 9000 MB system for 2 months  Stool culture: in L-J medium for 2 months |
| Ereqat et al. ([2011](#_ENREF_64))  Palestine | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=95 sputum samples from 84 patients  Mean age 46.4 ± 2.5 years  HIV status not reported | Inclusion  Patients suspected of having pulmonary TB  Exclusion  Not reported | The sputum samples were processed using the NALC-NaOH method | DNA was extracted from ZN-stained material scraped off from the microscopic slides  PCR used primers targeting a 123-bp segment of IS*6110* | ZN-stained AFB microscopy | L-J medium culture (37 °C, up to 8 weeks) |
| Fan et al. ([2014](#_ENREF_65))  China | Level III-1:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ☺  Flow and timing ☺  Applicability: C1, P2 | N=200 AFB –ve respiratory samples  Mean age 43 ± 18 years  120 sputum  80 BAL | Inclusion  Patients suspected of pulmonary TB > 18 years of age with abnormal CXR findings that had three consecutive negative AFB microscopy results or were sputum scarce  Exclusion  Patients who were AFB +ve or HIV+ or were missing culture specimens | Not reported | Simultaneous amplification and testing for MTB (SAT-TB) assay  MTB 16S rRNA was reverse transcribed to generate a 170-bp DNA fragment in a real-time PCR | AFB microscopy | MGIT culture was performed in the BD BACTEC MGIT960 Mycobacteria Culture System |
| George, Mony & Kenneth ([2011](#_ENREF_73))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=78 sputum samples  Age and HIV status not reported | Inclusion  TB suspects  Exclusion  Not reported | Sputum samples were decontaminated using NALC-NaOH method and stored at –20 °C Decontaminated sputum was processed using the Amplicor respiratory specimen preparation kit | LAMP assay specific for the *rimM* sequence of MTB and *Mycobacterium bovis* | AUR fluorescence microscopy | L-J culture and MGIT culture |
| Ghaleb, Afifi & El-Gohary ([2013](#_ENREF_74))  Egypt | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=100 urine samples  75 males with mean age 37.5 ±7.5 years  25 females with mean age 37.0 ± 9.0 years  HIV status not reported | Inclusion  Patients with symptoms suggestive of renal TB  Exclusion  None reported | Urine specimens were treated with NALC-NaOH method for the decontamination | PCR targeting IS*6110* | AFB microscopy with ZN staining | L-J solid and BACTEC 12B liquid culture |
| Gholoobi et al. ([2014](#_ENREF_75))  Iran | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=30 clinical samples:  4 urine,  1 gastric washout,  18 BAL,  5 pleural fluid,  1 ascites tap,  1 lung washout)  Age and HIV status not reported | Inclusion  Specimens from patients suspected of having TB, collected from the Ghaem University Teaching Hospital  Exclusion  None stated | Each sample was used for three procedures, one for decontamination processing and two (1 mL each) for DNA extraction and PCR | PCR was performed using three sets of specific MTB primers targeting the 16S–23S ITS region, the variable *rpoB* region from MTB and IS*6110* | AFB smear preparation, ZN staining and slide reading were carried out according to the recommendations outlined in the *Manual of TB Bacteriology* | Samples were decontaminated, homogenised and cultured on L-J medium using the Petroff technique |
| Gomez et al. ([2011](#_ENREF_77))  Southern Texas (USA, 7%) and Mexico (93%) | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ?  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=174 initial participants (136 TB suspects and 38 non-TB controls)  24 were excluded, leaving 150 sputum samples  All patients were Hispanics in their mid-40s | Inclusion  Patients with suspected pulmonary TB or individuals in whom TB had been ruled out or was unlikely  Exclusion  Jail inmates, people < 18 years of age, and patients who had received anti-TB treatment for more than 7 days | Sputum was decontaminated using NALC-NaOH and centrifuged, and the pellet was resuspended in a 0.5x final volume of the original sputum | qPCR: targets were IS*6110*, *RD1* and IS*1081* | AFB microscopy (method not recorded) | Decontaminated sample was inoculated in MGIT and L-J media |
| Haldar et al. ([2007](#_ENREF_80))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ?  Index test ☺  Comparator ☹  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=148 sputum samples (selected were direct AFB –ve samples or with low bacterial load)  Age and HIV status not reported | Inclusion  Subjects attending directly observed treatment short-course centre  Patients had negative direct smear or low bacterial load  Exclusion  Not reported | USP solution was used: [6 M guanidinium hydrochloride, 50 mM Tris/Cl (pH 7.5), 25 mM EDTA, 0.5% Sarcosyl, 0.1 M ß–  Mercaptoethanol] | PCR: target genes were *devR* and IS*6110*  Two detection formats were employed: molecular-beacon-based end-point detection using the fluorimetric method, and gel detection using ethidium bromide | USP AFB microscopy with ZN staining | Culture: USP-processed deposits were inoculated in 7H9 liquid media containing albumin dextrose complex and PANTA (polymyxin B, amphotericin B, nalidixic acid, trimethoprim and azlocillin) supplement (Becton Dickinson) |
| Halse et al. ([2010](#_ENREF_81))  USA | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P1 | N=1,316 specimens for diagnosis of TB  Age and HIV status not reported  n=1,201 respiratory (sputum, BAL and bronchial wash)  n=115 non-respiratory (abscess, aspirates, CSF, gastric fluid, tissue, pleural fluid, wound, liver tissue and lymph node) | Inclusion  Clinical specimens received for routine mycobacterial cultivation in the Mycobacteriology Laboratory at the Wadsworth Center, New York State  Exclusion  Specimens from diagnosed cases of TB | Each respiratory specimen was treated with NALC-NaOH to break up the mucin and to decontaminate the specimens  Lung and tissue specimens were ground in disposable tissue grinders until homogeneous, prior to processing | qPCR was performed using IS*6110* and *rpoB* primer sequences  qPCR-positive specimens were subjected to pyrosequencing analysis | Smears were prepared by the ZN acid-fast staining method | Processed specimen was inoculated into MGIT tubes and incubated for up to 8 weeks, or until they were found to be positive by the Bactec MGIT 960 instrument  L-J slants and Middlebrook selective biplates were also inoculated and incubated at 37 °C, and held for 8 weeks  DST for RIF was performed with the MGIT liquid culture |
| Hanrahan et al. ([2014](#_ENREF_83))  South Africa | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=2,082 individuals had valid culture result (sputum samples)  Median age 37 years (IQR 29–46)  58% were HIV+ | Inclusion  Johannesburg: people aged > 14 years suspected of TB  Cape Town: adults aged > 17 years suspected of TB  No participants were on TB treatment  Exclusion  Not reported | Decontamination with NALC-NaOH | Samples were tested using Xpert MTB/RIF G3 cartridge in Johannesburg  In Cape Town the second sputum specimen was frozen at −20 °C for later testing using Xpert G2 cartridge | Fluorescence AFB microscopy | Liquid culture using BACTEC MGIT 960 |
| Helb et al. ([2010](#_ENREF_84))  Vietnam | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=107 sputum samples from 107 patients  Median age 34 years (range 18–76)  1/107 (0.9%) HIV+ | Inclusion  Sputum samples from 107 consecutively enrolled patients suspected of having TB | Two sputum samples per patient  The first sample was homogenised and split, with some frozen at −70 °C for later analysis by the Xpert MTB/RIF assay and the remainder subjected to AFB microscopy and culture | 2–3 mL of digested sputum was transferred to the Xpert MTB/RIF cartridge, the lid was closed, and the cartridge was loaded into the GeneXpert instrument, where all subsequent steps occurred automatically | AFB microscopy | Quantitative culture on L-J medium, and Bactec MGIT 960 liquid culture |
| Hillemann et al. ([2011](#_ENREF_86))  Germany | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=521 non-respiratory specimens  Age and HIV status not reported  n=91 urine n=30 gastric aspirate n=245 tissue samples n=113 pleural fluid n=19 CSF n=23 stool | Inclusion  Consecutive specimens from patients with suspected MTB or NTM infection, not selected by the use of any special criteria  Exclusion  None | All specimens were processed using the standard NALC-NaOH method | The treated specimen sample was transferred to the Xpert MTB/RIF cartridge and the test was run in the GeneXpert instrument | Smears were stained by the KCS method and examined with a light microscope | DST for RIF was performed with the MGIT 960 method |
| Ioannidis et al. ([2011](#_ENREF_91))  Greece | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=105 AFB –ve pulmonary and extrapulmonary samples  Age and HIV status not reported | Inclusion  Specimens were selected from patients with strong clinical indications for TB  Exclusion  None | All specimens were processed using the standard NALC-NaOH method | The treated specimen sample was transferred to the Xpert MTB/RIF cartridge and the test was run in the GeneXpert instrument | AFB smears of the processed specimens were prepared and examined | Solid (L-J) and liquid (MIGT 960) culture media were inoculated  RIF resistance of bacterial colonies were investigated with the GenoType MTBDRplus assay and confirmed by DST using the proportion method on L-J culture medium and/or MGIT for RIF |
| Jiang et al. ([2012](#_ENREF_93))  China | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=235 mixed specimens:  sputum (88.1%), pleural fluid (3.0%), lymph node (3.0%), CSF (2.1%),  urine (1.7%), abscess and exudate (1.7%) and  faeces (0.4%)  Age and HIV status not reported | Inclusion  Clinical specimens were obtained from patients with suspected TB  Exclusion  None | Respiratory specimens were decontaminated with NALC-NaOH Extrapulmonary specimens from closed and normally sterile sites were used directly without decontamination after a single centrifugation | qRT-PCR using MTB 16S rRNA-specific primers | AFB smears with ZN stain | Liquid MGIT 960 and solid L-J cultures |
| Keys et al. ([2012](#_ENREF_97))  Australia | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ?  Index test ?  Comparator ?  Reference std ?  Flow and timing ?  Applicability: C1, P1 | N=6 pleural biopsied from children  Age and HIV status not reported | Inclusion  Children with clinical suspicion of TB with both respiratory and constitutional symptoms  Exclusion  None stated | Not reported | PCR, details not provided | AFB microscopy | Culture |
| Khan, Cheema & Khan ([2013](#_ENREF_98))  Egypt | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ?  Reference std ?  Flow and timing ?  Applicability: C1, P2 | N=50 urine samples  Median age of patients 38 years (range 20–76)  HIV status not reported | Inclusion  Patients with symptoms suggestive of GUTB  Exclusion  None reported | Urine specimens were treated using NALC-NaOH method for the decontamination | PCR, details not provided | AFB microscopy with ZN staining | Culture on L-J medium |
| Khosravi et al. ([2010](#_ENREF_100))  Iran | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=200 urine samples  Mean age 37.8 years  HIV status not reported | Inclusion  Patients with symptoms suggestive of renal TB  Exclusion  None reported | Three urine samples collected on three consecutive days as early morning urine, pooled and concentrated | nPCR targeting IS*6110* | AFB microscopy with ZN staining | Culture on L-J medium with a conventional identification procedure |
| Kibiki et al. ([2007](#_ENREF_101))  Tanzania | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=120 BAL samples from 120 HIV+ patients  Mean age 39 years | Inclusion  HIV+ patients aged > 17 years with features of chest infection and referred for bronchoscopy > 80% had previous antibiotic treatment for pneumonia  Exclusion  Pregnant women and patients with oxygen saturation < 90% under 6 L/minute | BAL samples were pre-treated by decontamination with NaOH and centrifuged  The sediment was used for the different diagnostic tests | PCR (40 cycles) targeting IS*6110* | Direct smears were examined for AFB after ZN staining | MTB culture was performed using in-house L-J solid medium, with a maximum incubation period of 8 weeks |
| Kim et al. ([2008](#_ENREF_102))  Korea | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=2,973 patients  Age and HIV status not reported  n=1,134 pulmonary specimens:  863 sputum 271 bronchial aspirate  n=1,839 extrapulmonary specimens:  834 pleural fluid 313 CSF 248 urine 147 tissue 109 pus 59 peritoneal fluid 34 blood 12 gastric aspirate 9 pericardial fluid 7 bone marrow 67 other | Inclusion  Patients who visited Kyung Hee Medical Center between July 2003 and July 2006 for TB diagnosis  Exclusion  None | Sputum, bronchial aspirate, urine and pus were incubated with NaOH and then centrifuged  Tissues were minced with scissors and treated with proteinase K and then centrifuged  Cerebrospinal and other body fluids were centrifuged without any pre-treatment | nPCR using primers targeting IS*6110* | AUR-stain positive specimens were confirmed with ZN microscopy | Specimens were inoculated onto 3% Ogawa media and then incubated for at least 8 weeks at 37 °C |
| Kurbatova et al. ([2013](#_ENREF_108))  Russia | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ?  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=238 sputum specimens from 201 patients  Age and HIV status not reported | Inclusion  Adults (> 17 years of age) with presumptive or recently diagnosed pulmonary TB  Exclusion  Receiving anti-TB drugs within 60 days prior to specimen collection | Sputum samples were homogenised and split into two portions. From one portion, 1.0 mL was tested by Xpert and a smear prepared for ZN microscopy  The remaining portion (≥ 3 mL) was decontaminated with NALC-NaOH and centrifuged for culture and Xpert | The Xpert MTB/RIF assay was performed according to the manufacturer’s instructions  The results were obtained using the Xpert MTB/RIF software | Direct and AUR fluorescence microscopy | Sample was inoculated onto L-J solid medium and BACTEC MGIT 960 liquid medium  Culture-based DST was performed using either the BACTEC MGIT 960 system or the absolute concentration method on L-J medium |
| Lee et al. ([2013](#_ENREF_115))  Korea | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=35 culture-positive Xpert-positive bronchoscopy samples  Age and HIV status not reported | Inclusion  Retrospective review of all records for patients with suspected PTB, among whom the AFB microscopy, culture and Xpert assays were performed using bronchial washings or BAL  Exclusion  Patients diagnosed with sputum AFB +ve PTB before bronchoscopy or who had received anti-TB medication for ≥ 2 weeks within 90 days before bronchoscopy | Samples were decontaminated with NaOH and centrifuged for AFB microscopy, culture and Xpert | The Xpert MTB/RIF assay was performed following the manufacturer’s instructions | The AFB smears were examined after AUR staining | Culture-based DST was performed using the proportion method on 3% Ogawa medium |
| Lee, Chen & Peng ([2009](#_ENREF_116))  Taiwan | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ?  Applicability: C1, P2 | N=150 sputum specimens  Age and HIV status not reported | Inclusion  Suspected TB patients admitted to Kaohsiung Medical University Hospital  Exclusion  Not reported | Decontamination using NALC-NaOH treatment, and subsequent concentration by centrifugation | LAMP assay for detection of 16S rRNA in clinical isolates of MTB using an ELISA detection system | AFB staining (method not specified) | Mycobacterial culture (method not specified) |
| Ligthelm et al. ([2011](#_ENREF_120))  South Africa | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=48 lymph node FNAs  Mean age of patients 27.9 ± 15.1 years  36/48 had unknown HIV status  9/12 (75%) patients tested were HIV+ | Inclusion  All patients referred for FNA biopsy with possible TB lymphadenitis  Exclusion  Inadequate sample for testing | Sample used directly. | The Xpert MTB/RIF assay was performed following the manufacturer’s instructions | AFB smears with both ZN staining and fluorescence microscopy | MGIT 960 for growth detection |
| Makeshkumar, Madhavan & Narayanan ([2014](#_ENREF_125))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=178 extrapulmonary specimens  Age and HIV status not reported  59 ascetic fluid 54 pleural fluid 25 CSF 12 FNA 8 urine 7 pus 6 synovial fluid 7 other | Inclusion  All clinically suspected extrapulmonary TB patients who were visiting SRM Medical College Hospital during the period May 2008 – May 2009  Exclusion  None | Sterile body fluid samples (ascitic fluid, pleural fluid, CSF, synovial fluid, pericardial fluid and pancreatic cyst fluid) were centrifuged  Pus specimens were decontaminated using Petroff’s method  Biopsy and skin tissue samples were ground and then centrifuged | PCR using primers targeting IS*6110* | AFB microscopy with ZN stain | Specimens were inoculated onto solid L-J medium and examined every second day during the first week and weekly for up to 8 weeks |
| Malbruny et al. ([2011](#_ENREF_126))  France | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=180 specimens from 132 patients  Age and HIV status not reported  N=91 respiratory:  18 sputum 31 bronchial aspirate 9 BAL 33 gastric aspirate  N=89 non-respiratory:  15 CSF 23 lymph node 6 vertebral biopsy 5 joint fluid 12 pleural fluid 3 peritoneal fluid 3 urine 22 other | Inclusion  Specimens from patients clinically suspected of TB were prospectively collected  Exclusion  None | All respiratory samples were digested and decontaminated using NALC-NaOH, whereas most of the non-respiratory samples were not  All biopsy samples were processed using a homogeniser  All samples except CSF were concentrated by centrifugation | The treated specimen sample was transferred to the Xpert MTB/RIF cartridge and the test was run in the GeneXpert instrument | Fixed preparations were stained with AUR and visualised under a fluorescence microscope | Liquid medium (MGIT) and Coletsos slants were inoculated  Liquid cultures were monitored by the automated MGIT 960 system for up to 6 weeks, while solid media were kept for up to 12 weeks Positive cultures were confirmed using a commercial immuno-chromatographic assay |
| Marchi et al. ([2008](#_ENREF_128))  Brazil | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=117 sputum specimens  Age and HIV status not reported | Inclusion  Suspected TB patients whose sputum samples were sent to the Municipal Public Laboratory for *Mycobacterium* spp. testing  Exclusion  Not reported | For culture and PCR, samples were treated with NaOH and SDS, followed by neutralisation with phosphoric acid | PCR was carried out using primers specific for 123-bp product of IS*6110* | ZN staining was carried out directly on sputum sample smears | Culture of the treated samples was carried out in L-J-MTBAC culture media and incubated at 37 ºC for 8 weeks |
| Marlowe et al. ([2011](#_ENREF_130))  USA | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P1 | N=217 respiratory specimens (126 AFB +ve and  91 AFB –ve)  Age and HIV status not reported | Inclusion  Specimens ordered at three different sites in western USA for routine mycobacterial testing were included in the study  Exclusion  None stated | The NALC-NaOH method was used to digest, decontaminate and concentrate respiratory specimens | The treated specimen sample was transferred to the Xpert MTB/RIF cartridge and the test was run in the GeneXpert instrument | A smear of the processed sediment was prepared, stained and read  Method not stated | Culture method not described  DST was performed by a broth micro-dilution method |
| Mashta et al. ([2011](#_ENREF_132))  India | Level III-1: A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ☺  Flow and timing ☺  Applicability: C1, P2 | N=463 sputum samples  Age and HIV status not reported | Inclusion  Samples from patients suspected of TB  Exclusion  Not reported | Sputum samples used directly for AFB microscopy and culture at NDTB centre  Transferred cool to NII, where samples were sputum liquefaction and decontamination occurred | PCR, targeting IS*6110* and *devR* | AFB smear: staining by free carbol fuchsin, decolourising by 25% sulphuric acid and counterstained by 0.1% methylene blue | L-J medium culture Samples were liquefied by 4% NaOH solution for 20 minutes, centrifuged at 3,000 g, and pellet was washed twice with distilled water |
| Maurya et al. ([2011a](#_ENREF_135))  India | Level III-1:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ☺  Flow and timing ☹  Applicability: C1, P2 | N=102 pleural effusions from 102 patients  Mean age 30.4 ± 13.2 years  2/102 (2%) were HIV+ | Inclusion  Clinically suspected cases of pleural TB  Exclusion  Patients with undetermined aetiology | Specimens were divided into two parts and kept at −20 °C until processing (method not described) | PCR was performed using IS*6110* primer sequences | Smear examination was by ZN staining | BACTEC vials were incubated and interpreted as per the Becton Dickinson instruction manual |
| Maurya et al. ([2011b](#_ENREF_136))  India | Level III-1:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ☺  Flow and timing ☺  Applicability: C1, P2 | N=328 extrapulmonary specimens from new cases suspected of TB  Mean patient age 39.8 ± 16.1 years  HIV status not reported  Lymph node aspirates, cold abscesses, pleural fluid, CSF, synovial fluid, ascetic fluid, urine, gastric aspirate, pus, bone marrow, wound and pus swabs, and biopsy tissues | Inclusion  Non-repeated specimens from suspected cases of extrapulmonary TB  Exclusion  None stated | Specimens were divided into two parts and kept at −20 °C until processing (method not described) | PCR was performed using IS*6110* primer sequences | Smear examination was by ZN staining | BACTEC vials were incubated and interpreted as per the Becton Dickinson instruction manual |
| Michelon et al. ([2011](#_ENREF_139))  Brazil | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=476 sputum specimens  Age and HIV status not reported  301 induced sputum specimens  175 spontaneous sputum specimens:  47 patients with a single collection that were processed in duplicate  128 patients with two collections on different days that were processed at a single time | Inclusion  Samples of suspected TB patients  Exclusion  Not reported | All samples were treated with NALC-NaOH  Mycobacterial culture and AFB microscopy were carried out for all clinical samples and the association of these results was chosen as the gold standard | PCR amplification reactions were performed with biotinylated primers derived from IS*6110*  This was followed by a microwell hybridisation assay to detect the amplified product | Method not reported | Method not reported |
| Min et al. ([2010](#_ENREF_141))  Korea | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=136 bronchial aspirates  Age range 17–88 years  HIV status not reported | Inclusion  Consecutive patients suspected of TB who did not produce sputum or who produced AFB-negative sputum and underwent RT-PCR in bronchial aspirate for the diagnosis of TB  Exclusion  HIV+ and immunocompromised patients | Bronchial aspirate was digested and decontaminated with NALC-NaOH | qPCR was performed using primers targeting the *senX3-regX3* intergenic region  This was designed to be positive for MTB and negative for *Mycobacterium bovis* bacille Calmette-Guérin | AFB microscopy | Mycobacteria were cultured on 3% Ogawa media for a maximum period of 8 weeks |
| Mittal et al. ([2011](#_ENREF_145))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=50 lymph node FNAs  Mean age of patients 27.9 ± 15.1 years  HIV status not reported | Inclusion  Patients with peripheral lymphadenopathy clinically suspected to be of TB origin  Exclusion  Patients with clinically non-palpable lymph nodes, those already on anti-TB treatment and those who had a known malignancy | The material was used directly for ZN staining and culture, and a portion was frozen at −20 °C for use in a PCR | PCR was performed using IS*6110* primers | AFB microscopy with ZN staining | Cultures were inoculated on L-J medium and incubated at 37 °C The L-J slants were examined weekly for any growth for 8 weeks |
| Moure, Martin & Alcaide ([2012](#_ENREF_147))  Spain | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P1 | N=149 AFB-negative extrapulmonary specimens  Age and HIV status not reported  14 CSF 31 pleural fluid 7 joint fluid 3 ascitic fluid 3 pericardial fluid 8 gastric aspirates 4 urine 38 FNA (lymph nodes) 19 abscess aspirates 20 tissue biopsies 2 stool | Inclusion  AFB –ve samples (one sample per patient) collected from July 1999 to May 2011 in Costa Ponent  Exclusion  None | Non-sterile clinical samples were pre-treated using the NALC-NaOH digestion-decontamination method  Sterile fluid specimens were directly processed, and biopsy specimens were disaggregated with a mortar and then resuspended | The treated specimen sample was transferred to the Xpert MTB/RIF cartridge and the test was run in the GeneXpert instrument | Microscopic examination with AUR and ZN stains | Mycobacterial culture using L-J and MGIT mediums  Positive cultures were confirmed as MTBC by the use of DNA probes |
| Nakiyingi et al. ([2012](#_ENREF_151))  Uganda | Level III-1: A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Some risk of bias  Patient selection ☺  Index test ☺  Comparator: ☺  Reference std ☺  Flow and timing ?  Applicability: C1, P2 | N= 205 patients with AFB –ve sputum samples  Mean age 34.7 ± 10.4 years  176/205 (86%) were HIV+ | Inclusion  TB suspects with cough for ≥ 2 weeks with/without sputum production, who had other signs of TB  Exclusion  AFB-positive patients | Sputum was decontaminated using NALC-NaOH and centrifuged | PCR, targeting IS*6110* | AFB microscopy using ZN staining | Sputum was inoculated into L-J culture bottles and incubated at 37 °C for up to 3 months |
| Nicol et al. ([2011](#_ENREF_158))  South Africa | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=452 children with at least one induced sputum specimen  Median age 19.4 months (IQR 11–46)  108/452 (24%) were HIV+ | Inclusion  Consecutive children, aged 15 years or younger, admitted to hospital with suspected pulmonary TB on the basis of having a cough for more than 14 days plus one more sign suggestive of pulmonary TB  Exclusion  More than 72 hours of TB treatment, could not be followed up, no informed consent, or if an induced sputum specimen could not be obtained | Sputum specimens were processed within 2 hours of collection in an accredited routine diagnostic microbiology laboratory by trained technicians who used standardised NALC-NaOH protocols | The concentrated sample was added to the Xpert MTB/RIF sample reagent in a 1:3 ratio, and 2 mL of this mixture was added to the Xpert MTB/RIF cartridge and run in the machine in accordance with manufacturer’s instructions | A drop of sediment was used for fluorescent AFB microscopy | Automated liquid MGIT culture was done with 0.5 mL of the resuspended pellet  Cultures were incubated for 6 weeks if negative |
| Pahwa et al. ([2005](#_ENREF_163))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☹  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=100 FNAs from 100 patients  55 had PCR results  Age range 2.5 months – 60 years  HIV status not reported | Inclusion  Patients with clinically and cytologically suspected TB lymphadenitis  The clinical symptoms suggestive of TB were fever, anorexia or weight loss, and lymphadenopathy | FNAs from the involved lymph node were divided into seven parts; five were used for AFB stains, one for PCR and one for L-J medium culture | PCR was performed on all specimens, targeting the gene encoding the MPB64 protein | AFB using ZN and fluorescent staining | L-J medium culture FNAs were liquefied and digested using N-acetyl L-cysteine, decontaminated by standard procedure using Petroff’s method, inoculated on to L-J slants and incubated at 37 ºC for 6–8 weeks |
| Park et al. ([2013](#_ENREF_166))  Korea | Level III-1:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ☺  Flow and timing ☺  Applicability: C1, P2 | N=320 respiratory specimens from 311 adult patients  Age and HIV status not reported  254 sputum 66 BAL | Inclusion  Samples were prospectively collected from patients with suspected pulmonary TB between 26 May 2011 and 2 December 2011 at a tertiary care hospital  Exclusion  None stated | The respiratory specimens were processed with NALC-NaOH, followed by centrifugation  For the Xpert assay, 1 mL of a respiratory specimen without decontamination or concentration was used | The specimen sample was transferred to the Xpert MTB/RIF cartridge and the test was run in the GeneXpert instrument | Specimens were examined blindly by fluorescence staining | Specimens were examined by cultures with both solid and liquid media |
| Rachow et al. ([2011](#_ENREF_173))  Tanzania | Level II:  A comparison against independent, blinded reference standard among consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ☺  Flow and timing ☹  Applicability: C1, P2 | N=292 patients with sputum samples (each provided three samples, results were recorded from one—the morning sample)  Mean age 39.2 ± 13.8 years  58.9% were HIV+ | Inclusion  Patients with symptoms suggestive of pulmonary TB  Exclusion  Not able to produce sputum at recruitment, lost to follow-up during recruitment procedures | Sputum samples were split into two aliquots, one of which was stored at –80 ºC; the other was processed for standard AFB microscopy and culture  Sputa were decontaminated using the NALC-NaOH method | Frozen sputa were thawed and processed according to the Xpert MTB/RIF assay test procedure | AFB microscopy with ZN staining | L-J solid and MGIT liquid culture |
| Santos et al. ([2006](#_ENREF_180))  Brazil | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=218 sputum samples  60 non-Indigenous 158 Indigenous  Age and HIV status not reported | Inclusion  Non-Indigenous and Indigenous patients presenting with respiratory symptoms and suspected of pulmonary TB, providing sputum sample  Exclusion  Not reported | 48 samples had to be transported in cetylpyridinium chloride solution and were then homogenised | PCR targeting IS*6110* | AFB microscopy using direct and concentrated techniques  48 samples were stained with bromothymol blue | L-J medium culture (using NaOH as decontaminant) |
| Sharma et al. ([2012](#_ENREF_182))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=80 osteoarticular TB (OATB) specimens  67 synovial fluid 13 pus  Age and HIV status not reported | Inclusion  Specimens received for AFB staining and culture for diagnosis of OATB  Exclusion  None stated | The specimens were concentrated by centrifugation | M-PCR with primers targeting IS*6110* and *MPB64* | AFB microscopy with ZN staining | Culture was on L-J medium |
| Sharma et al. ([2013](#_ENREF_183))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=50 endoscopic ileocaecal biopsies  Age range 19–68 years  HIV status not reported | Inclusion  Endoscopic ileocaecal biopsy received for acid-fast staining and culture were tested from December 2008 to March 2010  Exclusion  None stated | Samples were decontaminated and concentrated using NALC-NaOH method The samples were centrifuged and the sediment was resuspended and prepared for AFB microscopy, culture and M-PCR | M-PCR using primers specific for IS*6110* and *MPB64* | ZN AFB microscopy | Culture was done on two L-J slants using standard procedures and incubated for 6 weeks |
| Shukla et al. ([2011](#_ENREF_184))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=140 clinical samples from patients mostly 21–30 years of age  HIV status not reported  N=86 pulmonary:  74 sputa 12 gastric aspirates  N=54 extrapulmonary:  16 CSF 38 endometrial biopsies | Inclusion  Patients attending outpatient and inpatient departments were selected for this study on the basis of radiological diagnosis and other investigations  Exclusion  None | The sputum was digested and decontaminated using NALC-NaOH method, and concentrated by centrifugation  Biopsy tissues were first ground in a sterile mortar and pestle, then decontaminated CSF was used directly | A two-step nPCR to amplify a 123-bp DNA segment belonging to IS*6110* | Direct microscopic examination using ZN method | L-J slants were inoculated, then incubated at 37 °C for 6–8 weeks |
| Singh et al. ([2006](#_ENREF_185))  India | Level III-1:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ☺  Flow and timing ☺  Applicability: C1, P2 | N=85 bone-marrow aspirates  Age and HIV status not reported | Inclusion  Patients who had fever of unknown origin alone or associated with cervical lymphadenopathy, ascites, bone marrow transplant, as well as those with pyrexia accompanying renal failure or aplastic anaemia were investigated for TB  Exclusion  None | The samples were decontaminated using NALC-NaOH processing | PCR targeting the *MPT64* gene of MTB | AFB smears were prepared using ZN stain | Culture was on duplicate L-J slopes, and growth was monitored for 8 weeks |
| Sohn et al. ([2014](#_ENREF_186))  Canada | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P1 | N=436 sputum samples  Median age of patients 44 years (IQR 31–61)  12/49 (24%) patients tested were HIV+ | Inclusion  Consecutive patients aged > 17 years, referred for evaluation of suspected active pulmonary TB  Exclusion  Not reported | Not reported | The Xpert MTB/RIF was performed at the TB clinic according to the standard protocol for unprocessed samples, per the manufacturer | AFB microscopy with AUR staining | Liquid culture on three processed samples was followed by phenotypic culture-based DST at the provincial reference laboratory |
| Suzuki et al. ([2006](#_ENREF_190))  Japan | Level II:  A comparison against independent, blinded reference standard among consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=138 sputum specimens  Age and HIV status not reported | Inclusion  Patients hospitalised in Minami–Yokohama National Hospital, under suspicion of TB during a designed 2-month period  Exclusion  Not reported | The clinical specimens were treated with Sputerzyme and then decontaminated using the NALC-NaOH method | PCR–ICA DNA amplification with labelled primers targeting d*naJ* and using immune-chromatographic detection of the amplified product by application on a sample pad of the test strip | Specimens were fixed and stained with AUR, and their fluorescence was examined using microscopy  The presence of AFBs was confirmed by ZN staining | Specimens were inoculated into MGIT 960 tubes  Growth of MTB was evaluated on the consumption of oxygen in the medium, as monitored using the MGIT 960 system |
| Teo et al. ([2011](#_ENREF_195))  Singapore | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=162 non-duplicated clinical specimens  Age and HIV status not reported  N=131 respiratory:  124 sputum 5 BAL 2 tracheal aspirate  N=31 non-respiratory:  5 gastric aspirates 3 urine samples 7 CSF 5 body fluids (pleural, pericardial, ascites) 10 miscellaneous such as pus and biopsies | Inclusion  Patients attending outpatient and inpatient departments were selected for this study on the basis of radiological diagnosis and other investigations  Exclusion  None | Specimens of a fluid nature were decontaminated according to standard methods using NALC-NaOH  Tissue specimens were thoroughly minced using a pair of sterile scissors before being used  For normally sterile body fluids, decontamination was not performed  Specimens were then concentrated by centrifugation | The treated specimen sample was transferred to the Xpert MTB/RIF cartridge and the test was run in the GeneXpert instrument | Direct microscopic examination using ZN method | MGIT tubes were inoculated with 0.5 mL of the processed specimen and then incubated in the MGIT 960 instrument at 37 °C  L-J slants were inoculated and then incubated at 37 °C for 6–8 weeks |
| Therese, Jayanthi & Madhavan ([2005](#_ENREF_197))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=280 extrapulmonary clinical samples  Age and HIV status not reported  104 peritoneal fluids 3 pericardial fluid 120 CSF 44 lymph node FNA 9 tissue biopsies | Inclusion  Specimens from patients who were clinically and/or radiologically diagnosed as having TB  Exclusion  None | Aspirated fluid specimens such as ascitic fluid and cerebrospinal fluid were concentrated by centrifugation  Tissue specimens were cut into tiny pieces with sharp scissors and homogenised in a glass tissue grinder and used directly | nPCR using primers targeting for MPB64 protein | AFB smears were stained by ZN method | Cultures were on L-J medium in duplicate |
| Theron et al. ([2013](#_ENREF_198))  South Africa | Level III-2:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=156 patients with BAL samples  Median age 46.1 years (IQR 33.1–55.7)  46/156 (35%) were HIV+ | Inclusion  Patients > 17 years of age with suspected pulmonary TB who were referred for bronchoscopy  Exclusion  Patients on anti-TB treatment, contaminated culture | BAL fluid was split and one aliquot was decontaminated by NALC-NaOH and examined by microscopy and culture; the second aliquot was used for Xpert NAAT | The Xpert MTB/RIF assay was performed on 1 mL of BAL fluid and, when available, a median volume of 10 mL was concentrated and resuspended in 1 mL of sterile phosphate-buffered saline | Fluorescence AFB microscopy | Liquid culture for MTB using the BACTEC MGIT 960 system  Culture-positive isolates underwent routine phenotypic DST for rifampicin and isoniazid using the MGIT 960 SIRE kit |
| Theron et al. ([2012](#_ENREF_199))  South Africa | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=480 patients (each had two sputum samples)  Age and HIV status not reported | Consecutive patients with suspected TB, who provided two sputum samples, and provided informed consent  Exclusion  Not reported | Not reported | 2–3 mL of digested sputum was transferred to the Xpert MTB/RIF cartridge, the lid was closed, and the cartridge was loaded into the GeneXpert instrument, where all subsequent steps occurred automatically | Concentrated fluorescent AFB microscopy | Culture using BACTEC MGIT 960 medium |
| Tortoli et al. ([2012](#_ENREF_205))  Italy | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=1,493 extrapulmonary samples corresponding to 1,068 patients  Age and HIV status not reported  330 pleural fluids 224 gastric aspirates 195 pus 133 CSF 130 urine 94 cavity fluids 368 tissue biopsies | Inclusion  Retrospective results from consecutive extrapulmonary specimens accepted by eight Italian laboratories for the diagnosis of EP0-TB  Exclusion  None | Non-sterile samples were decontaminated using standard NALC-NaOH procedure and concentrated by centrifugation  Sterile samples were mechanically homogenised (if needed) before concentration | The treated specimen sample was transferred to the Xpert MTB/RIF cartridge and test was run in the GeneXpert instrument | AFB microscopy used AUR staining | Culture was in both solid (L-J) and liquid (MGIT) media |
| Vadwai et al. ([2011](#_ENREF_209))  India | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=547 extrapulmonary specimens from 547 patients  Median age 37 years (range 8 months – 94 years)  HIV status not reported  284 biopsy specimens (147 from tissues, 82 from lymph nodes and 55 FNAs) 147 pus 93 body fluids (11 synovial, 3 pericardial, 66 pleural and 13 peritoneal) 23 CSF | Inclusion  Samples from consecutive patients suspected of extrapulmonary TB in a private tertiary care hospital if they could provide detailed clinical history and radiological and histology/cytology reports, and an adequate amount of specimen material  Exclusion  None reported | The sample was divided equally into three parts  One part was processed with NALC-NaOH and centrifuged prior to culture | A 2:1 volume of sample reagent buffer was added to biopsy specimens after they had been chopped into very small pieces with a sterile blade in a sterile petri dish prior to adding to the cartridge  The Xpert MTB/RIF test was run in the GeneXpert instrument | Direct and concentrated AFB microscopy with ZN staining | L-J medium and liquid medium (MGIT) culture-positive results were confirmed for MTB by a p-nitrobenzoic acid assay and subjected to indirect DST with MGIT SIRE |
| Van Rie et al. ([2013b](#_ENREF_213))  South Africa | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=361 HIV+ patients with two lymph node FNA samples  Mean age 35.8 years (range 18–73) | Inclusion  HIV+ patients clinically suspected of having lymph node TB, age > 17 years, not receiving treatment for active or latent TB | The first FNA was smeared on two slides and fixed for cytology and AFB ZN microscopy  The second FNA was smeared on a slide and air-dried for AUR staining | Xpert MTB/RIF  1 mL of the needle washing liquid was mixed with 2 mL of the Xpert sample reagent buffer | AFB microscopy with AUR staining | The remainder of the needle washing saline solution for Xpert was sent for processing and inoculation into a MGIT culture medium |
| Walusimbi et al. ([2013](#_ENREF_215))  Uganda | Level III-1:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator: ☺  Reference std ☺  Flow and timing ☹  Applicability: C1, P2 | N=430 AFB –ve, HIV+ sputum samples  Median age 34 years (IQR 29–40)  369 had valid culture and Xpert results | Inclusion  HIV+ patients with symptoms of TB, giving consent, providing spot and early-morning sputum sample  Exclusion  Patients on TB treatment or unable to produce sputum | The samples were digested and decontaminated using the NALC-NaOH method, and then concentrated by centrifugation | For the Xpert MTB/RIF assay, a sample reagent was added to the processed sample in a 3:1 ratio  The mixture was introduced into a cartridge, which was then loaded into the GeneXpert instrument, where the test was performed automatically When sufficient residual was available, repeat testing was carried out when an ‘invalid’ or ‘error’ result was obtained | Fluorescent microscopy (unprocessed) using standard AUR reagent | Culture using MGIT and L-J medium |
| Zar et al. ([2013](#_ENREF_226))  South Africa | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺  Index test ☺  Comparator ☺  Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=384 children with induced sputum samples  Median age 38.3 months (IQR 21.2–56.5)  31/384 (8%) were HIV+ | Inclusion  Consecutive children < 15 years of age presenting from 1 August 2010 to 30 July 2012 with suspected pulmonary TB  Exclusion  None reported | Samples were decontaminated using standard NALC-NaOH procedure and concentrated by centrifugation | The treated specimen sample was transferred to the Xpert MTB/RIF cartridge and test was run in the GeneXpert instrument | Fluorescent AFB microscopy using AUR | MGIT culture was done using 0.5 mL of resuspended pellet on sputum specimens and incubated for up to 6 weeks |
| Zeka, Tasbakan & Cavusoglu ([2011](#_ENREF_227))  Turkey | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☺  Index test ?  Comparator ☺  Reference std ?  Flow and timing ☹  Applicability: C1, P2 | N=429 specimens from 429 patients  Median age 47.5 ± 22.2 years  HIV status not reported  N=253 pulmonary (sputum, BAL, bronchial aspirate and gastric fluid specimens)  N=176 extrapulmonary (pleural fluid, lymph node biopsy, disc material, ascitic fluid, cerebrospinal fluid, pericardial fluid, skin biopsy and urine specimens) | Inclusion  Samples from patients suspected of TB sent to the Department of Medical Microbiology, Mycobacteriology Laboratory between February 2010 and November 2010  Exclusion  None | Non-sterile clinical specimens were processed using the conventional NALC-NaOH method | The treated specimen sample was transferred to the Xpert MTB/RIF cartridge and the test was run in the GeneXpert instrument | After decontamination, smears were prepared by the AUR acid-fast staining method | Decontaminated specimens were inoculated to L-J solid medium and MB/BacT liquid medium for growth detection  DST was performed on the first positive culture from each specimen using the proportional method with 7H10 agar medium and confirmed by the GenoType MTBDR plus assay |

AUR = auramine-based fluorochrome; BAL = bronchoalveolar lavage; CSF = cerebrospinal fluid; CT = computed tomography; DST = drug susceptibility testing; FGTB = female genital tuberculosis; FNA = fine-needle aspirate; GUTB = genitourinary tract TB; HIV = human immunodeficiency virus; KCS = Kinyoun cold staining; LAMP = loop-mediated isothermal amplification; L-J = Lowenstein-Jensen; MGIT = Mycobacterium Growth Indicator Tubes; M-PCR = multiplex PCR; MTB = *Mycobacterium tuberculosis*; NALC-NaOH = N-acetyl-L-cysteine and sodium hydroxide; nPCR = nested PCR; OATB = osteoarticular TB; PCR = polymerase chain reaction; PCR-ICA = PCR-immunochromatographic assay; qPCR = quantitative (real-time) PCR; RT-PCR = reverse transcription PCR; TB = tuberculosis; USP = universal sample processing; ZN = Ziehl-Neelsen

Table 97 Study profiles of included studies providing linked evidence on the change in management following NAAT on patients suspected of having TB

| **Study setting** | **Study design Quality appraisal** | **Study population** | **Selection criteria** | **Intervention** | **Comparator** | **Outcomes** |
| --- | --- | --- | --- | --- | --- | --- |
| Boehme et al. ([2010](#_ENREF_27))  Foundation for Innovative New Diagnostics, Geneva, Switzerland  Conducted at:  Urban health centres in: Lima (Peru), Baku (Azerbaijan), Cape Town (South Africa), Kampala (Uganda), Vellore (India), Manila (Philippines) | Historical control study  Level: III-3  Quality: 18/26  Some risk of bias | N=6,648 (5,862 suspected of TB, 786 suspected of MDR-TB)  Median age: 38 years (IQR 29–50)  2,605 (39%) females  1,255 (19%) HIV infected  3,509 (53%) HIV status unknown | Inclusion:  Adults aged > 17 years with > 2 weeks of cough, provided at least two sputum samples  Exclusion:  Second sputum sample was collected > 1 week from the first, no (valid) culture conducted, no valid MTB/RIF result, AFB-positive with no positive culture, only one positive culture with 20 or fewer colonies for solid culture or more than 28 days to positivity for liquid culture, a positive culture during follow-up only, only one positive culture with missing speciation result, a positive culture with NTM growth, or discrepant RIF results by conventional drug susceptibility testing in two samples | Xpert MTB/RIF assay  Routine AFB microscopy, and culture | Same tests, but in comparator group Xpert results were not reported to clinicians or used for patient management | Proportion of results reported to the clinics for each method from date of first sputum sample  Time to TB detection (by each method)  Time to treatment |
| Buchelli Ramirez et al. ([2014](#_ENREF_32))  Hospital Universitario Central de Asturias, Oviedo, Spain  Conducted at:  Hospital Universitario Central de Asturias, Oviedo, Spain | Retrospective cohort study  Level: III-3  Quality: 19.5/26  Some risk of bias | N=128 patients  Mean age 52 ± 23 years  43 (33.6%) females | Inclusion  All patients diagnosed with pulmonary TB between January 2010 and July 2012, including cases with bronchial confirmation alone  Exclusion:  Not reported | Xpert MTB/RIF, AFB microscopy and mycobacterial culture | NA | CIM: time to treatment  System-related treatment delay |
| Davis et al. ([2014](#_ENREF_46))  San Francisco General Hospital, University of California, San Francisco, USA  Conducted at:  San Francisco Department of Public Health | Prospective cohort  Level: III-3  Quality: 17/26  Some risk of bias | N=227/538 included, but only 156 were tested by NAAT  Median age: 52 years (IQR 39–60)  54 (35%) females  13 (8%) HIV infected  Two key groups of patients for Xpert NAAT: (1) those initiating empiric treatment for active TB and (2) those coming from congregate settings (e.g. homeless shelters, behavioural treatment programs, dialysis centres) | Inclusion:  Consecutive adults undergoing evaluation for active pulmonary TB at the San Francisco Department of Public Health TB clinic between May 2010 and June 2011  Exclusion:  Patients with incomplete microbiologic or clinical follow-up data, reporting TB treatment at time of Xpert NAAT | Xpert MTB/RIF on sputum specimen, AFB microscopy and culture for MTB | (Empiric treatment decision pending other test results) | Unnecessary treatment rate |
| Fan et al. ([2014](#_ENREF_65))  Tuberculosis center for diagnosis and treatment, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China  Conducted at:  Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China | Prospective cohort  Level: III-3  Quality: 17.5/26  Some risk of bias | N=280/335 included  Mean age: 43 ± 18 years  54 (25%) females | Inclusion:  Patients with abnormal chest radiographic findings compatible with active TB (TB suspects), > 18 years of age, sputum scarce or with negative AFB microscopy  Exclusion:  AFB-positive patients and HIV positive patients | SAT-TB assay (in-house) and culture (liquid medium) | NA | CIM: time to detection of TB |
| Guerra et al. ([2007](#_ENREF_78))  School of Medicine, Johns Hopkins University, Baltimore, MD, USA  Conducted at:  Baltimore City Health Department, USA | Historical control study  Level: III-3  Quality: 14.5/26  High risk of bias | N=107 (50 in NAAT group and 57 in non-NAAT group)  Median age NAAT: 46.5 years, non-NAAT: 47 years  20 (40%) females in NAAT group, 11 (19.3%) females in non-NAAT group  18 (36%) HIV infected in NAAT group (10 unknown), 19 (33.3%) HIV infected in non-NAAT group (10 unknown) | Inclusion:  AFB-positive pulmonary TB suspects undergoing initial diagnostic evaluation between December 2000 and March 2006  Exclusion:  Anti-TB therapy for > 6 days prior to sputum collection | Amplified MTD Direct Test, AFB microscopy and culture for MTB | AFB microscopy and culture | Unnecessary TB treatment time  Concordance between MTB results and definitive diagnosis, compared with no MTB results |
| Hanrahan et al. ([2013](#_ENREF_82))  University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA  Conducted at:  Primary care clinic in Johannesburg, South Africa | Prospective cohort study  Level: III-3  Quality: 16.5/26  Some risk of bias | N=641 (50 NAAT-positive, 591 NAAT-negative)  Median age: 35 years (IQR 29–44)  415 (65%) females  443 (69%) HIV infected  36 (6%) unknown | Inclusion: TB suspects presenting at the clinic, providing consent  Exclusion:  Not reported | Xpert MTB/RIF assay, sputum AFB FL microscopy and liquid culture for MTB | NA | Number of cases starting TB treatment  Median time to TB treatment |
| Kwak et al. ([2013](#_ENREF_109))  Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea  Conducted at:  Seoul National University Hospital | Retrospective cohort  Level: III-3  Quality: 16.5/26  Some risk of bias | N=681 patients requested for NAAT  Median age: 61 years (IQR 47.5–73.0)  255 (37.4%) females  5 (0.7%) HIV infected | Inclusion:  Patients in whom NAAT was requested due to suspicion of pulmonary TB between 1 January 2011 and 31 May 2013  Exclusion:  Not reported | Xpert MTB/RIF assay, mycobacterial culture (liquid and/or solid) and AFB microscopy | NA | Time to report of results from laboratory  Time to confirmation of results by physician  Time to treatment |
| Lacroix et al. ([2008](#_ENREF_111))  University of Sherbrooke, Sherbrooke, Quebec, Canada  Conducted at:  Public Health Department in Montegrie (Quebec) | Retrospective cohort  Level: III-3  Quality: 12/26  High risk of bias | N=115/134 included (77 NAAT, 38 no NAAT)  43 (37.4%) females  7 (9.9%) HIV infected | Inclusion:  Contagious (pulmonary, laryngeal, miliary) active TB cases declared to the Public Health Department between 1 January 1998 and 30 June 2007  Exclusion:  Non-respiratory TB, clinical case not confirmed by culture or PCR, incomplete file, previous episode of TB, incidentally found cases | PCR (in-house, not specified) | No PCR (culture, AFB microscopy, chest X-ray) | Average delay in diagnosis |
| Lippincot et al. ([2014](#_ENREF_121))  Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, USA  Conducted at:  University of North Carolina Hospital | Prospective cohort  Level: III-3  Quality: 18/26  Some risk of bias | N=207/246 included  Median age: 51 years (IQR 39–63),  74 (35.8%) females  49 (23.7%) HIV infected  31 (15%) unknown | Inclusion:  Consecutive inpatient adults with presumptive TB, for whom at least one sputum specimen was submitted  Exclusion:  Patients with cystic fibrosis | Xpert MTB/RIF assay, AFB microscopy and culture | NA | Median laboratory processing time |
| Marks et al. ([2013](#_ENREF_129))  US Centers for Disease Control and Prevention, Atlanta, Georgia, USA  Conducted at:  Metropolitan Atlanta, Georgia, four areas of Maryland and Massachusetts | Retrospective cohort  Level: III-2  Quality: 16.5/26  Some risk of bias | N=2,140 (920 NAAT)  880 (41%) females  353 (25%) HIV infected | Inclusion:  Suspected pulmonary TB in 2008–10  Exclusion:  Patients lacking AFB microscopy/culture results | NAAT (MTD, Gen-Probe, San Diego, California), AFB microscopy and culture | (No NAAT)  AFB microscopy and/or culture | Change in management after negative NAAT  Change in management after positive NAAT  Average outpatient days on TB medication (vs no NAAT)  Differences in procedures  Days to final TB determination |
| Omrani et al. ([2014](#_ENREF_162))  Prince Sultan Military Medical City, Riyadh, Saudi Arabia | Retrospective cohort  Level: III-3  Quality: 17/26  Some risk of bias | N=140 (76 NAAT, 64 no NAAT)  Median age: 44.5 years (range 13–97)  61 (44%) females  0 HIV infected  44 (38.6%) pulmonary TB, 86 (61.4%) extrapulmonary TB | Inclusion:  Patients who were commenced on anti-TB therapy for a diagnosis of active TB between 1 March 2011 and 28 February 2013  Exclusion:  Not reported | Xpert MTB/RIF assay, with/without AFB microscopy and/or culture | Mycobacterial culture and/or AFB microscopy | Impact on time to start anti-TB treatment  Rate of discontinuing treatment after negative NAAT |
| Sohn et al. ([2014](#_ENREF_186))  McGill International TB Centre and McGill University, Montreal, Canada | Prospective cohort  Level: III-3  Quality: 16.5/26  Some risk of bias | N=502  Median age: 44 years (IQR 31–61 years)  223 (44.4%) females  12 (2.4%) HIV infected | Inclusion:  Patients aged > 17 years for evaluation of suspected active pulmonary TB  Exclusion:  Not reported | Xpert MTB/RIF assay | AFB microscopy and/or culture | Time to test result  Time to treatment initiation  Impact on treatment given |
| Taegtmeyer et al. ([2008](#_ENREF_191))  Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, UK | Retrospective cohort study  Level: III-3  Quality: 14.5/26  High risk of bias | N=87 patients were indicated for NAAT (AFB +ve)  51 received NAAT, 36 no NAAT | Inclusion: Patients with AFB-positive clinical samples submitted between January 2002 and December 2006  Exclusion:  Not reported | NAAT using the INNO-LiPA Rif.TB assay (Immunogenetics, Zwijndrecht, Belgium) | AFB microscopy and/or mycobacterial culture | Time to identification of TB and rifampicin resistance  Change in treatment |
| Theron et al. ([2014](#_ENREF_200))  University of Cape Town, South Africa  Conducted at:  Five primary healthcare facilities in areas of southern Africa with a high HIV prevalence | Randomised controlled trial (multicentre)  Level: II  Quality: 23/26  Low risk of bias | N=1,502  Median age: 37 years (IQR 30–46)  643 (43%) females  895 (60%) HIV infected  758 assigned to AFB microscopy  744 assigned to Xpert MTB/RIF | Inclusion:  > 17 years of age, one or more symptoms of pulmonary TB (according to WHO criteria), able to provide sputum specimens, no anti-TB treatment in the past 60 days  Exclusion:  Not reported | Xpert MTB/RIF assay on sputum specimen by nurse who received a 1-day training session | AFB microscopy on sputum specimen Positive if any smear revealed AFB over 100 fields (1000x for light microscopy and 400x for fluorescence microscopy) | Treatment initiation at baseline  Treatment initiation as a result of clinical evidence  % of TB patients not initiating treatment  Time to treatment initiation |
| Van Rie et al. ([2013a](#_ENREF_212))  Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA  Conducted at:  Witkoppen Health and Welfare Centre, Johannesburg, South Africa | Prospective cohort study  Level: III-3  Quality: 13.5/26  High risk of bias | N=160/180 had valid results  Median age: 36 years (IQR 30–44 years)  113 (57%) females  144 (72%) HIV infected | Inclusion:  TB suspects who were AFB-negative and returned for their result  Exclusion:  Not reported | Xpert MTB/RIF assay  Patients also underwent fluorescent AFB microscopy and liquid culture | - | Time to treatment initiation |
| Van Rie et al. ([2013b](#_ENREF_213))  Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA  Conducted at:  Helen Joseph Hospital, Johannesburg, South Africa | Prospective cohort study  Level: III-3  Quality: 19.5/26  Some risk of bias | N=344 patients, with 162 positive Xpert FNAs  Age: 53% were < 36 years  164 (49%) females  100% were HIV infected | Inclusion  HIV-infected, clinically suspected of lymph node TB, aged > 17 years, not receiving treatment for active or latent TB | Xpert MTB/RIF  Patients also underwent AFB microscopy (ZN and FL staining) and mycobacterial culture (MGIT medium) | NA | CIM: median time of FNA collection and diagnosis  Time to treatment initiation |
| Yoon et al. ([2012](#_ENREF_225))  Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of San Francisco, San Francisco, California, USA  Conducted at:  Mulago Hospital, Kampala, Uganda | Historical cohort study  Level: III-3  Quality: 18.5/26  Some risk of bias | N=477/525 patients  Median age: 33 years (IQR 27–40)  229 (48%) female  362 (76%) HIV infected | Inclusion:  Consecutive adults > 17 years of age admitted to hospital with cough for >2 weeks but < 6 months duration, and provided consent  Exclusion:  Receiving TB treatment at the time of enrolment, no available culture results, no NAAT on implementation phase, death within 3 days of hospital admission | Xpert MTB/RIF assay, sputum AFB microscopy and mycobacterial culture | Same tests, but in comparator group Xpert results were not reported to clinicians or used for patient management | Time to TB detection  Time to TB treatment |

CIM = change in management; FL = fluorescent; FNA = fine-needle aspirate; HIV = human immunodeficiency virus; IQR = interquartile range; MDR = multidrug-resistant; NAAT = nucleic acid amplification test; NTM = non-tuberculous mycobacteria; RIF = rifampicin; TB = tuberculosis; WHO = World Health Organization; ZN = Ziehl-Neelsen

Table 98 Study profiles of included studies on the effectiveness of change in management due to early treatment of TB in those with low pre-test probability of having active TB

| **Study setting** | **Study design Quality appraisal** | **Study population** | **Selection criteria** | **Intervention** | **Comparator** | **Outcomes** |
| --- | --- | --- | --- | --- | --- | --- |
| Ponticiello et al. ([2001](#_ENREF_169))  Monaldi Hospital, Naples, Italy  TB referral center for Campania | Prospective cohort study  Level: III-2  Quality: 16/26  High risk of bias | N=90 cases of TB  100% Caucasian  48 (53%) had cavity type lesion on chest X-ray  Average delay in diagnosis 2.25 ± 1.0 months  3 (2.7%) TST-negative  Contacts:  N=277 (out of 346 identified contacts)  44 did not comply with protocol  25 refused consent | Inclusion  All patients with newly diagnosed pulmonary TB during the period January 1997 – December 1998 and their contacts (those sharing the same indoor environment for prolonged periods)  AFB in sputum or bronchial smear and positive culture for MTB  Exclusion  Patients with HIV and their contacts  No written informed consent  Failure to comply with study protocol | Delay to diagnosis ≤ 1 month  Delay defined as period from onset of any TB symptoms to diagnosis | Delay in diagnosis:  1.5 months  2.0 months  (also examines up to 5 months) | Proportion of contacts TST-positive  Proportion of contacts TST-negative  Odds TST+/TST–  OR (TST+/TST–) Various lengths of delay compared with reference ≤ 1 month delay  Analysis of clinical risk factors  ORs and their 95%CIs were calculated by means of univariate and multivariate logistic regression |
| Golub et al. ([2006](#_ENREF_76))  Maryland, USA | Prospective cohort study  Level: III-2  Quality: 16/26  High risk of bias | N=124 total patients with pulmonary TB included  34 excluded due to no contacts identified/tested  N=54 (44%) born in USA  US patients:  65% male  72% black  59% < 50 years of age  57% AFB sputum-positive  19% chest X-ray with cavitation  385 contacts, of whom 310 (81%) skin tested | Inclusion  All verified pulmonary TB patients who reported to the Maryland Department of Health and Mental Hygiene between 1 June 2000 and 30 November 2001 and their close contacts  Close contacts included those living in the same household, working in a closed environment with patient, and reported close friends and relatives  Exclusion  No contacts identified or no contacts tested | Treatment delay either:  ≤ 60 days or  ≤ 90 days  Delay treated as a dichotomous variable, analysed for cut-offs of 60 and 90 days  Total treatment delay defined as interval from first TB symptoms to initiation of treatment for TB | Treatment delay > 60 days  Treatment delay > 90 days | Number of contacts infected TST-positive (tested at baseline and 10–12 weeks later) |
| Van der Oest, Kelly & Hood ([2004](#_ENREF_210))  Waikato Health District, New Zealand | Retrospective cohort study  Level: III-2  Quality: 11/26  High risk of bias | N=244 (189 new cases, 37 relapse cases, 18 unclassified):  52% male  110 (45%) Maori  46 (19%) non-Indigenous New Zealanders  81 (33%) born overseas, 40 of whom were refugees  number with length of diagnostic delay reported 152 (62% of cases)  outcome of treatment reported for 214 (88%) of cases | Inclusion  All notified cases of TB who were residing in the Waikato Health District at the time of notification from 1 January 1992 to 31 December 2001 | No diagnostic delay  Delay defined as time between development of symptoms and notification/diagnosis of the case | Increasing diagnostic delay | Favourable treatment outcome as defined by WHO (i.e. cure or treatment completed)  Statistical analysis  Logistic regression was used for multivariate and univariate comparisons  Chi-square test |

AFB = acid-fast bacilli; HIV = human immunodeficiency virus; OR = odds ratio; TB = tuberculosis; TST = tuberculin skin test; WHO = World Health Organization

Table 99 Study profiles of included studies on the effectiveness of change in management due to rifampicin-resistance mutations being identified

| **Study setting** | **Study design**  **Quality appraisal** | **Study population** | **Selection criteria** | **Intervention** | **Comparator** | **Outcomes** |
| --- | --- | --- | --- | --- | --- | --- |
| Drobniewski et al. ([2002](#_ENREF_58))  UK | Cohort study  Level: III-2  Quality: 19/26  Some risk of bias | N=90 MDR-TB patients  36 born in UK, 7 in Pakistan, 5 in India, 4 in Bangladesh, 20 in Africa, 4 in Europe, 1 each from USA, Australia, Philippines, Japan, Trinidad, Jamaica  All cases were resistant to at least isoniazid and RIF, and 29 and 33 cases were resistant to pyrazinamide and ethambutol, respectively | Inclusion  All mycobacterial cultures identified by the Public Health Laboratory Service, Mycobacterium Reference Unit, Scottish Mycobacteria Reference Laboratory, and PHLS Regional Centres for Mycobacteria | Treatment with at least three drugs to which the bacterium was susceptible | Treatment with fewer drugs to which the bacterium was susceptible | Median survival period  Chance of death |
| Lam et al. ([2014](#_ENREF_112))  Thailand | Retrospective chart review  Level: III-2  Quality: 18.5/26  Some risk of bias | N=190 RIF-resistant or MDR-TB patients | Inclusion  Patients with DST results demonstrating infection with RIF-resistant or MDR-TB who were registered for TB treatment during October 2004 – September 2008 at health facilities within the Thailand TBAactive Surveillance Network  Exclusion  Patients from health facilities operated by private practitioners, non-governmental organisations, or facilities serving solely as referral centres, patients with incomplete laboratory data and patients with NTM infection or a change in diagnosis | Treatment other than Category II | Category II treatment (streptomycin, isoniazid, ethambutol, RIF and pyrazinamide) | Odds for poor outcome (treatment fail, death) |
| Meyssonnier et al. ([2014](#_ENREF_138))  France | Retrospective cohort study  Level: III-2  Quality: 18/26  Some risk of bias | N=39 RIF-mono-resistant TB patients, data about treatment and outcome were available for 30 patients  19 males (49%), median age 43 years (IQR 29–58)  Foreign born 18 (46%) | Inclusion  All patients diagnosed with RIF-mono-resistant TB reported to the national network in France between 2005 and 2010 | Treatment with antibiotics other than RIF | Treatment with RIF-containing antibiotic regimen | Health outcomes (recovery, lost to follow-up, death, relapse) |

IQR = interquartile range; MDR = multidrug-resistant; NTM = non-tuberculous mycobacteria; RIF = rifampicin; TB = tuberculosis; DST = drug susceptibility testing

Table 100 Study profiles of SRs assessing the safety and adverse effects of active TB therapies

| **Author**  **Country** | **Study design**  **Quality appraisal** | **Research question**  **Included studies (N)** | **Population** | **Intervention** | **Comparator** | **Outcomes** |
| --- | --- | --- | --- | --- | --- | --- |
| Forget and Menzies ([2006](#_ENREF_66))  Canada | Systematic review (literature search of Medline, relevant articles from authors’ files and pearled references from cited articles)  Quality appraisal: poor  High risk of bias | Research question:  NS  Included studies:  NS | Active TB patients  Latent TB patients  TB patients on multidrug regimens | Isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin  Multidrug regimens | Various | Discontinuation rate  AE rate  Mortality rate  Risk factors for development of AEs |
| Frydenberg & Graham ([2009](#_ENREF_69))  Australia | Systematic review (literature search of PubMed, EMBASE and Cochrane Library Reference, hand-search of reference lists)  Quality appraisal: medium  Some risk of bias | Research question:  To review the frequency and manifestations of toxicities in children to current first-line anti-TB therapy  Included studies:  NS | Children (0–18 years of age) undergoing first-line therapy for TB, or therapy for latent TB | Anti-TB agents, isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin  Combination therapies | NS | Adverse reaction incidence  AE rate |
| van der Werf et al. ([2012](#_ENREF_211))  The Netherlands | Systematic review and meta-analysis (methodology according to the Cochrane Handbook for Systematic Reviews and PRISMA)  Quality appraisal: good  Low risk of bias | Research question:  To assess the risk of development of MDR-TB after the use of inappropriate TB regimens  Included studies:  4 (2 studies included in meta-analysis) | Non-MDR patients receiving treatment for TB and who underwent drug-resistance measurement and genotype of the isolated MTB bacilli before treatment started, and drug resistance and genotype in failure and/or recurrent TB cases | Inappropriate treatment regimens for diagnosed non-MDR-TB | Appropriate treatment regimens for non-MDR-TB | MDR-TB |

AE = adverse events; MDR = multidrug-resistant; NS = not stated; TB = tuberculosis

Table 101 Study profiles of included studies on the effectiveness of NAAT in diagnosing NTM infections

| **Study setting** | **Study design Quality appraisal** | **Study population** | **Selection criteria** | **Intervention** | **Comparator** | **Reference standard** |
| --- | --- | --- | --- | --- | --- | --- |
| Abdalla et al. ([2009](#_ENREF_2))  Brazil | Level II:  A comparison against independent, blinded reference standard among consecutive patients  Quality: High risk of bias  Patient selection ☹ Index test ☹  Comparator ? Reference std ☺  Flow and timing ☹  Applicability: C1, P2 | N=34 FFPE skin biopsy specimens from 32 consecutive patients suspected of cutaneous TB or atypical mycobacterial infection  Aged 14–79 years  14/32 male | Inclusion  All consecutive patients suspected of cutaneous TB or atypical mycobacterial infection who attended the Dermatologic Clinic of the University of São Paulo Medical School Hospital during the period January 2001 – January 2004 | PCR using an assay based on oligonucleotide primers specific for the 65-kDa antigen gene of mycobacteria on DNA extracted from FFPE tissue to detect NTM | Results of AFB microscopy were obtained from patient records | Results of L-J culture were obtained from patient records  Also used a clinical reference standard defined as successful treatment for NTM |
| Bogner et al. ([1997](#_ENREF_28))  Germany  Multicentre study of AIDS treatment centres | Level III-1:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: Low risk of bias  Patient selection ☺ Index test ☺  Reference std ? Comparator ☹  Flow and timing ☺  Applicability: C1, P1 | N=540 blood specimens from 107 AIDS patient suspected of having MAC infection, recruited between May 1994 and May 1995, followed up for average of 17.2 ± 11 weeks  Mean age 40.3 ± 9.2 years  Majority male | Inclusion  HIV infection, age > 18 years, either symptoms suggestive of MAC disease without other explanation, or MAC positivity in one specimen but no symptoms  Exclusion  Patients with MTB or MAC disease in past, use of anti-TB drugs in previous 8 weeks, life expectancy of < 4 weeks and low Karnofsky index of < 50% | PCR (using not-commercially available PCR test kids by Roche) of blood samples to detect *Mycobacterium avium* | Not done | Culture of specimens grown in BACTEC 12B vials and on L-J media |
| Choi et al. ([2012](#_ENREF_41))  Korea | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☹ Index test ☺  Comparator ? Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=531 respiratory specimens from 230 patients with suspected mycobacterial infection  482 sputum  49 BAL | Inclusion  People with suspected MTB as well as other mycobacteria in July and August 2011 | Respiratory specimens tested with qPCT-based assay (PNAqPCR TB/NTM kit) targeting the 16S-23S rRNA internal transcribed spacer region to detect NTM | AFB microscopy with AUR stain | Respiratory specimens cultured in BACTEC MGIT 960 for 6 weeks at 36 ºC |
| Frevel et al. ([1999](#_ENREF_68))  Germany | Level III-1:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: High risk of bias  Patient selection ☹ Index test ☹  Comparator ☹ Reference std ☺  Flow and timing ☹  Applicability: C1, P1 | N=69 FFPE pulmonary and extrapulmonary samples from patients who were suspected of mycobacterial infections | Inclusion  229 FFPE samples from 141 patients who, either for clinical (51%) or histological (49%) reasons, were suspected of MTB or NTM infections initially included in study | Pulmonary and extrapulmonary specimens tested with PCR, targeting gene for 65-kDa heat shock protein to detect NTM | AFB microscopy using ZN staining was done routinely but results not reported | The microbiological results were obtained from patient records |
| Gamboa et al. ([1997](#_ENREF_70))  Spain | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☹ Index test ?  Comparator ☺ Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=136 blood specimens from AIDS patients suspected of having disseminated mycobacterial infection Median age 31 years (range 2–55) 80% male | Inclusion  Blood specimens and BM aspirates from AIDS patients who were suspected of having disseminated mycobacterial infections and were not receiving anti-TB therapy, and attended April–December 1996 | Blood and BM specimens tested using the Roche Amplicor MAI PCR-based test to detect *Mycobacterium avium* and *M. intracellulare* | AFB microscopy using AUR and positive slides confirmed with ZN staining | BACTEC 13A cultures were incubated at 37 °C for 8 weeks, and examined for growth with the BACTEC 460 radiometer twice weekly for the first 2 weeks and once weekly thereafter |
| Gazzola et al. ([2008](#_ENREF_72))  Italy | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☹ Index test ?  Comparator ? Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=71 blood samples from 65 AIDS patients suspected of having disseminated mycobacterial infection  N=46 BM specimens from 41 AIDS patients | Inclusion  Between March 1999 and April 2004 all episodes of suspected disseminated mycobacterial infections in AIDS patients | Blood and BM specimens tested with PCR to detect *Mycobacterium avium* (no details provided) | AFB microscopy using ZN staining for BM specimens only | Culture of blood and BM specimens (radiometric BACTEC AFB system)  CRS was clinical diagnosis based on suggestive signs and symptoms plus histopathologic results and response to anti-MAC therapy |
| Kox et al. ([1997](#_ENREF_106))  The Netherlands | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☹ Index test ☺  Comparator ? Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=259 samples from 177 patients:  31 sputum specimens 87 biopsy specimens 37 lymph node biopsies 7 faeces specimens 6 urine specimens 10 blood samples 36 CSF specimens 6 ascitic fluid 15 pleural fluid 3 pericardial fluid 20 BAL 1 gastric lavage | Inclusion  Patients for whom difficulties with diagnosis were experienced or could be anticipated (e.g. with granulomatous disease, suspected extrapulmonary TB), immunocompromised patients (i.e. HIV-positive or with AIDS), immigrants and refugees from countries with high incidence of TB, and patients in whom mycobacterial infection other than by MTB was suspected | The PCR assays were performed at the Royal Tropical Institute, targeting the 16S DNA sequence to detect NTM, and results were reported to the clinicians within 3 days | AFB microscopy done according to standard methods at laboratories of hospitals to which patients were referred | Culture done according to standard methods at laboratories of hospitals to which patients were referred  CRS defined as clinical assessment after resolution of discrepancies |
| Mahaisavariya et al. ([2005](#_ENREF_124))  Thailand | Level III-1:  A comparison against independent, blinded reference standard among non-consecutive patients  Quality: High risk of bias  Patient selection ☹ Index test ☹  Comparator ? Reference std ☺  Flow and timing ☹  Applicability: C1, P2 | N=131 FFPE tissues from 111 patients  Only 120 specimens were cultured at time of processing  Mean age 34.6 years (range 2–73)  58 males | Inclusion  Patients with suspected mycobacterial infections (e.g. asymptomatic and slowly progressive skin lesions or cervical lymphadenitis with draining sinus) who attended the Granuloma Clinic, Siriraj Hospital, Mahidol University, Bangkok, between 1994 and 2000  Exclusion  Cases with leprosy and deep fungal infection | DNA extracted from FFPE specimens  One-tube nested and multiplex PCR using 16S rRNA sequence as the target to detect NTM | Histopathologic sections were reviewed blindly for AFB detection by two independent observers | Culture results were retrieved from the patient records |
| Matsumoto et al. ([1998](#_ENREF_133))  Japan | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺ Index test ☺  Comparator ☺ Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=141 bronchial wash specimens from 127 patients  All were HIV– | Inclusion  Retrospective analysis of bronchial washing specimens collected from patients suspected of mycobacteriosis, peripheral lung cancer or other miscellaneous pulmonary diseases from August 1995 to March 1997  Exclusion  Patients with a final diagnosis of TB | PCR using Amplicor PCR assay to detect *Mycobacterium avium* | AFB microscopy using ZN staining | Culture on Ogawa egg medium for up to 8 weeks |
| Ninet et al. ([1997](#_ENREF_159))  Switzerland | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: High risk of bias  Patient selection ☹ Index test ☺  Comparator ☹ Reference std ?  Flow and timing ☹  Applicability: C1, P1 | N=201 blood samples from HIV-infected patients | Inclusion  Retrospective study conducted in the Division of Infectious Disease, Hospital Cantonal Universitaire, Geneva, using blood samples from HIV-infected patients collected over a 2-year period | DNA isolated from blood was stored frozen prior to use in PCR with Amplicor MAI (Roche)  Tested for *Mycobacterium avium, M. intracellulare* and MTB | Not done | Culture of whole blood in BACTEC 13A medium |
| Phillips et al. ([2005](#_ENREF_168))  Ghana | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Low risk of bias  Patient selection ☺ Index test ☺  Comparator ☺ Reference std ?  Flow and timing ☺  Applicability: C1, P2 | N=70 biopsy specimens from 70 patients | Inclusion  Punch biopsy specimens were obtained from subjects with a strong clinical suspicion of *Mycobacterium ulcerans* disease (Buruli ulcer) prior to treatment of the lesion by excision, who presented at St Martin’s Hospital, Agroyesum, Nkawie Hospital and Tepa Hospital between September 2003 and June 2004 | PCR to detect *M. ulcerans* targeting IS*2404* | AFB microscopy using ZN staining | L-J slopes were incubated at 31 °C, and the cultures were examined weekly until visible growth occurred  CRS was defined as histological diagnosis, or a positive culture for *M. Ulcerans* |
| Tran et al. ([2014](#_ENREF_207))  USA | Level III-2:  A comparison with reference standard (not blinded or blinding not known)  Quality: Some risk of bias  Patient selection ☹ Index test ?  Comparator ☺ Reference std ?  Flow and timing ☺  Applicability: C1, P1 | N=464 respiratory specimens (sputum and bronchial washes) | Inclusion  Specimens received in the Mycobacteriology Laboratory at the Wadsworth Center, New York State, between 1 May 2012 and 1 February 2013 including MTB culture-positive specimens | MTBC-MAC multiplex qPCR using 1 forward primer, 5 reverse primers and 2 probes designed to detect the 16S-23S rRNA internal transcribed spacer region of all MAC strains | AFB microscopy using ZN staining | Specimens were cultured using the BACTEC MGIT 960 system |

AIDS = acquired immunodeficiency syndrome; AUR = auramine-based fluorochrome; BAL = bronchoalveolar lavage; BM = bone marrow; CRS = clinical reference standard; CSF = cerebrospinal fluid; FFPE = formalin fixed, paraffin embedded; L-J = Lowenstein-Jensen; MAC = *Mycobacterium avium* complex; MGIT= Mycobacterium Growth Indicator Tubes; MTB = *Mycobacterium tuberculosis*; NALC-NaOH = N-acetyl-L-cysteine-sodium hydroxide; qPCR = real-time PCR; PCR = polymerase chain reaction; ZN = Ziehl-Neelsen

# Appendix G Excluded studies

Studies published from 2005 onwards that met the PICO criteria to assess the diagnostic accuracy of AFB microscopy and NAAT compared with culture, but were excluded for the reasons listed below.

**No 2x2 data**

Abdelwahab, AE 2009, 'Immunological and molecular diagnosis of *Mycobacterium tuberculosis* between two environmentally different regions', *Current Research in Tuberculosis*, vol. 1, no. 1, pp. 7–14.

Abebe, G, Deribew, A, Apers, L, Abdissa, A, Kiflie, Y, Koole, O & Colebunders, R 2013, 'Evaluation of the 2007 WHO guideline to diagnose smear negative tuberculosis in an urban hospital in Ethiopia', *BMC Infectious Diseases*, vol. 13, no. 1.

Aggarwal, M, Aggarwal, KC & Nair, D 2012, 'Have we made any headway in the diagnosis of neurotuberculosis? Place of real time PCR or real time PCR', *Journal of Pediatric Infectious Diseases*, vol. 7, no. 4, pp. 139–143.

Alli, OAT, Ogbolu, OD & Alaka, OO 2011, 'Direct molecular detection of *Mycobacterium tuberculosis* complex from clinical samples: an adjunct to cultural method of laboratory diagnosis of tuberculosis', *North American Journal of Medical Sciences*, vol. 3, no. 6, pp. 281–288.

Alvarez-Uria, G, Azcona, JM, Midde, M, Naik, PK, Reddy, S & Reddy, R 2012, 'Rapid diagnosis of pulmonary and extrapulmonary tuberculosis in HIV-infected patients: comparison of LED fluorescent microscopy and the GeneXpert MTB/RIF assay in a district hospital in India', *Tuberculosis Research and Treatment*, doi: 10.1155/2012 /932862.

Amin, I, Idrees, M, Awan, Z, Shahid, M, Afzal, S & Hussain, A 2011, 'PCR could be a method of choice for identification of both pulmonary and extra-pulmonary tuberculosis', *BMC Research Notes*, vol. 4, p. 332.

Amini, M, Attaran, D, Ghazvini, K, Esmaily, H & Bagheri, M 2009, 'Tissue PCR diagnosis of patients suspicious for tuberculous pleurisy', *Iranian Journal of Basic Medical Sciences*, vol. 12, no. 2, pp. 121–125.

Anderson, ST, Kaforou, M, Brent, AJ, Wright, VJ, Banwell, CM, Chagaluka, G, Crampin, AC, Dockrell, HM, French, N, Hamilton, MS, Hibberd, ML, Kern, F, Langford, PR, Ling, L, Mlotha, R, Ottenhoff, THM, Pienaar, S, Pillay, V, Scott, JAG, Twahir, H, Wilkinson, RJ, Coin, LJ, Heyderman, RS, Levin, M & Eley, B 2014, 'Diagnosis of childhood tuberculosis and host RNA expression in Africa', *New England Journal of Medicine*, vol. 370, no. 18, pp. 1712–1723.

Anie, Y, Sumi, S, Varghese, P, Madhavi, LGK, Sathish, M & Radhakrishnan, VV 2007, 'Diagnostic approaches in patients with tuberculous pleural effusion', *Diagnostic Microbiology and Infectious Disease,* vol. 59, no. 4, pp. 389–394.

Bandyopadhyay, D, Gupta, S, Banerjee, S, Gupta, S, Ray, D, Bhattacharya, S & Bhattacharya, B 2008, 'Adenosine deaminase estimation and multiplex polymerase chain reaction in diagnosis of extra-pulmonary tuberculosis', *International Journal of Tuberculosis and Lung Disease*, vol. 12, no. 10, pp. 1203–1208.

Baxi, A, Neema, H, Kaushal, M, Sahu, P & Baxi, D 2011, 'Genital tuberculosis in infertile women: assessment of endometrial TB PCR results with laparoscopic and hysteroscopic features', *Journal of Obstetrics and Gynecology of India*, vol. 61, no. 3, pp. 301–306.

Bhanothu, V, Theophilus, JP, Reddy, PK & Rozati, R 2014, 'Occurrence of female genital tuberculosis among infertile women: a study from a tertiary maternal health care research centre in South India', *European Journal of Clinical Microbiology & Infectious Diseases*.

Boehme, CC, Nabeta, P, Henostroza, G, Raqib, R, Rahim, Z, Gerhardt, M, Sanga, E, Hoelscher, M, Notomi, T, Hase, T & Perkins, MD 2007, 'Operational feasibility of using loop-mediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries', *Journal of Clinical Microbiology*, vol. 45, no. 6, pp. 1936–1940.

Bonnave, PE, Raoult, D & Drancourt, M 2013, 'Gastric aspiration is not necessary for the diagnosis of pulmonary tuberculosis', *European Journal of Clinical Microbiology and Infectious Diseases*, vol. 32, no. 4, pp. 569–571.

Boonsarngsuk, V, Suwannaphong, S & Laohavich, C 2012, 'Combination of adenosine deaminase activity and polymerase chain reaction in bronchoalveolar lavage fluid in the diagnosis of smear-negative active pulmonary tuberculosis'*, International Journal of Infectious Diseases*, vol. 16, no. 9, pp. e663–e668.

Chang, HJ, Huang, MY, Yeh, CS, Chen, CC, Yang, MJ, Sun, CS, Lee, CK & Lin, SR 2010, 'Rapid diagnosis of tuberculosis directly from clinical specimens using a gene chip', *Clinical Microbiology and Infection*, vol. 16, no. 8, pp. 1090–1096.

Chowdhury, IH, Sen, A, Bahar, B, Hazra, A, Chakraborty, U, Choudhuri, S, Goswami, A, Pal, NK & Bhattacharya, B 2012, 'A molecular approach to identification and profiling of first-line drug-resistant mycobacteria from sputum of pulmonary tuberculosis patients', *Journal of Clinical Microbiology*, vol. 50, no. 6, pp. 2082–2084.

Darban-Sarokhalil, D, Imani Fooladi, AA, Maleknejad, P, Bameri, Z, Aflaki, M, Nomanpour, B, Yaslianifard, S, Modarresi, MH & Feizabadi, MM 2013, 'Comparison of smear microscopy, culture, and real-time PCR for quantitative detection of *Mycobacterium tuberculosis* in clinical respiratory specimens', *Scandinavian Journal of Infectious Diseases*, vol. 45, no. 4, pp. 250–255.

da Silva, RM, Machado, T & Bazzo, ML 2012, 'Diagnosis of the pulmonary tuberculosis by polymerase chain reaction: a comparative study between HIV-positive and -negative individuals', *Brazilian Journal of Microbiology*, vol. 43, no. 1, pp. 261–265.

Dhasmana, DJ, Ross, C, Bradley, CJ, Connell, DW, George, PM, Singanayagam, A, Jepson, A, Craig, C, Wright, C, Molyneaux, PL, Wickremasinghe, M, Lalvani, A, Cooke, GS & Kon, OM 2014, 'Performance of Xpert MTB/RIF in the diagnosis of tuberculous mediastinal lymphadenopathy by endobronchial ultrasound', *Annals of the American Thoracic Society*, vol. 11, no. 3, pp. 392–396.

Dheda, K, Smit, RNV, Sechi, LA, Badri, M, Meldau, R, Symons, G, Khalfey, H, Carr, I, Maredza, A, Dawson, R, Wainright, H, Whitelaw, A, Bateman, ED & Zumla, A 2009, 'Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting', PLOS ONE, vol. 4, no. 3.

Duarte, EL, Paixao, E & David, S 2012, 'Bridging the gap between PCR detection of *Mycobacterium tuberculosis* complex and tuberculosis diagnosis', *International Journal of Tuberculosis and Lung Disease*, vol. 16, no. 3, pp. 391–393.

Elhassan, MM, Saeed, SM, Elmekki, MA, Al-Jarie, AA & Hamid, ME 2012, 'Detection of multidrug-resistant tuberculosis using PCR compared to the conventional proportional method', *Bahrain Medical Bulletin*, vol. 34, no. 1, pp. 1–7.

Gao, Y, Ou, Q, Huang, F, Wang, S, Shen, L, Shen, Y, Wu, J, Zheng, J, Weng, X, Zhang, W & Shao, L 2012, 'Improved diagnostic power by combined interferon-gamma release assay and nested-PCR in tuberculous pleurisy in high tuberculosis prevalence area', *FEMS Immunology and Medical Microbiology*, vol. 66, no. 3, pp. 393–398.

Garberi, J, Labrador, J, Garberi, F, Garberi, JE, Peneipil, J, Garberi, M, Scigliano, L & Troncoso, A 2011, 'Diagnosis of *Mycobacterium tuberculosis* using molecular biology technology', *Asian Pacific Journal of Tropical Biomedicine*, vol. 1, no. 2, pp. 89–93.

Garberi, J, Labrador, J, Garberi, F, Garberi, JE, Peneipil, J, Garberi, M, Scigliano, L & Troncoso, A 2013, 'Rapid and biosecure diagnostic test for tuberculosis', *Cell Biochemistry and Biophysics*, vol. 65, no. 2, pp. 173–179.

Garcia-Elorriaga, G, Carrillo-Montes, MG, del Rey-Pineda, G & Gonzalez-Bonilla, CR 2006, 'Detection of *Mycobacterium tuberculosis* from respiratory samples with the liquid culture system MB/BacT and verified by PCR', *Revista de Investigacion Clinica*, vol. 58, no. 6, pp. 573–579.

Garcia-Elorriaga, G, Gracida-Osorno, C, Carrillo-Montes, G & Gonzalez-Bonilla, C 2009, 'Clinical usefulness of the nested polymerase chain reaction in the diagnosis of extrapulmonary tuberculosis', *Salud Publica de Mexico*, vol. 51, no. 3, pp. 240–245.

Gazzola, L, Zanini, F, Zerbi, P, Franzetti, F & Gori, A 2008, 'The usefulness of PCR assay in diagnosing disseminated mycobacterial infection in AIDS patients', *European Journal of Clinical Microbiology & Infectious Diseases*, vol. 27, no. 2, pp. 163–166.

Ghazvini, K, Sani, AT, Rastegari, S, Ghanaat, J & Behdani, M 2007, 'Detection of rifampin resistant tuberculosis meningitis by polymerase chain reaction linked single strand conformation polymorphism analysis of cerebrospinal fluid', *Neurosciences*, vol. 12, no. 2, pp. 105–108.

Gill, MK, Kukreja, S & Chhabra, N 2013, 'Evaluation of nested polymerase chain reaction for rapid diagnosis of clinically suspected tuberculous pleurisy', *Journal of Clinical and Diagnostic Research*, vol. 7, no. 11, pp. 2456–2458.

Gopinath, K & Singh, S 2009, 'Multiplex PCR assay for simultaneous detection and differentiation of *Mycobacterium tuberculosis*, *Mycobacterium avium* complexes and other mycobacterial species directly from clinical specimens'*, Journal of Applied Microbiology*, vol. 107, no. 2, pp. 425–435.

Gopinath, K & Singh, S 2009, 'Urine as an adjunct specimen for the diagnosis of active pulmonary tuberculosis', *International Journal of Infectious Diseases*, vol. 13, no. 3, pp. 374–379.

Gous, N, Scott, LE, Wong, E, Omar, T, Venter, WDF & Stevens, W 2012, 'Performance of the Roche LightCycler Real-Time PCR assay for diagnosing extrapulmonary tuberculosis', *Journal of Clinical Microbiology*, vol. 50, no. 6, pp. 2100–2103.

Gupta, N, Sharma, JB, Mittal, S, Singh, N, Misra, R & Kukreja, M 2007, 'Genital tuberculosis in Indian infertility patients', *International Journal of Gynecology & Obstetrics*, vol. 97, no. 2, pp. 135–138.

Hajia, M, Rahbar, M & Amini, R 2009, 'Is PCR assay reliable for diagnosis of extrapulmonary tuberculosis?' *African Journal of Microbiology Research*, vol. 3, no. 12, pp. 877–881.

Hallur, V, Sharma, M, Sethi, S, Sharma, K, Mewara, A, Dhatwalia, S, Yadav, R, Bhasin, D, Sinha, SK, Rana, S & Joshi, K 2013, 'Development and evaluation of multiplex PCR in rapid diagnosis of abdominal tuberculosis', *Diagnostic Microbiology and Infectious Disease*, vol. 76, no. 1, pp. 51–55.

Iguchi, H, Wada, T, Matsushita, N, Teranishi, Y & Yamane, H 2013, 'Clinical analysis of 21 cases of cervical tuberculous lymphadenitis without active pulmonary lesion', *Acta Oto-Laryngologica*, vol. 133, no. 9, pp. 977–983.

Imani Fooladi, AA, Tarvedi Zadeh, Y, Mehrab, R, Halabian, R & Azizi, T 2013, 'Evaluation of FLASH: PCR for rapid detection of *Mycobacterium tuberculosis* from clinical specimens', *Iranian Journal of Microbiology*, vol. 5, no. 4, pp. 383–390.

Iqbal, S, Ahmed, R, Adhami, SU & Mumtaz, A 2011, 'Importance of polymerase chain reaction in diagnosis of pulmonary and extra-pulmonary tuberculosis', *Journal of Ayub Medical College, Abbottabad: JAMC*, vol. 23, no. 1, pp. 73–76.

Jafari, C, Thijsen, S, Sotgiu, G, Goletti, D, Benítez, JA, Losi, M, Eberhardt, R, Kirsten, D, Kalsdorf, B, Bossink, A, Latorre, I, Migliori, GB, Strassburg, A, Winteroll, S, Greinert, U, Richeldi, L, Ernst, M & Lange, C 2009, 'Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study', *American Journal of Respiratory & Critical Care Medicine*, vol. 180, no. 7, pp. 666–673.

Kalantri, Y, Hemvani, N & Chitnis, DS 2011, 'Evaluation of real-time polymerase chain reaction, interferon-gamma, adenosine deaminase, and immunoglobulin A for the efficient diagnosis of pleural tuberculosis'*, International Journal of Infectious Diseases*, vol. 15, no. 4, pp. e226–e231.

Kasana, D, Verma, J, Dhavan, I & Prasad, HK 2012, 'Comparative analysis of various diagnostic techniques for tubercular lymphadenitis: a pilot study from a resource poor country', *Journal International Medical Sciences Academy*, vol. 25, no. 3, pp. 167–169.

Kathirvel, M, Kommoju, V, Brammacharry, U, Ravibalan, T, Ravishankar, N, Radhakrishnan, B & Muthaiah, M 2014, 'Clinical evaluation of mtp40 polymerase chain reaction for the diagnosis of extra pulmonary tuberculosis', *World Journal of Microbiology & Biotechnology*, vol. 30, no. 5, pp. 1485–1490.

Laraque, F, Griggs, A, Slopen, M & Munsiff, SS 2009, 'Performance of nucleic acid amplification tests for diagnosis of tuberculosis in a large urban setting', *Clinical Infectious Diseases*, vol. 49, no. 1, pp. 46–54.

Lazzeri, E, Santoro, F, Oggioni, MR, Iannelli, F & Pozzi, G 2012, 'Novel primer-probe sets for detection and identification of mycobacteria by PCR-microarray assay', *Journal of Clinical Microbiology*, vol. 50, no. 11, pp. 3777–3779.

Li, J, Xin, J, Zhang, L, Jiang, L, Cao, H & Li, L 2012, 'Rapid detection of *rpoB* mutations in rifampin resistant *M. tuberculosis* from sputum samples by denaturing gradient gel electrophoresis', *International Journal of Medical Sciences*, vol. 9, no. 2, pp. 148–156.

Lima, SS, Clemente, WT, Palaci, M, Rosa, RV, Antunes, CM & Serufo, JC 2008, 'Conventional and molecular techniques in the diagnosis of pulmonary tuberculosis: a comparative study', *Jornal Brasileiro de Pneumologia*, vol. 34, no. 12, pp. 1056–1062.

Lira, LAS, Santos, FCF, Carvalho, MSZ, Montenegro, RA, Lima, JFC, Schindler, HC & Montenegro, LML 2013, 'Evaluation of a IS6110-Taqman real-time PCR assay to detect *Mycobacterium tuberculosis* in sputum samples of patients with pulmonary TB', *Journal of Applied Microbiology*, vol. 114, no. 4, pp. 1103–1108.

Liu, KT, Su, WJ & Perng, RP 2007, 'Clinical utility of polymerase chain reaction for diagnosis of smear-negative pleural tuberculosis', *Journal of the Chinese Medical Association,* vol. 70, no. 4, pp. 148–151; discussion 146–147.

Luo, RF, Scahill, MD & Banaei, N 2010, 'Comparison of single-copy and multicopy real-time PCR targets for detection of *Mycobacterium tuberculosis* in paraffin-embedded tissue', *Journal of Clinical Microbiology*, vol. 48, no. 7, pp. 2569–2570.

Macente, S, Fujimura Leite, CQ, Santos, ACB, Siqueira, VLD, Machado, LNC, Marcondes, NR, Hirata, MH, Hirata, RDC & Cardoso, RF 2013, 'Evaluation of hsp65 nested PCR-restriction analysis (PRA) for diagnosing tuberculosis in a high burden country', *BioMed Research International*, 2013: 391549.

Magana-Arachchi, D, Perera, J, Gamage, S & Chandrasekharan, V 2008, 'Low cost in-house PCR for the routine diagnosis of extra-pulmonary tuberculosis', *International Journal of Tuberculosis and Lung Disease*, vol. 12, no. 3, pp. 275–280.

Marks, SM, Cronin, W, Venkatappa, T, Maltas, G, Chon, S, Sharnprapai, S, Gaeddert, M, Tapia, J, Dorman, SE, Etkind, S, Crosby, C, Blumberg, HM & Bernardo, J 2013, 'The health-system benefits and cost-effectiveness of using *Mycobacterium tuberculosis* direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States', *Clinical Infectious Diseases*, vol. 57, no. 4, pp. 532–542.

Meldau, R, Peter, J, Theron, G, Calligaro, G, Allwood, B, Symons, G, Khalfey, H, Ntombenhle, G, Govender, U, Binder, A, van Zyl-Smit, R & Dheda, K 2014, 'Comparison of same day diagnostic tools including GeneXpert and unstimulated IFN-(gamma) for the evaluation of pleural tuberculosis: a prospective cohort study', *BMC Pulmonary Medicine*, vol. 14, no. 1.

Mirsadraee, M, Shafahie, A, Reza Khakzad, M & Sankian, M 2014, 'Value of the polymerase chain reaction method for detecting tuberculosis in the bronchial tissue involved by anthracosis', *Journal of Bronchology & Interventional Pulmonology*, vol. 21, no. 2, pp. 131–134.

Moon, HW, Hur, M, Kim, H, Kim, JY, Park, CM & Yun, YM 2012, 'Isothermal target and probe amplification for *Mycobacterium tuberculosis* identification from broth cultures', *International Journal of Tuberculosis and Lung Disease*, vol. 16, no. 4, pp. 516–520.

Narotam, S, Veena, S, Chandra, NS, Raj, SP, Kushwaha, RS, Shivani, S, Shayan, G, Ahmer, N & Singh, RK 2012, 'Conventional PCR usage for the detection of *Mycobacterium tuberculosis* complex in cerebrospinal fluid by MPB64-target PCR', *International Journal of Drug Development and Research*, vol. 4, no. 4, pp. 206–210.

Negi, SS, Anand, R, Basir, SF, Pasha, ST, Gupta, S, Khare, S & Lal, S 2006, 'Protein antigen b (Pab) based PCR test in diagnosis of pulmonary & extra-pulmonary tuberculosis', *Indian Journal of Medical Research*, vol. 124, no. 1, pp. 81–88.

Negi, SS, Anand, R, Pasha, ST, Basir, SF, Gupta, S, Khare, S & Lal, S 2006, 'Detection of *M. tuberculosis* in clinical samples of diversified nature by IS6110 based PCR', *Journal of Communicable Diseases*, vol. 38, no. 4, pp. 325–332.

Negi, SS, Anand, R, Pasha, ST, Gupta, S, Basir, SF, Khare, S & Lal, S 2007, 'Diagnostic potential of IS6110, 38kDa, 65kDa and 85B sequence-based polymerase chain reaction in the diagnosis of *Mycobacterium tuberculosis* in clinical samples', *Indian* *Journal of Medical Microbiology*, vol. 25, no. 1, pp. 43–49.

Negi, SS, Gupta, S, Khare, S & Lal, S 2005, 'Comparison of various microbiological tests including polymerase chain reaction for the diagnosis of osteoarticular tuberculosis', *Indian Journal of Medical Microbiology*, vol. 23, no. 4, pp. 245–248.

Negi, SS, Khan, SF, Gupta, S, Pasha, ST, Khare, S & Lal, S 2005, 'Comparison of the conventional diagnostic modalities, bactec culture and polymerase chain reaction test for diagnosis of tuberculosis', *Indian Journal of Medical Microbiology*, vol. 23, no. 1, pp. 29–33.

Nhu, NTQ, Ha, DTM, Anh, ND, Thu, DDA, Duong, TN, Quang, ND, Lan, NTN, Van Quyet, T, Tuyen, NTB, Ha, VT, Giang, DC, Dung, NH, Wolbers, M, Farrar, J & Caws, M 2013, 'Evaluation of Xpert MTB/RIF and MODS assay for the diagnosis of pediatric tuberculosis', *BMC Infectious Diseases*, vol. 13, no. 1.

Nhu, NTQ, Heemskerk, D, Thu, DDA, Chau, TTH, Mai, NTH, Nghia, HDT, Loc, PP, Ha, DTM, Merson, L, Van Thinh, TT, Day, J, Van Vinh Chau, N, Wolbers, M, Farrar, J & Caws, M 2014, 'Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis', *Journal of Clinical Microbiology*, vol. 52, no. 1, pp. 226–233.

Omrani, M, Ansari, MH & Agaverdizadae, D 2009, 'PCR and Elisa methods (IgG and IgM): their comparison with conventional techniques for diagnosis of *Mycobacterium tuberculosis'*, *Pakistan Journal of Biological Sciences*, vol. 12, no. 4, pp. 373–377.

Osores, F, Nolasco, O, Verdonck, K, Arevalo, J, Ferrufino, JC, Agapito, J, Huayanay, L, Gotuzzo, E & Maguina, C 2006, 'Clinical evaluation of a 16S ribosomal RNA polymerase chain reaction test for the diagnosis of lymph node tuberculosis', *Clinical Infectious Diseases*, vol. 43, no. 7, pp. 855–859.

Parrado, R, Lozano, D, Garcia, L, Torrico, MC, Delgado, R, Torrico, F, Laserna, M & Reithinger, R 2008, 'Multiprimer PCR system diagnosis of pulmonary tuberculosis in Cochabamba, Bolivia', *Journal of Clinical Microbiology*, vol. 46, no. 2, pp. 830–831.

Patil, N, Saba, H, Marco, A, Samant, R & Mukasa, L 2014, 'Initial experience with GeneXpert MTB/RIF assay in the Arkansas tuberculosis control program', *Australasian Medical Journal*, vol. 7, no. 5, pp. 203–207.

Portillo-Gomez, L, Murillo-Neri, MV, Gaitan-Mesa, J & Sosa-Iglesias, EG 2008, 'Nested polymerase chain reaction in the diagnosis of cervical tuberculous lymphadenitis in Mexican children', *International Journal of Tuberculosis and Lung Disease*, vol. 12, no. 11, pp. 1313–1319.

Rachow, A, Clowes, P, Saathoff, E, Mtafya, B, Michael, E, Ntinginya, EN, Kowour, D, Rojas-Ponce, G, Kroidl, A, Maboko, L, Heinrich, N, Reither, K & Hoelscher, M 2012, 'Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study', *Clinical Infectious Diseases*, vol. 54, no. 10, pp. 1388–1396.

Rosso, F, Michelon, CT, Sperhacke, RD, Verza, M, Olival, L, Conde, MB, Guerra, RL, Zaha, A & Rossetti, ML 2011, 'Evaluation of real-time PCR of patient pleural effusion for diagnosis of tuberculosis', *BMC Research Notes*, vol. 4, p. 279.

Rozales, FP, Machado, ABMP, De Paris, F, Zavascki, AP & Barth, AL 2014, 'PCR to detect *Mycobacterium tuberculosis* in respiratory tract samples: evaluation of clinical data', *Epidemiology and Infection*, vol. 142, no. 7, pp. 1517–1523.

Rudeeaneksin, J, Bunchoo, S, Srisungngam, S, Sawanpanyalert, P, Chamnangrom, S, Kamolwat, A, Thanasripakdeekul, P, Taniguchi, T, Nakajima, C, Suzuki, Y & Phetsuksiri, B 2012, 'Rapid identification of *Mycobacterium tuberculosis* in BACTEC MGIT960 cultures by in-house loop-medicated isothermal amplification', *Japanese Journal of Infectious Diseases*, vol. 65, no. 4, pp. 306–311.

Runa, F, Yasmin, M, Hoq, MM, Begum, J, Rahman, ASMM & Ahsan, CR 2011, 'Molecular versus conventional methods: clinical evaluation of different methods for the diagnosis of tuberculosis in Bangladesh', *Journal of Microbiology, Immunology and Infection*, vol. 44, no. 2, pp. 101–105.

Sankar, MM, Kumar, P, Munawwar, A, Kumar, M, Singh, J, Singh, A, Parashar, D, Malhotra, N, Duttagupta, S & Singh, S 2013, 'Usefulness of multiplex PCR in the diagnosis of genital tuberculosis in females with infertility', *European Journal of Clinical Microbiology and Infectious Diseases*, vol. 32, no. 3, pp. 399–405.

Sastry, AS, Sandhya Bhat, K & Kumudavathi 2013, 'The diagnostic utility of Bact/ALERT and nested PCR in the diagnosis of tuberculous meningitis', *Journal of Clinical and Diagnostic Research*, vol. 7, no. 1, pp. 74–78.

Scherer, LC, Sperhacke, RD, Jarczewski, C, Cafrune, PI, Michelon, CT, Rupenthal, R, Ribeiro, MO, Netto, AR, Rossetti, MLR & Kritski, AL 2011, 'Comparison of two laboratory-developed PCR methods for the diagnosis of pulmonary tuberculosis in Brazilian patients with and without HIV infection', *BMC Pulmonary Medicine*, vol. 11.

Scherer, LC, Sperhacke, RD, Jarczewski, C, Cafrune, PI, Minghelli, S, Ribeiro, MO, Mello, FCQ, Ruffino-Netto, A, Rossetti, ML & Kritski, AL 2007, 'PCR colorimetric dot-blot assay and clinical pretest probability for diagnosis of pulmonary tuberculosis in smear-negative patients', *BMC Public Health*, vol. 7.

Scherer, LC, Sperhacke, RD, Rossetti, ML, Ruffino-Netto, A & Kritski, AL 2011, 'Usefulness of the polymerase chain reaction dot-blot assay, used with Ziehl-Neelsen staining, for the rapid and convenient diagnosis of pulmonary tuberculosis in human immunodeficiency virus-seropositive and ‑seronegative individuals', *Current Infectious Disease Reports*, vol. 3, no. 1, p. e3.

Scott, LE, McCarthy, K, Gous, N, Nduna, M, van Rie, A, Sanne, I, Venter, WF, Duse, A & Stevens, W 2011, 'Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study', *PLOS Medicine*, vol. 8, no. 7.

Seagar, AL, Neish, B & Laurenson, IF 2012, 'Comparison of two in-house real-time PCR assays with MTB Q-PCR Alert and GenoType MTBDRplus for the rapid detection of mycobacteria in clinical specimens', *Journal of Medical Microbiology*, vol. 61, no. 10, pp. 1459–1464.

Sekar, B, Selvaraj, L, Alexis, A, Ravi, S, Arunagiri, K & Rathinavel, L 2008, 'The utility of IS6110 sequence based polymerase chain reaction in comparison to conventional methods in the diagnosis of extra-pulmonary tuberculosis'*, Indian Journal of Medical Microbiology*, vol. 26, no. 4, pp. 352–355.

Sethi, S, Yadav, R, Mewara, A, Dhatwalia, SK, Sharma, M & Gupta, D 2012, 'Evaluation of in-house mpt64 real-time PCR for rapid detection of *Mycobacterium tuberculosis* in pulmonary and extra-pulmonary specimens', *Brazilian Journal of Infectious Diseases*, vol. 16, no. 5, pp. 493–494.

Sethi, SK, Singh, S, Dhatwalia, SK, Yadav, R, Mewara, A, Singh, M, Tewari, R & Sharma, M 2013, 'Evaluation of in-house loop-mediated isothermal amplification (LAMP) assay for rapid diagnosis of *M. tuberculosis* in pulmonary specimens', *Journal of Clinical Laboratory Analysis*, vol. 27, no. 4, pp. 272–276.

Sharma, M, Sethi, S, Mishra, AK, Chatterjee, SS, Wanchu, A & Nijhawan, R 2010, 'Efficacy of an in-house polymerase chain reaction assay for rapid diagnosis of *Mycobacterium tuberculosis* in patients with tubercular lymphadenitis: comparison with fine needle aspiration cytology and conventional techniques', *Indian Journal of Pathology and Microbiology*, vol. 53, no. 4, pp. 714–717.

Sharma, SK, Sethi, S, Sharma, M, Meharwal, SK, Katoch, VM, Jindal, SK & Tewari, R 2012, 'Development and evaluation of a multiplex polymerase chain reaction for the detection of *Mycobacterium tuberculosis* from pulmonary specimens', *Scandinavian Journal of Infectious Diseases*, vol. 44, no. 10, pp. 739–744.

Singh, DD, Vogel, M, Muller-Stover, I, El Scheich, T, Winzer, M, Gobels, S, Huttig, F, Heinrich, S, MacKenzie, C, Jensen, B, Reuter, S, Haussinger, D & Richter, J 2011, 'TB or not TB? Difficulties in the diagnosis of tuberculosis in HIV-negative immigrants to Germany', *European Journal of Medical Research*, vol. 16, no. 9, pp. 381–384.

Singh, RK, Sharma, N, Sharma, V, Singh, PR, Sailwal, S, Kushwaha, RS, Singh, RK, Nautiyal, SC, Mishra, P & Masood, T 2013, 'Diagnostic value of PCR in genitourinary tuberculosis', *Indian Journal of Clinical Biochemistry*, vol. 28, no. 3, pp. 305–308.

Singh, S, Saluja, TP, Kaur, M & Khilnani, GC 2008, 'Comparative evaluation of FASTPlaque assay with PCR and other conventional in-vitro diagnostic methods for the early detection of pulmonary tuberculosis', *Journal of Clinical Laboratory Analysis*, vol. 22, no. 5, pp. 367–374.

Solis, AH, Gonzalez, NEH, Cazarez, F, Perez, PM, Diaz, HO, Escobar-Gutierrez, A, Ortiz, IC, Gonzalez, HG, Reding-Bernal, A & Sabido, RC 2012, 'Skin biopsy: a pillar in the identification of cutaneous *Mycobacterium tuberculosis* infection', *Journal of Infection in Developing Countries*, vol. 6, no. 8, pp. 626–631.

Sun, YS, Lou, SQ, Wen, JM, Lv, WX, Jiao, CG, Yang, SM & Xu, HB 2011, 'Clinical value of polymerase chain reaction in the diagnosis of joint tuberculosis by detecting the DNA of *Mycobacterium tuberculosis*', *Orthopaedic Surgery*, vol. 3, no. 1, pp. 64–71.

Thangappah, RBP, Paramasivan, CN & Narayanan, S 2011, 'Evaluating PCR, culture and histopathology in the diagnosis of female genital tuberculosis', *Indian Journal of Medical Research*, vol. 134, no. 7, pp. 40–46.

Theegarten, D, Totsch, M, Worm, K, Darwiche, K, Anhenn, O & Wohlschlager, J 2013, 'Diagnosis of pulmonary tuberculosis using Ziehl-Neelsen stain and polymerase chain reaction', *Pathologe*, vol. 34, no. 4, pp. 305–309.

Theron, G, Peter, J, van Zyl-Smit, R, Mishra, H, Streicher, E, Murray, S, Dawson, R, Whitelaw, A, Hoelscher, M, Sharma, S, Pai, M, Warren, R & Dheda, K 2011, 'Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting', *American Journal of Respiratory & Critical Care Medicine*, vol. 184, no. 1, pp. 132–140.

Theron, G, Pinto, L, Peter, J, Mishra, HK, Mishra, HK, Van Zyl-Smit, R, Sharma, SK & Dheda, K 2012, 'The use of an automated quantitative polymerase chain reaction (Xpert MTB/RIF) to predict the sputum smear status of tuberculosis patients', *Clinical Infectious Diseases*, vol. 54, no. 3, pp. 384–388.

Torrea, G, Van de Perre, P, Ouedraogo, M, Zougba, A, Sawadogo, A, Dingtoumda, B, Diallo, B, Defer, MC, Sombie, I, Zanetti, S & Sechi, LA 2005, 'PCR-based detection of the *Mycobacterium* *tuberculosis* complex in urine of HIV-infected and uninfected pulmonary and extrapulmonary tuberculosis patients in Burkina Faso', *Journal of Medical Microbiology*, vol. 54, no. 1, pp. 39–44.

Trajman, A, Kaisermann, C, Luiz, RR, Sperhacke, RD, Rossetti, ML, Saad, MHF, Sardella, IG, Spector, N & Kritski, AL 2007, 'Pleural fluid ADA, IgA-ELISA and PCR sensitivities for the diagnosis of pleural tuberculosis', *Scandinavian Journal of Clinical & Laboratory Investigation*, vol. 67, no. 8, pp. 877–884.

ul ain Hanif, Q, Muhammad, J, Hussain, T, Ahmad Sheikh, A, Ullah Qazi, O, Akram, S, Abid, K & Yaqub, S 2014, 'Evaluation of conventional and molecular techniques in diagnosis of clinical samples of *Mycobacterium tuberculosis'*, *World Applied Sciences Journal*, vol. 30, no. 6, pp. 762–764.

Walters, E, Gie, RP, Hesseling, AC, Friedrich, SO, Diacon, AH & Gie, RP 2012, 'Rapid diagnosis of pediatric intrathoracic tuberculosis from stool samples using the Xpert MTB/RIF assay: a pilot study', *Pediatric Infectious Disease Journal*, vol. 31, no. 12, p. 1316.

Wang, X, Wu, Y, Zhang, K, Guan, C, Gao, X & Wang, M 2013, 'Value of real-time polymerase chain reaction in bronchoalveolar lavage fluid for diagnosis of pediatric pulmonary tuberculosis', *Brazilian Journal of Infectious Diseases*, vol. 17, no. 6, pp. 718–719.

Zmak, L, Jankovic, M & Jankovic, VK 2013, 'Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia'*, International Journal of Mycobacteriology*, vol. 2, no. 3, pp. 179–182.

**No comparator**

Adhikari, BR, Pandey, BD, Ghimire, P, Shrestha, B, Khadka, M, Yoda, T & Suzuki, Y 2009, 'Loop-mediated isothermal amplification (LAMP) for the direct detection of human pulmonary infections with environmental (nontuberculosis) mycobacteria', *Japanese Journal of Infectious Diseases*, vol. 62, no. 3, pp. 212–214.

Causse, M, Ruiz, P, Gutierrez-Aroca, JB & Casal, M 2011, 'Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis', *Journal of Clinical Microbiology*, vol. 49, no. 8, pp. 3065–3067.

Dora, JM, Geib, G, Chakr, R, de Paris, F, Mombach, AB, Lutz, L, de Souza, CFM & Goldani, LZ 2008, 'Polymerase chain reaction as a useful and simple tool for rapid diagnosis of tuberculous meningitis in a Brazilian tertiary care hospital'*, Brazilian Journal of Infectious Diseases*, vol. 12, no. 3, pp. 245–247.

Dubey, A, Gwal, R & Agrawal, S 2013, '*Mycobacterium* *tuberculosis* detection in blood using multiplex nested polymerase chain reaction', *International Journal of Tuberculosis and Lung Disease*, vol. 17, no. 10, pp. 1341–1345.

e Bona, MGM, Leal, MJS, Martins, LMS, da Silva, RN, de Castro, JAF & do Monte, SJH 2011, 'Restriction enzyme analysis of the hsp65 gene in clinical isolates from patients suspected of having pulmonary tuberculosis in Teresina, Brazil', *Jornal Brasileiro de Pneumologia*, vol. 37, no. 5, pp. 628–635.

Falih, MN 2013, 'Diagnosis of *Mycobacterium tuberculosis* by Elisa and real time PCR', *International Journal of Pharma and Bio Sciences*, vol. 4, no. 3, pp. B1186–B1190.

Feasey, NA, Banada, PP, Howson, W, Sloan, DJ, Mdolo, A, Boehme, C, Chipungu, GA, Allain, TJ, Heyderman, RS, Corbett, EL & Alland, D 2013, 'Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms *Mycobacterium tuberculosis* bacteremia as an indicator of poor prognosis', *Journal of Clinical Microbiology*, vol. 51, no. 7, pp. 2311–2316.

Haldar, S, Sharma, N, Gupta, VK & Tyagi, JS 2009, 'Efficient diagnosis of tuberculous meningitis by detection of *Mycobacterium tuberculosis* DNA in cerebrospinal fluid filtrates using PCR', *Journal of Medical Microbiology*, vol. 58, no. 5, pp. 616–624.

Hira, RS, Sarangdhar, VC, Hira, SK & DuPont, HL 2010, 'Peripheral blood PCR for detection of *Mycobacterium tuberculosis* in patients with HIV/AIDS in Mumbai, India', *Internet Journal of Microbiology*, vol. 9, no. 1.

Jafari, C, Ernst, M, Kalsdorf, B & Lange, C 2013, 'Comparison of molecular and immunological methods for the rapid diagnosis of smear-negative tuberculosis', *International Journal of Tuberculosis and Lung Disease*, vol. 17, no. 11, pp. 1459–1465.

Lawn, SD, Kerkhoff, AD, Vogt, M & Wood, R 2012, 'High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay', *Journal of Acquired Immune Deficiency Syndromes*, vol. 60, no. 3, pp. 289–294.

Lily Therese, K, Gayathri, R, Dhanurekha, L, Sridhar, R, Meenakshi, N, Madhavan, HN, Edwin Manoj, S & Kamala Vinayagam, A 2012, 'Detection of *Mycobacterium tuberculosis* directly from sputum specimens & phenotypic drug resistance pattern of *M. tuberculosis* isolates from suspected tuberculosis patients in Chennai', *Indian Journal of Medical Research*, vol. 135, no. 5, pp. 778–782.

Lima, JFD, Montenegro, LML, Montenegro, RD, Cabral, MML, Lima, AS, Abath, FGC & Schindler, HC 2009, 'Performance of nested PCR in the specific detection of *Mycobacterium tuberculosis* complex in blood samples of pediatric patients', *Jornal Brasileiro de Pneumologia*, vol. 35, no. 7, pp. 690–697.

Nandagopal, B, Sankar, S, Lingesan, K, Appu, KC, Sridharan, G & Gopinathan, AK 2010, 'Evaluation of a nested PCR targeting IS6110 of *Mycobacterium tuberculosis* for detection of the organism in the leukocyte fraction of blood samples', *Indian Journal of Medical Microbiology*, vol. 28, no. 3, pp. 227–232.

Pinto, H, Jr, Bica, CG, Palaci, M, Dietze, R, Basso, LA & Santos, DS 2007, 'Using polymerase chain reaction with primers based on the plcB–plcC intergenic region to detect *Mycobacterium tuberculosis* in clinical samples', *Jornal Brasileiro de Pneumologia*, vol. 33, no. 4, pp. 437–442.

Rafi, W, Venkataswamy, MM, Nagarathna, S, Satishchandra, P & Chandramuki, A 2007, 'Role of IS6110 uniplex PCR in the diagnosis of tuberculous meningitis: experience at a tertiary neurocentre', *International Journal of Tuberculosis and Lung Disease*, vol. 11, no. 2, pp. 209–214.

Rafi, W, Venkataswamy, MM, Ravi, V & Chandramuki, A 2007, 'Rapid diagnosis of tuberculous meningitis: a comparative evaluation of in-house PCR assays involving three mycobacterial DNA sequences, IS6110, MPB-64 and 65 kDa antigen', *Journal of Neurological Science*, vol. 252, no. 2, pp. 163–168.

Sekadde, MP, Wobudeya, E, Joloba, ML, Ssengooba, W, Kisembo, H, Bakeera-Kitaka, S & Musoke, P 2013, 'Evaluation of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: a cross-sectional diagnostic study'*, BMC Infectious Diseases*, vol. 13, no. 1.

Simonnet, C, Lacoste, V, Drogoul, AS & Rastogi, N 2011, 'Automated extraction and amplification for direct detection of *Mycobacterium tuberculosis* complex in various clinical samples', *Journal of Clinical Microbiology*, vol. 49, no. 4, pp. 1700–1701.

Singh, HB, Singh, P, Jadaun, GP, Srivastava, K, Sharma, VD, Chauhan, DS, Sharma, SK & Katoch, VM 2006, 'Simultaneous use of two PCR systems targeting IS*6110* and *MPB64* for confirmation of diagnosis of tuberculous lymphadenitis', *Journal of Communicable Diseases*, vol. 38, no. 3, pp. 274–279.

Soo, PC, Horng, YT, Hsueh, PR, Shen, BJ, Wang, JY, Tu, HH, Wei, JR, Hsieh, SC, Huang, CC & Lai, HC 2006, 'Direct and simultaneous identification of *Mycobacterium* *tuberculosis* complex (MTBC) and *Mycobacterium tuberculosis* (MTB) by rapid multiplex nested PCR-ICT assay', *Journal of Microbiological Methods*, vol. 66, no. 3, pp. 440–448.

Sun, L, Yuan, Q, Feng, JM, Yang, CM, Yao, L, Fan, QL, Liu, LL, Ma, JF & Wang, LN 2010, 'Rapid diagnosis in early stage renal tuberculosis by real-time polymerase chain reaction on renal biopsy specimens', *International Journal of Tuberculosis and Lung Disease*, vol. 14, no. 3, pp. 341–346.

Walters, E, Goussard, P, Bosch, C, Hesseling, AC & Gie, RP 2013, 'GeneXpert MTB/RIF on bronchoalveolar lavage samples in children with suspected complicated intrathoracic tuberculosis: a pilot study', *Pediatric Pulmonology,* doi: 10.1002/ppul.22970.

**Wrong reference standard**

Ali, B, Anjum, A, Mahmood, S, Wadood, MA & Shakoori, AR 2013, 'Identification of bovine and human tuberculosis in AFB positive and negative patients', *Pakistan Journal of Zoology*, vol. 45, no. 1, pp. 255–260.

Ansari, HQF & Mustafa, M 2011, 'Efficacy of polymerase chain reaction over Ziehl-Neelsen staining in the diagnosis of *Mycobacterium tuberculosis', International Journal of Pharma and Bio Sciences*, vol. 2, no. 4, pp. 272–278.

Balne, PK, Modi, RR, Choudhury, N, Mohan, N, Barik, MR, Padhi, TR, Sharma, S, Panigrahi, SR & Basu, S 2014, 'Factors influencing polymerase chain reaction outcomes in patients with clinically suspected ocular tuberculosis', *Journal of Ophthalmic Inflammation and Infection*, vol. 4, no. 1, pp. 1–6.

Barani, R, Sarangan, G, Antony, T, Periyasamy, S, Kindo, AJ & Srikanth, P 2012, 'Improved detection of *Mycobacterium tuberculosis* using two independent PCR targets in a tertiary care centre in South India', *Journal of Infection in Developing Countries*, vol. 6, no. 1, pp. 46–52.

Boondireke, S, Mungthin, M, Tan-ariya, P, Boonyongsunchai, P, Naaglor, T, Wattanathum, A, Treewatchareekorn, S & Leelayoova, S 2010, 'Evaluation of sensitivity of multiplex PCR for detection of *Mycobacterium tuberculosis* and *Pneumocystis jirovecii* in clinical samples', *Journal of Clinical Microbiology*, vol. 48, no. 9, pp. 3165–3168.

Chawla, A & Chawla, K 2010, 'Can tissue PCR augment the diagnosis of gutb?', *Journal of Urology*, vol. 183, no. 4, p. e242.

Chawla, A, Chawla, K, Reddy, S, Arora, N, Bairy, I, Rao, S, Hegde, P & Thomas, J 2012, 'Can tissue PCR augment the diagnostic accuracy in genitourinary tract tuberculosis?', *Urologia Internationalis*, vol. 88, no. 1, pp. 34–38.

Chawla, K, Gupta, S, Mukhopadhyay, C, Rao, PS & Bhat, SS 2009, 'PCR for *M. tuberculosis* in tissue samples'*, Journal of Infection in Developing Countries*, vol. 3, no. 2, pp. 83–87.

da Cruz, HLA, Montenegro, RD, Lima, JFD, Poroca, DD, Lima, JFD, Montenegro, LML, Crovella, S & Schindler, HC 2011, 'Evaluation of a nested-PCR for *Mycobacterium tuberculosis* detection in blood and urine samples', *Brazilian Journal of Microbiology*, vol. 42, no. 1, pp. 321–329.

Goel, MM, Budhwar, P, Goel, M, Tiwari, V & Jain, A 2006, 'Nucleic acid amplification of *Mycobacterium tuberculosis* complex DNA from archival fine needle aspiration smear scrapings vs. fresh fine needle aspirates of tuberculous lymphadenitis', *Acta Cytologica*, vol. 50, no. 4, pp. 393–397.

Gupta, N, Sharma, K, Barwad, A, Sharma, M, Rajwanshi, A, Dutta, P & Sharma, A 2011, 'Thyroid tuberculosis: role of PCR in diagnosis of a rare entity', *Cytopathology*, vol. 22, no. 6, pp. 392–396.

Jain, A, Verma, RK, Tiwari, V & Goel, MM 2005, 'Dot-ELISA vs. PCR of fine needle aspirates of tuberculous lymphadenitis: a prospective study in India'*, Acta Cytologica*, vol. 49, no. 1, pp. 17–21.

Kashyap, RS, Nayak, AR, Gaherwar, HM, Bhullar, SS, Husain, AA, Shekhawat, SD, Jain, RK, Gaikwad, SS, Satav, AR, Purohit, HJ, Taori, GM & Daginawala, HF 2013, 'Laboratory investigations on the diagnosis of tuberculosis in the malnourished tribal population of Melghat, India', *PLOS ONE*, vol. 8, no. 9.

Khan, MA, Mirza, SH, Abbasi, SA, Butt, T & Anwar, M 2006, 'Peripheral blood-based polymerase chain reaction in diagnosis of pulmonary tuberculosis', *Journal of Ayub Medical College, Abbottabad*, vol. 18, no. 2, pp. 25–28.

Kim, DW, Jung, SJ, Ha, TK & Park, HK 2013, 'Individual and combined diagnostic accuracy of ultrasound diagnosis, ultrasound-guided fine-needle aspiration and polymerase chain reaction in identifying tuberculous lymph nodes in the neck', *Ultrasound in Medicine and Biology*, vol. 39, no. 12, pp. 2308–2314.

Kulkarni, S, Vyas, S, Supe, A & Kadival, G 2006, 'Use of polymerase chain reaction in the diagnosis of abdominal tuberculosis', *Journal of Gastroenterology and Hepatology*, vol. 21, no. 5, pp. 819–823.

Kumar Balne, P, Ranjan Barik, M, Sharma, S & Basu, S 2013, 'Development of a loop-mediated isothermal amplification assay targeting the *mpb64* gene for diagnosis of intraocular tuberculosis', *Journal of Clinical Microbiology*, vol. 51, no. 11, pp. 3839–3840.

Miller, MB, Popowitch, EB, Backlund, MG & Ager, EPC 2011, 'Performance of Xpert MTB/RIF RUO assay and IS6110 real-time PCR for *Mycobacterium tuberculosis* detection in clinical samples', *Journal of Clinical Microbiology*, vol. 49, no. 10, pp. 3458–3462.

Nicol, MP, Spiers, K, Workman, L, Isaacs, W, Munro, J, Black, F, Zemanay, W & Zar, HJ 2013, 'Xpert MTB/RIF testing of stool samples for the diagnosis of pulmonary tuberculosis in children', *Clinical Infectious Diseases*, vol. 57, no. 3, pp. e18–e21.

Nimesh, M, Joon, D, Pathak, AK & Saluja, D 2013, 'Comparative study of diagnostic accuracy of established PCR assays and in-house developed sdaA PCR method for detection of *Mycobacterium tuberculosis* in symptomatic patients with pulmonary tuberculosis', *Journal of Infection*, vol. 67, no. 5, pp. 399–407.

Pandie, S, Peter, JG, Kerbelker, ZS, Meldau, R, Theron, G, Govender, U, Ntsekhe, M, Dheda, K & Mayosi, BM 2014, 'Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-gamma in a high burden setting: a prospective study', *BMC Medicine*, vol. 12, no. 1, p. 101.

Peter, JG, Theron, G, Muchinga, TE, Govender, U & Dheda, K 2012, 'The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce', *PLOS ONE*, vol. 7, no. 7.

Raizada, N, Sachdeva, KS, Sreenivas, A, Vadera, B, Gupta, RS, Parmar, M, Kulsange, S, Babre, A, Thakur, R, Gray, C, Ramachandran, R, Alavadi, U, Ghedia, M, Vollepore, B, Dewan, P, Boehme, C & Paramsivan, CN 2014, 'Feasibility of decentralised deployment of Xpert MTB/RIF test at lower level of health system in India', *PLOS ONE*, vol. 9, no. 2.

Rufai, SB, Kumar, P, Singh, A, Prajapati, S, Balooni, V & Singh, S 2014, 'Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant *Mycobacterium tuberculosis*', *Journal of Clinical Microbiology*, vol. 52, no. 6, pp. 1846–1852.

Sankar, S, Balakrishnan, B, Nandagopal, B, Thangaraju, K & Natarajan, S 2010, 'Comparative evaluation of two polymerase chain reactions targeting different genomic regions to detect *Mycobacterium tuberculosis* in sputum', *Indian Journal of Medical Microbiology*, vol. 28, no. 4, pp. 303–307.

Savelkoul, PHM, Catsburg, A, Mulder, S, Oostendorp, L, Schirm, J, Wilke, H, van der Zanden, AGM & Noordhoek, GT 2006, 'Detection of *Mycobacterium tuberculosis* complex with real time PCR: comparison of different primer-probe sets based on the IS6110 element', *Journal of Microbiological Methods*, vol. 66, no. 1, pp. 177–180.

Shah, SK, Kumar, AMV, Dogar, OF, Khan, MA, Qadeer, E, Tahseen, S, Masood, F, Chandio, AK & Edginton, ME 2013, 'Xpert® MTB/RIF under routine conditions in diagnosing pulmonary tuberculosis: a study in two hospitals in Pakistan', *Public Health Action*, vol. 3, no. 1, pp. 20–22.

Tarhan, G, Ceyhan, I, Simsek, H & Tuncer, S 2009, 'Evaluation of the efficacy of five DNA extraction methods for the detection of *Mycobacterium tuberculosis* DNA in direct and processed sputum by an in-house PCR method', *Turkish Journal of Medical Sciences*, vol. 39, no. 2, pp. 253–257.

Varma-Basil, M, Pathak, R, Singh, K, Dwivedi, SKD, Garima, K, Kumar, S, Sharma, D, Dhiman, B & Bose, M 2010, 'Direct early identification of *Mycobacterium tuberculosis* by PCR-restriction fragment length polymorphism analysis from clinical samples', *Japanese Journal of Infectious Diseases*, vol. 63, no. 1, pp. 55–57.

Wekesa, C, Kirenga, BJ, Joloba, ML, Bwanga, F, Katamba, A & Kamya, MR 2014, 'Chest x-ray vs. Xpert® MTB/RIF assay for the diagnosis of sputum smear-negative tuberculosis in Uganda', *International Journal of Tuberculosis and Lung Disease*, vol. 18, no. 2, pp. 216–219.

**Could not retrieve on time**

Bayram, A, Celiksoz, C, Karsligil, T & Balci, I 2006, 'Automatized PCR evaluation of *Mycobacterium tuberculosis* complex in respiratory and nonrespiratory specimens', *FEMS Immunology and Medical Microbiology*, vol. 46, no. 1, pp. 48–52.

Betancourt, MLD, Florez, ER, Rincon, JCC & Quinonez, LBG 2005, 'Diagnosis of tuberculosis in fluid samples by polymerase chain reaction'*, Enfermedades Infecciosas y Microbiologia*, vol. 25, no. 2.

Blandenier, LES, De Suárez, CAB, Rabucha, A & Peniza, AV 2011, 'Pleural biopsy in patients with pleural effusion as diagnostic element of tuberculosis: correlative study with tissue culture and pleural fluid', *Gaceta Medica de Caracas*, vol. 119, no. 4, pp. 297–309.

Christina, AS & Daniel, GS 2010, 'Role of polymerase chain reaction (PCR) in differential diagnosis of tuberculosis: a comparative study'*, Journal of Pure and Applied Microbiology*, vol. 4, no. 1, pp. 247–250.

Cruciani, M & Mengoli, C 2009, 'An overview of meta-analyses of diagnostic tests in infectious diseases', *Infectious Disease Clinics of North America*, vol. 23, no. 2, pp. 225–267.

Garberi, J, Labrador, J, Peneipil, J, Scigliano, L & Troncoso, A 2012, 'Rapid and safe diagnosis of *Mycobacterium tuberculosis* directly from sputum and biological fluids specimens using a low cost molecular biology dedicated system', *BioTechnology*, vol. 6, no. 4–5, pp. 103–110.

Ghani, R, ul Hassan, H, Ali, H, Usman, M, Bukhari, MH, Akram, M & Iqbal, A 2012, 'Rapid detection of typical and atypical *Mycobacterium tuberculosis* by polymerase chain reaction (PCR) and its comparison with Ziehl Neelsen staining technique', *African Journal of Biotechnology*, vol. 11, no. 15, pp. 3681–3685.

Golia, S, Hittinahalli, V, Reddy, M & Karjigi, S 2012, 'PCR as a faster mode of supportive tool in laboratory diagnosis of *Mycobacterium tuberculosis*’*,* *Journal of Pure and Applied Microbiology*, vol. 66, no. 4, pp. 1913–1916.

Hasan, MM, Hossain, MA, Paul, SK, Mahmud, C, Khan, ER, Rahman, MM, Rukunuzzaman, M, Hasan, MS & Kubayashi, N 2012, 'Evaluation of PCR with culture for the diagnosis of pulmonary tuberculosis', *Mymensingh Medical Journal*, vol. 21, no. 3, pp. 399–403.

Iacob, S, Banica, D, Cojocaru, M & Iacob, D 2010, 'Improved diagnosis of central nervous system tuberculosis is by 6110 nested PCR', *Archives of the Balkan Medical Union*, vol. 45, no. 1, pp. 5–13.

Khalid, J, Subhi, R, Bahjet, S & Ibrahim, Y 2010, 'Diagnosis of tuberculosis in respiratory center in Baghdad', *New Iraqi Journal of Medicine*, vol. 6, no. 3, pp. 86–88.

Montenegro, LML, da Silva, BC, Lima, JFC, da Cruz, HLA, Montenegro, RA, Lundgren, FLC, de Albuquerque Filho, APL & Schindler, HC 2013, 'The performance of an in-house nested-PCR technique for pleural tuberculosis diagnoses'*, Revista da Sociedade Brasileira de Medicina Tropical*, vol. 46, no. 5, pp. 594–599.

Moon, JW, Chang, YS, Kim, SK, Kim, YS, Lee, HM, Kim, SK & Chang, J 2005, 'The clinical utility of polymerase chain reaction for the diagnosis of pleural tuberculosis', *Clinical Infectious Diseases*, vol. 41, no. 5, pp. 660–666.

Rufino, RL, Siqueira, HR, Caldas, PCS, Pereira, MADS, Medeiros, RFM, Freitas, FAD, Ramos, JP, Galvao, TC, Fandinho, FCO & Costa, CHD 2011, 'Faster detection of rifampicin and isoniazid resistant *Mycobacterium tuberculosis* by Mas-PCR method', *American Journal of Respiratory and Critical Care Medicine*, vol. 183, no. 1.

Sharma, P, Chawla, K, Chawla, A, Hegde, P & Thomas, J 2014, 'Role of PCR in the diagnosis of male genital tuberculosis', *Indian Journal of Urology*, vol. 30, p. S152.

Zar, HJ, Workman, L, Boehme, C, Eley, B & Nicol, MP 2011, 'Cartridge-based automated nucleic acid amplification test (XPERT MTB/RIF) for the diagnosis of pulmonary tuberculosis in HIV-infected and uninfected children: a prospective study', *American Journal of Respiratory and Critical Care Medicine*, vol. 183, no. 1.

**Commercial test is not TGA-approved**

Abdel-Aziz, NA, Al-Harbi, KM, Morsy, MMF, Turkistani, KA & Kurdi, FN 2011, 'Evaluation of direct detection of *Mycobacterium tuberculosis* in clinical samples using the BD ProbeTec ET system', *Saudi Medical Journal*, vol. 32, no. 2, pp. 123–127.

Aggarwal, VK, Nair, D, Khanna, G, Verma, J, Sharma, VK & Batra, S 2012, 'Use of amplified *Mycobacterium tuberculosis* direct test (Gen-Probe Inc., San Diego, CA, USA) in the diagnosis of tubercular synovitis and early arthritis of knee joint'*, Indian Journal of Orthopaedics*, vol. 46, no. 5, pp. 531–535.

Alfaresi, MS, Abdulsalam, AI & Elkoush, AA 2006, 'Comparison of the automated Cobas Amplicor *Mycobacterium tuberculosis* assay with the conventional methods for direct detection of *Mycobacterium tuberculosis* complex in respiratory and extrapulmonary specimens', *Saudi Medical Journal*, vol. 27, no. 9, pp. 1346–1351.

Alnimr, A & Alnemer, A 2012, 'Diagnostic performance of isothermal strand displacement amplification of *Mycobacterium tuberculosis* IS6110 in tissue samples', *International Journal of Mycobacteriology*, vol. 1, no. 4, pp. 170–176.

Alvarado-Esquivel, C, Garcia-Corral, N, Carrero-Dominguez, D, Enciso-Moreno, JA, Gurrola-Morales, T, Portillo-Gomez, L, Rossau, R & Mijs, W 2009, 'Molecular analysis of *Mycobacterium* isolates from extrapulmonary specimens obtained from patients in Mexico', *BMC Clinical Pathology*, vol. 9, p. 1.

Anscombe, C, Arnold, C, McHugh, TD & Shorten, R 2012, 'Comparison of two PCR systems for the detection and management of tuberculosis infection', *Clinical Microbiology and Infection*, vol. 18, p. 562.

Bang, D, Andersen, AB & Thomsen, VO 2006, 'Rapid genotypic detection of rifampin- and isoniazid-resistant *Mycobacterium tuberculosis* directly in clinical specimens', *Journal of Clinical Microbiology*, vol. 44, no. 7, pp. 2605–2608.

Bang, HI, Choi, TY & Shin, JW 2011, 'Comparison of Ogawa media, BACTEC MGIT 960 system and TB/NTM real-time PCR for detecting *Mycobacterium* species', *Tuberculosis and Respiratory Diseases*, vol. 71, no. 4, pp. 249–253.

Barber, P 2008, 'Evaluation of the BD ProbeTec ET system for the direct detection of *Mycobacterium tuberculosis* from clinical samples', *British Journal of Biomedical Science*, vol. 65, no. 1, pp. 7–12.

Bhutia, R, Narain, K, Devi, KR, Singh, TSK & Mahanta, J 2013, 'Direct and early detection of *Mycobacterium tuberculosis* complex and rifampicin resistance from sputum smears', *International Journal of Tuberculosis and Lung Disease*, vol. 17, no. 2, pp. 258–261+i.

Bicmen, C, Gunduz, AT, Coskun, M, Senol, G, Cirak, AK & Ozsoz, A 2011, 'Molecular detection and identification of *Mycobacterium tuberculosis* complex and four clinically important nontuberculous mycobacterial species in smear-negative clinical samples by the genotype mycobacteria direct test', *Journal of Clinical Microbiology*, vol. 49, no. 8, pp. 2874–2878.

Bloemberg, GV, Voit, A, Ritter, C, Deggim, V & Bottger, EC 2013, 'Evaluation of Cobas TaqMan MTB for direct detection of the *Mycobacterium tuberculosis* complex in comparison with Cobas Amplicor MTB', *Journal of Clinical Microbiology*, vol. 51, no. 7, pp. 2112–2117.

Chandran, SP & Kenneth, J 2010, 'Evaluation of COBAS TaqMan real time PCR assay for the diagnosis of *Mycobacterium tuberculosis', Indian Journal of Medical Research*, vol. 132, no. 7, pp. 100–102.

Chen, X, Yang, Q, Kong, H & Chen, Y 2012, 'Real-time PCR and Amplified MTD® for rapid detection of *Mycobacterium tuberculosis* in pulmonary specimens', *International Journal of Tuberculosis and Lung Disease*, vol. 16, no. 2, pp. 235–239.

Cho, SY, Kim, MJ, Suh, JT & Lee, HJ 2011, 'Comparison of diagnostic performance of three real-time PCR kits for detecting *Mycobacterium* species', *Yonsei Medical Journal*, vol. 52, no. 2, pp. 301–306.

Choi, YJ, Kim, HJ, Shin, HB, Nam, HS, Lee, SH, Park, JS, Park, KS & Baek, KA 2012, 'Evaluation of peptide nucleic acid probe-based real-time PCR for detection of *Mycobacterium tuberculosis* complex and nontuberculous mycobacteria in respiratory specimens', *Annals of Laboratory Medicine*, vol. 32, no. 4, pp. 257–263.

Chou, PC, Wang, CH, Huang, CD, Lo, YL, Lee, KY, Yu, CT, Lin, SM, Lin, HC & Kuo, HP 2012, 'Nucleic acid amplification test and bronchoscopy improve the diagnostic accuracy of smear-negative tuberculosis', *International Journal of Tuberculosis and Lung Disease*, vol. 16, no. 12, pp. 1674–1679.

Chua, HC, Tay, L, Wang, SX & Chan, YC 2005, 'Use of ligase chain reaction in early diagnosis of tuberculous meningitis', *Annals of the Academy of Medicine, Singapore*, vol. 34, no. 2, pp. 149–153.

Crudu, V, Stratan, E, Romancenco, E, Allerheiligen, V, Hillemann, A & Moraru, N 2012, 'First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances', *Journal of Clinical Microbiology*, vol. 50, no. 4, pp. 1264–1269.

de Luna, FFA, Ruiz, P, Gutierrez, J & Casal, M 2006, 'Evaluation of the GenoType Mycobacteria Direct assay for detection of *Mycobacterium tuberculosis* complex and four atypical mycobacterial species in clinical samples', *Journal of Clinical Microbiology*, vol. 44, no. 8, pp. 3025–3027.

Dinic, L, Idigbe, OE, Meloni, S, Rawizza, H, Akande, P, Eisen, G, Onwujekwe, D, Agbaji, O, Ani, A & Kanki, PJ 2013, 'Sputum smear concentration may misidentify acid-fast bacilli as *Mycobacterium Tuberculosis* in HIV-infected patients', *Journal of Acquired Immune Deficiency Syndromes*, vol. 63, no. 2, pp. 168–177.

Dorman, SE, Chihot, VN, Lewis, JJ, Van Meulen, MD, Mathem, B, Beylis, N, Fielding, KL, Grant, AD & Churchyard, GJ 2012, 'Genotype MTBDRplus for direct detection of *Mycobacterium tuberculosis* and drug resistance in strains from gold miners in South Africa', *Journal of Clinical Microbiology*, vol. 50, no. 4, pp. 1189–1194.

Drews, SJ, Eshaghi, A, Pyskir, D, Chedore, P, Lombos, E, Broukhanski, G, Higgins, R, Fisman, DN, Blair, J & Jamieson, F 2008, 'The relative test performance characteristics of two commercial assays for the detection of *Mycobacterium tuberculosis* complex in paraffin-fixed human biopsy specimens', *Diagnostic Pathology*, vol. 3.

Eigner, U, Veldenzer, A & Holfelder, M 2013, 'Evaluation of the fluorotype MTB assay for the rapid and reliable detection of *Mycobacterium tuberculosis* in respiratory tract specimens', *Clinical Laboratory*, vol. 59, no. 9–10, pp. 1179–1181.

Eigner, U, Veldenzer, A, Weizenegger, M & Holfelder, M 2012, 'Evaluation of the new HyBeacon-based PCR assay, FluoroType MTB, for the direct detection of *Mycobacterium tuberculosis* in respiratory and nonrespiratory specimens', *Clinical Microbiology and Infection*, vol. 18, p. 547.

El-Mahallawy, HA, Eissa, SA, Rafeh, NG, Salem, AES, Eissa, SA & Allian, SA 2010, 'Tuberculosis in cancer patients: role of newer techniques in relation to conventional diagnostic methods', *Journal of Advanced Research*, vol. 1, no. 2, pp. 157–162.

el-Sayed Zaki, M & Abou-el Hassan, S 2008, 'Clinical evaluation of Gen-Probe's amplified *Mycobacterium tuberculosis* direct test for rapid diagnosis of *Mycobacterium tuberculosis* in Egyptian children at risk for infection', *Archives of Pathology & Laboratory Medicine*, vol. 132, no. 2, pp. 244–247.

El-Sharif, A, Afifi, S, El-Dahshan, R, Rafeh, N & Eissa, S 2012, 'Characterization of *Mycobacterium tuberculosis* isolated from cancer patients with suspected tuberculosis infection in Egypt: identification, prevalence, risk factors and resistance pattern', *Clinical Microbiology and Infection*, vol. 18, no. 11, pp. E438–E445.

Fang, RD, Li, X, Hu, L, You, QM, Li, J, Wu, J, Xu, P, Zhong, HY, Luo, Y, Mei, J & Gao, Q 2009, 'Cross-priming amplification for rapid detection of *Mycobacterium tuberculosis* in sputum specimens', *Journal of Clinical Microbiology*, vol. 47, no. 3, pp. 845–847.

Fegou, E, Jelastopulu, E, Sevdali, M, Anastassiou, ED, Dimitracopoulos, G & Spiliopoulou, I 2005, 'Sensitivity of the Cobas Amplicor system for detection of *Mycobacterium tuberculosis* in respiratory and extrapulmonary specimens', *Clinical Microbiology and Infection*, vol. 11, no. 7, pp. 593–596.

Ganavalli, SA, Shetty, PC, Kulkarni, RD & Biradar, U 2013, 'PCR as a diagnostic tool for extra-pulmonary tuberculosis', *Journal of Clinical and Diagnostic Research*, vol. 7, no. 6, pp. 1012–1015.

Gladwin, MT, Plorde, JJ & Martin, TR 1998, 'Clinical application of the *Mycobacterium tuberculosis* direct test: case report, literature review, and proposed clinical algorithm', *Chest*, vol. 114, no. 1, pp. 317–323.

Goessens, WHF, de Man, P, Koeleman, JGM, Luijendijk, A, te Witt, R, Endtz, HP & van Belkum, A 2005, 'Comparison of the Cobas Amplicor MTB and BDProbeTec ET assays for detection of *Mycobacterium tuberculosis* in respiratory specimens', *Journal of Clinical Microbiology*, vol. 43, no. 6, pp. 2563–2566.

Guo, Y, Zhou, Y, Wang, C, Zhu, L, Wang, S, Li, Q, Jiang, G, Zhao, B, Huang, H, Yu, H, Xing, W, Mitchelson, K, Cheng, J & Zhao, Y 2009, 'Rapid, accurate determination of multidrug resistance in *M. tuberculosis* isolates and sputum using a biochip system', *International Journal of Tuberculosis and Lung Disease*, vol. 13, no. 7, pp. 914–920.

Hida, Y, Hisada, K, Shimada, A, Yamashita, M, Kimura, H, Yoshida, H, Iwasaki, H & Iwano, M 2012, 'Rapid detection of the *Mycobacterium tuberculosis* complex by use of quenching probe PCR (geneCube)', *Journal of Clinical Microbiology*, vol. 50, no. 11, pp. 3604–3608.

Hofmann-Thiel, S, Turaev, L & Hoffmann, H 2010, 'Evaluation of the hyplex® TBC PCR test for detection of *Mycobacterium tuberculosis* complex in clinical samples', *BMC Microbiology*, vol. 10.

Huang, CK, Huang, TS, Lin, HH, Lee, SSJ & Liu, YC 2010, 'Comparison of the Amplicor *Mycobacterium* test with microscopy and culture for diagnosis of pulmonary tuberculosis', *Journal of Internal Medicine of Taiwan*, vol. 21, no. 2, pp. 117–124.

Hung, HC, Chan, CH, Tsao, SM, Chen, SC, Wu, TC, Lu, MC, Wu, DJ, Huang, SJ & Lee, YT 2012, 'Effectiveness of the BDProbeTec ET system for detection of *Mycobacterium tuberculosis* complex in sputum and bronchoalveolar lavage specimens', *Brazilian Journal of Infectious Diseases*, vol. 16, no. 3, pp. 242–249.

Hur, M, Moon, HW, Yun, YM, Kang, TY, Kim, HS, Kim, HS, Lee, KM, Kang, SH & Lee, EH 2011, 'Detection of tuberculosis using artus® *M. tuberculosis* PCR kit and COBAS® Amplicor® *Mycobacterium tuberculosis* test', *International Journal of Tuberculosis and Lung Disease*, vol. 15, no. 6, pp. 795–798+i.

Ikegame, S, Sakoda, Y, Fujino, N, Taguchi, K, Kawasaki, M & Kajiki, A 2012, 'Clinical evaluation of COBAS TaqMan PCR for the detection of *Mycobacterium tuberculosis* and *M. avium* complex', *Tuberculosis Research and Treatment,* 2012: 170459.

Jafari, C, Kessler, P, Sotgiu, G, Ernst, M & Lange, C 2011, 'Impact of a *Mycobacterium tuberculosis*-specific interferon-(gamma) release assay in bronchoalveolar lavage fluid for a rapid diagnosis of tuberculosis', *Journal of Internal Medicine*, vol. 270, no. 3, pp. 254–262.

Jin, WM 2007, 'Sensitivity of polymerase chain reaction for pleural tuberculosis according to the amount of pleural effusion specimens', *Tuberculosis and Respiratory Diseases*, vol. 62, no. 3, pp. 184–191.

Kalafati-Tzimaka, E, Georgitzikis, I, Delikatzi, D, Chatzidimitriou, D, Tzimaka, M & Patakas, D 2008, 'Use of the amplified *Mycobacterium tuberculosis* direct test for the diagnosis of tuberculosis', *Eastern Mediterranean Health Journal*, vol. 14, no. 5, pp. 1119–1125.

Kheawon, N, Chuang-ngam, S, Mitsoongneun, S, Peam-am, J & Visalsawadi, J 2012, 'Sensitivity and specificity of real time polymerase chain reaction (RT-PCR) in bronchial washing for diagnostic pulmonary tuberculosis at Maharat Nakhorn Ratchasima Hospital', *Journal of the Medical Association of Thailand*, vol. 95, no. 11, pp. 1396–1403.

Kim, JH, Kim, YJ, Ki, CS, Kim, JY & Lee, NY 2011, 'Evaluation of COBAS® TaqMan MTB PCR for detection of *Mycobacterium tuberculosis'*, *Journal of Clinical Microbiology*, vol. 49, no. 1, pp. 173–176.

Kim, JW, Choi, YJ, Kim, HJ, Park, JS, Nam, HS, Hwangbo, Y, Kim, DU & Park, KS 2013, 'Comparison of PNA probe-based real-time PCR and COBAS® TaqMan MTB for detection of MTBC', *Biochip Journal*, vol. 7, no. 2, pp. 85–88.

Kiraz, N, Saglik, I, Kiremitci, A, Kasifoglu, N & Akgun, Y 2010, 'Evaluation of the GenoType Mycobacteria Direct assay for direct detection of the *Mycobacterium tuberculosis* complex obtained from sputum samples', *Journal of Medical Microbiology*, vol. 59, no. 8, pp. 930–934.

Krogh, K, Surén, P, Mengshoel, AT & Brandtzæg, P 2010, 'Tuberculosis among children in Oslo, Norway, from 1998 to 2009', *Scandinavian Journal of Infectious Diseases*, vol. 42, no. 11–12, pp. 866–872.

Kurtoglu, MG, Ozdemir, M, Kesli, R & Baysal, B 2014, 'Comparison of the GenoType® MTBC molecular genetic assay with culture methods in the diagnosis of tuberculosis', *Archives of Medical Science*, vol. 10, no. 2, pp. 315–318.

Lara-Oya, A, Mendoza-Lopez, P, Rodriguez-Granger, J, Fernandez-Sanchez, AM, Bermudez-Ruiz, MP, Toro-Peinado, I, Palop-Borras, B, Navarro-Mari, JM & Martinez-Lirola, MJ 2013, 'Evaluation of the Speed-oligo® direct *Mycobacterium tuberculosis* assay for molecular detection of mycobacteria in clinical respiratory specimens', *Journal of Clinical Microbiology*, vol. 51, no. 1, pp. 77–82.

Lee, H, Park, KG, Lee, G, Park, J, Park, YG & Park, YJ 2014, 'Assessment of the quantitative ability of AdvanSure TB/NTM real-time PCR in respiratory specimens by comparison with phenotypic methods', *Annals of Laboratory Medicine*, vol. 34, no. 1, pp. 51–55.

Lee, J, Lee, SY, Choi, KJ, Lim, JK, Yoo, SS, Lee, SY, Cha, SI, Park, JY & Kim, CH 2013, 'Clinical utility of CT-based bronchial aspirate TB-PCR for the rapid diagnosis of pleural tuberculosis', *Tuberculosis and Respiratory Diseases*, vol. 75, no. 4, pp. 150–156.

Lee, JE, Lee, BJ, Roh, EY, Kim, DK, Chung, HS & Lee, CH 2011, 'The diagnostic accuracy of tuberculosis real-time polymerase chain reaction analysis of computed tomography-guided bronchial wash samples', *Diagnostic Microbiology and Infectious Disease*, vol. 71, no. 1, pp. 51–56.

Lee, MR, Chung, KP, Wang, HC, Lin, CB, Yu, CJ, Lee, JJ & Hsueh, PR 2013, 'Evaluation of the Cobas® TaqMan MTB real-time PCR assay for direct detection of *Mycobacterium tuberculosis* in respiratory specimens', *Journal of Medical Microbiology*, vol. 62, no. 8, pp. 1160–1164.

Lim, J, Kim, J, Kim, JW, Im, C, Sohn, YH, Cho, HJ, Kim, J & Koo, SH 2014, 'Multicenter evaluation of Seegene Anyplex TB PCR for the detection of *Mycobacterium tuberculosis* in respiratory specimens', *Journal of Microbiology and Biotechnology*, 30 April.

Lin, CB, Chou, HW, Lin, WC, Lin, TY, Lin, TP, Luh, KT & Lee, JJ 2011, 'Is it appropriate to routinely use a nucleic acid amplification test for the diagnosis of tuberculosis?', *Kaohsiung Journal of Medical Sciences*, vol. 27, no. 4, pp. 138–143.

Lin, CM, Lin, SM, Chung, FT, Lin, HC, Lee, KY, Huang, CD, Kuo, CH, Liu, CY, Wang, CH & Kuo, HP 2012, 'Amplified *Mycobacterium tuberculosis* direct test for diagnosing tuberculous pleurisy: a diagnostic accuracy study', *PLOS ONE*, vol. 7, no. 9.

Linasmita, P, Srisangkaew, S, Wongsuk, T, Bhongmakapat, T & Watcharananan, SP 2012, 'Evaluation of real-time polymerase chain reaction for detection of the 16s ribosomal RNA gene of *Mycobacterium tuberculosis* and the diagnosis of cervical tuberculous lymphadenitis in a country with a high tuberculosis incidence', *Clinical Infectious Diseases*, vol. 55, no. 3, pp. 313–321.

Ling, DI, Zwerling, AA & Pai, M 2008, 'GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis', *European Respiratory Journal*, vol. 32, no. 5, pp. 1165–1174.

Luetkemeyer, AF, Kendall, MA, Wu, X, Lourenço, MC, Jentsch, U, Swindells, S, Qasba, SS, Sanchez, J, Havlir, DV, Grinsztejn, B, Sanne, IM & Firnhaber, C 2014, 'Evaluation of two line probe assays for rapid detection of *Mycobacterium tuberculosis*, tuberculosis (TB) drug resistance, and non-TB mycobacteria in HIV-infected individuals with suspected TB', *Journal of Clinical Microbiology*, vol. 52, no. 4, pp. 1052–1059.

Mamouha, S, Velentza, A, Bassoulis, D, Bouza, K, Perakis, G, Stamoulos, K, Pavlou, K, Papafragas, E & Fakiri, E 2010, 'Laboratory approach to the mycobacterial infections in a tertiary hospital: five years’ results (2005–2009)', *Acta Microbiologica Hellenica*, vol. 55, no. 2, pp. 133–141.

Marlowe, EM, Novak-Weekley, SM & Cumpio, JV 2010, 'Comparison of three molecular methods for the direct detection of *Mycobacterium tuberculosis* complex from respiratory and non-respiratory specimens', *Journal of Molecular Diagnostics*, vol. 12, no. 6, p. 885.

Michos, AG, Daikos, GL, Tzanetou, K, Theodoridou, M, Moschovi, M, Nicolaidou, P, Petrikkos, G, Syriopoulos, T, Kanavaki, S & Syriopoulou, VP 2006, 'Detection of *Mycobacterium tuberculosis* DNA in respiratory and nonrespiratory specimens by the Amplicor®MTB PCR', *Diagnostic Microbiology and Infectious Disease*, vol. 54, no. 2, pp. 121–126.

Miragliotta, G, Antonetti, R, Di Taranto, A, Mosca, A & Del Prete, R 2005, 'Direct detection of *Mycobacterium tuberculosis* complex in pulmonary and extrapulmonary samples by BDProbeTec® ET system', *Microbiologica*, vol. 28, no. 1, pp. 67–73.

Moore, DF, Guzman, JA & Mikhail, LT 2005, 'Reduction in turnaround time for laboratory diagnosis of pulmonary tuberculosis by routine use of a nucleic acid amplification test', *Diagnostic Microbiology and Infectious Disease*, vol. 52, no. 3, pp. 247–254.

Moure, R, Torres, M, Martin, R & Alcaidea, F 2012, 'Direct detection of *Mycobacterium tuberculosis* complex in clinical samples by a molecular method based on GenoQuick technology', *Journal of Clinical Microbiology*, vol. 50, no. 6, pp. 2089–2091.

Neonakis, IK, Gitti, Z, Baritaki, S, Petinaki, E, Baritaki, M & Spandidos, DA 2009, 'Evaluation of GenoType *Mycobacteria* direct assay in comparison with Gen-Probe *Mycobacterium tuberculosis* amplified direct test and GenoType MTBDRplus for direct detection of *Mycobacterium tuberculosis* complex in clinical samples', *Journal of Clinical Microbiology*, vol. 47, no. 8, pp. 2601–2603.

Ou, XC, Li, Q, Xia, H, Pang, Y, Wang, SF, Zhao, B, Song, YY, Zhou, Y, Zheng, Y, Zhang, ZJ, Zhang, ZY, Li, JC, Dong, HY, Zhang, J, Kam, KM, Chi, JY, Huan, ST, Chin, DP & Zhao, YL 2014, 'Diagnostic accuracy of the PURE-LAMP test for pulmonary tuberculosis at the county-level laboratory in China', *PLOS ONE*, vol. 9, no. 5.

Ozekinci, T, Mese, S, Atmaca, S, Akpolat, N & Gul, K 2007, 'Evaluation of the Ehrlich-Ziehl-Neelsen (EZN) and amplified *Mycobacterium tuberculosis* direct test according to the BACTEC method in respiratory and nonrespiratory samples', *Turkish Journal of Medical Sciences*, vol. 37, no. 3, pp. 145–149.

Ozkutuk, A, Kirdar, S, Ozden, S & Esen, N 2006, 'Evaluation of Cobas® Amplicor MTB test to detect *Mycobacterium tuberculosis* in pulmonary and extrapulmonary specimens', *New Microbiologica*, vol. 29, no. 4, pp. 269–273.

Papaventsis, D, Ioannidis, P, Karabela, S, Nikolaou, S, Syridou, G, Marinou, I, Konstantinidou, E, Amanatidou, V, Spyridis, N, Kanavaki, S & Tsolia, M 2012, 'Impact of the Gen-Probe amplified MTD® test on tuberculosis diagnosis in children', *International Journal of Tuberculosis and Lung Disease*, vol. 16, no. 3, pp. 384–390.

Patwardhan, SA, Bhargava, P, Bhide, VM & Kelkar, DS 2011, 'A study of tubercular lymphadenitis: a comparison of various laboratory diagnostic modalities with a special reference to tubercular polymerase chain reaction', *Indian Journal of Medical Microbiology*, vol. 29, no. 4, pp. 389–394.

Perandin, F, Pinsi, G, Signorini, C & Manca, N 2006, 'Evaluation of INNO-LiPA assay for direct detection of mycobacteria in pulmonary and extrapulmonary specimens', *New Microbiologica*, vol. 29, no. 2, pp. 133–138.

Peter-Getzlaff, S, Luthy, J, Voit, A, Bloemberg, GV & Bottger, EC 2010, 'Detection and identification of *Mycobacterium* spp. in clinical specimens by combining the Roche Cobas Amplicor *Mycobacterium tuberculosis* assay with *Mycobacterium* genus detection and nucleic acid sequencing', *Journal of Clinical Microbiology*, vol. 48, no. 11, pp. 3943–3948.

Piersimoni, C, Bornigia, S & Gherardi, G 2012, 'Performance of a commercial nucleic acid amplification test with extrapulmonary specimens for the diagnosis of tuberculosis', *European Journal of Clinical Microbiology and Infectious Diseases*, vol. 31, no. 3, pp. 287–293.

Piersimoni, C, Nista, D, Zallocco, D, Galassi, M, Cimarelli, ME & Tubaldi, A 2005, 'Clinical suspicion as a primary guidance to use commercial amplification tests for rapid diagnosis of pulmonary tuberculosis', *Diagnostic Microbiology and Infectious Disease*, vol. 53, no. 3, pp. 195–200.

Pounder, JI, Aldous, WK & Woods, GL 2006, 'Comparison of real-time polymerase chain reaction using the Smart Cycler and the Gen-Probe amplified *Mycobacterium tuberculosis* direct test for detection of *M. tuberculosis* complex in clinical specimens', *Diagnostic Microbiology and Infectious Disease*, vol. 54, no. 3, pp. 217–222.

Raslan, WF, Rabaan, A & Al-Tawfiq, JA 2014, 'The predictive value of Gen-Probe's amplified *Mycobacterium tuberculosis* direct test compared with culturing in paraffin-embedded lymph node tissue exhibiting granulomatous inflammation and negative acid fast stain', *Journal of Infection and Public Health*, 8 March.

Safianowska, A, Walkiewicz, R, Nejman-Gryz, P & Grubek-Jaworska, H 2012, 'Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis', *Pneumonologia i Alergologia Polska*, vol. 80, no. 1, pp. 6–12.

Selman B, C, Poggi M, H, Juan C, R, García C, P & Lagos L, M 2009, 'Assessment of the Amplicor PCR® for the detection of *Mycobacterium tuberculosis* in smear negative respiratory and nonrespiratory specimens: a retrospective analysis', *Revista Chilena de Infectologia*, vol. 26, no. 6, pp. 495–498.

Sener, AG, Kurultay, N & Afsar, I 2008, 'Evaluation of the results of *Mycobacterium tuberculosis* direct test (MTD) and mycobacterial culture in urine samples', *Brazilian Journal of Microbiology*, vol. 39, no. 4, pp. 673–675.

Seoudi, N, Mitchell, SL, Brown, TJ, Dashti, F, Amin, AK & Drobniewski, FA 2012, 'Rapid molecular detection of tuberculosis and rifampicin drug resistance: retrospective analysis of a national UK molecular service over the last decade', *Thorax*, vol. 67, no. 4, pp. 361–367.

Solomons, R, Visser, D, Van Toorn, R & Schoeman, J 2012, 'The value of fluorescent microscopy and PCR in the early diagnosis of tuberculous meningitis and mycobacterial resistance: preliminary observations', *Developmental Medicine and Child Neurology*, vol. 54, p. 16.

Somoskovi, A, Dormandy, J, Rivenburg, J, Pedrosa, M, McBride, M & Salfinger, M 2008, 'Direct comparison of the GenoType MTBC and genomic deletion assays in terms of ability to distinguish between members of the *Mycobacterium tuberculosis* complex in clinical isolates and in clinical specimens’*, Journal of Clinical Microbiology*, vol. 46, no. 5, pp. 1854–1857.

Suh, S, Lee, O, Choi, H, Kee, S, Shin, J, Ryang, D & Park, B 2013, 'Use in routine clinical practice of two commercial real-time PCR assays for detection of *Mycobacterium tuberculosis* complex: comparison of cobas TaqMan MTB test and AdvanSure TB/NTM real-time PCR', *Journal of Molecular Diagnostics*, vol. 15, no. 6, p. 888.

Suh, S, Lee, O, Kee, S, Shin, M, Shin, J, Ryang, D & Park, B 2012, 'Comparison of whole-blood IGRA, TST, PCR, and HRCT for rapid diagnosis of smear-negative pulmonary tuberculosis in Korea', *Journal of Molecular Diagnostics*, vol. 14, no. 6, pp. 677–678.

Syre, H, Myneedu, VP, Arora, VK & Grewal, HMS 2009, 'Direct detection of mycobacterial species in pulmonary specimens by two rapid amplification tests, the Gen-Probe amplified *Mycobacterium tuberculosis* direct test and the GenoType Mycobacteria direct test', *Journal of Clinical Microbiology*, vol. 47, no. 11, pp. 3635–3639.

Szpinda, I, Myhre, A, Hamsun, H, Grewal, H & Tonjum, T 2010, 'Improved sensitivity of rapid detection of *Mycobacterium tuberculosis* in clinical specimens by real-time PCR', *Clinical Microbiology and Infection*, vol. 16, p. S52.

Takakura, S, Tsuchiya, S, Isawa, Y, Yasukawa, K, Hayashi, T, Tomita, M, Suzuki, K, Hasegawa, T, Tagami, T, Kurashima, A & Ichiyama, S 2005, 'Rapid detection of *Mycobacterium tuberculosis* in respiratory samples by transcription-reverse transcription concerted reaction with an automated system', *Journal of Clinical Microbiology*, vol. 43, no. 11, pp. 5435–5439.

Tanaka, H, Hirose, H, Kato, Y, Kida, S & Miyajima, E 2010, 'Clinical evaluation of TRCRapid M.TB for detection of *Mycobacterium tuberculosis* complex in respiratory and nonrespiratory specimens', *Journal of Clinical Microbiology*, vol. 48, no. 5, pp. 1536–1541.

Tortoli, E & Marcelli, F 2007, 'Use of the INNOLiPA Rif.TB for detection of *Mycobacterium tuberculosis* DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility', *European Journal of Clinical Microbiology & Infectious Diseases*, vol. 26, no. 1, pp. 51–55.

Tortoli, E, Urbano, P, Marcelli, F, Simonetti, TM & Cirilloa, DM 2012, 'Is real-time PCR better than conventional PCR for *Mycobacterium tuberculosis* complex detection in clinical samples?', *Journal of Clinical Microbiology*, vol. 50, no. 8, pp. 2810–2813.

Totten, S, May, R & Heifets, LB 2011, 'Comparative study of two diagnostic tools for the rapid detection of *Mycobacterium tuberculosis* complex from smear positive respiratory specimens', *American Journal of Respiratory and Critical Care Medicine*, vol. 183, no. 1.

Traore, H, van Deun, A, Shamputa, IC, Rigouts, L & Portaels, F 2006, 'Direct detection of *Mycobacterium tuberculosis* complex DNA and rifampin resistance in clinical specimens from tuberculosis patients by line probe assay', *Journal of Clinical Microbiology*, vol. 44, no. 12, pp. 4384–4388.

van den Wijngaert, S, Scheen, R, Vandenberg, O & Dediste, A 2009, 'A prospective evaluation of selection criteria for the use of nucleic acid amplification techniques to test for the presence of *Mycobacterium tuberculosis* in respiratory tract samples', *Clinical Laboratory*, vol. 55, no. 11–12, pp. 441–446.

Vorkas, C, Kayira, D, van der Horst, C, Hoffman, I, Hosseinipour, M, Kanyemba, C, Nguluwe, N, Chikaonda, T, Kalikhoka, M, Kalaundi, D, Namarika, D, Gilligan, P & Krysiak, R 2012, 'Tuberculosis drug resistance and outcomes among tuberculosis inpatients in Lilongwe, Malawi', *Malawi Medical Journal*, vol. 24, no. 2, pp. 21–24.

Wang, JY, Lee, LN, Hsu, HL, Hsueh, PR & Luh, KT 2006, 'Performance assessment of the DR. MTBC screen assay and the BD ProbeTec ET system for direct detection of *Mycobacterium tuberculosis* in respiratory specimens', *Journal of Clinical Microbiology*, vol. 44, no. 3, pp. 716–719.

Wang, JY, Lee, LN, Lai, HC, Hsu, HL, Jan, IS, Yu, CJ, Hsueh, PR & Yang, PC 2007, 'Performance assessment of the Capilia TB assay and the BD ProbeTec ET system for rapid culture confirmation of *Mycobacterium tuberculosis'*, *Diagnostic Microbiology and Infectious Disease*, vol. 59, no. 4, pp. 395–399.

Wiener, RS, Della-Latta, P & Schluger, NW 2005, 'Effect of nucleic acid amplification for *Mycobacterium tuberculosis* on clinical decision making in suspected extrapulmonary tuberculosis', *Chest*, vol. 128, no. 1, pp. 102–107.

Yang, YC, Lu, PL, Huang, SC, Jenh, YS, Jou, R & Chang, TC 2011, 'Evaluation of the Cobas® TaqMan MTB test for direct detection of *Mycobacterium tuberculosis* complex in respiratory specimens', *Journal of Clinical Microbiology*, vol. 49, no. 3, pp. 797–801.

Zhang, L, Ye, Y, Duo, L, Wang, T, Song, X, Lu, X, Ying, B & Wang, L 2011, 'Application of Genotype MTBDRplus in rapid detection of the *Mycobacterium tuberculosis* complex as well as its resistance to isoniazid and rifampin in a high volume laboratory in Southern China', *Molecular Biology Reports*, vol. 38, no. 3, pp. 2185–2192.

# Appendix H Economic literature search

#### Literature search for previously published economic evaluations of NAAT

(tuberculosis OR MTB OR MTB/RIF OR “tubercle bacillus” OR Tuberculosis [MeSH] OR “M. bovis” OR “M. africanum” OR “M. microti” OR “M. canetti”) AND (Amplicor OR Amplified OR “Direct Test” OR “Direct Detection” OR TaqMan OR Xpert OR “nucleic acid amplification” OR NAAT OR “Nucleic Acid Amplification Techniques” [MeSH]) AND (economic evaluation OR cost effectiveness OR cost utility OR decision model)

|  |  |
| --- | --- |
| **Database** | **Last updated** |
| Centre for Reviews and Dissemination database – including Database of Abstracts of Reviews of Effects, the Health Technology Assessment Database, the NHS Economic Evaluation Database | 19 May 2014 |
| PubMed | 19 May 2014 |

#### Literature search for utility weights in TB

Tuberculosis AND (quality of life OR utility OR EQ-5D OR euroqol OR time trade off OR standard gamble OR visual analogue scale OR VAS OR SF-36 OR SF-6D OR SF 6D OR SF 36 OR EQ 5D)

|  |  |
| --- | --- |
| **Database** | **Last updated** |
| PubMed | 15 August 2014 |

# Appendix I Additional information relating to the economic evaluation

#### Amikacin administration costs

Table 102 Amikacin administration costs

| - | False-positive MDR-TB | True MDR-TB |
| --- | --- | --- |
| Average administrations per week | 5 | 4 |
| Weeks treated | 8.7 | 26.1 |
| Total amikacin administrations | 43.5 | 104.4 |
| In-patient administrations | 9.3 | 14.9 |
| Outpatient administrations | 34.2 | 89.5 |
| Cost of outpatient administration | $234 | $234 |
| Total administration costs | $8,002 | $20,943 |

MDR-TB = multidrug-resistant tuberculosis

#### Utility values

Table 103 Utility values identified in studies that elicit utilities in a TB population

| Study | Utility weight | Comments |
| --- | --- | --- |
| Winetsky et al. ([2012](#_ENREF_224)) | No TB / recovered 1.00  Active TB ± MDR, undiagnosed 0.73  Active TB ± MDR, AFB− treated 0.68  Active TB ± MDR, AFB+ treated 0.60 | Former Soviet Union prison inmates—unclear how preferences were elicited |
| Kittikraisak et al. ([2012](#_ENREF_104)) | TB (treated) 0.65  MDR-TB (treated) 0.49  Cured TB ± MDR 0.89  HIV (no TB) 0.75  HIV with TB (treated) 0.62  Cured TB ± MDR with HIV 0.88 | Thai patients diagnosed with TB (including those on treatment and those who had completed treatment) and/or HIV  EQ-5D weights adjusted for age and monthly household income (also presents unadjusted weights with standard error) |
| Awaisu et al. ([2012](#_ENREF_14)) | At baseline 0.70  At 3 months treatment 0.87  At 6 months treatment 0.91 | Malaysian smokers newly diagnosed with TB  EQ-5D weights for control group (treatment administered by DOTS) |
| Kruijshaar et al. ([2010](#_ENREF_107)) (reported in Jit et al. ([2011](#_ENREF_94))) | Untreated TB 0.68  After 2 months treatment 0.81 | UK patients diagnosed with active TB were administered generic health-related quality-of-life questionnaires (EQ-5D and SF-36) at diagnosis and 2 months into therapy. The median time between questionnaires was 73 days (IQR: 54-104)  Overall scores are not reported in Krujisharr et al. ([2010](#_ENREF_107)), but are reported in Jit et al. ([2011](#_ENREF_94)) |
| Babikako et al. ([2010](#_ENREF_15)) | At baseline 0.607  At 2 months treatment 0.671  At 8 months treatment 0.785 | Ugandan patients with known HIV status and TB enrolled based on duration of TB therapy: started at 2 months and completed at 8 months |
| Guo et al. ([2008](#_ENREF_79)) | Active TB (treated) 0.68 (0.65–0.72)  By severity of TB symptoms:  Very mild 0.84 (0.11)  Mild 0.68 (0.05)  Moderate 0.64 (0.10)  Severe 0.59 (0.15)  Very severe 0.54 (0.08) | Canadian patients with recent diagnosis of active TB (within 2 months)  Measure using the SF-6D (also HUI2, HUI3 and VAS)  Also reports by self-reported symptom control |

AFB = acid-fast bacilli; DOTS = directly observed treatment, short-course; HIV = human immunodeficiency virus; IQR = inter-quartile range; MDR = multidrug-resistant; MDR-TB = multidrug-resistant tuberculosis; TB = tuberculosis; VAS = visual analogue scale

#### Results of the economic evaluation

Results of the economic evaluation, AFB model arm

Figure 55 Results of the economic evaluation, AFB model arm

AFB = acid-fast bacilli test; C = culture; MDR = multidrug-resistant; R = resistance; RIF res = rifampicin-resistant; RIF suscept = rifampicin-susceptible; S = susceptibility; TB = tuberculosis

Results of the economic evaluation, AFB plus NAAT model arm

Figure 56 Results of the economic evaluation, AFB plus NAAT model arm

AFB = acid-fast bacilli test; C = culture; MDR = multidrug-resistant; NAAT = nucleic acid amplification test; R = resistance; RIF res = rifampicin-resistant; RIF suscept = rifampicin-susceptible; S = susceptibility; TB = tuberculosis

#### Additional scenarios

###### TB low-suspicion scenario

Table 104 Outcome state probabilities, TB low scenario

| True status | Treated status | AFB | AFB + NAAT | Difference |
| --- | --- | --- | --- | --- |
| No TB | Untreated | 76.4% | 77.2% | 0.75% |
| No TB | Standard treatment | 1.6% | 0.8% | –0.76% |
| No TB | MDR treatment | 0.0% | 0.0% | 0.01% |
| TB | Untreated | 9.5% | 3.1% | –6.40% |
| TB | Standard treatment | 12.1% | 18.3% | 6.21% |
| TB | MDR treatment | 0.0% | 0.2% | 0.18% |
| MDR-TB | Untreated | 0.2% | 0.1% | –0.13% |
| MDR-TB | Standard treatment | 0.2% | 0.0% | –0.22% |
| MDR-TB | MDR treatment | 0.0% | 0.3% | 0.35% |
| **TOTAL** | **-** | **100%** | **100%** | **0%** |

Note: The probabilities associated with the correct treatment are highlighted.

AFB = acid-fast bacilli; MDR = multidrug-resistant; NAAT = nucleic acid amplification test; TB = tuberculosis

Table 105 Breakdown of incremental costs, TB low scenario

| Cost | AFB | AFB + NAAT | Increment |
| --- | --- | --- | --- |
| Treatment | $556.06 | $580.41 | $24.36 |
| Treatment of AEs | $3.02 | $2.97 | –$0.05 |
| Management | $174.78 | $172.86 | –$1.92 |
| Hospitalisation | $1,212.03 | $1,176.62 | –$35.40 |
| TB transmissions | $159.54 | $85.96 | –$73.58 |
| NAAT cost | $0.00 | $130.00 | $130.00 |
| **TOTAL** | **$2,105.43** | **$2,148.83** | **$43.39** |

AEs = adverse events; AFB = acid fast bacilli; NAAT = nucleic acid amplification test; TB = tuberculosis

Table 106 Weighted utility by outcome state, TB low scenario

| True status | Treated status | AFB | AFB + NAAT | Increment |
| --- | --- | --- | --- | --- |
| No TB | Untreated | 1.075 | 1.085 | 0.011 |
| No TB | Standard treatment | 0.022 | 0.011 | –0.011 |
| No TB | MDR treatment | 0.000 | 0.000 | 0.000 |
| TB | Untreated | 0.127 | 0.041 | –0.085 |
| TB | Standard treatment | 0.165 | 0.250 | 0.085 |
| TB | MDR treatment | 0.000 | 0.002 | 0.002 |
| MDR-TB | Untreated | 0.002 | 0.001 | –0.002 |
| MDR-TB | Standard treatment | 0.003 | 0.000 | –0.003 |
| MDR-TB | MDR treatment | 0.000 | 0.004 | 0.004 |
| **TOTAL** | **-** | **1.394** | **1.396** | **0.002** |

Note: The outcomes associated with the correct treatment are highlighted.

AFB = acid-fast bacilli; MDR = multidrug-resistant; NAAT = nucleic acid amplification test; TB = tuberculosis

###### Perfect clinical judgement scenario

Table 107 Outcome state probabilities, perfect clinical judgement scenario

| True status | Treated status | AFB | AFB + NAAT | Difference |
| --- | --- | --- | --- | --- |
| No TB | Untreated | 76.4% | 77.2% | 0.75% |
| No TB | Standard treatment | 1.6% | 0.8% | –0.76% |
| No TB | MDR treatment | 0.0% | 0.0% | 0.01% |
| TB | Untreated | 0.0% | 0.0% | 0.00% |
| TB | Standard treatment | 21.6% | 21.4% | –0.18% |
| TB | MDR treatment | 0.0% | 0.2% | 0.18% |
| MDR-TB | Untreated | 0.0% | 0.0% | 0.00% |
| MDR-TB | Standard treatment | 0.4% | 0.1% | –0.35% |
| MDR-TB | MDR treatment | 0.0% | 0.3% | 0.35% |
| **TOTAL** | **-** | **100%** | **100%** | **0%** |

Note: The probabilities associated with the correct treatment are highlighted.

AFB = acid-fast bacilli; MDR = multidrug-resistant; NAAT = nucleic acid amplification test; TB = tuberculosis

Table 108 Breakdown of incremental costs, perfect clinical judgement scenario

| Cost | AFB | AFB + NAAT | Increment |
| --- | --- | --- | --- |
| Treatment | $557.70 | $580.95 | $23.25 |
| Treatment of AEs | $3.05 | $2.98 | –$0.07 |
| Management | $175.21 | $173.00 | –$2.21 |
| Hospitalisation | $1,212.03 | $1,176.62 | –$35.40 |
| TB transmissions | $68.22 | $56.24 | –$11.98 |
| NAAT cost | $0.00 | $130.00 | $130.00 |
| **TOTAL** | **$2,016.20** | **$2,119.79** | **$103.59** |

AEs = adverse events; AFB = acid-fast bacilli; NAAT = nucleic acid amplification test; TB = tuberculosis

Table 109 Weighted utility by outcome state, perfect clinical judgement scenario

| True status | Treated status | AFB | AFB + NAAT | Increment |
| --- | --- | --- | --- | --- |
| No TB | Untreated | 1.075 | 1.085 | 0.011 |
| No TB | Standard treatment | 0.022 | 0.011 | –0.011 |
| No TB | MDR treatment | 0.000 | 0.000 | 0.000 |
| TB | Untreated | 0.000 | 0.000 | 0.000 |
| TB | Standard treatment | 0.295 | 0.293 | –0.003 |
| TB | MDR treatment | 0.000 | 0.002 | 0.002 |
| MDR-TB | Untreated | 0.000 | 0.000 | 0.000 |
| MDR-TB | Standard treatment | 0.005 | 0.001 | –0.004 |
| MDR-TB | MDR treatment | 0.000 | 0.004 | 0.004 |
| **TOTAL** | **-** | **1.397** | **1.397** | **0.0001** |

Note: the outcomes associated with the correct treatment are highlighted.

AFB = acid-fast bacilli; MDR = multidrug-resistant; NAAT = nucleic acid amplification test; TB = tuberculosis

###### TB high-suspicion scenario

Table 110 Outcome state probabilities, TB high scenario

| True status | Treated status | AFB | AFB + NAAT | Difference |
| --- | --- | --- | --- | --- |
| No TB | Untreated | 0.0% | 0.0% | 0.00% |
| No TB | Standard treatment | 78.0% | 78.0% | –0.01% |
| No TB | MDR treatment | 0.0% | 0.0% | 0.01% |
| TB | Untreated | 0.0% | 0.0% | 0.00% |
| TB | Standard treatment | 21.6% | 21.4% | –0.18% |
| TB | MDR treatment | 0.0% | 0.2% | 0.18% |
| MDR-TB | Untreated | 0.0% | 0.0% | 0.00% |
| MDR-TB | Standard treatment | 0.4% | 0.1% | –0.35% |
| MDR-TB | MDR treatment | 0.0% | 0.3% | 0.35% |
| **TOTAL** | **-** | **100%** | **100%** | **0.00%** |

Note: The probabilities associated with the correct treatment are highlighted.

AFB = acid-fast bacilli; MDR = multidrug-resistant; NAAT = nucleic acid amplification test; TB = tuberculosis

Table 111 Breakdown of incremental costs, TB high scenario

| Cost | AFB | AFB + NAAT | Increment |
| --- | --- | --- | --- |
| Treatment | $1,206.95 | $1,236.56 | $29.61 |
| Treatment of AEs | $12.44 | $12.46 | $0.02 |
| Management | $404.91 | $404.95 | $0.04 |
| Hospitalisation | $4,826.22 | $4,826.22 | $0.00 |
| TB transmissions | $93.90 | $82.17 | –$11.73 |
| NAAT cost | $0.00 | $130.00 | $130.00 |
| **TOTAL** | **$6,544.41** | **$6,692.36** | **$147.95** |

AEs = adverse events; AFB = acid-fast bacilli; NAAT = nucleic acid amplification test; TB = tuberculosis

Table 112 Weighted utility by outcome state, TB high scenario

| True status | Treated status | AFB | AFB + NAAT | Increment |
| --- | --- | --- | --- | --- |
| No TB | Untreated | 0.000 | 0.000 | 0.000 |
| No TB | Standard treatment | 1.091 | 1.091 | 0.000 |
| No TB | MDR treatment | 0.000 | 0.000 | 0.000 |
| TB | Untreated | 0.000 | 0.000 | 0.000 |
| TB | Standard treatment | 0.295 | 0.293 | –0.003 |
| TB | MDR treatment | 0.000 | 0.002 | 0.002 |
| MDR-TB | Untreated | 0.000 | 0.000 | 0.000 |
| MDR-TB | Standard treatment | 0.005 | 0.001 | –0.004 |
| MDR-TB | MDR treatment | 0.000 | 0.004 | 0.004 |
| **TOTAL** | **-** | **1.391** | **1.391** | **0.0001** |

Note: The outcomes associated with the correct treatment are highlighted.

AFB = acid-fast bacilli; MDR = multidrug-resistant; NAAT = nucleic acid amplification test; TB = tuberculosis

###### Incorporating costs in a stepped manner

Table 113 Stepped economic evaluation, TB low and TB high scenarios

| Utilities considered | Costs included (NAAT cost applied in AFB + NAAT arm) | ICER |
| --- | --- | --- |
| **TB low scenario** | - | - |
| Index patient utility | Treatment only | $75,861 |
| Index patient utility | Treatment and AEs | $75,835 |
| Index patient utility | Treatment, AEs and management | $74,891 |
| Index patient utility | Treatment, AEs, management and hospitalisation | $57,491 |
| Index patient utility | Treatment, AEs, management, hospitalisation and transmission | $21,327 |
| Index and secondary case utility | Treatment, AEs, management, hospitalisation and transmission | $18,533 |
| **Perfect clinical judgment scenario** | - | - |
| Index patient utility | Treatment only | $1,174,732 |
| Index patient utility | Treatment and AEs | $1,174,199 |
| Index patient utility | Treatment, AEs and management | $1,157,291 |
| Index patient utility | Treatment, AEs, management and hospitalisation | $885,893 |
| Index patient utility | Treatment, AEs, management, hospitalisation and transmission | $794,067 |
| Index and secondary case utility | Treatment, AEs, management, hospitalisation and transmission | $724,423 |
| **TB high scenario** | - | - |
| Index patient utility | Treatment only | $2,163,187 |
| Index patient utility | Treatment and AEs | $2,163,492 |
| Index patient utility | Treatment, AEs and management | $2,164,093 |
| Index patient utility | Treatment, AEs, management and hospitalisation | $2,164,093 |
| Index patient utility | Treatment, AEs, management, hospitalisation and transmission | $2,005,150 |
| Index and secondary case utility | Treatment, AEs, management, hospitalisation and transmission | $1,713,838 |

AEs = adverse events; ICER = incremental cost-effectiveness ratio

# Appendix J Alternative NAAT fees

Table 114 The effect on the ICER of alternative NAAT item fees

| NAAT fee | ICER |
| --- | --- |
| $28.65 | Dominant |
| $40.00 | Dominant |
| $70.00 | $26,768 |
| $82.00 | $39,560 |
| $100.50 | $59,281 |
| **$130.00** | **$90,728** |
| $200.00 | $165,348 |

Note: Figures in **bolded** text were used in the base case analysis.

Table 115 The effect on the financial implications of alternative NAAT item fees

| - | 2015 | 2016 | 2017 | 2018 | 2019 |
| --- | --- | --- | --- | --- | --- |
| *NAAT fee: $28.65* | - | - | - | - | - |
| Total cost of NAAT for TB | $538,276 | $562,973 | $587,640 | $612,336 | $637,004 |
| Total cost of NAAT (inc. NAAT for NTM) | $1,759,496 | $1,840,223 | $1,920,855 | $2,001,581 | $2,082,214 |
| *NAAT fee: $40.00* | - | - | - | - | - |
| Total cost of NAAT for TB | $751,520 | $786,000 | $820,440 | $854,920 | $889,360 |
| Total cost of NAAT (inc. NAAT for NTM) | $1,972,740 | $2,063,250 | $2,153,655 | $2,244,165 | $2,334,570 |
| *NAAT fee: $70.00* | - | - | - | - | - |
| Total cost of NAAT for TB | $1,315,160 | $1,375,500 | $1,435,770 | $1,496,110 | $1,556,380 |
| Total cost of NAAT (inc. NAAT for NTM) | $2,536,380 | $2,652,750 | $2,768,985 | $2,885,355 | $3,001,590 |
| *NAAT fee: $82.00* | - | - | - | - | - |
| Total cost of NAAT for TB | $1,540,616 | $1,611,300 | $1,681,902 | $1,752,586 | $1,823,188 |
| Total cost of NAAT (inc. NAAT for NTM) | $2,761,836 | $2,888,550 | $3,015,117 | $3,141,831 | $3,268,398 |
| *NAAT fee: $100.50* | - | - | - | - | - |
| Total cost of NAAT for TB | $1,888,194 | $1,974,825 | $2,061,356 | $2,147,987 | $2,234,517 |
| Total cost of NAAT (inc. NAAT for NTM) | $3,109,414 | $3,252,075 | $3,394,571 | $3,537,232 | $3,679,727 |
| ***NAAT fee: $130.00*** | **-** | **-** | **-** | **-** | **-** |
| **Total cost of NAAT for TB** | **$2,442,440** | **$2,554,500** | **$2,666,430** | **$2,778,490** | **$2,890,420** |
| **Total cost of NAAT (inc. NAAT for NTM)** | **$3,663,660** | **$3,831,750** | **$3,999,645** | **$4,167,735** | **$4,335,630** |
| *NAAT fee: $200.00* | - | - | - | - | - |
| Total cost of NAAT for TB | $3,757,600 | $3,930,000 | $4,102,200 | $4,274,600 | $4,446,800 |
| Total cost of NAAT (inc. NAAT for NTM) | $4,978,820 | $5,207,250 | $5,435,415 | $5,663,845 | $5,892,010 |

Note: Figures in **bolded** text were used in the base-case financial analysis.

# References

Abbara, A & Davidson, RN 2011, 'Etiology and management of genitourinary tuberculosis', *Nature Reviews Urology*, vol. 8, no. 12, pp. 678–688.

Abdalla, CM, de Oliveira, ZN, Sotto, MN, Leite, KR, Canavez, FC & de Carvalho, CM 2009, 'Polymerase chain reaction compared to other laboratory findings and to clinical evaluation in the diagnosis of cutaneous tuberculosis and atypical mycobacteria skin infection', *International Journal of Dermatology*, vol. 48, no. 1, pp. 27–35.

Abes, GT, Abes, FLLB & Jamir, JC 2011, 'The variable clinical presentation of tuberculosis otitis media and the importance of early detection', *Otology and Neurotology*, vol. 32, no. 4, pp. 539–543.

Ablanedo-Terrazas, Y, Alvarado-de la Barrera, C, Hernández-Juan, R, Ruiz-Cruz, M & Reyes-Terán, G 2014, 'Xpert MTB/RIF for diagnosis of tuberculous cervical lymphadenitis in HIV-infected patients', *The Laryngoscope*, vol. 124, no. 6, pp. 1382–1385.

Abubakar, I, Zignol, M, Falzon, D, Raviglione, M, Ditiu, L, Masham, S, Adetifa, I, Ford, N, Cox, H, Lawn, SD, Marais, BJ, McHugh, TD, Mwaba, P, Bates, M, Lipman, M, Zijenah, L, Logan, S, McNerney, R, Zumla, A, Sarda, K, Nahid, P, Hoelscher, M, Pletschette, M, Memish, ZA, Kim, P, Hafner, R, Cole, S, Migliori, GB, Maeurer, M, Schito, M & Zumla, A 2013, 'Drug-resistant tuberculosis: time for visionary political leadership', *The Lancet Infectious Diseases*, vol. 13, no. 6, pp. 529–539.

Al-Ateah, SM, Al-Dowaidi, MM & El-Khizzi, NA 2012, 'Evaluation of direct detection of *Mycobacterium tuberculosis* complex in respiratory and non-respiratory clinical specimens using the Cepheid GeneXpert® system', *Saudi Medical Journal*, vol. 33, no. 10, pp. 1100–1105.

Al-Mezaine, HS, Al-Muammar, A, Kangave, D & Abu El-Asrar, AM 2008, 'Clinical and optical coherence tomographic findings and outcome of treatment in patients with presumed tuberculous uveitis', *International Ophthalmology*, vol. 28, no. 6, pp. 413–423.

Al-Serhani, AM 2001, 'Mycobacterial infection of the head and neck: presentation and diagnosis', *The Laryngoscope*, vol. 111, no. 11, pp. 2012–2016.

American Thoracic Society 1992, 'Control of tuberculosis in the United States', *American Review of Respiratory Disease*, vol. 146, no. 6, pp. 1623–1633.

Ani, A, Okpe, S, Akambi, M, Ejelionu, E, Yakubu, B, Owolodun, O, Ekeh, P, Oche, A, Tyem, D & Idoko, J 2009, 'Comparison of a DNA based PCR method with conventional methods for the detection of *M. tuberculosis* in Jos, Nigeria', *Journal of Infection in Developing Countries*, vol. 3, no. 6, pp. 470–475.

Armitage, P, Berry, G & Matthews, JNS 2002, *Statistical methods in medical research*, fourth edn, Blackwell Science, Oxford.

Association of Public Health Laboratories 2013, *Fact sheet: Cepheid GeneXpert® MTB/RIF assay. Laboratory considerations for use of Cepheid GeneXpert® MTB/RIF Assay*, viewed 18 June 2014,

<<http://www.aphl.org/AboutAPHL/publications/Documents/ID_2013Nov_Cepheid-Xpert-Fact-Sheet.pdf>>.

Australian Government Department of Health 2012, *National Hospital Cost Data Collection: Cost Report Round 14 (2009–10)*, Commonwealth of Australia, viewed 15 September 2014, <<http://www.health.gov.au/internet/main/publishing.nsf/Content/Round_14-cost-reports>>

Awaisu, A, Haniki Nik Mohamed, M, Noordin, NM, Muttalif, AR, Aziz, NA, Syed Sulaiman, SA & Mahayiddin, AA 2012, 'Impact of connecting tuberculosis directly observed therapy short-course with smoking cessation on health-related quality of life', *Tobacco Induced Diseases*, vol. 10, p. 2.

Babikako, HM, Neuhauser, D, Katamba, A & Mupere, E 2010, 'Feasibility, reliability and validity of health-related quality of life questionnaire among adult pulmonary tuberculosis patients in urban Uganda: cross-sectional study', *Health and Quality of Life Outcomes*, vol. 8, p. 93.

Balcells, ME, Garcia, P, Chanqueo, L, Bahamondes, L, Lasso, M, Gallardo, AM & Cifuentes, L 2012, 'Rapid molecular detection of pulmonary tuberculosis in HIV-infected patients in Santiago, Chile', *International Journal of Tuberculosis and Lung Disease*, vol. 16, no. 10, pp. 1349–1353.

Bandolier editorial 1999, 'Diagnostic testing emerging from the gloom?', *Bandolier*, vol. 70.

Bani-Hani, KE, Yaghan, RJ, Matalka, II & Mazahreh, TS 2005, 'Tuberculous mastitis: a disease not to be forgotten', *International Journal of Tuberculosis and Lung Disease*, vol. 9, no. 8, pp. 920–925.

Bates, M, O'Grady, J, Maeurer, M, Tembo, J, Chilukutu, L, Chabala, C, Kasonde, R, Mulota, P, Mzyece, J, Chomba, M, Mukonda, L, Mumba, M, Kapata, N, Rachow, A, Clowes, P, Hoelscher, M, Mwaba, P & Zumla, A 2013, 'Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study', *The Lancet Infectious Diseases*, vol. 13, no. 1, pp. 36–42.

Baveja, CP, Gumma, V, Jain, M, Choudhary, M, Talukdar, B & Sharma, VK 2009, 'Newer methods over the conventional diagnostic tests for tuberculous meningitis: do they really help?', *Tropical Doctor*, vol. 39, no. 1, pp. 18–20.

Ben Kahla, I, Ben Selma, W, Marzouk, M, Ferjeni, A, Ghezal, S & Boukadida, J 2011, 'Evaluation of a simplified IS6110 PCR for the rapid diagnosis of *Mycobacterium tuberculosis* in an area with high tuberculosis incidence', *Pathologie Biologie*, vol. 59, no. 3, pp. 161–165.

Berbari, EF, Hanssen, AD, Duffy, MC, Steckelberg, JM & Osmon, DR 1998, 'Prosthetic joint infection due to *Mycobacterium tuberculosis*: a case series and review of the literature', *American Journal of Orthopedics*, vol. 27, no. 3, pp. 219–227.

Bhanothu, V, Theophilus, JP & Rozati, R 2014, 'Use of endo-ovarian tissue biopsy and pelvic aspirated fluid for the diagnosis of female genital tuberculosis by conventional versus molecular methods', *PLoS ONE*, vol. 9, no. 5.

Bhanu, NV, Singh, UB, Chakraborty, M, Suresh, N, Arora, J, Rana, T, Takkar, D & Seth, P 2005, 'Improved diagnostic value of PCR in the diagnosis of female genital tuberculosis leading to infertility', *Journal of Medical Microbiology*, vol. 54, no. 10, pp. 927–931.

Bhigjee, AI, Padayachee, R, Paruk, H, Hallwirth-Pillay, KD, Marais, S & Connoly, C 2007, 'Diagnosis of tuberculous meningitis: clinical and laboratory parameters', *International Journal of Infectious Diseases*, vol. 11, no. 4, pp. 348–354.

Biadglegne, F, Mulu, A, Rodloff, AC & Sack, U 2014, 'Diagnostic performance of the Xpert MTB/RIF assay for tuberculous lymphadenitis on fine needle aspirates from Ethiopia', *Tuberculosis*, vol. 94, no. 5, pp. 502–505.

Boehme, CC, Nabeta, P, Hillemann, D, Nicol, MP, Shenai, S, Krapp, F, Allen, J, Tahirli, R, Blakemore, R, Rustomjee, R, Milovic, A, Jones, M, O'Brien, SM, Persing, DH, Ruesch-Gerdes, S, Gotuzzo, E, Rodrigues, C, Alland, D & Perkins, MD 2010, 'Rapid molecular detection of tuberculosis and rifampin resistance', *New England Journal of Medicine*, vol. 363, no. 11, pp. 1005–1015.

Bogner, JR, Rusch-Gerdes, S, Mertenskotter, T, Loch, O, Emminger, C, Baumgarten, R, Brockmeyer, NH, Brockhaus, W, Jablonowski, H, Stoehr, A, Roth, A, Albrecht, H, Roth, K, Tschauder, S, Dietrich, M & German, ASG 1997, 'Patterns of *Mycobacterium avium* culture and PCR positivity in immunodeficient HIV-infected patients: Progression from localized to systemic disease', *Scandinavian Journal of Infectious Diseases*, vol. 29, no. 6, pp. 579-584.

Borchardt, RA & Rolston, KV 2013, 'Nontuberculous mycobacterial infections: in vitro growth rates are clues to sites and susceptibility', *Journal of the American Academy of Physician Assistants*, vol. 26, no. 3, pp. 18, 25.

Borrell, S & Gagneux, S 2009, 'Infectiousness, reproductive fitness and evolution of drug-resistant *Mycobacterium tuberculosis*', *International Journal of Tuberculosis and Lung Disease*, vol. 13, no. 12, pp. 1456–1466.

Boyle, D & Pai, M 2012, *Tuberculosis Diagnostic Technology Landscape.* , UNITAID, World Health Organization, Geneva Switzerland, viewed 18 November 2014,

<<http://www.unitaid.eu/en/resources/publications/technical-reports>>

Buchelli Ramirez, HL, Garcia-Clemente, MM, Alvarez-Alvarez, C, Palacio-Gutierrez, JJ, Pando-Sandoval, A, Gagatek, S, Arias-Guillen, M, Quezada-Loaiza, CA & Casan-Clara, P 2014, 'Impact of the Xpert® MTB/RIF molecular test on the late diagnosis of pulmonary tuberculosis', *International Journal of Tuberculosis and Lung Disease*, vol. 18, no. 4, pp. 435–437.

Byrd, RB, Horn, BR, Solomon, DA & Griggs, GA 1979, 'Toxic effects of isoniazid in tuberculosis chemoprophylaxis: role of biochemical monitoring in 1,000 patients', *Journal of the American Medical Association*, vol. 241, no. 12, pp. 1239–1241.

Carriquiry, G, Otero, L, Gonzalez-Lagos, E, Zamudio, C, Sanchez, E, Nabeta, P, Campos, M, Echevarria, J, Seas, C & Gotuzzo, E 2012, 'A diagnostic accuracy study of Xpert® MTB/RIF in HIV-positive patients with high clinical suspicion of pulmonary tuberculosis in Lima, Peru', *PLoS ONE*, vol. 7, no. 9.

Casali, N, Nikolayevskyy, V, Balabanova, Y, Harris, SR, Ignatyeva, O, Kontsevaya, I, Corander, J, Bryant, J, Parkhill, J, Nejentsev, S, Horstmann, RD, Brown, T & Drobniewski, F 2014, 'Evolution and transmission of drug-resistant tuberculosis in a Russian population', *Nature Genetics*, vol. 46, no. 3, pp. 279–286.

CDNA 2013, *National Guidelines for Public Health Units – Management of TB*, Communicable Disease Network Australia, Commonwealth of Australia, Canberra, ACT, viewed 13 June 2014, <<http://www.health.gov.au/internet/main/publishing.nsf/Content/cdna-song-tuberculosis>>

Cepheid, *Xpert MTB/RIF brochure*, viewed 18 June 2014,

<<http://www.cepheid.com/en/cepheid-solutions-uk/clinical-ivd-tests/critical-infectious-diseases/xpert-mtb-rif>>

Chakravorty, S, Dudeja, M, Hanif, M & Tyagi, JS 2005, 'Utility of universal sample processing methodology, combining smear microscopy, culture, and PCR, for diagnosis of pulmonary tuberculosis', *Journal of Clinical Microbiology*, vol. 43, no. 6, pp. 2703–2708.

Chakravorty, S, Pathak, D, Dudeja, M, Haldar, S, Hanif, M & Tyagi, JS 2006, 'PCR amplification of shorter fragments from the *devR* (Rv3133c) gene significantly increases the sensitivity of tuberculosis diagnosis', *Fems Microbiology Letters*, vol. 257, no. 2, pp. 306–311.

Choi, HW, Miele, K, Dowdy, D & Shah, M 2013, 'Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States', *International Journal of Tuberculosis and Lung Disease*, vol. 17, no. 10, pp. 1328–1335.

Choi, YJ, Kim, HJ, Shin, HB, Nam, HS, Lee, SH, Park, JS, Park, KS & Baek, KA 2012, 'Evaluation of peptide nucleic acid probe-based real-time PCR for detection of *Mycobacterium tuberculosis* complex and nontuberculous mycobacteria in respiratory specimens', *Annals of Laboratory Medicine*, vol. 32, no. 4, pp. 257–263.

Cohen, T & Murray, M 2004, 'Modeling epidemics of multidrug-resistant *M. tuberculosis* of heterogeneous fitness', *Nature Medicine*, vol. 10, no. 10, pp. 1117–1121.

Cox, HS, Niemann, S, Ismailov, G, Doshetov, D, Orozco, JD, Blok, L, Gerdes, SR & Kebede, Y 2007, 'Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance', *Clinical Infectious Diseases*, vol. 44, no. 11, pp. 1421–1427.

Cruz-Knight, W & Blake-Gumbs, L 2013, 'Tuberculosis: an overview', *Primary Care*, vol. 40, no. 3, pp. 743–756.

Davis, JL, Huang, L, Kovacs, JA, Masur, H, Murray, P, Havlir, DV, Worodria, WO, Charlebois, ED, Srikantiah, P, Cattamanchi, A, Huber, C, Shea, YR, Chow, Y & Fischer, SH 2009, 'Polymerase chain reaction of *secA1* on sputum or oral wash samples for the diagnosis of pulmonary tuberculosis', *Clinical Infectious Diseases*, vol. 48, no. 6, pp. 725–732.

Davis, JL, Kawamura, LM, Chaisson, LH, Grinsdale, J, Benhammou, J, Ho, C, Babst, A, Banouvong, H, Metcalfe, JZ, Pandori, M, Hopewell, PC & Cattamanchi, A 2014, 'Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting: a hypothetical trial', *American Journal of Respiratory and Critical Care Medicine*, vol. 189, no. 12, pp. 1551–1559.

de Albuquerque, YMM, Lima, ALMA, Lins, AK, Magalhaes, M & Magalhaes, V 2014, 'Quantitative real-time PCR (Q-PCR) for sputum smear diagnosis of pulmonary tuberculosis among people with HIV/AIDS', *Revista do Instituto de Medicina Tropical de Sao Paulo*, vol. 56, no. 2, pp. 139–142.

de Perio, MA, Tsevat, J, Roselle, GA, Kralovic, SM & Eckman, MH 2009, 'Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers', *Archives of Internal Medicine*, vol. 169, no. 2, pp. 179–187.

Deeks, JJ 2001, 'Systematic reviews of evaluations of diagnostic and screening tests', in M Egger, G Davey Smith & DG Altman (eds), *Systematic Reviews in Healthcare: Meta-Analysis in Context*, second edn, BMJ Publishing Group, London, pp. 248–282.

Deeks, JJ, Macaskill, P & Irwig, L 2005, 'The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed', *Journal of Clinical Epidemiology*, vol. 58, no. 9, pp. 882–893.

Deggim, V, Somoskovi, A, Voit, A, Bottger, EC & Bloemberg, GV 2013, 'Integrating the Xpert MTB/RIF assay into a diagnostic workflow for rapid detection of *Mycobacterium tuberculosis* in a low-prevalence area', *Journal of Clinical Microbiology*, vol. 51, no. 7, pp. 2396–2399.

Denholm, JT, Leslie, DE, Jenkin, GA, Darby, J, Johnson, PD, Graham, SM, Brown, GV, Sievers, A, Globan, M, Brown, LK & McBryde, ES 2012, 'Long-term follow-up of contacts exposed to multidrug-resistant tuberculosis in Victoria, Australia, 1995–2010', *International Journal of Tuberculosis and Lung Disease*, vol. 16, no. 10, pp. 1320–1325.

Derese, Y, Hailu, E, Assefa, T, Bekele, Y, Mihret, A, Aseffa, A, Hussien, J, Ali, I & Alemayehu, MA 2012, 'Comparison of PCR with standard culture of fine needle aspiration samples in the diagnosis of tuberculosis lymphadenitis', *Journal of Infection in Developing Countries*, vol. 6, no. 1, pp. 53–57.

Desai, D, Nataraj, G, Kulkarni, S, Bichile, L, Mehta, P, Baveja, S, Ramakrishna, R, Raut, A & Shenoy, A 2006, 'Utility of the polymerase chain reaction in the diagnosis of tuberculous meningitis', *Research in Microbiology*, vol. 157, no. 10, pp. 967–970.

Deshmukh, M, Nikam, C, Ragte, T, Shetty, A & Rodrigues, C 2013, 'Is a composite reference standard (CRS) an alternative to culture in assessment and validation of a single tube nested in-house PCR for TB diagnosis?', *Egyptian Journal of Chest Diseases and Tuberculosis*, vol. 62, no. 4, pp. 805–815.

Dowdy, DW, Maters, A, Parrish, N, Beyrer, C & Dorman, SE 2003, 'Cost-effectiveness analysis of the Gen-Probe amplified *Mycobacterium tuberculosis* Direct Test as used routinely on smear-positive respiratory specimens', *Journal of Clinical Microbiology*, vol. 41, no. 3, pp. 948–953.

Downs, SH & Black, N 1998, 'The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions', *Journal of Epidemiology and Community Health*, vol. 52, no. 6, pp. 377–384.

Drobniewski, F, Eltringham, I, Graham, C, Magee, JG, Smith, EG & Watt, B 2002, 'A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK', *Thorax*, vol. 57, no. 9, pp. 810–816.

Drouillon, V, Delogu, G, Dettori, G, Lagrange, PH, Benecchi, M, Houriez, F, Baroli, K, Ardito, F, Torelli, R, Chezzi, C, Fadda, G & Herrmann, JL 2009, 'Multicenter evaluation of a transcription-reverse transcription concerted assay for rapid detection of *Mycobacterium tuberculosis* complex in clinical specimens', *Journal of Clinical Microbiology*, vol. 47, no. 11, pp. 3461–3465.

Drouillon, V, Lagrange, PH & Herrmann, JL 2007, 'Molecular diagnosis of pulmonary tuberculosis by automated extraction and real-time PCR on non-decontaminated pulmonary specimens', *European Journal of Clinical Microbiology & Infectious Diseases*, vol. 26, no. 4, pp. 291–293.

Ekrami, A, Samarbaf-Zadeh, AR, Khosravi, A, Zargar, B, Alavi, M, Amin, M & Kiasat, A 2011, 'Validity of bioconjugated silica nanoparticles in comparison with direct smear, culture, and polymerase chain reaction for detection of Mycobacterium tuberculosis in sputum specimens', *International Journal of Nanomedicine*, vol. 6, pp. 2729–2735.

El-Hajj, HH, Marras, SAE, Tyagi, S, Kramer, FR & Alland, D 2001, 'Detection of rifampin resistance in *Mycobacterium tuberculosis* in a single tube with molecular beacons', *Journal of Clinical Microbiology*, vol. 39, no. 11, pp. 4131–4137.

El Khechine, A, Henry, M, Raoult, D & Drancourt, M 2009, 'Detection of *Mycobacterium tuberculosis* complex organisms in the stools of patients with pulmonary tuberculosis', *Microbiology*, vol. 155, pp. 2384–2389.

Ereqat, S, Bar-Gal, GK, Nasereddin, A, Said, S, Greenblatt, CL, Azmi, K, Qaddomi, SE, Spigelman, M, Ramlawi, A & Abdeen, Z 2011, 'Pulmonary tuberculosis in the West Bank, Palestinian Authority: molecular diagnostic approach', *Tropical Medicine and International Health*, vol. 16, no. 3, pp. 360–367.

Fan, L, Zhang, Q, Cheng, LP, Liu, ZB, Ji, XB, Cui, ZL, Ju, JL & Xiao, HP 2014, 'Clinical diagnostic performance of the simultaneous amplification and testing methods for detection of the *Mycobacterium tuberculosis* complex for smear-negative or sputum-scarce pulmonary tuberculosis in China', *Chinese Medical Journal*, vol. 127, no. 10, pp. 1863–1867.

Forget, EJ & Menzies, D 2006, 'Adverse reactions to first-time antituberculosis drugs', *Expert Opinion on Drug Safety*, vol. 5, no. 2, pp. 231–249.

Francis, JR, Blyth, CC, Colby, S, Fagan, JM & Waring, J 2014, 'Multidrug-resistant tuberculosis in Western Australia, 1998–2012', *Medical Journal of Australia*, vol. 200, no. 6, pp. 328–332.

Frevel, T, Schafer, KL, Totsch, M, Bocker, W & Dockhorn-Dworniczak, B 1999, 'PCR based detection of mycobacteria in paraffin wax embedded material routinely processed for morphological examination', *Molecular Pathology*, vol. 52, no. 5, pp. 283–288.

Frydenberg, AR & Graham, S, M. 2009, 'Toxicity of first-line drugs for treatment of tuberculosis in children: review', *Tropical Medicine and International Health*, vol. 14, no. 11, pp. 1329–1337.

Gamboa, F, Manterola, JM, Lonca, J, Matas, L, Vinado, B, Gimenez, M, Cardona, PJ, Padilla, E & Ausina, V 1997, 'Detection and identification of mycobacteria by amplification of RNA and DNA in pretreated blood and bone marrow aspirates by a simple lysis method', *Journal of Clinical Microbiology*, vol. 35, no. 8, pp. 2124–2128.

Garcia-Monco, JC 2014, 'Tuberculosis', *Handbook of Clinical Neurology*, vol. 121, pp. 1485–1499.

Gazzola, L, Zanini, F, Zerbi, P, Franzetti, F & Gori, A 2008, 'The usefulness of PCR assay in diagnosing disseminated mycobacterial infection in AIDS patients', *European Journal of Clinical Microbiology and Infectious Diseases*, vol. 27, no. 2, pp. 163–166.

George, G, Mony, P & Kenneth, J 2011, 'Comparison of the efficacies of loop-mediated isothermal amplification, fluorescence smear microscopy and culture for the diagnosis of tuberculosis', *PLoS ONE*, vol. 6, no. 6.

Ghaleb, K, Afifi, M & El-Gohary, M 2013, 'Assessment of diagnostic techniques of urinary tuberculosis', *Mediterranean Journal of Hematology and Infectious Diseases*, vol. 5, no. 1, pp. 1–7.

Gholoobi, A, Masoudi-Kazemabad, A, Meshkat, M & Meshkat, Z 2014, 'Comparison of culture and PCR methods for diagnosis of Mycobacterium tuberculosis in different clinical specimens', *Jundishapur Journal of Microbiology*, vol. 7, no. 2.

Golub, J, Bur, S, Cronin, WA, Gange, S, Baruch, N, Comstock, GW & Chaisson, RE 2006, 'Delayed tuberculosis diagnosis and tuberculosis transmission', *International Journal of Tuberculosis and Lung Disease*, vol. 10, no. 1, pp. 24–30.

Gomez, DI, Mullin, CS, Mora-Guzman, F, Crespo-Solis, JG, Fisher-Hoch, SP, McCormick, JB & Restrepo, BI 2011, 'Rapid DNA extraction for specific detection and quantitation of Mycobacterium tuberculosis DNA in sputum specimens using TaqMan assays', *Tuberculosis*, vol. 91, no. SUPPL. 1, pp. S43–S48.

Guerra, RL, Hooper, NM, Baker, JF, Alborz, R, Armstrong, DT, Maltas, G, Kiehlbauch, JA & Dorman, SE 2007, 'Use of the amplified *Mycobacterium tuberculosis* Direct Test in a public health laboratory: test performance and impact on clinical care', *CHEST*, vol. 132, no. 3, pp. 946–951.

Guo, N, Marra, CA, Marra, F, Moadebi, S, Elwood, RK & Fitzgerald, JM 2008, 'Health state utilities in latent and active tuberculosis', *Value Health*, vol. 11, no. 7, pp. 1154–1161.

Haldar, S, Chakravorty, S, Bhalla, M, De Majumdar, S & Tyagi, JS 2007, 'Simplified detection of *Mycobacterium tuberculosis* in sputum using smear microscopy and PCR with molecular beacons', *Journal of Medical Microbiology*, vol. 56, no. 10, pp. 1356–1362.

Halse, TA, Edwards, J, Cunningham, PL, Wolfgang, WJ, Dumas, NB, Escuyer, VE & Musser, KA 2010, 'Combined real-time PCR and *rpoB* gene pyrosequencing for rapid identification of *Mycobacterium tuberculosis* and determination of rifampin resistance directly in clinical specimens', *Journal of Clinical Microbiology*, vol. 48, no. 4, pp. 1182–1188.

Hanrahan, CF, Selibas, K, Deery, CB, Dansey, H, Clouse, K, Bassett, J, Scott, L, Stevens, W, Sanne, I & van Rie, A 2013, 'Time to treatment and patient outcomes among TB suspects screened by a single point-of-care Xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa', *PLoS ONE*, vol. 8, no. 6.

Hanrahan, CF, Theron, G, Bassett, J, Dheda, K, Scott, L, Stevens, W, Sanne, I & Van Rie, A 2014, 'Xpert MTB/RIF as a measure of sputum bacillary burden: variation by HIV status and immunosuppression', *American Journal of Respiratory and Critical Care Medicine*, vol. 189, no. 11, pp. 1426–1434.

Helb, D, Jones, M, Story, E, Boehme, C, Wallace, E, Ho, K, Kop, J, Owens, MR, Rodgers, R, Banada, P, Safi, H, Blakemore, R, Lan, NT, Jones-Lopez, EC, Levi, M, Burday, M, Ayakaka, I, Mugerwa, RD, McMillan, B, Winn-Deen, E, Christel, L, Dailey, P, Perkins, MD, Persing, DH & Alland, D 2010, 'Rapid detection of *Mycobacterium tuberculosis* and rifampin resistance by use of on-demand, near-patient technology', *Journal of Clinical Microbiology*, vol. 48, no. 1, pp. 229–237.

Higgins, JP, Thompson, SG, Deeks, JJ & Altman, DG 2003, 'Measuring inconsistency in meta-analyses', *British Medical Journal*, vol. 327, no. 7414, pp. 557–560.

Hillemann, D, Rusch-Gerdes, S, Boehme, C & Richter, E 2011, 'Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system', *Journal of Clinical Microbiology*, vol. 49, no. 4, pp. 1202–1205.

HKCS/BMRC 1987, 'Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service / British Medical Research Council', *American Review of Respiratory Disease*, vol. 136, no. 6, pp. 1339–1342.

Holland, DP, Sanders, GD, Hamilton, CD & Stout, JE 2009, 'Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection', *American Journal of Respiratory and Critical Care Medicine*, vol. 179, no. 11, pp. 1055–1060.

Hughes, R, Wonderling, D, Li, B & Higgins, B 2012, 'The cost-effectiveness of nucleic acid amplification techniques for the diagnosis of tuberculosis', *Respiratory Medicine*, vol. 106, no. 2, pp. 300–307.

Independent Hospital Pricing Authority 2014, *National Pricing Model Technical Specifications 2014–15. 4: Derivation of a reference cost*, viewed 6 November 2014,

<<http://www.ihpa.gov.au/internet/ihpa/publishing.nsf/Content/npm-tech-spec-2014-15-html~attach-b~ref-cost>.>

Ioannidis, P, Papaventsis, D, Karabela, S, Nikolaou, S, Panagi, M, Raftopoulou, E, Konstantinidou, E, Marinou, I & Kanavaki, S 2011, 'Cepheid geneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy results', *Journal of Clinical Microbiology*, vol. 49, no. 8, pp. 3068-3070.

Jenkins, N, Dedicoat, M & Cook, R 2013, *Guideline for the prescribing and administration of once daily intravenous amikacin for mycobacterial infections in the community*, National Health Service, Heart of England NHS Foundation Trust, viewed 5 November 2014, <<http://tuberculosis.heartofengland.nhs.uk/wp-content/uploads/g3.pdf>.>

Jiang, LJ, Wu, WJ, Wu, H, Ryang, SS, Zhou, J, Wu, W, Li, T, Guo, J, Wang, HH, Lu, SH & Li, Y 2012, 'Rapid detection and monitoring therapeutic efficacy of Mycobacterium tuberculosis complex using a novel real-time assay', *Journal of Microbiology and Biotechnology*, vol. 22, no. 9, pp. 1301–1306.

Jit, M, Stagg, HR, Aldridge, RW, White, PJ & Abubakar, I 2011, 'Dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation', *Bmj*, vol. 343, p. d5376.

Johnston, J, Admon, A, Ibrahim, A, Elwood, K, Tang, P, Cook, V & Fitzgerald, M 2012, 'Long term follow-up of drug resistant and drug susceptible tuberculosis contacts in a low incidence setting', *BMC Infectious Diseases*, vol. 12, p. 266.

Kakkar, S, Kapila, K, Singh, MK & Verma, K 2000, 'Tuberculosis of the breast', *Acta Cytologica*, vol. 44, no. 3, pp. 292–296.

Keys, C, McLeod, E, Pesti, C & Armstrong, D 2012, 'Thoracoscopic pleural biopsy as an aid to diagnosis in pediatric tuberculosis with pleural involvement', *European Journal of Pediatric Surgery*, vol. 22, no. 4, pp. 315–317.

Khan, FUR, Cheema, FA & Khan, MU 2013, 'Accuracy of urinary PCR as compared with urine culture for early diagnosis of genitourinary tuberculosis', *Pakistan Journal of Medical and Health Sciences*, vol. 7, no. 3, pp. 675–678.

Khan, K, Muennig, P, Behta, M & Zivin, JG 2002, 'Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States', *New England Journal of Medicine*, vol. 347, no. 23, pp. 1850–1859.

Khosravi, AD, Hashemzadeh, M, Ghorbani, A & Seghatoleslami, S 2010, 'Comparison of nested-PCR technique and culture method in detection of *Mycobacterium tuberculosis* from patients suspected to genitourinary tuberculosis', *African Journal of Biotechnology*, vol. 9, no. 14, pp. 2151–2155.

Kibiki, GS, Mulder, B, van der Ven, AJ, Sam, N, Boeree, MJ, van der Zanden, A & Dolmans, WM 2007, 'Laboratory diagnosis of pulmonary tuberculosis in TB and HIV endemic settings and the contribution of real time PCR for *M. tuberculosis* in bronchoalveolar lavage fluid', *Tropical Medicine and International Health*, vol. 12, no. 10, pp. 1210–1217.

Kim, MH, Yang, HY, Suh, JT & Lee, HJ 2008, 'Comparison of in-house PCR with conventional techniques and COBAS® Amplicor M–tuberculosis™ kit for detection of *Mycobacterium tuberculosis*', *Yonsei Medical Journal*, vol. 49, no. 4, pp. 537–544.

Kind, P, Hardman, G & Macran, S 1999, *UK population norms for EQ-5D*, vol. 172, Centre for Health Economics, University of York, UK.

Kittikraisak, W, Kingkaew, P, Teerawattananon, Y, Yothasamut, J, Natesuwan, S, Manosuthi, W, Chongsuvivatwong, V & Whitehead, SJ 2012, 'Health related quality of life among patients with tuberculosis and HIV in Thailand', *PLoS One*, vol. 7, no. 1.

Kopanoff, DE, Snider, DE, Jr. & Caras, GJ 1978, 'Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study', *American Review of Respiratory Disease*, vol. 117, no. 6, pp. 991–1001.

Kox, LF, Jansen, HM, Kuijper, S & Kolk, AH 1997, 'Multiplex PCR assay for immediate identification of the infecting species in patients with mycobacterial disease', *Journal of Clinical Microbiology*, vol. 35, no. 6, pp. 1492–1498.

Kruijshaar, ME, Lipman, M, Essink-Bot, ML, Lozewicz, S, Creer, D, Dart, S, Maguire, H & Abubakar, I 2010, 'Health status of UK patients with active tuberculosis', *International Journal of Tuberculosis and Lung Disease*, vol. 14, no. 3, pp. 296–302.

Kurbatova, EV, Kaminski, DA, Erokhin, VV, Volchenkov, GV, Andreevskaya, SN, Chernousova, LN, Demikhova, OV, Ershova, JV, Kaunetis, NV, Kuznetsova, TA, Larionova, EE, Smirnova, TG, Somova, TR, Vasilieva, IA, Vorobieva, AV, Zolkina, SS & Cegielski, JP 2013, 'Performance of Cepheid Xpert® MTB/RIF and TB-Biochip® MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis', *European Journal of Clinical Microbiology and Infectious Diseases*, vol. 32, no. 6, pp. 735–743.

Kwak, N, Choi, SM, Lee, J, Park, YS, Lee, CH, Lee, SM, Yoo, CG, Kim, YW, Han, SK & Yim, JJ 2013, 'Diagnostic accuracy and turnaround time of the Xpert MTB/RIF assay in routine clinical practice', *PLoS ONE*, vol. 8, no. 10.

Lab Tests Online 2012, *AFB smear and culture*, viewed 19 June 2014,

<<http://www.labtestsonline.org.au/>>

Lacroix, C, Martin, P, Turcotte, S, DeRoche, S, Magluilo, V & Lacroix, C 2008, 'The delay in diagnosis of tuberculosis in the Monteregie region of Quebec, Canada', *McGill Journal of Medicine*, vol. 11, no. 2, pp. 124–131.

Lam, E, Nateniyom, S, Whitehead, S, Anuwatnonthakate, A, Monkongdee, P, Kanphukiew, A, Inyaphong, J, Sitti, W, Chiengsorn, N, Moolphate, S, Kavinum, S, Suriyon, N, Limsomboon, P, Danyutapolchai, J, Sinthuwattanawibool, C & Podewils, LJ 2014, 'Use of drug-susceptibility testing for management of drug-resistant tuberculosis, Thailand, 2004–2008', *Emerging Infectious Diseases*, vol. 20, no. 3, pp. 400–408.

Lavender, CJ, Brown, LK & Johnson, PD 2009, 'Multidrug-resistant tuberculosis in Victoria: a 10-year review', *Medical Journal of Australia*, vol. 191, no. 6, pp. 315–318.

Lawn, SD, Mwaba, P, Bates, M, Piatek, A, Alexander, H, Marais, BJ, Cuevas, LE, McHugh, TD, Zijenah, L, Kapata, N, Abubakar, I, McNerney, R, Hoelscher, M, Memish, ZA, Migliori, GB, Kim, P, Maeurer, M, Schito, M & Zumla, A 2013, 'Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test', *The Lancet Infectious Diseases*, vol. 13, no. 4, pp. 349–361.

Lee, HY, Seong, MW, Park, SS, Hwang, SS, Lee, J, Park, YS, Lee, CH, Lee, SM, Yoo, CG, Kim, YW, Han, SK & Yim, JJ 2013, 'Diagnostic accuracy of Xpert® MTB/RIF on bronchoscopy specimens in patients with suspected pulmonary tuberculosis', *International Journal of Tuberculosis and Lung Disease*, vol. 17, no. 7, pp. 917–921.

Lee, MF, Chen, YH & Peng, CF 2009, 'Evaluation of reverse transcription loop-mediated isothermal amplification in conjunction with ELISA-hybridization assay for molecular detection of Mycobacterium tuberculosis', *Journal of Microbiological Methods*, vol. 76, no. 2, pp. 174–180.

Lemos, AC & Matos, ED 2013, 'Multidrug-resistant tuberculosis', *Braz Journal of Infectious Diseases*, vol. 17, no. 2, pp. 239–246.

Liberati, A, Altman, DG, Tetzlaff, J, Mulrow, C, Gotzsche, PC, Ioannidis, JP, Clarke, M, Devereaux, PJ, Kleijnen, J & Moher, D 2009, 'The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration', *PLoS Medicine*, vol. 6, no. 7, p. e1000100.

Light, RJ & Pillemer, DB 1984, *Summing up: the science of reviewing research*, Harvard University Press, Cambridge, MA.

Ligthelm, LJ, Nicol, MP, Hoek, KGP, Jacobson, R, Van Helden, PD, Marais, BJ, Warren, RM & Wright, CA 2011, 'Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens', *Journal of Clinical Microbiology*, vol. 49, no. 11, pp. 3967–3970.

Lippincott, CK, Miller, MB, Popowitch, EB, Hanrahan, CF & Van Rie, A 2014, 'Xpert MTB/RIF assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States', *Clinical Infectious Diseases*, vol. 59, no. 2, pp. 186–192.

Lumb, R 2000, 'New approaches to drug susceptibility testing of Mycobacterium tuberculosis', *Microbiology Australia*, vol. 21, no. 1, pp. 8-10.

Lumb, R, Bastian, I, Carter, R, Jelfs, P, Keehner, T & Sievers, A 2013, 'Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2010. A report of the Australian Mycobacterium Reference Laboratory Network', *Communicable Diseases Intelligence Quarterly Report*, vol. 37, no. 1, pp. E40–E46.

Mahaisavariya, P, Chaiprasert, A, Manonukul, J, Khemngern, S & Tingtoy, N 2005, 'Detection and identification of *Mycobacterium* species by polymerase chain reaction (PCR) from paraffin-embedded tissue compare to AFB staining in pathological sections', *Journal of the Medical Association of Thailand*, vol. 88, no. 1, pp. 108–113.

Makeshkumar, V, Madhavan, R & Narayanan, S 2014, 'Polymerase chain reaction targeting insertion sequence for the diagnosis of extrapulmonary tuberculosis', *Indian Journal of Medical Research*, vol. 139, pp. 161–166.

Malbruny, B, Le Marrec, G, Courageux, K, Leclercq, R & Cattoir, V 2011, 'Rapid and efficient detection of *Mycobacterium tuberculosis* in respiratory and non-respiratory samples', *International Journal of Tuberculosis and Lung Disease*, vol. 15, no. 4, pp. 553–555.

Marais, B, Sorrell, T & Britton, W 2012, *Drug-resistant tuberculosis in PNG and Torres Strait islands*, The Conversation, viewed 18 June 2014, <<http://theconversation.com/drug-resistant-tuberculosis-in-png-and-torres-strait-islands-10754>>

Marchi, AM, Juttel, ID, Kawacubo, EM, Dalmarco, EM, Blatt, SL & Cordova, CMM 2008, 'Evaluation of methods for detection and identification of *Mycobacterium* species in patients suspected of having pulmonary tuberculosis', *Brazilian Journal of Microbiology*, vol. 39, no. 4, pp. 613–618.

Marks, SM, Cronin, W, Venkatappa, T, Maltas, G, Chon, S, Sharnprapai, S, Gaeddert, M, Tapia, J, Dorman, SE, Etkind, S, Crosby, C, Blumberg, HM & Bernardo, J 2013, 'The health-system benefits and cost-effectiveness of using *Mycobacterium tuberculosis* direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States', *Clinical Infectious Diseases*, vol. 57, no. 4, pp. 532–542.

Marlowe, EM, Novak-Weekley, SM, Cumpio, J, Sharp, SE, Momeny, MA, Babst, A, Carlson, JS, Kawamura, M & Pandori, M 2011, 'Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of *Mycobacterium tuberculosis* complex in respiratory specimens', *Journal of Clinical Microbiology*, vol. 49, no. 4, pp. 1621–1623.

Martin-Casabona, N, Bahrmand, AR, Bennedsen, J, Thomsen, VO, Curcio, M, Fauville-Dufaux, M, Feldman, K, Havelkova, M, Katila, ML, Koksalan, K, Pereira, MF, Rodrigues, F, Pfyffer, GE, Portaels, F, Urgell, JR, Rusch-Gerdes, S, Tortoli, E, Vincent, V & Watt, B 2004, 'Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey', *International Journal of Tuberculosis and Lung Disease*, vol. 8, no. 10, pp. 1186–1193.

Mashta, A, Mishra, P, Philipose, S, Tamilzhalagan, S, Mahmud, H, Bhaskar, S & Upadhyay, P 2011, 'Diagnosis of tuberculosis: the experience at a specialized diagnostic laboratory', *Journal of Negative Results in BioMedicine*, vol. 10, no. 1.

Matsumoto, H, Tsuyuguchi, K, Suzuki, K, Tanaka, E, Amitani, R & Kuze, F 1998, 'Evaluation of Roche Amplicor PCR assay for *Mycobacterium avium* complex in bronchial washing', *International Journal of Tuberculosis and Lung Disease*, vol. 2, no. 11, pp. 935–940.

Matthys, F, Rigouts, L, Sizaire, V, Vezhnina, N, Lecoq, M, Golubeva, V, Portaels, F, Van der Stuyft, P & Kimerling, M 2009, 'Outcomes after chemotherapy with WHO Category II regimen in a population with high prevalence of drug resistant tuberculosis', *PLoS ONE*, vol. 4, no. 11.

Maurya, AK, Kant, S, Kushwaha, RA, Nag, VL, Kumar, M & Dhole, TN 2011a, 'The advantage of using IS*6110*-PCR vs. BACTEC culture for rapid detection of *Mycobacterium tuberculosis* from pleural fluid in northern India', *Bioscience Trends*, vol. 5, no. 4, pp. 159–164.

Maurya, AK, Kant, S, Nag, VL, Kushwaha, RAS, Kumar, M & Dhole, TN 2011b, 'Comparative evaluation of IS*6110* PCR via conventional methods in rapid diagnosis of new and previously treated cases of extrapulmonary tuberculosis', *Tuberkuloz ve Toraks*, vol. 59, no. 3, pp. 213–220.

Merlin, T, Weston, A & Tooher, R 2009, 'Extending an evidence hierarchy to include topics other than treatment: revising the Australian 'levels of evidence'', *BMC Medical Research Methodology*, vol. 9, p. 34.

Meyssonnier, V, Bui, TV, Veziris, N, Jarlier, V & Robert, J 2014, 'Rifampicin mono-resistant tuberculosis in France: a 2005–2010 retrospective cohort analysis', *BMC Infectious Diseases*, vol. 14, no. 1.

Michelon, CT, Rosso, F, Schmid, KB, Sperhacke, RD, Oliveira, MM, Kritski, AL, Rezende Jr, L, Costa, ERD, Ribeiro, AW, Verza, M, Cafrune, PI, Silva, MSN, Kuhleis, D, Zaha, A & Rossetti, MLR 2011, 'Colorimetric microwell plate reverse-hybridization assay for *Mycobacterium tuberculosis* detection', *Memorias do Instituto Oswaldo Cruz*, vol. 106, no. 2, pp. 194–199.

Millman, AJ, Dowdy, DW, Miller, CR, Brownell, R, Metcalfe, JZ, Cattamanchi, A & Davis, JL 2013, 'Rapid molecular testing for TB to guide respiratory isolation in the U.S.: a cost-benefit analysis', *PLoS ONE*, vol. 8, no. 11, p. e79669.

Min, JW, Yoon, HI, Park, KU, Song, JH, Lee, CT & Lee, JH 2010, 'Real-time polymerase chain reaction in bronchial aspirate for rapid detection of sputum smear-negative tuberculosis', *International Journal of Tuberculosis and Lung Disease*, vol. 14, no. 7, pp. 852-858.

Mitchell, JR, Thorgeirsson, UP, Black, M, Timbrell, JA, Snodgrass, WR, Potter, WZ, Jollow, HR & Keiser, HR 1975, 'Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites', *Clinical Pharmacology and Therapeutics*, vol. 18, no. 1, pp. 70-79.

Mitchell, JR, Zimmerman, HJ, Ishak, KG, Thorgeirsson, UP, Timbrell, JA, Snodgrass, WR & Nelson, SD 1976, 'Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis', *Annals of Internal Medicine*, vol. 84, no. 2, pp. 181-192.

Mitchison, DA 2012, 'Prevention of drug resistance by combined drug treatment of tuberculosis', *Handbook of Experimental Pharmacology*, no. 211, pp. 87-98.

Mittal, P, Handa, U, Mohan, H & Gupta, V 2011, 'Comparative evaluation of fine needle aspiration cytology, culture, and PCR in diagnosis of tuberculous lymphadenitis', *Diagnostic Cytopathology*, vol. 39, no. 11, pp. 822–826.

Moore, DF, Guzman, JA & Mikhail, LT 2005, 'Reduction in turnaround time for laboratory diagnosis of pulmonary tuberculosis by routine use of a nucleic acid amplification test', *Diagnostic Microbiology and Infectious Disease*, vol. 52, no. 3, pp. 247–254.

Moure, R, Martin, R & Alcaide, F 2012, 'Effectiveness of an integrated real-time PCR method for detection of the *Mycobacterium tuberculosis* complex in smear-negative extrapulmonary samples in an area of low tuberculosis prevalence', *Journal of Clinical Microbiology*, vol. 50, no. 2, pp. 513–515.

MSAC 2005, *Guidelines for the assessment of diagnostic technologies*, Medical Services Advisory Council, Commonwealth of Australia, Canberra, ACT.

Mulherin, SA & Miller, WC 2002, 'Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation', *Annals of Internal Medicine*, vol. 137, no. 7, pp. 598–602.

Muttarak, M, ChiangMai, WN & Lojanapiwat, B 2005, 'Tuberculosis of the genitourinary tract: imaging features with pathological correlation', *Singapore Medical Journal*, vol. 46, no. 10, pp. 568–574.

Nakiyingi, L, Kateete, DP, Ocama, P, Worodria, W, Sempa, JB, Asiimwe, BB, Katabazi, FA, Katamba, A, Huang, L, Joloba, ML & Mayanja-Kizza, H 2012, 'Evaluation of in-house PCR for diagnosis of smear-negative pulmonary tuberculosis in Kampala, Uganda', *BMC Research Notes*, vol. 5, p. 487.

National Pathology Accreditation Advisory Council 2014, *Requirements for the development and use of in-house in vitro diagnostic medical devices*, third edn, Commonwealth of Australia, Canberra, ACT, viewed 19 June 2014,

<<http://www.health.gov.au/internet/main/publishing.nsf/Content/health-npaac-dhaivd.htm>>

National Tuberculosis Advisory Committee 2006, 'Guidelines for Australian mycobacteriology laboratories', *Communicable Diseases Intelligence Quarterly Report*, vol. 30, no. 1, pp. 116–128.

National Tuberculosis Advisory Committee 2012, 'The strategic plan for control of tuberculosis in Australia: 2011–2015', *Communicable Diseases Intelligence Quarterly Report*, vol. 36, no. 3, pp. E286–E293.

NHMRC 1999, *A guide to the development, implementation and evaluation of clinical practice guidelines*, National Health and Medical Research Council, Commonwealth of Australia, Canberra, ACT.

NHMRC 2000, *How to use the evidence: assessment and application of scientific evidence*, Handbook series on preparing clinical practice guidelines, National Health and Medical Research Council, Commonwealth of Australia, Canberra, ACT.

NHMRC 2009, *NHMRC levels of evidence and grades for recommendations for developers of guidelines.*, National Health and Medical Research Council, Commonwealth of Australia, Canberra, ACT, viewed 1 October 2010,

<<https://www.nhmrc.gov.au/guidelines/resources-guideline-developers>>

Nicol, MP, Workman, L, Isaacs, W, Munro, J, Black, F, Eley, B, Boehme, CC, Zemanay, W & Zar, HJ 2011, 'Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study', *The Lancet Infectious Diseases*, vol. 11, no. 11, pp. 819–824.

Ninet, B, Auckenthaler, R, Rohner, P, Delaspre, O & Hirschel, B 1997, 'Detection of *Mycobacterium avium-intracellulare* in the blood of HIV-infected patients by a commercial polymerase chain reaction kit', *European Journal of Clinical Microbiology and Infectious Diseases* vol. 16, no. 7, pp. 549–551.

Nolan, CM, Goldberg, SV & Buskin, SE 1999, 'Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic', *Journal of the American Medical Association*, vol. 281, no. 11, pp. 1014–1018.

Nybo, K 2012, *PCR 2013: an evolving technology. Year in review*, BioTechniques The International Journal of Life Science Methods, <<http://www.biotechniques.com/news/PCR-2013-An-Evolving-Technology--2012-Year-in-Review/biotechniques-338209.html>>.

Omrani, AS, Al-Otaibi, MF, Al-Ateah, SM, Al-Onazi, FM, Baig, K, El-Khizzi, NA & Albarrak, AM 2014, 'GeneXpert MTB/RIF testing in the management of patients with active tuberculosis: a real life experience from Saudi Arabia', *Infection and Chemotherapy*, vol. 46, no. 1, pp. 30–34.

Pahwa, R, Hedau, S, Jain, S, Jain, N, Arora, VM, Kumar, N & Das, BC 2005, 'Assessment of possible tuberculous lymphadenopathy by PCR compared to non-molecular methods', *Journal of Medical Microbiology*, vol. 54, no. 9, pp. 873–878.

Pai, M, Flores, LL, Hubbard, A, Riley, LW & Colford, JM 2004, 'Nucleic acid amplification tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis', *Bmc Infectious Diseases*, vol. 4, p. 6.

Pai, M, Flores, LL, Pai, N, Hubbard, A, Riley, LW & Colford, JM 2003, 'Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis', *The Lancet Infectious Diseases*, vol. 3, no. 10, pp. 633–643.

Park, KS, Kim, JY, Lee, JW, Hwang, YY, Jeon, K, Koh, WJ, Ki, CS & Lee, NY 2013, 'Comparison of the Xpert MTB/RIF and COBAS TaqMan MTB assays for detection of *Mycobacterium tuberculosis* in respiratory specimens', *Journal of Clinical Microbiology*, vol. 51, no. 10, pp. 3225–3227.

Phillips, B, Ball, C, Sackett, D, Badenoch, D, Straus, S, Haynes, B & Dawes, M 2001, *Oxford Centre for Evidence-Based Medicine levels of evidence (May 2001)*, Oxford, UK.

Phillips, R, Horsfield, C, Kuijper, S, Lartey, A, Tetteh, I, Etuaful, S, Nyamekye, B, Awuah, P, Nyarko, KM, Osei-Sarpong, F, Lucas, S, Kolk, AH & Wansbrough-Jones, M 2005, 'Sensitivity of PCR targeting the IS*2404* insertion sequence of *Mycobacterium ulcerans* in an assay using punch biopsy specimens for diagnosis of Buruli ulcer', *Journal of Clinical Microbiology*, vol. 43, no. 8, pp. 3650–3656.

Ponticiello, A, Perna, F, Sturkenboom, M, Marchetiello, I, Bocchino, M & Sanduzzi, A 2001, 'Demographic risk factors and lymphocyte populations in patients with tuberculosis and their healthy contacts', *International Journal of Tuberculosis and Lung Disease*, vol. 5, no. 12, pp. 1148–1155.

Possuelo, LG, Castelan, JA, de Brito, TC, Ribeiro, AW, Cafrune, PI, Picon, PD, Santos, AR, Teixeira, RL, Gregianini, TS, Hutz, MH, Rossetti, ML & Zaha, A 2008, 'Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil', *European Journal of Clinical Pharmacology*, vol. 64, no. 7, pp. 673–681.

Public Health and Ambulatory Care, NMHS 2012, *Laboratory diagnosis of tuberculosis. WA Tuberculosis Control Program Policy 1.1, North Metropolitan Health Service, Departm*ent of Health, Government of Western Australia.

Quy, HT, Lan, NT, Borgdorff, MW, Grosset, J, Linh, PD, Tung, LB, van Soolingen, D, Raviglione, M, Co, NV & Broekmans, J 2003, 'Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate?', *International Journal of Tuberculosis and Lung Disease*, vol. 7, no. 7, pp. 631–636.

Rachow, A, Zumla, A, Heinrich, N, Rojas-Ponce, G, Mtafya, B, Reither, K, Ntinginya, EN, O'Grady, J, Huggett, J, Dheda, K, Boehme, C, Perkins, M, Saathoff, E & Hoelscher, M 2011, 'Rapid and accurate detection of *Mycobacterium tuberculosis* in sputum samples by Cepheid Xpert MTB/RIF assay: a clinical validation study', *PLoS ONE*, vol. 6, no. 6.

Rajalahti, I, Ruokonen, EL, Kotomaki, T, Sintonen, H & Nieminen, MM 2004, 'Economic evaluation of the use of PCR assay in diagnosing pulmonary TB in a low-incidence area', *European Respiratory Journal*, vol. 23, no. 3, pp. 446–451.

Rattan, A, Kalia, A & Ahmad, N 1998, *Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives*, Centers for Disease Control and Prevention. Emerging Infectious Diseases [serial on the internet] viewed 16 June 2014,

<<http://wwwnc.cdc.gov/eid/article/4/2/98-0207.htm>>

Reuter, H, Burgess, L, van Vuuren, W & Doubell, A 2006, 'Diagnosing tuberculous pericarditis', *Quarterly Journal of Medicine*, vol. 99, no. 12, pp. 827–839.

Rudolf, F, Joaquim, LC, Vieira, C, Bjerregaard-Andersen, M, Andersen, A, Erlandsen, M, Sodemann, M, Andersen, PL & Wejse, C 2013, 'The Bandim tuberculosis score: reliability and comparison with the Karnofsky performance score', *Scandinavian Journal of Infectious Diseases*, vol. 45, no. 4, pp. 256–264.

Runyon, EH 1959, 'Anonymous mycobacteria in pulmonary disease', *Medical Clinics of North America*, vol. 43, no. 1, pp. 273–290.

Sackett, DL & Haynes, RB 2002, 'The architecture of diagnostic research', *British Medical Journal*, vol. 324, pp. 539–541.

Santos, RM, Ogusku, MM, Miranda Jde, M, Dos-Santos, MC & Salem, JI 2006, 'Evaluation of polymerase chain reaction in the diagnosis of pulmonary tuberculosis in indigenous and non-indigenous patients', *Jornal Brasileiro de Pneumologia*, vol. 32, no. 3, pp. 234–240.

Scherer, LC, Sperhacke, RD, Jarczewski, C, Cafrune, PI, Michelon, CT, Rupenthal, R, Ribeiro, MO, Netto, AR, Rossetti, ML & Kritski, AL 2011, 'Comparison of two laboratory-developed PCR methods for the diagnosis of pulmonary tuberculosis in Brazilian patients with and without HIV infection', *BMC Pulmonary Medicine*, vol. 11, p. 15.

Sharma, K, Sharma, A, Sharma, SK, Sen, RK, Dhillon, MS & Sharma, M 2012, 'Does multiplex polymerase chain reaction increase the diagnostic percentage in osteoarticular tuberculosis? A prospective evaluation of 80 cases', *International Orthopaedics*, vol. 36, no. 2, pp. 255–259.

Sharma, K, Sinha, SK, Sharma, A, Nada, R, Prasad, KK, Goyal, K, Rana, SS, Bhasin, DK & Sharma, M 2013, 'Multiplex PCR for rapid diagnosis of gastrointestinal tuberculosis', *Journal of Global Infectious Diseases*, vol. 5, no. 2, pp. 49–53.

Shukla, I, Varshney, S, Sarfraz, Malik, A & Ahmad, Z 2011, 'Evaluation of nested PCR targeting IS*6110* of *Mycobacterium tuberculosis* for the diagnosis of pulmonary and extra-pulmonary tuberculosis', *Biology and Medicine*, vol. 3, no. 2 (special issue), pp. 171–175.

Singh, UB, Bhanu, NV, Suresh, VN, Arora, J, Rana, T & Seth, P 2006, 'Utility of polymerase chain reaction in diagnosis of tuberculosis from samples of bone marrow aspirate', *American Journal of Tropical Medicine and Hygiene*, vol. 75, no. 5, pp. 960–963.

Sohn, H, Aero, AD, Menzies, D, Behr, M, Schwartzman, K, Alvarez, GG, Dan, A, McIntosh, F, Pai, M & Denkinger, CM 2014, 'Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact', *Clinical Infectious Diseases*, vol. 58, no. 7, pp. 970–976.

Sonnenberg, P, Murray, J, Glynn, JR, Shearer, S, Kambashi, B & Godfrey-Faussett, P 2001, 'HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers', *The Lancet*, vol. 358, no. 9294, pp. 1687–1693.

Stata Corporation 2013, *Intercooled Stata 12.0 for Windows*, [computer program], Stata Corporation, College City, Texas.

Street, A, McBryde, ES, Denholm, JT & Eisen, D 2012, *Management of tuberculosis: a handbook for clinicians.*, Victorian Infectious Diseases Service, Parkville, Victoria.

Suzuki, T, Tanaka, M, Otani, S, Matsuura, S, Sakaguchic, Y, Nishimura, T, Ishizaka, A & Hasegawa, N 2006, 'New rapid detection test with a combination of polymerase chain reaction and immunochromatographic assay for *Mycobacterium tuberculosis* complex', *Diagnostic Microbiology and Infectious Disease*, vol. 56, no. 3, pp. 275–280.

Taegtmeyer, M, Beeching, NJ, Scott, J, Seddon, K, Jamieson, S, Squire, SB, Mwandumba, HC, Miller, ARO, Davies, PDO & Parry, CM 2008, 'The clinical impact of nucleic acid amplification tests on the diagnosis and management of tuberculosis in a British hospital', *Thorax*, vol. 63, no. 4, pp. 317–321.

Takwoingi, Y, Leeflang, MMG & Deeks, JJ 2013, 'Empirical evidence of the importance of comparative studies of diagnostic test accuracy', *Annals of Internal Medicine*, vol. 158, no. 7, pp. 544–554.

Tan, MC, Marra, CA, Sadatsafavi, M, Marra, F, Moran-Mendoza, O, Moadebi, S, Elwood, RK & FitzGerald, JM 2008, 'Cost-effectiveness of LTBI treatment for TB contacts in British Columbia', *Value Health*, vol. 11, no. 5, pp. 842–852.

TBFacts.org, *Drug susceptibility testing*, The TB Charity GHE, United Kingdom, viewed 19 June 2014, <<http://www.tbfacts.org/drug-susceptibility.html>>

Teo, J, Jureen, R, Chiang, D, Chan, D & Lin, R 2011, 'Comparison of two nucleic acid amplification assays, the Xpert MTB/RIF assay and the amplified M-tuberculosis Direct Assay, for detection of *Mycobacterium tuberculosis* in respiratory and nonrespiratory specimens', *Journal of Clinical Microbiology*, vol. 49, no. 10, pp. 3659–3662.

Therapeutic Goods Administration 2011, *Overview of the regulatory framework for in-vitro diagnostic medical devices*, Australia Government Department of Health and Ageing, Canberra, Australia.

Therese, KL, Jayanthi, U & Madhavan, HN 2005, 'Application of nested polymerase chain reaction (nPCR) using *MPB64* gene primers to detect *Mycobacterium tuberculosis* DNA in clinical specimens from extrapulmonary tuberculosis patients', *Indian Journal of Medical Research*, vol. 122, no. 2, pp. 165–170.

Theron, G, Peter, J, Meldau, R, Khalfey, H, Gina, P, Matinyena, B, Lenders, L, Calligaro, G, Allwood, B, Symons, G, Govender, U, Setshedi, M & Dheda, K 2013, 'Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid', *Thorax*, vol. 68, no. 11, pp. 1037–1042.

Theron, G, Pooran, A, Peter, J, Van Zyl-Smit, R, Mishra, HK, Meldau, R, Calligaro, G, Allwood, B, Sharma, SK, Dawson, R & Dheda, K 2012, 'Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?', *European Respiratory Journal*, vol. 40, no. 1, pp. 161–168.

Theron, G, Zijenah, L, Chanda, D, Clowes, P, Rachow, A, Lesosky, M, Bara, W, Mungofa, S, Pai, M, Hoelscher, M, Dowdy, D, Pym, A, Mwaba, P, Mason, P, Peter, J & Dheda, K 2014, 'Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial', *The Lancet*, vol. 383, no. 9915, pp. 424–435.

Thomson, RM 2010, 'Changing epidemiology of pulmonary nontuberculous mycobacteria infections', *Emerging Infectious Diseases*, vol. 16, no. 10, pp. 1576–1583.

Thomson, RM, Carter, R, Tolson, C, Coulter, C, Huygens, F & Hargreaves, M 2013, 'Factors associated with the isolation of Nontuberculous mycobacteria (NTM) from a large municipal water system in Brisbane, Australia', *BMC Microbiology*, vol. 13, no. 1, pp. 1–8.

Tomita, N, Mori, Y, Kanda, H & Notomi, T 2008, 'Loop-mediated isothermal amplification (LAMP) of gene sequences and simple visual detection of products', *Nature Protocols*, vol. 3, no. 5, pp. 877–882.

Torres, C, Vitalis, EA, Baker, BR, Gardner, SN, Torres, MW & Dzenitis, JM 2011, 'LAVA: an open-source approach to designing LAMP (loop-mediated isothermal amplification) DNA signatures', *BMC Bioinformatics*, vol. 12, p. 240.

Tortoli, E, Russo, C, Piersimoni, C, Mazzola, E, Dal Monte, P, Pascarella, M, Borroni, E, Mondo, A, Piana, F, Scarparo, C, Coltella, L, Lombardi, G & Cirillo, DM 2012, 'Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis', *European Respiratory Journal*, vol. 40, no. 2, pp. 442–447.

Tostmann, A, Boeree, MJ, Aarnoutse, RE, de Lange, WC, van der Ven, AJ & Dekhuijzen, R 2008, 'Antituberculosis drug-induced hepatotoxicity: concise up-to-date review', *Journal of Gastroenterology and Hepatology*, vol. 23, no. 2, pp. 192–202.

Tran, AC, Halse, TA, Escuyer, VE & Musser, KA 2014, 'Detection of *Mycobacterium avium* complex DNA directly in clinical respiratory specimens: opportunities for improved turn-around time and cost savings', *Diagnostic Microbiology and Infectious Disease*, vol. 79, no. 1, pp. 43–48.

Tsevat, J, Taylor, WC, Wong, JB & Pauker, SG 1988, 'Isoniazid for the tuberculin reactor: take it or leave it', *American Review of Respiratory Disease*, vol. 137, no. 1, pp. 215–220.

Vadwai, V, Boehme, C, Nabeta, P, Shetty, A, Alland, D & Rodrigues, C 2011, 'Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?', *Journal of Clinical Microbiology*, vol. 49, no. 7, pp. 2540–2545.

van der Oest, A, Kelly, R & Hood, D 2004, 'The changing face of tuberculosis control in a rural district of New Zealand', *International Journal of Tuberculosis and Lung Disease*, vol. 8, no. 8, pp. 969–975.

van der Werf, MJ, Langendam, MW, Huitric, E & Manissero, D 2012, 'Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis', *European Respiratory Journal*, vol. 39, no. 6, pp. 1511–1519.

Van Rie, A, Page-Shipp, L, Hanrahan, CF, Schnippel, K, Dansey, H, Bassett, J, Clouse, K, Scott, L, Stevens, W & Sanne, I 2013a, 'Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa', *International Journal of Tuberculosis and Lung Disease*, vol. 17, no. 3, pp. 368–372.

Van Rie, A, Page-Shipp, L, Mellet, K, Scott, L, Mkhwnazi, M, Jong, E, Omar, T, Beylis, N, Stevens, W, Sanne, I & Menezes, CN 2013b, 'Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis', *European Journal of Clinical Microbiology and Infectious Diseases*, vol. 32, no. 11, pp. 1409–1415.

Victoria State Government Department of Health 2014, *Fees and charges of acute health services in Victoria. Section A: fees for admitted patients. 8: Eligible (including reciprocal health care) and ineligible patients*, State of Victoria, viewed 5 November 2014, <<http://health.vic.gov.au/feesman/fees6.htm>>

Walusimbi, S, Bwanga, F, Costa, AD, Haile, M, Hoffner, S & Joloba, M 2013, 'Evaluation of the Xpert® MTB/Rif test, microscopic observation drug susceptibility test and nitrate reductase assay, for rapid and accurate diagnosis of smear-negative tuberculosis in HIV patients', *International Journal of Mycobacteriology*, vol. 2, no. 3, pp. 148–155.

Wejse, C, Gustafson, P, Nielsen, J, Gomes, VF, Aaby, P, Andersen, PL & Sodemann, M 2008, 'TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course', *Scandinavian Journal of Infectious Diseases*, vol. 40, no. 2, pp. 111–120.

Whiting, PF, Rutjes, AW, Reitsma, JB, Bossuyt, PM & Kleijnen, J 2003, 'The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews.', *BMC Medical Research Methodology*, vol. 3, no. 1, p. 25.

Whiting, PF, Rutjes, AW, Westwood, ME, Mallett, S, Deeks, JJ, Reitsma, JB, Leeflang, MM, Sterne, JA & Bossuyt, PM 2011, 'QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies', *Annals of Internal Medicine*, vol. 155, no. 8, pp. 529–536.

WHO 2007, *TB diagnostics and laboratory strengthening - WHO policy*, World Health Organization, Geneva, Switzerland, viewed 19 June 2014,

<<http://www.who.int/tb/laboratory/policy_liquid_medium_for_culture_dst/en/>>

WHO 2008, *Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008*, World Health Organization, Geneva, Switzerland,

<<http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf>>

WHO 2010, *Treatment of tuberculosis guidelines*, fourth edn, World Health Organization, Geneva, switzerland,

<<http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf>>

WHO 2013, *Global tuberculosis report 2013*, World Health Organisation, Geneva, Switzerland, viewed 13 June 2014,

<<http://www.who.int/tb/publications/global_report/en/>>

WHO 2014, *Xpert MTB/RIF implementation manual. Technical and operational ‘how-to’: practical considerations*, second edn, World Health Organization, Geneva, Switzerland, viewed 2 November 2014, <<http://www.who.int/tb/laboratory/policy_statements/en/>>

Winetsky, DE, Negoescu, DM, DeMarchis, EH, Almukhamedova, O, Dooronbekova, A, Pulatov, D, Vezhnina, N, Owens, DK & Goldhaber-Fiebert, JD 2012, 'Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis', *PLoS Medicine*, vol. 9, no. 11.

Yoon, C, Cattamanchi, A, Davis, JL, Worodria, W, den Boon, S, Kalema, N, Katagira, W, Kaswabuli, S, Miller, C, Andama, A, Albert, H, Nabeta, P, Gray, C, Ayakaka, I & Huang, L 2012, 'Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda', *PLoS ONE*, vol. 7, no. 11.

Zar, HJ, Workman, L, Isaacs, W, Dheda, K, Zemanay, W & Nicol, MP 2013, 'Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of Xpert MTB/RIF on respiratory specimens: a prospective study', *The Lancet Global Health*, vol. 1, no. 2, pp. e97–e104.

Zeka, AN, Tasbakan, S & Cavusoglu, C 2011, 'Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens', *Journal of Clinical Microbiology*, vol. 49, no. 12, pp. 4138–4141.

Zumla, A, Raviglione, M, Hafner, R & von Reyn, CF 2013, 'Tuberculosis', *New England Journal of Medicine*, vol. 368, no. 8, pp. 745–755.

1. Available from URL: <http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3801-pdf-cnt.htm/$FILE/cdi3801i.pdf> (accessed 3 November 2014) [↑](#footnote-ref-1)
2. Defined as resistant to rifampicin and isoniazid [↑](#footnote-ref-2)
3. Defined as resistant to rifampicin, isoniazid, fluoroquinolones, and any of the second-line injectable drugs such as capreomycin, amikacin and kanamycin [↑](#footnote-ref-3)
4. US Food and Drug Administration, ‘Medical devices, nucleic acid based tests’. Available from URL: <http://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm330711.htm> (accessed 12 June 2014) [↑](#footnote-ref-4)
5. Alfred Health Pathology Service, *Mycobacterium tuberculosis* PCR. Available from URL: <http://pathology.alfred.org.au/handbook/> (accessed 19 June 2014) [↑](#footnote-ref-5)
6. PathWest Laboratory Medicine WA, *Mycobacterium tuberculosis* PCR. Available from URL: <http://www.pathwest.com.au/testdirectory/> (accessed 19 June 2014) [↑](#footnote-ref-6)
7. Therapeutic Goods Administration, Australian Register of Therapeutic Goods (ARTG). Available from URL: <https://www.ebs.tga.gov.au/> (accessed 19 June 2014) [↑](#footnote-ref-7)
8. Personal communication, received 1 october 2014 [↑](#footnote-ref-8)
9. Centers for Disease Control and Prevention. URL: <http://www.cdc.gov/> (accessed during writing of the protocol) [↑](#footnote-ref-9)
10. Available from URL: <http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3801-pdf-cnt.htm/$FILE/cdi3801i.pdf> (accessed 3 November 2014) [↑](#footnote-ref-10)
11. Available from URL: <http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3801-pdf-cnt.htm/$FILE/cdi3801i.pdf> (accessed 3 November 2014) [↑](#footnote-ref-11)
12. World Health Organization (WHO) estimates of tuberculosis incidence, 2012 (WHO 2013) [↑](#footnote-ref-12)
13. Mortality rates were adjusted for compliance [↑](#footnote-ref-13)
14. The authors calculated adjusted pooled incidence based on different definitions of hepatoxicity/hepatitis. The incidence was much lower (6.7/1000) in studies using clinical criteria to define hepatitis than in those using biochemical criteria alone [↑](#footnote-ref-14)
15. Available from URL: <http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3801-pdf-cnt.htm/$FILE/cdi3801i.pdf> (accessed 3 November 2014) [↑](#footnote-ref-15)
16. Available from URL: <http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3801-pdf-cnt.htm/$FILE/cdi3801i.pdf> (accessed 3 November 2014) [↑](#footnote-ref-16)
17. Available from URL: <http://search.informit.com.au/documentSummary;dn=967413476493835;res=IELHEA> (accessed 13 June 2014) [↑](#footnote-ref-17)
18. Available from URL: <http://www.healthinfonet.ecu.edu.au/closing-the-gap/key-facts/what-is-closing-the-gap> (accessed 3 November 2014) [↑](#footnote-ref-18)
19. *The Strategic Plan for Control of Tuberculosis in Australia: 2011–2015*. Available from URL: <http://search.informit.com.au/documentSummary;dn=967413476493835;res=IELHEA> (accessed 13 June 2014) [↑](#footnote-ref-19)
20. Personal communication from applicant via Department of Health, received 25 September 2014 [↑](#footnote-ref-20)
21. Personal communication, received 1 October 2014 [↑](#footnote-ref-21)
22. Sydney South West Pathology Service ([www.sswahs.nsw.gov.au/sswps](http://www.sswahs.nsw.gov.au/sswps)) and Pathology North (<http://www.palms.com.au/php/labinfo/info_index.php?tc=MYCPCR&site=RNSH&tn=Mycobacteria%20PCR&s=Induced%20Sputum&sid=59>) [↑](#footnote-ref-22)
23. Melbourne Pathology <http://mpscsp1.sonichealthcare.com.au/pseudompp/tcm/csp/searchview.csp> [↑](#footnote-ref-23)
24. Personal communication, received 1 September 2014 [↑](#footnote-ref-24)
25. Personal communication, received 4 November 2014 [↑](#footnote-ref-25)
26. Personal communication from applicant via Department of Health, received 18 August 2014 [↑](#footnote-ref-26)
27. The hospital pharmacy department requested that it not be identified for reasons of commercial confidence [↑](#footnote-ref-27)
28. ($14,230−$904)/14.58 [↑](#footnote-ref-28)
29. Hughes et al. ([2012](#_ENREF_89)) cites Holland et al. ([2009](#_ENREF_88)), in which utility of no TB health state = 1 and a utility decrement of 0.25 is assumed for ‘treatment-limiting toxicity’. As a utility of 0.86 is assumed in the model, a 25% reduction of 0.86 (0.22) is applied for toxicity associated with TB and a 16% reduction of 0.86 (0.14) for toxicity associated with no TB [↑](#footnote-ref-29)
30. Available from URL: <http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3801-pdf-cnt.htm/$FILE/cdi3801i.pdf> (accessed 3 November 2014) [↑](#footnote-ref-30)